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Abstract 
Lectins are carbohydrate-binding proteins found throughout nature in plants, viruses, pro- and 
eukaryotes. Their carbohydrate specificity as well as their biological functions are highly 
diverse. Lectins in humans primarily serve as cell-surface receptors and are mainly involved 
in the immunogenic processes. Bacterial lectins are often involved in conferring pathogenesis 
by binding to carbohydrates of the host. In this thesis, structural, functional, and 
pharmacological insights on the mammalian lectin E-selectin and the bacterial lectin FimH 
are given.  
E-selectin is a C-type lectin involved in leukocyte recruitment during inflammation by 
binding to the tetrasaccharide ligand sialyl Lewisx (sLex). It is involved in numerous diseases, 
e.g. asthma, psoriasis, stroke, rheumatoid arthritis or cancer metastasis. Targeting E-selectin 
with glycomimetic antagonists is therefore in the focus of drug discovery. The following 
aspects of E-selectin were investigated: 
• Publication 1 – The thermodynamic driving forces of the interaction of E-selectin 
with sLex and glycomimetics thereof were investigated. We demonstrated that sLex 
binding is an entropy-driven process, which is an uncommon feature of carbohydrate-
lectin interactions. 
• Manuscript 1 – The co-crystallization of E-selectin with sLex or a more potent 
glycomimetics thereof revealed a previously unseen induced fit of the binding site 
involving alterations in the first two domains. We showed that this induced fit occurs 
in solution and discuss the physiological relevance. 
• Manuscript 2 – A flexible and a pre-organized E-selectin antagonist were 
characterized for their kinetic and thermodynamic properties, which revealed an 
unexpected loss in entropy for the pre-organized antagonist. Co-crystallization with a 
series of antagonists revealed the reason for this behavior. 
• Publication 2 – The single nucleotide polymorphism which leads to the S128R 
mutation in E-selectin has been correlated with an increased risk of developing 
various diseases. We investigated the binding behavior of this mutant and 
demonstrated that glycomimetics are efficacious in inhibiting E-selectin-S128R 
mediated binding. 
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• Manuscript 3 – Mice are able to express the N-glycolyl form of sLex, unlike humans. 
Therefore, the specificity of murine E-selectin might be altered. We investigated the 
binding specificity of murine E-selectin and evaluated the potency of antagonists 
designed for human E-selectin. We confirmed the efficacy of E-selectin antagonists 
towards murine E-selectin, thus demonstrating the validity of mouse models. 
The bacterial lectin FimH is presented by uropathogenic E. coli (UPEC) on the tip of type 1 
pili and mediates the adhesion to mannosylated structure in the lower urinary tract. This 
interaction allows UPEC to colonize the bladder, the initial step in bladder infection. 
Mannoside-based FimH antagonists are under investigation as treatment for bladder 
infections. 
• Manuscript 4 – The goal of a drug discovery program aimed to develop a treatment 
for urinary tract infections is to identify high-affinity, orally available, and safe FimH 
antagonists. Starting from the carboxylate substituted biphenyl α-D-mannopyranoside, 
affinity as well as the relevant pharmacokinetic parameters (solubility, permeability, 
renal excretion) could be substantially improved by a bioisosteric approach.  
• Manuscript 5 – To comprehend and further develop potent FimH antagonists, 
structural data on ligand-protein interaction is essential. In this manuscript we present 
the X-ray co-crystal structures of FimH with three antagonist classes for which 
structural data were unavailable to date and provide an explanation for the observed 
entropy-enthalpy compensation by NMR. 
• Manuscript 6 – Crystallographic studies of FimH with alkyl- or aryl-substituted α-D-
mannopyranosides have demonstrated alternative binding poses with differing 
involvement of the residues Tyr48 and Tyr137 at the binding site entrance. 
Thermodynamic and molecular modeling analysis provided insights into the 
importance of the tyrosine-gate. 
• Manuscript 7 – Several mutations of FimH are found in clinical isolates, which 
influence the binding phenotype of FimH by altering the interaction of the two FimH 
domains (lectin- and pilin domain). To date, FimH antagonists have never been tested 
on clinically relevant FimH variants. We demonstrated that antagonist affinity 
correlated with the binding behavior of different FimH variants. 
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1. Introduction to the Lectin Family 
The lectins are a family of proteins that share specific binding towards carbohydrates. They 
are widespread throughout nature, as they exist in plants (e.g. concanavalin A first isolated 
from Canavalia ensiformis1), viruses (e.g. hemagglutinin2), and in pro- and eukaryotic 
cells3,4. Since their initial discovery in 1888, numerous lectins with a wide range of functions 
have been identified. While initially plant lectins have been thoroughly investigated, the main 
focus has shifted towards animal lectins since the 1970s, in particular human lectins.  
1.1. Human Lectins 
Lectins in humans cover a variety of functions, e.g. in cell-cell adhesion, cell signaling, host 
immune response, embryonic development etc5,6. Based on their sequence homology and 
their functional relationship, mammalian lectins have been classified into four major 
categories. 
• C-type lectins which share a common requirement of one or more Ca2+ ions for 
carbohydrate recognition and binding, while having a diverse carbohydrate 
specificity7. The family of selectins, the Dendritic Cell-Specific Intercellular adhesion 
molecule-3-Grabbing Non-integrin (DC-SIGN), and asialoglycoprotein receptors are 
among the most thoroughly investigated C-type lectins. 
• Galectins (formerly known as S-type lectins) with specificity towards β-galactosides 
share conserved amino acid residues among their carbohydrate binding domains, 
which are directly involved in carbohydrate binding8. They have widespread 
functions, since they are involved in immune response, inflammation, apoptosis and 
in embryonic development. 
• P-type lectins which require mannose-6-phosphate (M6P) for binding affinity9. Two 
P-type lectins have been identified: The cation dependent receptor (CD-MPR), and 
the cation-independent receptor (CI-M6P). Both are involved in the generation of 
functional lysozymes. 
• I-type lectins that belong to the immunoglobulin superfamily and contain at least one 
immunoglobulin-like fold10. The family of Siglecs is the most prominent group of 
I-type lectins, which all share a requirement of sialic acid (NeuNAc). Their function 
ranges from cell-cell adhesion in the host immune response (Sialoadhesin) to the 
inhibition of myelination in neuronal growth (Myelin-associated glycoprotein). 
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As summarized above, mammalian lectins are present in a wide variety, each with distinct 
function and carbohydrate specificities and affinities. Dysfunction or override of some of 
these lectins can lead to diseases, e.g. B-cell non-hodgkin lymphoma, where Siglec-2 is 
involved11 or DC-SIGN, which is exploited as an entry point by numerous microbials, such 
as the HI-virus12. Furthermore, the selectin family is also involved in numerous diseases. A 
more detailed description on their function in health and disease is noted in Section 2.1. 
1.2. Microbial Lectins 
Microbial lectins are mainly located on bacterial fimbriae and mediate the initial adhesion to 
glycoproteins, glycolipids or proteoglycans presented on endo- and epithelial cells of the 
host13. Therefore, microbial lectins are commonly referred to as “adhesins” and represent 
important virulence factors for bacteria. The best characterized adhesins of Escherichia coli 
(E. coli) to date are: 
• FimH, located on type 1 pili with a specificity towards mannose structures presented 
on the urothelium14, 
• PapG, located on P pili with a specificity towards galabiose (Galα1–4Galβ) presented 
in the upper urinary tract15, 
• F17G, located on F17 pili with a specificity towards N-acetylglucosamine (GlcNAc) 
presented on intestinal mucosal cells16. 
The interaction of these adhesins with specific carbohydrates allows pathogenic E. coli to 
adhere and subsequently to invade host cells which present these carbohydrates on their 
surfaces. For example, E. coli initially adhere to the lower urinary tract via FimH, and, at a 
later stage of infection, to the upper urinary tract using PapG. A detailed overview on type 1 
pili and FimH is given in Section 3.1.  
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2.1. Introduction to the Selectins 
The selectins are type-1-membrane adhesion molecules consisting of the three members E-, 
L-, and P-selectin1,2. Since they have a functional requirement for a Ca2+ ion, the selectins 
belong to the class of C-type lectins. Their expression is restricted to bone-barrow derived 
cells and the vascular endothelium3. The main function of selectins is the guidance of 
leukocytes to specific tissues by allowing initial contacts (i.e. tethering) between free flowing 
leukocytes from the bloodstream and endothelial cells, e.g. during inflammation4,5 and 
homing of lymphocytes6. 
• E-selectin (also termed CD62E, ELAM-1, LECAM-2) is uniquely expressed on 
postcapillary vascular endothelial cells upon an inflammatory stimulus. Its main role 
is the capturing of free flowing leukocytes at a site of inflammation. 
• L-selectin (also termed CD62L, LAM-1, LECAM-1) is constitutively expressed on 
blood neutrophils, monocytes and on most blood-borne T- and B-cells7. Interaction of 
L-selectin with ligands on high endothelial cells (HEV) allows leukocytes to be 
captured, a prerequisite for their entry into secondary lymphoid organs. This process 
is known as lymphocyte homing8. 
• P-selectin (also termed CD62P, LECAM-3, GMP-140, PADGEM) is displayed on 
platelets9 as well as on vascular endothelial cells10 upon induction. As for E-selectin, 
the display of P-selectin on endothelial cells initially captures leukocytes from the 
blood stream. Expression on platelets leads to platelet aggregation during blood clot 
formation11. 
2.1.1. Overall Structure of the Selectins 
All three selectins share a similar overall protein structure as shown in Figure 2-1. The 
carbohydrate recognition domain (CRD), also referred to as the lectin domain, is located at 
the N-terminus, with the largest distance to the cell surface. This domain of 120–130 amino 
acids contains the ligand binding site and coordinates the Ca2+ ion12.  
The lectin domain is C-terminally connected to the epidermal growth factor-like (EGF-like) 
domain, a relatively small domain of approximately 36 amino acids. The function of this 
domain is less understood. The binding activity of the lectin domain however requires the 
presence of the EGF-like domain2, since deletion of the EGF-like domain strongly impairs 
selectin affinity13,14. Therefore, the two N-terminal domains are considered as the minimal 
requirement for selectin activity. As the EGF-like domain does not directly interact with the 
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carbohydrate ligand, it is proposed that it might stabilize the lectin domain. The X-ray 
structure of the E-selectin lectin- and EGF-like domain supports this notion, in which 
interactions of residues 135–139 of the EGF-like domain with residues of the lectin domain 
are observed (PDB code 1ESL)15. 
 
Figure 2-1. Overall structure of human selectins. The N-terminal carbohydrate recognition domain 
allows Ca2+ dependent binding. The lectin and EGF-like domain together are the minimal requirement 
for selectin binding activity. All selectins possess extensive N-linked glycosylation. 
The EGF-like domain is followed by a variable number of short consensus repeats (SCR), 
also called sushi domains or complement repeat domains, each with ∼60 amino acids and 
three disulfide bonds. In humans, P-selectin possesses nine, E-selectin six, and L-selectin two 
SCRs16. Their function remains unclear, since they are neither directly involved in ligand 
binding, nor in selectin oligomerization. Using cell-based assays it has been shown that 
increasing numbers of SCRs in E-selectin lead to augmented binding affinity17, and that 
substitution of SCRs among selectins alters their specificity18. The presence or absence of 
both SCRs in L-selectin has also been correlated with binding affinity19. Kolbinger et al., 
however, did not confirm that the SCRs determine ligand specificity20. A recent study 
suggests that SCR might act as springs under mechanical force21, as is present for leukocyte 
tethering under flow conditions. Finally, SCRs might merely act as spacer for the lectin 
domain, in order to protrude from the cell surface into the glycocalix22.  
The selectins are anchored to the cell membrane by a ∼23 amino acids transmembrane region. 
The C-terminal cytoplasmic domain consists of 17–35 amino acids, is involved in signaling 
functions23,24, and interacts with the cytoskeleton25. 
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The primary sequence homology between human selectins is relatively low. For the lectin 
domain it is ∼52%, for the EGF-like domain ∼47%, and for the SCRs ∼35%. The 
transmembrane and cytoplasmic domains do not share any homology, suggesting various 
effector functions of selectins. 
2.1.2. Ligands of Selectins 
While a variety of glycoproteins have been identified to serve as selectin ligands, they all 
share a common minimal binding epitope, namely sialyl Lewisx (sLex) and its regioisomer 
sialyl Lewisa (sLea) as shown in Figure 2-2. These two tetrasaccharides are recognized by all 
three selectins26,27. The glycoproteins thereby act as scaffolds bearing glycans terminally 
conjugated with sLex. The affinity of sLex itself to selectins is very weak, with 0.3–1.1 mM 
for E-selectin, and 7–9 mM for P-selectin28. 
 
Figure 2-2. The tetrasaccharides sialyl Lewisx (Neu5Ac(α2-3)Gal(β1-4)[Fuc(α1-3)]GlcNAc) or sialyl 
Lewisa (Neu5Ac(α2-3)Gal(β1-3)[Fuc(α1-4)]GlcNAc) are the minimal binding epitopes for all selectins. 
Glycoproteins bearing sLex (Figure 2-3) in some cases also provide additional interactions 
with selectins, which may influence specificity. A well studied natural selectin ligand is 
P-selectin glycoprotein ligand-1 (PSGL-1), a homodimeric glycoprotein presented on the tips 
of the microfolds on leukocytes29. While selectins in most cases bind with weak affinity to 
sLex bearing glycoproteins, a KD value of 320 nM for the interaction of P-selectin with 
PSGL-1 was measured using surface plasmon resonance (SPR)30. This high affinity is not 
only a result of the interaction of sLex with P-selectin, but with additional interactions of 
sulfated tyrosine residues on PSGL-1. The lack of secondary binding sites for sulfated groups 
leads to a vastly reduced binding affinity of E-selectin with PSGL-126,31, which nonetheless is 
considered as an E-selectin ligand. Another well investigated glycoprotein ligand is E-
selectin ligand-1 (ESL-1), a 150 kDa, non-sulfated glycoprotein located on leukocytes that 
binds exclusively to E-selectin with moderate affinity 62 µM32-34.  
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L-selectin has also exclusive sLex bearing glycoprotein ligands, e.g. addressin 
(MAdCAM-1)35,36, CD3437, endomucin38, endoglycan39, and glycosylation-dependent cell 
adhesion molecule-1 (GlyCAM-1)40. Most of these L-selectin ligands are sialomucins and are 
expressed on endothelial cells, enabling leukocyte trafficking. 
By regulating the sLex biosynthesis through glycosyltransferases and the modulation of 
protein sulfation by sulfo-transferases, leukocytes can effectively control their selectin 
specificity, and hence direct their adherence to various tissues3. 
 
Figure 2-3. Overview of selectin glycoprotein ligands all terminally bearing sLex. The homodimeric 
PSGL-1 is a ligand for both, E- and P-selectin. ESL-1 binds exclusively to E-selectin while L-selectin 
has its own set of ligands. 
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2.1.3. The Inflammatory Cascade 
Leukocytes are cells of the immune system circulating in the blood stream that defend against 
infections and foreign materials. Their mechanism of action requires leukocytes to traffic to 
the site of tissue damage. This is achieved by a well defined sequence of events termed the 
inflammatory cascade (Figure 2-4). 
 
Figure 2-4. Schematic representation of the inflammatory cascade (courtesy of Alexander Vögtli). An 
inflammatory stimulus (1) is caused by the release of cytokines upon tissue damage or irritation. This 
triggers the expression of selectins on the vascular endothelium (2), upon which leukocytes are able 
to initially tether and roll along the surface. Activation of integrins (3), allowing further cell-cell 
contacts, translates the rolling motion into a firm adhesion, after which leukocytes extravasate (5) into 
the tissue where they resolve the cause of inflammation. 
In the first step, pro-inflammatory cytokines are released at the site of tissue lesion. This 
initiates the presentation of E- and P-selectin on vascular endothelial cells. P-selectin is 
rapidly displayed on the cell surface, since it is stored in Weibel-Palade bodies (granules) 
within the endothelial cells. Upon the release of thrombin, histamine, activators of protein 
kinase C or complement fragments, these granules fuse with the cell membrane. Full display 
of P-selectin is usually complete after 10–20 minutes41,42. Furthermore, P-selectin is regulated 
on the level of mRNA transcription by lipopolysaccharides (LPS), tumor necrosis factor-α 
(TNF-α), and various interleukins, which ensures stable display after several hours at a later 
stage of inflammation43-45.  
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E-selectin, is solely regulated on the transcription level by the NFκB-pathway and is 
expressed upon increased levels of LPS, TNF-α, and interleukin-1β (IL-1β)46,47. Therefore, 
E-selectin is displayed only at later stages of inflammation, usually within 4–6 hours after 
stimulation. The late engagement of E-selectin was confirmed in E-selectin knockout mice, 
where leukocyte tethering in comparison to the control group was impaired only several 
hours after stimulation48.  
L-selectin, unlike E- and P-selectin being located on leukocytes, also plays a role in 
leukocyte tethering in the early stages of inflammation by interacting with glycoproteins 
presented on endothelial cells5. In addition, L-selectin interacts with already tethered 
leukocytes, further increasing the number of adherent cells by this secondary tethering49.  
Once leukocytes are initially captured they roll along the vasculature. This rolling motion is 
regulated by the force the blood flow exerts on the leukocyte, and by the kinetics of selectin-
ligand interaction (see Section 2.1.5.). While L-selectin allows high-velocity rolling, P-
selectin shows intermediate, and E-selectin only slow rolling. It is thought that the slow 
rolling on E-selectin facilitates the transition into firm adhesion4.  
Selectins alone however are not sufficient to enable leukocyte to transmigration into the 
surrounding tissue. The display of integrins on leukocytes is triggered via G-protein coupled 
activation once in contact with the endothelial cells. The interaction of integrins, e.g. the 
lymphocyte function-associated antigen-1 (LFA-1) for lymphocytes or macrophage-1 antigen 
(Mac-1) for macrophages, with the intercellular adhesion molecule-1 (ICAM-1) on 
endothelial cells mediates the complete arrest of leukocytes4. There is a co-dependence 
between the integrin system with the selectin system, since knockout animals of either system 
have impaired leukocyte extravastion50. 
In order to resolve the cause of inflammation, the immobilized leukocytes must overcome the 
endothelial cell layer and penetrate into the tissue. This is achieved with the involvement of 
numerous factors, which requires cytoskeletal rearrangement in both, the leukocytes and the 
endothelial cells. Two mechanisms have been identified, a paracellular pathway, were 
leukocytes transmigrate between cells, and a transcellular pathway51, in which leukocytes 
pass through endothelial cells. Both pathways are thought to occur during transmigration. 
Once in the tissue, chemokine gradients (IL-8) attract leukocytes towards the site of 
infection4. 
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2.1.4. Selectins in Pathology 
Selectins are responsible for trafficking of leukocytes in a well regulated fashion. However, 
dysregulation of selectins can lead to various states of disease. This often involves 
exaggerated leukocyte recruitment without an inflammatory stimulus, leading to destruction 
of healthy tissue52. This occurs in a variety of cardiovascular diseases such as 
atherosclerosis53, ischemia (e.g. myocardial infarction54), reperfusion injury55-57, 
hypertension58, and diabetes59. Also immune diseases are associated with selectins, e.g. 
rheumatoid arthritis60, systemic lupus erythematosus61, and asthma bronchiale62. 
Furthermore, selectin contributions have been found to be relevant in cancer metastasis and 
in sickle cell disease63. 
Single nucleotide point mutations (SNP) of E-selectin have also been associated with 
diseases. The S128R mutation, which is located in the EGF-like domain, has been correlated 
with an increased risk and severity of a number of diseases, e.g. myocardial infarction64, 
severe asthma65, colon metastasis formation66 etc. Another SNP in E-selectin which causes 
the Leu554Phe mutation in the transmembrane region is associated with atherosclerosis67 and 
hypertension68. 
While selectins themselves are usually not the causative agent of such diseases, their function 
as adhesion molecules sustains or even aggravates certain pathogenic processes. Therefore, 
inhibition of selectin function is considered as a highly relevant drug target. 
2.1.5. Selectin Binding Properties 
Kinetics 
The function of leukocytes is to allow the tethering of fast flowing leukocytes from the blood 
stream and to enable rolling along the vasculature. This requires specific binding properties 
regarding kinetics of selectins with their respective ligands (see Figure 2-5). A rapid and 
specific interaction is required during initial tethering and rolling (described by the 
association constant kon) at the leading edge of the leukocyte. The bond lifetime, on the other 
hand, must be short in order to break bonds at the trailing edge of the leukocyte and allow 
rolling (described by the dissociation constant koff). A balance of kon and koff is therefore of 
great importance for proper selectin function69. In addition, the surface densities of selectins 
and their ligands was also shown to influence rolling behavior70,71. 
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The KD value describes the equilibrium of binding in a static environment, which is never 
reached under flow conditions72,73. The mean velocity of rolling leukocytes is 10–100 fold 
lower than that of the blood flow. Surface plasmon resonance (SPR) studies were performed 
to investigate the kinetics of selectin binding. For the E-selectin–ESL-1 interaction, a KD of 
62 µM was determined with a koff rate of 4.6 s-1 and a kon rate of 7.4⋅104 M-1s-1. This translates 
into a half-life of only 0.15 seconds. For the P-selectin–PSGL-1 interaction kon of 
4.4·106 M-1s-1 and a koff of was 1.4 s-1 (KD = 0.3 µM). The half-life of 0.5 seconds is in the 
same order of magnitude as for the E-selectin–ESL-1 interaction, albeit the additional 
interactions of sulfated tyrosines PSGL-1. The faster kon of P-selectin suggests differential 
role of E- and P-selectin: while P-selectin is thought to mediate the very first leukocyte 
interaction, E-selectin is proposed to mediate the transition of fast to slow rolling and finally 
the full arrest of the cell34. E-selectin itself has only low potential in capturing leukocytes 
from the bulk flow74. 
Selectin Binding under Mechanical Force 
Selectin–ligand binding has been shown to be modulated under tensile force (see Figure 2-5). 
This force arises by the drag of leukocytes once bound to the endothelial cells, which pulls 
along the selectin–ligand axis. It has been reported that optimal selectin-mediated adherence 
and rolling requires a minimal shear threshold. The physiological wall shear stress in 
postcapillary venules is 1–10 dynes/cm2. For L-, E-, and P-selectin, the minimal wall shear 
stress threshold is 0.8, 0.25, and 0.5 dynes/cm2, respectively75. This is explained by 
stabilization of selectin–ligand interaction under tensile force. While the interaction is 
unstable under static conditions, stability is enhanced up to a certain point, after which 
stability decreases. This phenomenon is termed catch-bonds, in contrast to conventional slip 
bonds where bond lifetimes decrease under force. This binding behavior of the selectins has 
been studied using atomic force microscopy76, biomembrane force probes77, and flow 
chamber assays78.  
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Figure 2-5. Binding characteristics of selectins. Left: To enable rapid capturing of leukocytes, 
selectins must provide fast kon kinetics at the leading edge of the leukocytes. The breaking of bonds at 
the trailing edge is governed by the dissociation rate (koff) and allows for the rolling motion. Right: 
Selectins display catch-bond behavior. Most protein-ligand interactions are weakened when tensile 
force is applied to the bond (slip-bonds, green). For catch-bonds, bond lifetimes are initially increased 
to a certain threshold (orange). Catch-bonds are accompanied by a change in binding site 
conformations. 
Two models were developed to explain the catch-bond phenomenon for selectins. i) Based on 
two distinct crystal structures of P-selectin (see Section 2.1.7.), it is thought that allosteric 
alterations of selectins might strengthen the interaction by forcing P-selectin from a bent to 
an extended conformation and altering the binding site in a way that increases binding 
affinity79,80. Indeed, mutational studies which force selectins into the extended conformation 
under static conditions have shown to increase binding affinities81,82. ii) In the sliding-
rebinding model, on the other hand, it is thought that alignment of the binding interface along 
the applied force allows the ligand to slide along the surface and continuously form new 
interactions83. 
2.1.6. Molecular Insights of the E-selectin–sialyl Lewisx Interaction 
The interaction of sLex with E- and P-selectin has been characterized with numerous 
methods. Prior to the elucidation of E- and P-selectin X-ray structures with sLex, the 
hydroxyl groups of L-fucose have been identified as important pharmacophores84,85. 
Furthermore, the 4- and 6-hydroxyl groups of D-galactose have been identified as crucial for 
binding86-88, as well as the carboxylic acid of D-Neu5Ac85. The D-GlcNAc moiety has been 
shown not to directly interact with the protein89-91, which rather acts as spacer for the proper 
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orientation of pharmacophores92. Transferred Nuclear Overhauser Enhancement-NMR 
(tr-NOE-NMR) confirmed all previous studies on the sLex pharmacophores in the protein 
bound conformation28,93-95. Mutational studies on E-selectin revealed the relevant amino acid 
residues. Erbe et al. propose that the residues Ser43, Tyr48, Arg97, Lys111, and Lys113 are 
crucial residues in sLex binding12. 
The crystal structures of E- and P-selectin published in 2000 by Somers et al. confirmed the 
previously made assumptions on sLex pharmacophores and the residues involved in 
binding79. The following main observations for the E-selectin structure soaked with sLex 
(PDB code 1G1T)79 are made (Figure 3-6): 
• The L-fucose moiety coordinates with its 3- and 4-hydroxyl groups to the Ca2+ ion, 
which is also coordinated by residues of the protein. The 2-hydroxyl group of 
L-fucose mediates a water-bridged interaction to the protein. 
• The GlcNAc moiety shows no interaction to the protein. 
• The carboxylate group of Neu5Ac provides a salt bridge to Arg97 and Tyr48. 
• The oxygen between the glycosidic bond of Neu5Ac and D-galactose interacts with 
Arg97 side chain. 
• D-galactose provides hydrogen bonds with its 4- and 6-hydroxyl groups. 
• The binding surface has a large surface area of 275 Å2. 
 
Figure 2-6. Left: sLex in the binding site of E-selectin (PDB code 1G1T)79. The Ca2+ ion is depicted as 
grey sphere. Right: Schematic representation of the E-selectin–sLex interaction as observed in the 
soaked crystal structure. Relevant pharmacophores are marked in blue, while amino acid residues 
are marked in red. 
Chapter 2.1. – Introduction to the Selectins !
 16 
Superimposing the structures of E-selectin or P-selectin (PDB code 1G1Q)79 soaked with 
sLex reveals near identical protein conformation. Furthermore, the bioactive conformation of 
sLex in both structures is identical and is one of two conformations found in solution96-98. 
sLex is therefore a rigid molecule in solution and requires only slight conformational changes 
upon binding, an unusual feature for carbohydrates99. 
2.1.7. Selectin Crystal Structures 
There are six crystal structures of selectins deposited on the protein data base: 
• E-selectin lectin and EGF-like domain in absence of ligand (PDB code 1ESL)15. 
• E-selectin lectin and EGF-like domain soaked with sLex (PDB code 1G1T)79. 
• E-selectin lectin and EGF-like domain soaked with quinic acid100. The coordinates 
have not been deposited on the PDB. However the overall fold has been described to 
match previous E-selectin structures. 
• P-selectin lectin and EGF-like domain in absence of ligand (PDB code 1G1R)79. 
• P-selectin lectin and EGF-like domain soaked with sLex (PDB code 1G1Q)79. 
• P-selectin lectin and EGF-like domain co-crystallized with SGP-3, an sLex bearing 
peptide fragment of PSGL-1 (PDB code 1G1S)79. 
• L-selectin lectin and EGF-like domain in absence of ligand (PDB code 3CFW). 
The overall fold of all selectins in absence of ligand or soaked with sLex are similar and are 
in a bent conformation, with an extensive hydrogen network between the lectin and the 
EGF-like domain (Figure 2-7). However, the structure of P-selectin co-crystallized with SGP-
3 (PDB code 1G1S)79 shows a distinct overall conformation. SGP-3 is a peptide consisting of 
the first 19 N-terminal residues of PSGL-1, together with O-glycosylated Thr16 and three 
sulfated tyrosines (Tys6, Tys8, Tys11). The disruption of interdomain interactions in the 
P-selectin–SGP-3 structure leads to an extended conformation. This has also direct influence 
on the binding site and is thought to be a part of the allosteric mechanism involved in the 
catch-bond behavior of P-selectin. It is conceivable that this induced fit is not observed in 
soaked crystal structures, in which the protein is locked in preformed crystals.  
 
Chapter 2.1. – Introduction to the Selectins 
 17 
 
Figure 2-7. Superposition of available selectin structures. Left: The bent conformation as observed in 
apo- (blue, 1ESL)15 and sLex soaked (cyan, 1G1T)79 E-selectin, apo- (yellow, 1G1Q)79 and sLex 
soaked (orange, 1G1R)79 P-selectin, and apo-L-selectin (red, 3CFW). Right: Comparison of 
apo-P-selectin (yellow) in the bent conformation with P-selectin co-crystallized with SGP-1, a PSGL-1 
fragment (green, 1G1S). The Ca2+ ion is depicted as grey sphere. The ligands are not shown. 
The following main observations between the bent and the extended conformation of 
P-selectin were described by Springer80:  
• Three loops in the lectin domain are altered, while a core part of the lectin domain 
remains unaltered. 
• In the binding site, Asn83 and Asp89 exchange their position. Asp89 thereby replaces 
Asn83 as Ca2+ coordinating residue, and additionally makes a contact to the 
2-hydroxyl position of sLex. 
• Glu107 forms an additional interaction with the 2-hydroxyl group. 
• The movement occurs around a pivot, which is formed by the Trp1 residue. 
• The angle between the lectin domain and the EGF-like domain is opened by ∼30°. 
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2.1.8. Selectin Antagonists 
Two main strategies have been followed in the search for the treatment of selectin-related 
diseases. One approach is the application of biologicals, i.e. therapeutic antibodies or 
recombinant glycoproteins such as GSP-6101 (see Figure 2-8), which are not only specific for 
selectins, but also inhibit their function102-106. The major drawbacks of biologicals are their 
high production expenses and their requirement for intravenous application due to lack of 
oral bioavailability. Therefore, with a better understanding of the selectin–sLex interaction, 
efforts were subsequently focused on small-molecule selectin antagonists107. For several drug 
development programs, sLex served as lead structure. The replacement of non-binding 
portions of sLex by hydrophobic parts lead to CGP69669A108, which was further developed 
to the pan-selectin antagonist GMI-1070109 which is currently in phase 2 clinical trials for 
vascular occlusion in sickle cell disease. Other developments lead to biphenyl substituted 
D-mannose, which yielded the pan-selectin antagonist TBC1269, a compound which is in 
phase 2 clinical trials for psoriasis and asthma110. Finally, non-carbohydrate ligands were 
developed such as the quinoline salicylic acid PSI-697111, a P-selectin antagonists in phase I 
clinical trials. 
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Figure 2-8. Representative list of selectin antagonists in advanced stages of drug discovery and 
development. 
2.1.9. Recent Advances in Glycomimetic Antagonists for E-selectin 
Although several selectin antagonists have entered clinical trials, no small-molecule selectin 
antagonist with high affinity has been identified to date. The IC50/KD values usually range 
between micromolar to millimolar affinity. The low affinity is mainly attributed to the shape 
of the binding site, as observed in the selectin–sLex crystal structures. It is shallow and 
solvent exposed and does therefore not allow for tight binding. Concerning sLex-based 
glycomimetic compounds for E-selectin, rational drug design has been mainly guided by 
NMR studies. Using transferred tr-NOE NMR, the bioactive conformation of sLex was 
identified and has been shown to be crucial for binding affinity of glycomimetics94,95. In the 
example of CGP69669A with an IC50 value of 80 µM112, this bioactive conformation of the 
relevant pharmacophores is not entirely fulfilled in solution. By systematic introduction of 
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substituents, the bioactive conformation was locked in DS04-115, which improved the 
affinity almost seven-fold compared to CGP69669 (Figure 2-9). Another improvement in 
affinity was achieved in GMI-1077, which is one of the most potent E-selectin antagonist 
with a molecular weight below 1000 Da.  
 
Figure 2-9. Recent advances in sLex glycomimetics as E-selectin antagonists. IC50 values are taken 
from Schwizer et al112.
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Sialyl Lewisx: A “Pre-Organized Water Oligomer”?**
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In recent years, lectins, such as selectins,[1] galectins,[2] or
siglecs[3] have received increasing attention as drug targets.
Among them, selectins are the most extensively studied, since
they are key players in the early stages of inflammation and
therefore promising targets for the treatment of diseases with
an inflammatory component, such as stroke, asthma, psoriasis,
or rheumatoid arthritis.[4] The key role of selectins is to
promote the initial step of the inflammatory cascade, by
allowing leukocytes to roll along the vascular endothelial
surface. This step is followed by the integrin-mediated firm
adhesion and the final extravasation to the site of the
inflammatory stimulus.[5]
The specific interaction between E-selectin and its
physiological ligand ESL-1 (E-selectin ligand-1) is mediated
by the tetrasaccharide sialyl Lewisx (sLex, 1).[6] Consequently,
sLex (1) became the lead structure for the search of drug-like,
high-affinity selectin antagonists.[1,7] Elucidation of the struc-
ture activity relationship (SAR),[8] mutation studies,[9] trans-
ferred nuclear overhauser enhancement NMR spectroscopy
(trNOE-NMR),[10] saturation transfer difference NMR spec-
troscopy (STD-NMR),[11] molecular modeling,[12] and finally
X-ray crystallography[13] yielded a precise picture of the
interactions of sLex and E-selectin on an atomic level
(Figure 1). Because docking studies[7] and STD-NMR experi-
ments[11] revealed that the N-acetyl-d-glucosamine
(d-GlcNAc) and N-acetyl-d-neuraminic acid (d-Neu5Ac)
moieties have only weak interactions with the protein,[12]
they were replaced with structurally simplified mimics,
resulting in E-selectin antagonists with significantly improved
binding affinities. However, the affinity of these antagonists,
for example, 2 in Figure 1,[7a] is still only in the lowmicromolar
range.
Despite the progress made, the driving force of the
interaction of E-selectin with its ligands has not been fully
characterized to date, neither for sLex (1), nor for any low
molecular weight selectin antagonist. However, Wild et al.
estimated the enthaplic contribution of the E-selectin/ESL-
1 interaction by van!t Hoff analysis, which involves the
correlation of the binding affinity measured at different
temperatures. The results indicated that enthalpic changes
contribute only 10 to 25% of the binding free energy DG and
that the interaction is primarily driven by favorable entropy
changes.[14]
Recently, the thermodynamic aspects of protein–ligand
interactions have gained increasing interest in drug discov-
ery.[15] Particularly enthalpy and entropy changes provide
valuable information for lead optimization. Having access to
these individual components of binding affinity rather than
the overall value facilitates the successful design of high-
affinity ligands. Herein, we report a comprehensive study on
the thermodynamic fingerprint of a series of E-selectin
antagonists.
Figure 1. Top: Detailed representation of the interactions between sLex
(1) and E-selectin as observed in the crystal structure;[13] the pharma-
cophores of 1 are highlighed in blue. Bottom: The glycomimetic 2
exhibits a 13 mm affinity in a cell-free ligand-based competitive binding
assay.[7a]
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a scaffold to ensure the correct spatial orientation of l-Fuc
and d-Gal in the bioactive conformation, that is, its role is to
pre-organize the Lex core. d-GlcNAc itself has only weak
contacts with the target protein (Figure 2B).[13] A comparable
role is attributed to d-Neu5Ac, which only contributes to
binding through a salt bridge involving its carboxylate
group.[13] Consequently, mimics of d-GlcNAc and d-Neu5Ac
were designed to stabilize the bioactive conformation and to
keep the entropic costs for binding low or virtually the same
as for the highly pre-organized sLex (1). With (R,R)-cyclo-
hexane-1,2-diol (1!3) which was demonstrated to be a mod-
erate mimic of d-GlcNAc,[7a] substantial entropy costs arose
(!TDDS : 3.5 kJmol!1, Figure 3). When d-Neu5Ac in 3 was
replaced by (S)-cyclohexyl lactic acid (3!6, !TDDS :
0.6 kJmol!1), only a small entropy penalty emerged. Finally,
(1R,2R,3S)-3-methylcyclohexane-1,2-diol (6!2) proved to be
an optimal replacement of d-GlcNAc (Figure 3),[7a] resulting
in an entropy term similar to that of sLex (1; Table 1).
Compared to antagonist 6, the improved pre-organization of
the core conformation in 2 led to a substantial reduction of
the entropy costs (!TDDS : !2.4 kJmol!1). Because the
investigated mimics are significantly less polar than d-
GlcNAc and d-Neu5Ac, an additional effect needs to be
taken into account, namely a substantial alteration of the
solvation properties. Although only partial desolvation is
necessary, the desolvation of the carbocyclic mimics is
enthalpically less unfavorable compared to that of the more
polar d-GlcNAc or d-Neu5Ac moieties.[31]
Strikingly, the introduction of (R,R)-cyclohexane-1,2-diol
(1!3) has the same relative effect on enthalpy and entropy as
the exchange of d-Neu5Ac for (S)-cyclohexyllactic acid (1!
5), which is reflected in the same slope in the entropy–
enthalpy plot in Figure 4. In both cases, a significant gain in
enthalpy is partially compensated by a loss in entropy.
Furthermore, when both mimics are combined in one
molecule (!6), the effect is not additive, that is, less entropy
is lost but also less enthalpy is gained than expected (6 vs
6expected, Figure 4). Clearly, the exchange of the carbohydrate
moieties does not only change local conformational and
solvation properties, but rather the properties of the entire
ligand.
In summary, thermodynamic binding parameters for the
interaction of E-selectin with sLex (1) and the glycomimetics
2–6 were investigated by ITC. The interaction of sLex with E-
selectin is driven by a large favorable entropy term which is
partially compensated by an unfavorable enthalpy contribu-
tion. The exchange of residues acting as scaffolds with less
Figure 2. sLex (1) bound to E-selectin as observed in the crystal
structure (protein data bank (PDB) code: 1G1T).[13a] A) top view: the
binding epitope on E-selectin is dominated by polar residues [polar
residues in red (positively charged) and blue (negatively charged),
nonpolar in white]. The contact area is 275 !2. B) side view: Only
a small part of sLex directly contributes to binding (graphics generated
by Maestro[32]).
Figure 3. Thermodynamic signature (DG, DH, !TDS) of sLex (1) (the
corresponding data for the antagonists 2–6 are summarized in
Table 1) and the changes of the thermodynamic parameters (DDG,
DDH, and !TDDS) when d-GlcNAc in 1 is replaced by (R,R)-
cyclohexane-1,2-diol (1!3), d-Neu5Ac in antagonist 3 by (S)-cyclohexyl
lactic acid (3!6), and (R,R)-cyclohexane-1,2-diol in antagonist 6 by
(1R,2R,3S)-3-methylcyclohexane-1,2-diol (6!2).
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polar mimics, that is, d-Neu5Ac for (S)-cyclohexyllactic acid
and d-GlcNAc for (R,R)-cyclohexane-1,2-diol, resulted in
improved binding enthalpy, however accompanied by a loss of
binding entropy. Only for mimetic structures that maintain
the pre-organization of sLex (1) in its bioactive conformation,
as it is the case for the replacement of d-GlcNAc by
(1R,2R,3S)-3-methylcyclohexane-1,2-diol (1!4 or 5!2),
a similar entropy term was found. Overall, the almost 50-
fold improved affinity of 2 compared to 1 results from a gain
in binding enthalpy, whereas the binding entropy is not
significantly changed.
The development of glycomimetics with improved bind-
ing properties is intrinsically difficult because of the similarity
of the ligand (carbohydrate) and the solvent (water). The
results of this thermodynamic study suggest, that for a suc-
cessful development of glycomimetics, carbohydrate moieties
with predominantly structural tasks and no or only weak
contacts with the target protein should be replaced by
hydrophobic mimics, resulting in reduced desolvation penal-
ties and therefore improved enthalpic contributions to bind-
ing. In addition, the mimetic replacement should contribute
to an improved pre-organization of the binding conformation
to optimize the entropy term as well. When the carbohydrate
ligand is already almost optimally pre-organized in solution,
as it is the case for sLex (1), the identification of such mimics is
a most challenging task.[7a]
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The binding free energy (DG) associated with a protein–
ligand interaction is composed of enthalpic (DH) and entropic
(!TDS) contributions (DG=DH!TDS). The binding energy
under standard conditions (DG8), where all reactants and
products are at a concentration of 1 molL!1, is calculated
from the dissociation constant KD using the equation DG=
RT lnKD. With isothermal titration calorimetry (ITC),[16] KD
and the enthalpy DH are measured directly if no changes in
the protonation states occur during the interaction. The
enthalpic term (DH) represents the contribution of non-
covalent interactions upon binding,[15b] that is, hydrogen
bonds, electrostatic, and dipole–dipole interactions between
ligand and receptor.[17] The entropy term can be dissected into
translational and rigid-body rotational entropy,[18] solvation
entropy,[19] and conformational entropy.[20]
For our study, an E-selectin/IgG construct consisting of
the lectin domain, the EGF-like domain, and six short
consensus repeats fused to the Fc part of human IgG1 was
used.[21] The 148 kDa protein was expressed in Chinese
Hamster Ovarian cells and purified from the conditioned
culture medium by affinity chromatography, first with protein
A-Sepharose, followed by a second functional purification
with the monoclonal anti-hE-selectin antibody 7A9 (see the
Supporting Information). The high degree of purity and
functionality of the protein is reflected by the stoichiometry
(N) of the calorimetric experiments (Table 1). Batches of up
to 50 mg E-selectin/IgG were necessary for ITCmeasurement
to reach c values close to 1.
Our calorimetric investigation had two goals: first, the
determination of KD values of a series of E-selectin ligands
and their comparison with data collected by a competitive
binding assay (Table 1)[22] and second, the elucidation of the
thermodynamic fingerprints of these ligands. The KD value
for sLex (1) binding to E-selectin determined by ITC is (878"
93) mm and is thereby in good agreement with previously
reported data (e.g. 1.1 to 2.0 mm,[23] (0.7" 0.4) mm[10b]). In
addition, the relative KD values (rKD) for the antagonists 2 to
6 also nicely correlate with their relative IC50 values (rIC50). In
analogy to earlier findings,[7a] replacement of d-GlcNAc with
carbocyclic mimics enhanced binding affinity up to 25-fold
(1!4), whereas the replacement of d-Neu5Ac by (S)-cyclo-
hexyllactic acid improved binding 2- to 5-fold (1!5 ; 3!6 ;
4!2).
Except for some isolated cases,[14,27] lectin–oligosaccharide
interactions are typically enthalpy driven with mostly unfav-
orable entropies.[28] In contrast, the binding of sLex to E-
selectin is driven by a large entropy term (!TDS=
!23 kJmol!1). Clearly, the entropy costs caused by the loss
of translational and rotational degrees of freedom and
conformational changes of ligand and protein upon binding
are overcompensated by the beneficial entropy arising from
the release of bound water molecules.[29] This argumentation
is supported by two experimental observations. First, the
bound conformation was identified as one of two low-energy
solution conformations of sLex,[30] demanding only minor
conformational adjustments upon binding. Second, the com-
parison of the crystal structure of apo-E-selectin and E-
selectin bound to sLex revealed only minor conformational
differences.[13]
The beneficial entropy term, however, is partially com-
pensated by an unfavorable change in enthalpy. To enable the
pharmacophoric groups of sLex (1) to interact with their
target, a predominantly polar surface area of approximately
275 !2[13a] on both interacting moieties has to be desolvated.
Because the newly formed polar interactions between the
pharmacophores of sLex and E-selectin do not fully compen-
sate for the desolvation penalty of
the polar binding interface
(Figure 2),[31] a net loss of enthalpy
(DH8=+ 5.4 kJmol!1) is observed.
Thus, the directed polar interactions
of the pharmacophores contribute
to specificity rather than affinity.
Thus, sLex (1) represents a sur-
rogate of clustered water molecules
attached to a scaffold. As a “pre-
organized water oligomer” it offers
an array of directed hydrogen
bonds for the highly specific binding
to E-selectin. The clear entropic
benefit of the release of water
molecules from the large binding
interface to bulk water and the high
degree of pre-organization of sLex
result in the observed large entropy
gain which provides the impetus for
the binding process.
The concept of conformational
pre-organization was also exploited
for the development of selectin
antagonists (Figure 3). More pre-
cisely, in sLex (1), d-GlcNAc acts as
Table 1: Affinity and thermodynamic parameters for the interaction of 1–6 with E-selectin.[a]
Ligand rIC50 rKD KD [mm] DG
[kJmol!1]
DH
[kJmol!1]
!TDS
[kJmol!1]
N
1 1 1 878"93 !17.5"0.2 +5.4"0.7 !23"1 1
3 0.3 0.36 317 !20.0 !0.5 !19.5 1
4 0.05 0.04 38 !25.3 +0.9 !26.2 0.94
5 0.27 0.30 260 !20.5 !2.2 !18.3 1
6 0.08 0.07 59"4 !24.2"0.2 !5.3"0.4 !18.9"0.6 0.93"0.08
2 0.014 0.02 19"2 !27.1"0.2 !5.8"0.1 !21.3"0.4 0.97"0.01
[a] Relative IC50 values (rIC50) and relative KD values (rKD) are reported relative to the reference
compound sLex (1). IC50 values were determined in a competitive binding assay.
[22] KD and DH were
measured in ITC experiments, DG, and TDS were calculated according the equations DG=DH!TDS
and DG=RT lnKD. N= stoichiometric ratio of ligand and protein.
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1. Synthesis of ligand 4 
General Information 
NMR spectra were recorded on a Bruker Avance DMX-500 (500 MHz) spectrometer. 
Assignment of 1H and 13C NMR spectra was achieved using 2D methods (COSY, HSQC, 
HMQC, HMBC). Chemical shifts are given in ppm and were assigned in relation to the 
solvent signals on the d-scale[S1] or to tetramethylsilane (0 ppm) as internal standard. 
Coupling constants J are given in Hertz (Hz). Multiplicities were specified as follows: s 
(singlet), d (doublet), dd (doublet of a doublet), t (triplet), q (quartet), m (multiplet). For 
assignment of resonance signals to the appropriate nuclei the following abbreviations were 
used: Fuc (fucose), Gal (galactose), MeCy (3-methylcyclohexane-1,2-diol), Sia (sialic acid). 
Reactions were monitored by TLC using glass plates coated with silica gel 60 F254 (Merck) 
and visualized by using UV light and/or by charring with a molybdate solution (a 0.02 M 
solution of ammonium cerium sulfate dihydrate and ammonium molybdate tetrahydrate in 
aqueous 10% H2SO4. Column chromatography was performed using the RediSep Companion 
from Teledyne Isco with normal phase RediSep columns from the same manufacturer or 
reversed-phase columns containing LiChroprep RP-18 (40-63 µm) from Merck KGaA, 
Darmstadt, Germany. Size exclusion chromatography was performed with Bio-Gel® P-2 Gel 
(45-90 mm) from Bio-Rad. Solvents were purchased from Sigma-Aldrich. Dichloromethane 
(CH2Cl2) was dried by filtration over Al2O3 (Fluka, type 5016 A basic). Optical rotations 
were measured using a Perkin-Elmer Polarimeter 341. Electron spray ionization mass spectra 
(ESI-MS) were obtained on a Waters micromass ZQ. HRMS analysis were carried out using 
a Agilent 1100 LC equipped with a photodiode array detector and a Micromass QTOF I 
equipped with a 4 GHz digital-time converter. Microanalysis was performed at the Institute 
of Organic Chemistry at the University of Basel, Switzerland. Purity of final compounds was 
determined on an Agilent 1100 HPLC; detector: ELS, Waters 2420; column: Waters Atlantis 
dC18, 3 µm, 4.6 x 75 mm; eluents: A: water + 0.1% TFA; B: 90% acetonitrile + 10% water + 
0.1% TFA; linear gradient: 0 - 1 min 5% B; 1 - 20 min 5 to 70% B; flow: 0.5 mL/min. 
 
 
Chapter 2.2. – Publication 1 
 
 38 
 3 
HO
O
O
OBn
BnO
OBn
S2
+ a)
O
AcO
BzO
OAc
O
CO2Bn
OAc
AcHN
AcO
OAc
OAc
O
O
BnO
OBn
OBn
O
O
S3
b) c)
O
HO
HO
OH
O
CO2Na
OH
AcHN
HO
OH
OH
O
O
HO
OH
OH
O
O
4
O
AcO
BzO
OAc
O
CO2Bn
OAc
AcHN
AcO
OAc
OAc
O SEt
S1
 
Scheme a) DMTST, CH2Cl2, MS 4 Å, RT, 3 d, 55%; b) H2, Pd(OH)2/C, dioxane, H2O, RT, 12 h; c) 
aq. NaOH, MeOH, RT, 81% from S3. 
Donor S1[S2] was coupled to pseudodisaccharide S2[S3] using dimethyl(methylthio)sulfonium 
triflate (DMTST)[S4] as promotor (Scheme). Hydrogenolytic debenzylation followed by 
saponification with sodium hydroxide afforded 4.  
 
(Benzyl 5-acetamido-4,7,8,9-tetra-O-acetyl-3,5-dideoxy-D-glycero-〈-D-galacto-2- 
nonulopyranosynate)-(2? 3)-2,4-di-O-acetyl-6-O-benzoyl--D-galactopyranosyl-(1? 1)-
[2,3,4-tri-O-benzyl-α-L-fucopyranosyl-(1? 2)]-(1R,2R,3S)-3-methyl-cyclohexane-1,2-diol 
(S3). 
Compound S1 (300 mg, 0.31 mmol) and S2 (256 mg, 0.47 mmol) were dissolved in 
anhydrous CH2Cl2 (6.0 mL). Powdered activated molecular sieves 4 Å (0.6 g) were added 
and the mixture was stirred at RT under argon. After 3.5 h, a solution of DMTST (246 mg, 
0.95 mmol) in anhydrous CH2Cl2 (1.9 mL) that had been stirred with molecular sieves 4 Å 
(0.19 g) for 3.5 h, was added. After stirring for 3 d, the solution was diluted with CH2Cl2 (40 
mL), filtered, and successively washed with satd. aq. NaHCO3 (50 mL) and brine (50 mL). 
The aqueous layers were extracted with CH2Cl2 (2 · 50 mL) and the combined organic layers 
were dried over Na2SO4 and concentrated under reduced pressure. Column chromatography 
on silica (PE/EtOAc/MeOH 8/5/0.5 to 8/5/0.7) afforded S3 as white foam (248 mg, 0.17 
mmol, 55%). 
[α]D20 -18.9° (c 1.01, CHCl3); 1H NMR (500.1 MHz, CDCl3): δ 8.04-7.14 (m, 25H, Ar-H), 
5.48 (ddd, 3J = 2.6, 6.2, 9.1Hz, 1H, Sia-H8), 5.21 (A of AB, 2J = 12.0Hz, 1H, PhCH2), 5.20 
(dd, 3J = 2.8, 9.4Hz, 1H, Sia-H7), 5.01 (d, 3J = 3.7Hz, 2H, Fuc-H1, Gal-H4), 4.90 (A’ of 
A’B’, J = 12.0Hz, 1H, PhCH2), 4.88-4.64 (m, 10H, Fuc-H5, Gal-H2, SiaNH, Sia-H4, 3 
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 4 
PhCH2), 4.56 (d, 3J = 8.0Hz, 1H, Gal-H1), 4.48 (dd, 3J = 3.3, 10.2Hz, 1H, Gal-H3), 4.25 (dd, 
3J = 2.6Hz, 2J = 12.4Hz, 1H, Sia-H9a), 4.17 (dd, 3J = 6.4Hz, 2J = 10.8Hz, 1H, Gal-H6a), 
4.05 (dd, 3J = 3.7, 10.3Hz, 2H, Fuc-H2), 4.02-3.93 (m, 3H, Fuc-H3, Gal-H6b, Sia-H5), 3.90-
3.83 (m, 2H, Gal-H5, Sia-H9b), 3.59 (m, 1H, Fuc-H4), 3.50 (m, 1H, MeCy-H1), 3.37 (dd, 
1H, 3J = 2.7, 10.8Hz, Sia-H6), 3.18 (t, 3J = 9.2Hz, MeCy-H2), 2.50 (dd, 3J = 4.6Hz, 2J 
=12.7Hz, 1H, Sia-H3eq), 2.09, 2.05 (2s, 6H, 2 COCH3), 1.99 (m,1H, MeCy), 1.99, 1.94, 1.90, 
1.74, 1.72 (5s, 15H, 5 COCH3), 1.65-1.47 (m, 4H, Sia-H3ax, MeCy) 1.21-1.11 (m, 5H, Fuc-
H6, MeCy), 1.03 (d, 3J = 6.4Hz, 3H, MeCy-CH3), 0.98 (m, 1H, MeCy); 13C NMR (125.8 
MHz, CDCl3): δ 170.8, 170.7, 170.6, 170.4, 169.9, 169.5 (7C, COCH3), 167.5 (Sia-C1), 
165.8 (ArCO), 139.3, 139.1, 138.7, 134.9, 133.3, 128.9, 128.7, 128.6, 128.5, 128.4, 128.3, 
127.6, 127.4, 127.3 (30C, Ar-C), 99.4 (Gal-C1), 98.3 (Fuc-C1), 96.9 (Sia-C2), 82.2 (MeCy-
C2), 80.6, 80.5 (Fuc-C3, MeCy-C1), 77.8 (Fuc-C4), 76.7 (Fuc-C2), 74.6, 74.3, 72.7 (3C, 
PhCH2), 72.0, 71.9 (Gal-C3, Sia-C6), 70.0, 69.8 (Gal-C2, Gal-C5), 69.4 (Sia-C4), 68.4 
(PhCH2), 67.8 (2C, Gal-C4, Sia-C8), 67.1 (Sia C7), 66.3 (Fuc-C5), 62.8 (Sia-C9), 61.5 (Gal-
C6), 49.0 (Sia-C5), 39.2 (MeCy-C3) 37.5 (Sia-C3), 33.6 (MeCy-C4), 30.9 (MeCy-C6), 23.3 
(CH3CO), 23.1 (MeCy-C5), 21.5, 21.0, 20.9, 20.8 (6C, COCH3), 18.9 (MeCy-CH3), 17.1 
(Fuc-C6); MS (ESI) m/z: calcd. for C77H91NNaO26 [M+Na]+: 1468.6; found: 1468.6; 
elemental analysis calcd (%) for C77H91NO26 + 0.5 H2O (1455.55): C 63.54, H 6.37, N 0.96; 
found: C 63.58, H 6.35, N 0.80. 
(Sodium 5-acetamido-3,5-dideoxy-D-glycero-〈-D-galacto-2-nonulopyranosynate)- 
(2? 3)--D-galactopyranosyl-(1? 1)-[α-L-fucopyranosyl-(1? 2)]-(1R,2R,3S)-3-methyl-
cyclohexane-1,2-diol (4). 
Compound S3 (310 mg, 0.21 mmol) was dissolved in dioxane/water (4/1, 10 mL) under 
argon. Pd(OH)2/C (40 mg, 10% Pd(OH)2) was added and the resulting mixture was 
hydrogenated (4 bar H2) at RT. After 24 h, the mixture was filtered and the solvent removed 
under reduced pressure yielding 220 mg of a white solid, which was directly used for 
saponification. The crude product (75 mg) was stirred in aqueous NaOH (1 N, 1.5 mL) for 24 
h at RT, lyophilized, and purified via SEC and RP chromatography (H2O/MeOH). 
Lyophilization from water afforded 4 as white fluffy solid (42 mg, 0.056 mmol, 81%). 
[α]D20 -47.4° (c 0.89, MeOH); 1H NMR (500.1 MHz, D2O): δ 5.07 (d, 3J = 3.6Hz, 1H, Fuc-
H1), 5.05-4.71 (m, Fuc-H5), 4.53 (d, 3J = 7.8Hz, 1H, Gal-H1), 4.05 (dd, 3J = 2.4, 9.6Hz, 1H, 
Gal-H3), 3.92 (m, Gal-H4), 3.90-3.50 (m, 15H, Fuc-H2, Fuc-H3, Fuc-H4, Gal-H2, Gal-H5, 
Gal-H6a, Gal-H6b, MeCy-H1, Sia-H4, Sia-H5, Sia-H6, Sia-H7, Sia-H8, Sia-H9a, Sia-H9b), 
3.20 (t, 3J = 9.6Hz, 1H, MeCy-H2), 2.73 (dd, 3J = 4.4Hz, 2J = 12.1Hz, 1H, Sia-H3eq), 2.13 
Chapter 2.2. – Publication 1 
 
 40 
 5 
(m, 1H, MeCy-H6a), 2.00 (s, 3H, COCH3), 1.78 (t, 3J =2J = 12.1Hz, 1H, Sia-H3ax) 1.69-1.52 
(m, 3H, MeCy-H3, MeCy-H4a, MeCy-H5a), 1.33-1.17 (m, 2H, MeCy-H5b, MeCy-H6b), 
1.15 (d, 3J = 6.4Hz, 1H, Fuc-H6), 1.11-0.99 (m, 4H, MeCy-CH3, MeCy-H4b); 13C NMR 
(125.8 MHz, D2O, CD3ODref): δ 176.0 (COCH3), 175.0 (Sia-C1), 100.8 (Sia-C2), 100.5 (Gal-
C1), 99.8 (Fuc-C1), 85.0 (MeCy-C2), 79.4 (MeCy-C1), 76.9 (Gal-C3), 75.5 (Gal-C5), 73.8 
(Sia-C6), 73.0 (Fuc-C4), 72.7 (Sia-C8), 70.2 (Fuc-C3), 69.9 (Gal-C2), 69.4, 69.2, 69.1 (3C, 
Fuc-C2, Sia-C4, Sia-C7), 68.5 (Gal-C4), 67.5 (Fuc-C5), 63.6 (Sia-C9), 62.6 (Gal-C6), 52.7 
(Sia-C5), 40.6 (Sia-C3), 39.8 (MeCy-C3), 34.2 (MeCy-C4), 31.1 (MeCy-C6), 23.6 (MeCy-
C5), 23.0 (COCH3), 19.2 (MeCy-CH3), 16.4 (Fuc-C6); HR-MS (ESI) m/z: calcd for 
C30H50NNa2O19 [M+Na]+: 774.2767; found: 774.2768; HPLC-purity ≥ 99.5 %. 
2. Materials and methods 
Ham’sF-12 medium, RPMI 1640 medium, geneticin (G418) sulfate, αDMEM-medium, 
peroxidase ABTS (2,2’-azino-bis[3-ethylbenzthiazoline-6-sulfonic acid]) single solution, and 
FCS (fetal calf serum) were all purchased from Invitrogen (Paisley, UK). Sodium pyruvate, 
penicillin/streptomycin, HEPES, NaOH, CaCl2 x 2 H2O, Tween 20, amonium acetate, acetic 
acid, and cyanogen bromide-activated-Sepharose® 4B were purchased from Sigma-Aldrich 
Chemie GmbH (Steinheim, Germany). NaCl and HCl were purchased form Merck KGsA 
(Darmstadt, Germany). Tris was purchased from AppliChem GmbH (Darmstadt, Germany). 
Protein A-Sepharose® was purchased from BioVision (Mountain View, CA), sLea-PAA-
biotin was purchased from GlycoTech Corporation (Gaithersburg). The streptavidin 
peroxidase conjugate was purchased from Roche Diagnostic (Rotkreuz, Switzerland). The 
BioLogic Duo Flow fast protein liquid chromatography (FPLC) system and the UNOTM Q 
ion exchange column were purchased from BioRad (Reinach. Switzerland). The Vivaspin® 
20 centrifugal concentration tubes were purchased from Sartorius-Stedim (Göttingen, 
Germany). The SpectraMax 190 microplate reader was obtained from Molecular Devices 
(Sunnyvale, CA, USA). The VP-ITC apparatus was purchased from MicroCal Inc. (Uppsala, 
Sweden). Slide-A-Lyzer cassettes were obtained from Thermo Fisher Scientific (Rockford, 
IL, USA) 
3. Generation of the 7A9 antibody column 
For the purification of E-selectin/IgG, an affinity column with the functional monoclonal 
anti-hE-selectin antibody 7A9 was prepared. Mouse hybridoma cells expressing the 7A9 
antibody (ATCC No. HB-10135TM) were cultivated in suspension at 37 °C and 5% CO2 with 
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RPMI 1640 culture medium supplemented with 10-15% FCS, 100 U/mL penicillin, and 100 
µg/mL streptomycin. The cells were maintained at 105-106 cells/mL at all times. Culture 
medium was harvested once or twice weekly by centrifugation at 1000 rpm and 4 °C for 10 
minutes. The 7A9 antibody was purified using fast protein liquid chromatography, first on a 
Protein A-sepharose® column with the buffers A (50 mM Tris, 150 mM NaCl, pH 7.4, 0.05% 
Tween 20) for loading, B (5 mM ammonium acetate, pH 5) for washing, C (500 mM acetate, 
pH 3.0) for elution, and D (2 M Tris) for neutralizing. Higher purity was achieved by 
subsequent anion exchange chromatography on a UnoTM Q column with buffers E (20 mM 
Tris, pH 8.0) and F (20 mM Tris, 1 M NaCl, pH 8.0). Approximately 5 mg of purified 
antibody was coupled to 1 mL of swollen cyanogen bromide-activated-Sepharose® 4B 
according to the manufacturer’s protocol. 
4. E-selectin/IgG expression and purification 
CHO-K1 cells expressing the E-selectin/IgG construct, which includes the lectin domain, the 
EGF-like domain, and six complement repeat domains of human E-selectin fused to the Fc 
part of human IgG1 were generated as previously described.[S5] The cells were cultivated as 
monolayers at 37 °C, 5% CO2, in F-12 culture medium supplemented with 10 mM sodium 
pyruvate, 10% FCS, 100 U/mL penicillin, 100 µg/mL streptomycin, and 0.4 mg/mL geneticin 
(G418) sulfate. For the expression, the cells were adapted to 5% FCS and αDMEM-medium 
with the same additives as for the F-12 culture medium. Conditioned culture medium was 
harvested once a week and stored at -20 °C. 
E-selectin/IgG was purified from the conditioned culture medium by affinity 
chromatography, first with protein A-Sepharose®, followed by a second purification with the 
7A9-Sepharose® column. In both cases, buffers A, B, C, and D were used (see above). 
Purified E-selectin/IgG was concentrated by ultrafiltration (1610 x g, Vivaspin 20, 50 kDa 
cut off) and dialysed over night against assay buffer (10 mM HEPES, 150 mM NaCl, 1 mM 
CaCl2, pH 7.4) using Slide-A-Lyzer dialysis cassettes (cut off 10 kDa). The protein purity 
was confirmed by standard SDS-PAGE analysis and the concentration was determined by 
HPLC-UV against a BSA standard.[S6].  
The binding activity was verified with a carbohydrate polymer-binding assay for the EC50 
determination, similar to the protocols described in Ref[S7] Peroxidase coupled sLea-polymer 
was prepared as follows: 20 µL biotinylated sLea (sLea-PAA-biotin, 1 mg/mL), 80 µL 
streptavidin peroxidase conjugate (500 U/mL), 20 µL FCS, and 80 µL assay buffer were 
combined and incubated for 2 h at 37 °C. The complex is stable for several weeks at 4 °C. 
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Nunc MaxiSorpTM 96 well plates were coated with E-selectin/IgG (1 µg/ml, 100 µL/well) 
over night at 4 °C and were subsequently blocked with BSA (3% w/v in assay buffer, 200 
µL/well) for 2 h at 4 °C, followed by incubation for 3 h at room temperature with a serial 
dilution of peroxidase coupled sLea-polymer. The excess of sLea-polymer was washed, ABTS 
solution (100 µL/well) was added, and the colorimetric reaction was stopped after 10 min 
with 100 µL/well oxalic acid (2% w/v). The OD was measured at 415 nm with a microplate 
reader . 
5. Competitive binding assay  
The competitive binding assay was adapted from Ref[S7] Most steps were performed 
according to the EC50 determination (see above). In the incubation step, a constant 
concentration of sLea-polymer (100 ng/mL, 50 µL/well), and a serial dilution of antagonist 
(50 µL/well) was applied. 
6. Isothermal titration calorimetry 
ITC experiments were performed with a VP-ITC instrument. Protein samples were dialyzed 
over night against assay buffer using Slide-A-Lyzer dialysis cassettes (10 kDa cut-off). 
Protein and ligand samples were degassed with vacuum prior to the assays. All measurements 
were performed at 25 °C. Injections of 5 to 15 µL ligand solutions (1.4 - 12 mM) were added 
from a computer controlled 300 µl microsyringe at an interval of 5 min into the sample cell 
solution containing E-selectin/IgG (45 to 200 µM, sample cell volume 1.4037 mL or 1.4523 
mL) with stirring at 307 rpm. The quantity c = Mt(0) KD-1, where Mt(0) is the initial 
macromolecule concentration, is of importance in titration microcalorimetry and should be 
between 1 and 1000.[S8] The c-values for compound 2, 4, and 6 were between 1 and 5. The 
experiments with methyl sLex (1), 3, and 5 were performed with c values below 1. In these 
cases, the stoichiometry N was fixed to 1 to allow for reliable determination of the 
dissociation constant KD and the change in enthalpy ?H.[S9] Control experiments, i.e. ligand 
injection into buffer (10 mM HEPES, 150 mM NaCl, 1 mM CaCl2, pH 7.4) in absence of 
protein, showed that the heats of dilution were small and constant. The first injection was 
always excluded from data analysis as it usually suffers from sample loss during the 
mounting of the syringe and the equilibration preceding the actual titration. Raw data was 
collected and the area under each peak was integrated, followed by correction for heats of 
dilution and mixing by subtracting the final baseline consisting of small peaks of the same 
size to zero. The data were analyzed with ORIGIN Software (Microcal Inc.) by three-
parameter data fitting of a single-site binding isotherm, which yields ?H (enthalpy of 
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binding), KD (dissociation constant) and N (stoichiometry) for compounds 2, 4 and 6. A two-
parameter data fitting of a single-site binding isotherm was used for methyl sLex (1), 
compound 3 and 5, which yields ?H and KD.  
Thermodynamic parameters were calculated from equation S1. 
∆G = ∆H - T∆S = RTlnKD  (S1) 
where ?G, ?H, and ? S are the changes in free energy, enthalpy, and entropy, respectively. T 
is the absolute temperature, and R is the gas constant (8.314 J/molK). 
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7. Graphics 
The graphical abstract and Figure 2 are based on the crystal structure of sLex in complex with 
E-selectin (pdb-code 1G1T)[S10] and illustrated with the software Maestro version 9.1, 
Schrödinger, LLC, New York, NY, 2010. 
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9. Experimental data 
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E-Select in L igand Complexes Adopt an Extended High-
Aff inity  Conformation 
Roland C. Preston,† Roman P. Jakob,‡ Florian P. C. Binder, † Christoph P. Sager,† Beat Ernst,*, † and Timm 
Maier*,‡ 
†Institute of Molecular Pharmacy, University of Basel, Klingelbergstrasse 50, 4056 Basel (Switzerland) 
‡ Biozentrum, University of Basel, Klingelbergstrasse 50/70, 4056 Basel (Switzerland) 
ABSTRACT: E-selectin is a cell-adhesion molecule of the vascular endothelium that promotes essential leukocyte rolling in the early in-
flammatory response by binding to glycoproteins containing the tetrasaccharide sialyl Lewisx (sLex). Efficient leukocyte recruitment under 
vascular flow conditions depends on an increased lifetime of E-selectin/ligand complexes under tensile force in a so-called catch-bond bind-
ing mode. Co-crystal structures of a representative fragment of the extracellular E-selectin region with sLex and a glycomimetic antagonist 
thereof reveal an extended E-selectin conformation, which is identified as a high-affinity binding state of E-selectin by molecular dynamics 
simulations. Small-angle X-ray scattering experiments demonstrate a direct link between ligand binding and E-selectin conformational transi-
tion under static conditions in solution. This permits tracing a series of concerted structural changes connecting ligand binding to conforma-
tional stretching as the structural basis of E-selectin catch-bond mediated leukocyte recruitment. The detailed molecular view of the binding 
site paves the way for the design of a new generation of selectin antagonists. This is of special interest, since their therapeutic potential was 
recently demonstrated with the pan-selectin antagonists GMI-1070 (Rivipansel).  
INTRODUCTION 
E-, P- and L-selectin are a family of Ca2+-dependent C-type lec-
tins mediating cell-cell adhesion in the vascular system with a piv-
otal role in inflammation.1 They are expressed on the vascular 
endothelium (E-, P-selectin), platelets (P-selectin) or leukocytes 
(L-selectin) and bind to cell-surface glycoproteins e.g. P-selectin 
glycoprotein ligand-1 (PSGL-1) or E-selectin ligand-1 (ESL-1) 
presenting the minimal tetrasaccharide binding motif sialyl Lewisx 
(sLex, Figure 1a).2-4 Selectins exhibit catch-bond behavior: The 
lifetime of complexes of selectins with their ligands increases under 
tensile force-conditions5 as demonstrated first by atomic force 
microscopy and flow chamber assays for P-selectin,6,7 later also for 
L-selectin8-11 and most recently for E-selectin.12,13 For E- and 
P-selectin the catch-bond binding mode is required under flow 
conditions for efficient leukocyte tethering and rolling along the 
vascular endothelium, a prerequisite for subsequent firm adhesion 
and transmigration to sites of inflammation.14 Due to their essential 
role in leukocyte recruitment, selectins are an attractive target for 
therapeutic intervention against diseases involving excessive in-
flammatory response as found in numerous cardiovascular and 
autoimmune diseases.15 A first demonstration of the therapeutic 
potential of selectin inhibition was very recently achieved by suc-
cessful completion of phase-II clinical trials of the pan-selectin 
antagonists GMI-1070 (Rivipansel) for the treatment of the vaso-
occlusive crisis in sickle-cell disease.16,17 The success of GMI-1070 
now paves the way for the development of selectin-type specific 
antagonists for further indications. 
 
Figure  1 .  E-selectin ligands and selectin domain arrangement. (a) 
Chemical structures of sialyl Lewisx (sLex) and glycomimetic 1 .18 (b) 
Comparison of human L-, E- and P-selectin. The representative E-
selectin fragment used in this publication (E-selectin*) is boxed and 
domains are colored red, orange (SCR domains), magenta (EGF) and 
green (lectin) as in following figures. 
The selectins share a conserved domain architecture (Figure 1b) 
with an N-terminal lectin domain (Lec), which contains the carbo-
hydrate-binding site, an epidermal growth factor-like domain 
(EGF), variable numbers of short consensus repeat (SCR) do-
mains, a single-span transmembrane region, and a C-terminal 
cytoplasmic domain. Isolated Lec-EGF domain fragments are 
sufficient for ligand binding,19 however, as demonstrated in cell-
based assays, their affinity improves with an increasing number of 
attached SCR domains.20 Several models have been established to 
link the catch-bond phenomenon to the structure of selectins and 
their ligands. In the sliding-rebinding model, the alignment of the 
binding interface to the tensile force allows the ligand to slide along 
the protein surface and continuously form new interactions.9,21 
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of selectin Lec-EGF domains, align in both ligand complexes in a 
linear fashion with the EGF domain (Figure 2b). Since E-
selectin*/1 crystals diffract to higher resolution, the discussion 
focuses on this complex.  
 
Figure  2 .  E-selectin short consensus repeat domains are linear rigidi-
fied domains. (a) Structure of E-selectin with the N-terminal Lec, the 
EGF-like- and the first two SCR domains. The glycomimetic 1  coordi-
nates the Ca2+ ion (magenta) in the carbohydrate recognition site. 
Seven N-linked GlcNAc moieties are located at interdomain interfaces. 
(b) The SCR domains are aligned, with a 90° rotation of SCR2 relative 
to SCR1. Three disulfide bonds stabilize each SCR domain. Conserved 
tryptophans (Trp209/271) are wedged between the upper and central 
disulfide bond. SCR domain flexibility is limited by hydrogen bonds 
between Gly147 and Val157 or Gly192 and Val219. 
Rigidif ied short  consensus  repeats  at  the  basis  of  the  
se lect in  extracel lular  dom ain. In selectins, between two and 
nine SCR-domains provide the coupling of the Lec-EGF didomain 
to the cell surface. E-selectin comprises six SCR domains, two of 
which are included in E-selectin*. The sequence conservation of 
selectin SCR domains is low (Figure S3), however, they all consist 
of a 60 amino acid compact β-sheet fold (Figure 2b) and contain six 
conserved cysteines, two more than most other SCR domains 
(Table S5 and references therein). These cysteines form three 
intra-domain disulfide bonds, two common ones at each end of the 
domain, and an additional disulfide bond in the center. A con-
served tryptophan (SCR1: Trp209, SCR2: Trp271) is interlocked 
between the N-terminal and the central disulfide bond (Figure 2b) 
resulting in the formation of a tightly packed rigid core in selectin 
SCR domains. The two successive SCR domains are rotated by 90° 
relative to each other. This orientation is stabilized by an interac-
tion of the loop Gly192 backbone oxygen with the backbone NH of 
the linker region Val219. A similar stabilizing interaction is ob-
served at the EGF/SCR1 interface between Gly147 and Val157. 
The linker between the linearly arranged E-selectin SCR1-2 do-
mains is composed of only four residues (Asn217, Val218, Val219, 
and Glu220), while linker lengths of five to eight residues have 
been observed in non-linearly arranged SCR domains.34 In contrast 
to SCR domain linkers in other proteins, the pattern of hydrophilic-
hydrophobic-hydrophobic-hydrophilic amino acids is well con-
served in all selectin SCR linkers, except between SCR7 and 8 in P-
selectin (Figure S3), indicating a critical role of linker composition 
and stabilizing interdomain interactions for selectin function.  
The first E-selectin SCR domain possesses three N-linked glyco-
sylation sites (Asn158, Asn178, Asn182), while the second SCR2 
has a single site (Asn244). The observed glycosylation sites are 
located at the interface of the EGF-like/SCR1 and SCR1/SCR2 
domains. While SCR4 and SCR5 have no predicted glycosylation 
sites, SCR3 and SCR6 each carry two at position 291, 311 (SCR3) 
and 482, 506 (SCR6). Based on the SCR1/2 structure, glycosyla-
tion at residue 291 is located at the interface to SCR2, and both 
sites in SCR6 are in close proximity to the membrane surface. This 
arrangement indicates that glycosylation generally contributes to 
the stabilization of SCR domain linking regions. Together with the 
conserved tryptophans, the additional disulfide bond and the con-
served linker region, glycosylation thus contributes to the for-
mation of a reinforced SCR stalk for mechanosensing by the Lec-
EGF didomain.  
 
Figure  3 .  E-selectin adopts an extended overall conformation upon 
ligand binding. (a) Superposition of sLex soaked into preformed crys-
tals27 (gray, upper panel) and the co-crystallized glycomimetic 1  
(green, lower panel) onto the co-crystallized sLex (purple). (b) Apo-E-
selectin (blue, PDB code 1ESL)28 and E-selectin soaked with sLex 
(gray, PDB code 1G1T)27 adopt a bent conformation. The extended 
state observed in co-crystals with sLex (magenta) or glycomimetic 1  
(green) is characterized by a separation of the Lec- and EGF-like 
domains. Root-mean-square deviations (rmsd) were calculated for 
Lec- and EGF-like domains only. The ligand binding Ca2+ ion is de-
picted as a magenta sphere, Cα atoms of Trp1 (pivot) and Cys144 
(EGF-like domain) as red spheres. 
Ligand binding induces  the  extended select in  con-
form ation.  The relative orientation of the Lec- and EGF-domains 
observed here in both ligand complexes is considerably different 
from the bent conformation observed previously in crystals of a E-
selectin Lec-EGF didomain fragment without ligand or soaked with 
sLex.27,28 In the bent conformation, the angle between the Lec- and 
EGF domains is ~120°, while it is 141° and 151° in the current co-
crystal structures (Figure 3b, Video S1 available as web enhanced 
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object). This bent-to-extended movement occurs by a rotation 
around a pivot at the Lec-EGF interface and results in a separation 
of the two domains. Small-angle X-ray scattering (SAXS) of E-
selectin* demonstrates the impact of ligand binding on E-selectin in 
solution. In the absence of ligand, scattering curves are in good 
agreement with a bent model obtained by combining the apo-E-
selectin structure28 with the SCR domains from the current E-
selectin* structures (Figure 4a). Scattering curves in the presence of 
glycomimetic 1  reveal a significant shift at q = 0.3–0.4 Å-1 (Figure 
4b), which correlates well with calculated curves for the extended 
conformation. These results demonstrate that the solution confor-
mation closely resembles the conformation in the crystal structures. 
Ligand binding therefore indeed shifts the conformational equilib-
rium of E-selectin from the bent to the extended state, while the 
linear arrangement of SCR domains is maintained irrespective of 
the presence or absence of the ligand.  
 
Figure  4 .  In solution small-angle X-ray scattering analysis reveals the 
conformational differences between apo-E-selectin and the E-
selectin/1 complex. (a, b) Calculated (black or red lines) and experi-
mental (circles) scattering curves of E-selectin in absence (gray circles) 
or presence (green circles) of the ligand. (a) In absence of glycomimet-
ic 1 , E-selectin adopts the bent conformation. (b) In presence of the 
ligand, the experimental scattering curve shows a significant shift at q = 
0.3–0.4 Å-1 corresponding to a transition towards the extended con-
formation. 
The extended conform ation is  a  high-af f inity  state .  
Calculated binding free energies in a combined approach using 
molecular dynamics simulations with an explicit solvation envi-
ronment and a subsequent scoring of an ensemble of MD frames 
with the MM-GB/SA method demonstrate that additional interac-
tions of protein and ligand in the extended conformation result in 
higher interaction energies in comparison to the shallow binding 
site in the bent state (Table S4). This supports the notion that the 
extended conformation represents a high-affinity binding state of 
E-selectin. 
Alterat ions  in  the  lect in  dom ain connect  l igand bin d-
ing to  conform ational  change.  Three regions located in the 
Lec domain are affected by conformational changes upon ligand 
binding: The binding site loop 81-89 changes its conformation 
(Figure 5a), and a bridging region formed by two loops (residues 
52-75) transduces this motion (Figure 5b) to the pivot region 
consisting of the pivot residue Trp1 (Figure 5c) and surrounding 
residues in the Lec (residues 22–23 and 30–31, Figures 5c and 5d) 
and in the EGF-like domain (Asn138). These variable regions are 
mounted onto a rigid scaffold of the lectin domain, stabilized by 
two disulfide bonds (Cys19–Cys117 and Cys90–Cys109). The 
alterations extend over 35 Å from the carbohydrate-binding site to 
the interface with the EGF-like domain. 
The l igand binding s i te .  The most extensive conformational 
changes are observed within the binding site loop 81-89 (Figure 
5a), where the Cα atom of residue Gln85 moves by 10 Å (see Video 
S2 available as web enhanced object). This leads to a constriction 
around the central Ca2+ ion and the L-fucose (L-Fuc) moiety of the 
ligand, which coordinates the Ca2+ ion with its 3- and 4-hydroxyl 
groups. In the bent conformation Asn83 coordinates the Ca2+ ion, 
while in the extended conformation Glu88 swings inwards to coor-
dinate the Ca2+ ion and displaces Asn83 towards the solvent. This 
swapping is supported by an additional interaction between Glu88 
and the 2-hydroxyl group of L-Fuc. Gln85, which is solvent-exposed 
in the bent conformation, also shifts towards the ligand into hydro-
gen bonding distance to the 2-hydroxyl group. Thus, as a conse-
quence of the conformational adaptation, the 2-hydroxyl group of 
L-Fuc directly interacts with the protein in the extended confor-
mation, while it is only involved in water-mediated interactions to 
Glu107 and Asn83 in the bent conformation. These findings ex-
plain the importance of the L-Fuc 2-hydroxyl group for ligand 
affinity,35,36 which was not rationalized by earlier structural data.27 
Finally, also the loop around Pro46 shifts from an original distance 
of 6.8 Å to the 6-hydroxyl group of the D-galactose (D-Gal) moiety 
in the bent conformation towards 4.5 Å in the extended confor-
mation, where the backbone oxygen of Pro46 mediates a water-
bridged interaction to the 6-hydroxyl group of D-Gal. 
The bridging region.  The constriction around the L-Fuc 
binding site leads to the disruption of interactions at the interface of 
the binding site and the bridging loops 52-75 (Figure 5b) between 
the Asp89 and Arg54 side chains and Lys55 backbone, respectively. 
The bridging region itself shifts in a rigid body motion from the 
bent to the extended conformation. This rigidity is maintained by 
backbone interactions between Arg54 and Trp60/Val61, Gly52 
and Val63 as well as Trp60 and Leu69. The rigid body motion 
serves as an allosteric bridge for transmitting the conformational 
alteration from the binding site to the pivot region.  
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F igure  5 .  The bent and extended conformation of E-selectin exhibit differences in the ligand binding site reaching to the Lec-EGF domain interface. 
(a) The binding site is constricted by rearrangements of loop 81–89. Glu88 replaces Asn83 as Ca2+ coordinating residue and forms an additional 
interaction with the 2-hydroxyl group of L-Fuc. (b) The bridging region 52–70 undergoes a rigid body motion breaking the interactions of 
Arg54/Lys55 with Asp89 of the binding site. At the pivot interface, a water mediated hydrogen bond network involving Gly52, Val63 and Leu26 is 
perturbed. (c) Within the pivot region, Ile29 and Gln30 flip orientation, which disrupts interdomain interactions to Glu135 and favors a dislocation 
of Trp1, leading to the hinge-bending motion between the Lec and EGF domains. The Tyr37–Asn138 interdomain interaction is broken. (d) Anoth-
er shift in the pivot region originates at the GlcNAc residue linked to Asn4. The interaction of Arg22 with the carbohydrate further disrupts inter-
domain interactions and releases the Tyr118 side chain towards the pivot residue Trp1. 
The pivot  region.  The E-selectin bent conformation is stabi-
lized by an extensive hydrogen bond network between the Lec- 
and EGF-like domains with main contributions from Trp1, 
Thr24, Gln30, Tyr37, Ala120, Glu135, and Asn138 (Figure 5c 
and 5d). The Trp1 hinge residue is the only residue of the Lec 
domain that coherently moves with the EGF-like domain to the 
extended conformation. This motion is accompanied by (i) a flip 
of residues Ile29/Gln30 (Figure 5c), (ii) a flip of residues 
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Tyr23/Thr24 accompanied by an altered side chain confor-
mation of Arg22 (Figure 5d) and (iii) a disruption of the inter-
domain interaction between Tyr37/Asn138 (Figure 5c). A flip of 
the residues Ile29 and Gln30, located in a solvent exposed loop 
with increased flexibility between helix 1 and 2 of the lectin do-
main, facilitates the movement of Trp1 (Figure 5c). In the bent 
conformation, Ile29 is enclosed in a hydrophobic pocket, while 
Gln30 is involved in intra- and interdomain interactions to Glu34 
and Glu135. When the extended conformation is adopted, the 
steric hindrance of Trp1 on Ile29 and Gln30 is released and the 
flipped conformation of Gln30 is stabilized by new interactions 
with the backbone oxygen of Gly102 and the side chain of 
Trp104. These rearrangements in the pivot region disrupt a 
contact to the bridging region mediated by a water molecule 
bridging the backbone of Leu26 to Gly52/Gly64 (Figure 5b). As 
a consequence, the pivot and bridging regions are further separat-
ed and additional water molecules enter into the crevice between 
the domains. Tyr23 and Thr24 are restrained in the bent confor-
mation by the side chain of Arg22. While Arg22 stacks with 
Tyr18 in the bent conformation, its side chain is re-oriented in 
the extended conformation and interacts with the GlcNAc at-
tached to Asn4. The movement of Arg22 provides space for a flip 
of residues Tyr23 and Thr24 of the pivot region (Figure 5d). 
Tyr23 relaxes from an unfavorable into a favorable position in the 
Ramachandran plot. The new conformation is stabilized by an 
interaction of the Thr24 side chain with the Cys19 backbone 
oxygen. The flip of Tyr23/Thr24 further disrupts interactions 
between the Lec- and the EGF-like domain, namely between 
Thr24 backbone and Tyr118 backbone and Thr24 side chain 
with Ala120. The side chain of Tyr118 enters into a cleft that is 
opened by the movement of Trp1. A hydrogen bond between 
Tyr37 and Asn138 contributes to the interface between the Lec 
and EGF-like domain in the bent conformation of E- and L-
selectin (unpublished, PDB code 3CFW). In the E-selectin*/1 
structure, the Asn138 residue is pushed towards the Lec domain, 
thus disrupting the interdomain hydrogen bond to Tyr37 (Figure 
5c). This conformational change is additionally accompanied by 
a backbone flip between Ile137 and Asn138. 
A transition from bent to extended conformation in selectins 
has previously been observed only for the Lec-EGF didomain of 
P-selectin co-crystallized with a multivalent PSGL-1 peptide 
ligand.27 This peptide comprised the 19 N-terminal amino acids 
of mature PSGL-1, including an sLex-modified glycan attached to 
Thr16 and three sulfated tyrosine residues, which are directly 
involved in protein ligand interactions.27,37,38 Based on the P-
selectin/PSGL-1 crystal structure, a P-selectin specific mecha-
nism for conformational coupling was proposed.23 Despite a 
sequence identity in the Lec- and EGF-like domains of 62 % 
between E- and P-selectin (Figure S4), two key differences be-
tween E- and P-selectin supported the P-selectin-specificity of the 
proposed mechanism: First, E-selectin does not interact with 
sulfated tyrosines, while those mediate key protein-ligand interac-
tion in the P-selectin/PSGL-1 complex.39,40 Second, differences in 
the Lec-EGF domain interface suggested a stabilization of the 
bent conformation in E-selectin by an additional hydrogen 
bond.27,28 The current data demonstrate that E- and P-selectin 
undergo a similar overall conformational change, but with con-
siderable differences in the mechanism of conformational cou-
pling. (i) The E-selectin Lec-EGF-domain interface is locked by a 
hydrogen bond between Asn138 and Tyr37. This interaction is 
absent in P-selectin, which carries a glycine at position 138. The 
functional relevance of this interdomain interaction was demon-
strated on L-selectin, where an Asn138Gly mutant improved 
ligand binding under hydrodynamic force.9,41 It has been hypoth-
esized, that Asn138 would be forced into an unfavorable back-
bone conformation upon disruption of the Tyr37-Asn138 hydro-
gen bond, which would finally prevent the transition into the 
extended state.23 The backbone flip between residues 137 and 
138 observed here, now demonstrates how such non-favored 
conformation is avoided. (ii) While the Trp1 residue has also 
been identified as the pivot for P-selectin, the flip of the Ile29 and 
Gln30 side chains was not observed. (iii) Residue Tyr23 in the 
direct vicinity of the pivot residue Trp1 is unaltered in the bent 
and extended conformation of P-selectin, while it relaxes from an 
unfavorable into a favorable backbone conformation for E-
selectin.  
DISCUSSION 
The catch-bond behavior of selectins6,7,12,13 is crucial for their 
ability to mediate leukocyte rolling and is achieved by a transition 
between a bent and an extended conformational state. This has 
been elegantly demonstrated by forcing P-selectin into an ex-
tended conformation by modifications at the Lec-EGF interface: 
A P-selectin variant locked in an extended conformation displays 
enhanced ligand binding under static conditions, but its ability to 
mediate leukocyte rolling under flow conditions was impaired.7,41 
However, an extended conformation has so far only been ob-
served for P-selectin in complex with a glycopeptide ligand that 
interacts with its carbohydrate epitope as well as three sulfated 
tyrosines. Here, we reveal an extended state of E-selectin in com-
plex with its minimal binding motif sLex. Based on an analysis of 
protein-ligand interactions and quantitative analysis of molecular 
dynamics simulations, this extended conformation represents a 
true high affinity ligand binding state of E-selectin. SAXS meas-
urements confirm that ligand binding induces a conformational 
transition from the bent low affinity to the extended high-affinity 
state in solution and thus demonstrate that glycoprotein ligands 
such as PSGL-1 or ESL-1 are not strictly required for efficiently 
promoting conformational changes in selectins. Even a small 
molecular ligand such as sLex in the absence of flow conditions is 
sufficient to initiate a structural transition to an extended con-
formation. 
To analyze the functional mechanisms underlying catch-bond 
behavior, detailed structural knowledge of all relevant states of E-
selectin is required (Figure 6). Apo-E-selectin adopts a bent 
conformation of the Lec-EGF-domains as demonstrated by 
crystallographic analysis28 and SAXS data. The bent confor-
mation is capable of recognizing and weakly binding sLex, as 
demonstrated in a crystallographic ligand soaking experiment, 
where crystal packing restraints prevented the transition to the 
extended conformation.27 However, in solution ligand binding 
results in a conformational transition into the extended high-
affinity binding state revealed here by co-crystallization and 
SAXS. The conformational change from a bent to an extended 
conformation allows E-selectin to support fast binding of rapidly 
flowing leukocytes to the vascular endothelium at the leading 
edge of the cell while controlling the rate of unbinding at the 
trailing edge, thus providing mechanical stability to the rolling of 
leukocytes along the vasculature. Under in vivo flow conditions, 
the extended conformation is favored by tensile force pulling 
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along the E-selectin-ligand axis reinforcing the extended confor-
mation and thus increasing lifetime of the interaction. The rigidi-
ty of the linearly arranged SCR domains is promoted by con-
served interdomain contacts and three intradomain disulfide 
bonds and provides a basis for mechanosensing by the Lec-EGF 
didomain of E-selectin. Our findings provide direct evidence for 
the two-state-two-pathway model of conformational changes 
underlying catch-bond properties in E-selectin (Figure 6). The 
bent conformation is prevailing in solution and recognizes ligands 
in a low-affinity encounter complex. The encounter complex 
undergoes a conformational change to a high-affinity extended 
state already under no-force conditions, but tensile force acting 
along the Lec-EGF-ligand binding site axis further increases its 
lifetime. 
 
Figure  6 .  The ligand-dependent equilibrium between bent and 
extended conformation of E-selectin. In absence of ligand, E-selectin 
primarily adopts the bent conformation (a) and not an extended 
conformation (d). The bent conformation is capable of ligand bind-
ing (b), although with low affinity. Upon ligand binding E-selectin 
favors the extended high-affinity state (c). Tensile force along the E-
selectin-ligand axis exerted by tethered leukocytes under flow 
conditions increase the lifetime of the high affinity conformation. 
The ligand binding site undergoes dramatic conformational 
changes between the low-affinity and the high-affinity state (Vid-
eo S1 available as web enhanced object). The shallow binding 
surface is transformed into a pronounced binding pocket with 
multiple additional protein-ligand interactions, while the confor-
mation of the ligand remains unchanged. Co-crystallization with 
the glycomimetic 1  demonstrates the relevance of the high-
affinity conformation for the design of drug candidates targeting 
E-selectin. The detailed knowledge into ligand recognition of E- 
and P-selectin, opens the way towards the rational design of novel 
E-selectin specific antagonists. Based on the success of the pan-
selectin antagonist Rivipansel, E-selectin specific antagonists are 
promising drug candidates that may further target specific indica-
tions related to excessive inflammatory responses in human 
disease. In summary, the current results contribute to a compre-
hensive understanding of the mechanism of mechanosensing and 
catch-bond behavior in the selectin family and they reveal the 
pathway of ligand-induced conformational changes in E-selectin 
with critical relevance for ongoing targeted drug development. 
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Synthesis of sialyl Lewisx-OTMSE 
 
General methods:!NMR spectra were recorded on a Bruker Avance DMX-500 (500 MHz) 
spectrometer. Assignment of 1H and 13C NMR spectra was achieved using 2D methods 
(COSY, HSQC, HMQC, HMBC). Chemical shifts are given in ppm and were assigned in 
relation to the solvent signals on the δ-scale1 or to tetramethylsilane (0 ppm) as internal 
standard. Coupling constants J are given in Hertz (Hz). Multiplicities were specified as 
follows: s (singlet), d (doublet), dd (doublet of a doublet), t (triplet), q (quartet), m 
(multiplet). For assignment of resonance signals to the appropriate nuclei the following 
abbreviations were used: Fuc (fucose), Gal (galactose), GlcNAc (N-acetylglucosamine), Sia 
(sialic acid). Reactions were monitored by TLC using glass plates coated with silica gel 60 
F254 (Merck) and visualized by using UV light and/or by charring with a molybdate solution 
(a 0.02 M solution of ammonium cerium sulfate dihydrate and ammonium molybdate 
tetrahydrate in aqueous 10 % H2SO4. Column chromatography was performed manually 
using silica gel 60 (40–63 µm) from Fluka or using automated systems (RediSep Companion 
or RediSep Rf) from Teledyne Isco with normal phase RediSep columns from the same 
manufacturer or reversed-phase columns containing LiChroprep RP-18 (40–63 µm) from 
Merck KGaA (Darmstadt, Germany). LC-MS separations were carried out using Sunfire C18 
columns (19 x 150 mm, 5.0 µm) on a Waters 2525 LC, equipped with Waters 2996 
photodiode array and Waters micromass ZQ MS for detection. Size exclusion 
chromatography was performed with Bio-Gel® P-2 Gel (45-90 mm) from Bio-Rad. 
 
Solvents were purchased from Sigma-Aldrich or Acros. Solvents were dried prior to use 
where indicated. Tetrahydrofurane (THF) was dried by refluxing with sodium/benzophenone 
and distilled immediately before use. Dichloromethane (CH2Cl2) and dimethoxyethane 
(DME) were dried by filtration over Al2O3 (Fluka, type 5016 A basic). Methanol (MeOH) 
was dried by distillation from sodium methoxide, DMF by distillation from calcium hydride. 
Optical rotations were measured using a Perkin-Elmer Polarimeter 341. Electron spray 
ionization mass spectra (ESI-MS) were obtained on a Waters micromass ZQ. HRMS analysis 
were carried out using a Agilent 1100 LC equipped with a photodiode array detector and a 
Micromass QTOF I equipped with a 4 GHz digital-time converter. Microanalysis was 
performed at the Institute of Organic Chemistry at the University of Basel, Switzerland. 
Purity of final compounds was determined on an Agilent 1100 HPLC; detector ELS, Waters 
2420; column: Waters Atlantis dC18, 3 mm, 4.6 x 75 mm; eluents: A: water + 0.1% TFA; B: 
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90% acetonitrile + 10% water + 0.1% TFA; linear gradient: 0-1 min 5% B; 1-20 min 5 to 
70% B; flow: 0.5 mL/min. 
 
Thiofucoside S12 and D-GlcNAc acceptor S23 were coupled under in situ anomerization 
conditions to give disaccharide S34, which upon regioselective opening of the benzylidene 
acetal5 yielded acceptor S4 (Scheme S1). SLex precursor S6 was synthesized via DMTST6 
promoted coupling of S57 and S4. Hydrogenolytic debenzylation and saponification finally 
afforded TMSE protected sLex. 
 
 
Scheme S1. a) Br2, Bu4NBr, CH2Cl2, MS 4 Å, 0 °C to r.t., 12 h, 55%; b) Me3N·BH3, AlCl3, H2O, THF, r.t., 5 h, 
78%; c) DMTST, CH2Cl2, MS 4 Å, r.t., 5 d, 20%; d) H2, Pd(OH)2/C, dioxane, H2O, r.t., 24 h; e) aq. NaOH, 
MeOH, r.t., 20 h, 43% from S5. 
 
2-(Trimethylsilyl)ethyl (2,3,4-tri-O-benzyl-α-L-fucopyranosyl)-(1→3)-2-acetamido-4,6-
O-benzylidene-2-deoxy-β-D-glucopyranoside (S3). Bromine (0.18 mL, 3.50 mmol) was 
slowly added to a stirred solution of donor S1 (1.52 g, 3.18 mmol) in anhydrous CH2Cl2 (90 
mL) at 0 °C under argon. After 10 min, excess bromine was quenched by addition of 
cyclohexene. Powdered activated molecular sieves 4 Å (9 g), TBAB (1.54 g, 4.78 mmol) and 
S23 (0.65 g, 1.59 mmol) were added and the mixture was stirred at 0 °C for 2 h then warmed 
to r.t. and stirred overnight. The reaction mixture was filtered through celite and washed with 
water (100 mL) and brine (100 mL). The organic layer was dried over Na2SO4, filtered, and 
concentrated under reduced pressure. Column chromatography on silica (petroleum 
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ether/Et2O) afforded S3 (720 mg, 0.87 mmol, 55%) as white foam. 
1H NMR (500.1 MHz, CDCl3): δ = 7.51-7.23 (m, 20H, Ar-H), 5.59 (d, J = 6.7 Hz, 1H, NH), 
5.49 (s, CHPh), 5.04 (d, J = 3.2 Hz, Fuc-H1), 4.99 (d, J = 8.3 Hz, GlcNAc-H1), 4.96-4.88 
(m, 2H, CH2Ph), 4.75 (s, 2H, CH2Ph), 4.65 (B of AB, J = 11.7 Hz, CH2Ph), 4.58 (B’ of 
A’B’, J = 11.5 Hz, CH2Ph), 4.39-4.31 (m, 2H, GlcNAc-H3, GlcNAc-H6a), 4.12-4.04 (m, 2H, 
Fuc-H2, Fuc-H5), 3.98-3.86 (m, 2H, Fuc-H3, CH2CH2Si), 3.76 (t, J = 10.0 Hz, GlcNAc-
H6b), 3.63-3.45 (m, 4H, Fuc-H4, GlcNAc-H4, GlcNAc-H5, CH2CH2Si), 3.28 (m, 1H, 
GlcNAc-H2), 1.62 (s, 3H, COCH3), 1.01-0.82 (m, 2H, CH2CH2Si), 0.80 (d, J = 6.4 Hz, Fuc-
H6), 0.01 (s, 9H, Si(CH3)3); 13C NMR (125.8 MHz, CDCl3): δ = 170.6 (COCH3), 138.9, 
138.8, 138.7, 129.2, 128.8, 128.5, 128.4, 128.3, 128.0, 127.9, 127.7, 127.5, 126.4 (24C, Ar-
C), 101.8 (CHPh), 100.1 (GlcNAc-C1), 98.5 (Fuc-C1), 81.0 (GlcNAc-C4), 80.0 (Fuc-C3), 
77.7, 77.4 (Fuc-C2, Fuc-C4), 75.0 (CH2Ph), 74.9 (GlcNAc-C3), 74.3, 72.6 (CH2Ph), 69.1 
(GlcNAc-C6), 67.5 (CH2CH2Si), 66.9 (Fuc-C5), 66.3 (GlcNAc-C5), 59.1 (GlcNAc-C2), 23.4 
(COCH3), 18.2 (CH2CH2Si), 16.4 (Fuc-C6), -1.3 (3C, Si(CH3)3); [α]D -73.3 (c 0.96, CHCl3); 
MS (ESI): m/z: Calcd for C47H59NNaO10Si [M+Na]+: 848.4, found: 848.4; Elemental 
analysis: Calcd (%) for C47H59NO10Si: C 68.34, H 7.20, N 1.70, found: C 68.46, H 7.27, N 
1.66. 
 
2-(Trimethylsilyl)ethyl (2,3,4-tri-O-benzyl-α-L-fucopyranosyl)-(1→3)-2-acetamido-6-O-
benzyl-2-deoxy-β-D-glucopyranoside (S4). To a solution of S3 (600 mg, 0.73 mmol) in 
anhydrous THF (14 mL) were added Me3N⋅BH3 (212 mg, 2.91 mmol) and anhydrous AlCl3 
(580 mg, 4.35 mmol) with stirring under argon at r.t. When all reagents were dissolved, H2O 
(26 µL) was added and the mixture was stirred for 5 h. The reaction was quenched by 
addition of H2O (12 mL) and 1 N aq HCl (12 mL) and extracted with CH2Cl2 (3 × 30 mL). 
The organic layers were washed with brine (30 mL), dried over Na2SO4, and concentrated. 
Column chromatography on silica gel (petroleum ether/EtOAc, 7:3 to 1:1) afforded S4 (470 
mg, 0.57 mmol, 78%) as white foam. 
1H NMR (500.1 MHz, CDCl3): δ = 7.43-7.23 (m, 20H, Ar-H), 5.51 (d, J = 7.1 Hz, 1H, NH), 
4.96 (m, 2H, Fuc-H1, CH2Ph), 4.91 (d, J = 8.2 Hz, GlcNAc-H1), 4.86-4.57 (m, 7H, CH2Ph), 
4.13-4.04 (m, 2H, Fuc-H2, Fuc-H5), 4.02-3.89 (m, 3H, Fuc-H3, GlcNAc-H3, CH2CH2Si), 
3.83 (m, 1H, GlcNAc-H6a), 3.73-3.66 (m, 2H, Fuc-H4, GlcNAc-H6b), 3.59-3.47 (m, 2H, 
GlcNAc-H5, CH2CH2Si), 3.43 (dd, J = 8.8 Hz, 1H, GlcNAc-H4), 3.26 (m, GlcNAc-H2), 1.60 
(s, 3H, COCH3), 1.15 (d, J = 6.3 Hz, Fuc-H6), 1.02-0.84 (m, 2H, CH2CH2Si), -0.01 (s, 9H, 
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Si(CH3)3); 13C NMR (125.8 MHz, CDCl3): δ = 170.9 (COCH3), 138.6, 138.4, 128.7, 128.6, 
128.5, 128.4, 128.1, 128.0, 127.9, 127.8, 127.7, 127.6 (24C, Ar-C), 99.4, 99.3 (Fuc-C1, 
GlcNAc-C1), 84.1 (GlcNAc-C3), 79.3 (Fuc-C3), 77.4 (Fuc-C4), 76.0 (Fuc-C2), 75.1 
(CH2Ph), 75.0 (GlcNAc-C5), 74.1, 73.6, 73.0 (CH2Ph), 70.7 (GlcNAc-C4), 69.8 (GlcNAc-
C6), 68.1 (Fuc-C5), 67.0 (CH2CH2Si), 56.7 (GlcNAc-C2), 23.4 (COCH3), 18.2 (CH2CH2Si), 
16.8 (Fuc-C6), -1.3 (3C, Si(CH3)3); [α]D -36.7 (c 0.55, CHCl3); MS (ESI): m/z: Calcd for 
C47H61NNaO10Si [M+Na]+: 850.4, found: 850.5. 
 
2-(Trimethylsilyl)ethyl (benzyl 5-acetamido-4,7,8,9-tetra-O-acetyl-3,5-dideoxy-D-
glycero-α-D-galacto-2-nonulopyranosynate)-(2→3)-2,4-di-O-acetyl-6-O-benzoyl-β-D-
galactopyranosyl-(1→4)-[2,3,4-tri-O-benzyl-α-L-fucopyranosyl-(1→3)]-2-acetamido-6-
O-benzyl-2-deoxy-β-D-glucopyranoside (S6). Compounds S5 (300 mg, 0.31 mmol) and S4 
(380 mg, 0.46 mmol) were dissolved in anhydrous CH2Cl2 (8 mL). Powdered activated 
molecular sieves 4 Å (0.8 g) were added and the mixture was stirred at r.t. under argon. After 
3.5 h, a solution of DMTST (200 mg, 0.77 mmol) in anhydrous CH2Cl2 (2.0 mL), which had 
been stirred with molecular sieves 4 Å (0.2 g) for 3.5 h, was added. After stirring for 5 d, the 
solution was diluted with CH2Cl2 (10 mL), filtered and successively washed with satd aq 
NaHCO3 (20 mL) and brine (20 mL). The aqueous layers were extracted with CH2Cl2 (3 × 20 
mL) and the combined organic layers were dried over Na2SO4 and concentrated under 
reduced pressure. Column chromatography on silica (petroleum ether/EtOAc/MeOH, 8:5:0.5 
to 8:5:0.9) afforded S6 (110 mg, 0.06 mmol, 20%) as white solid. 
1H NMR (500.1 MHz, CDCl3): δ = 8.09-721 (m, 30H, Ar-H), 6.22 (d, J = 8.1 Hz, 1H, 
GlcNAc-NH), 5.62 (ddd, J = 2.5, 5.9, 8.7 Hz, 1H, Sia-H8), 5.43-5.32 (m, 2H, Sia-H7, 
PhCH2), 5.22 (d, J = 3.5 Hz, 1H, Fuc-H1), 5.20 (d, J = 3.5 Hz, 1H, Gal-H4), 5.07-4.95 (m, 
3H, Gal-H2, PhCH2), 4.92 (m, 1H, Sia-H4), 4.88-4.72 (m, 7H, Gal-H1, Gal-H3, GlcNAc-H1, 
PhCH2), 4.68 (B of AB, J = 11.8 Hz, 1H, PhCH2), 4.61 (A of AB, J = 12.0Hz, 1H, PhCH2), 
4.61 (B of AB, J = 12.0 Hz, 1H, PhCH2), 4.41-4.29 (m, 2H, Gal-H6a, Sia-H9a), 4.23 (dd, J = 
7.0, 11.0 Hz, 1H, Gal-H6b), 4.20-3.96 (m, 8H, Fuc-H2, Fuc-H5, Gal-H5, GlcNAc-H3, 
GlcNAc-H4, GlcNAc-H6a, Sia-H5, Sia-H9b), 3.93-3.78 (m, 5H, Fuc-H3, GlcNAc-H2, 
GlcNAc-H5, GlcNAc-H6b, CH2CH2Si), 3.56-3.47 (m, 3H, Fuc-H4, Sia-H6, CH2CH2Si), 2.64 
(dd, J = 4.5, 12.6 Hz, 1H, Sia-H3eq), 2.27, 2.15, 2.11, 2.03, 2.00, 1.94, 1.88, (7s, 24H, 8 
COCH3), 1.75 (t, J = 12.4 Hz, 1H, Sia-H3ax) 1.13 (d, J = 6.5 Hz, 3H, Fuc-H6), 1.06-0.77 (m, 
2H, CH2CH2Si), 0.00 (s, 9H, Si(CH3)3); 13C NMR (125.8 MHz, CDCl3): δ = 170.7, 170.6, 
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170.5, 170.4, 170.1, 169.8 (8C, COCH3), 167.5 (Sia-C1), 165.8 (ArCO), 139.2, 139.1, 138.8, 
138.6, 134.8, 133.4, 129.8, 129.0, 128.8, 128.6, 128.5, 128.4, 128.3, 127.8, 127.7, 127.6, 
127.5, 127.3 (36C, Ar-C), 99.2, 99.1 (Gal-C1, GlcNAc-C1), 97.0 (Sia-C2), 96.5 (Fuc-C1), 
79.5 (Fuc-C3), 77.7 (Fuc-C4), 76.6 (Fuc-C2), 74.6 (PhCH2), 74.2, 73.5, 73.4 (GlcNAc-C3, 
GlcNAc-C4, GlcNAc-C5), 73.0, 72.9 (3C, 3 CH2Ph), 72.2 (Sia-C6), 71.2, 70.7, 70.4, (Gal-
C2, Gal-C3, Gal-C5), 69.5 (GlcNAc-C6), 69.4 (Sia-C4), 68.5 (PhCH2), 67.8, 67.7, 67.2 66.9 
(Fuc-C5, Gal-C4, Sia-C7, Sia-C8), 66.6 (CH2CH2Si), 62.6 (Sia-C9), 61.7 (Gal-C6), 53.4 
(GlcNAc-C2), 49.0 (Sia-C5), 37.6 (Sia-C3), 23.3, 23.2, 21.5, 21.0, 20.9, 20.8, 20.7 (8C, 8 
COCH3), 18.0 (CH2CH2Si), 16.8 (Fuc-C6), -1.3 (3C, Si(CH3)3); [α]D -24.3 (c 0.58, CHCl3); 
MS (ESI): m/z: Calcd for C90H110N2NaO30Si [M+Na]+: 1749.7, found: 1749.8. 
 
2-(Trimethylsilyl)ethyl (sodium 5-acetamido-3,5-dideoxy-D-glycero-α-D-galacto-2-
nonulopyranosynate)-(2→3)-β-D-galactopyranosyl-(1→4)-[α-L-fucopyranosyl-(1→3)]-
2-acetamido-2-deoxy-β-D-glucopyranoside (sLex-OTMSE). Compound S6 (90 mg, 0.052 
mmol) was dissolved in dioxane/water (4:1, 10 mL) under argon. Pd(OH)2/C (20 mg, 10% 
Pd) was added and the resulting mixture was hydrogenated (4 bar H2) at r.t. After 24 h, the 
mixture was filtered and the solvent was removed under reduced pressure. The residue was 
redissolved in 1 N aq NaOH (10 mL) and MeOH (2 mL) and stirred at r.t. After 20 h the 
mixture was neutralized with 1 N HCl, the volatiles were removed under reduced pressure, 
and the crude product was purified by size-exclusion chromatography and RP 
chromatography (RP18, H2O/MeOH). Lyophilization from water afforded sLex-OTMSE (21 
mg, 0.022 mmol, 43%) as white fluffy solid. 
1H NMR (500.1 MHz, D2O/CD3OD): δ = 5.09 (d, J = 4.0 Hz, 1H, FucH-1), 4.80 (m, Fuc-
H5), 4.56 (d, J = 8.1 Hz, 1H, GlcNAc-H1), 4.52 (d, J = 7.8 Hz, 1H, Gal-H1), 4.08 (dd, J = 
3.1, 9.8 Hz, 1H, Gal-H3), 4.06-3.55 (m, 22H, CH2CH2Si, Fuc-H2, Fuc-H3, Fuc-H4, Gal-H4, 
Gal-H5, Gal-H6a, Gal-H6b, GlcNAc-H2, GlcNAc-H3, GlcNAc-H4, GlcNAc-H5, GlcNAc-
H6a, GlcNAc-H6b, Sia-H4, Sia-H5, Sia-H6, Sia-H7, Sia-H8, Sia-H9a, Sia-H9b), 3.52 (dd, J 
= 7.8, 9.8 Hz, Gal-H2), 2.76 (dd, J = 4.6, 12.1Hz, 1H, Sia-H3eq), 2.03, 2.01 (2s, 6H, 2 
COCH3), 1.79 (t, J = 12.1 Hz, 1H, Sia-H3ax), 1.17 (d, J = 6.6 Hz, 3H, Fuc-H6), 1.05-0.80 (m, 
2H, CH2CH2Si), 0.00 (s, 9H, Si(CH3)3); 13C NMR (125.8 MHz, D2O/CD3OD): δ = 176.0, 
175.1, 174.8 (2 NHCOCH3, Sia-C1) 102.6 (Gal-C1), 101.2, 100.6 (GlcNAc-C1, Sia-C2), 
100.6 (Fuc-C1), 99.6, 76.6, 76.3, 76.0, 75.9, 74.4, 73.9, 72.9, 72.8, 70.2, 69.3, 69.1, 68.7, 
68.3, 67.7, 63.6, 62.4, 60.6, 56.7, 52.7, 40.8 (Sia-C3), 23.3, 23.0 (2 NHCOCH3), 18.1 
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(CH2CH2Si), 16.2 (Fuc-C6), -1.5 (3C, Si(CH3)3); [α]D -43.9 (c 0.70, MeOH); HRMS (ESI): 
m/z: Calcd for C36H64N2NaO23Si+ [M+H]+: 943.3561, found: 943.3553; HPLC purity: > 
99.5%. 
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Molecular cloning 
 
Human E-selectin cDNA encoding the native E-selectin secretion signal, the Lec-, EGF- and 
first two SCR domains (E-selectin*, residues 1–280) was isolated and PCR amplified from 
previously generated full length human E-selectin-IgG(Fc) expressing Chinese hamster ovary 
(CHO-K1) cells.8 The Kozak consensus sequence was introduced to increase protein yield. E-
selectin* cDNA was cloned into the pcDNA3.1(+) expression vector (Life Technologies Ltd, 
UK) using standard cloning procedures and sequence verified. 
Stably transfected CHO-K1 cells (ATCC-No. CCL-61) were generated using FuGENE® HD 
Transfection Reagent (Roche Applied Science, Switzerland), G418 treatment, and subsequent 
clone selection. Single clones were screened for optimal protein expression. The CHO-K1 
cells were cultivated as monolayer in Ham’s Nutrient Mixture F-12 medium supplemented 
with 2 mM L-glutamine (Invitrogen, Lucerne, Switzerland), 5-10% (v/v) fetal calf serum 
(Invitrogen, Lucerne, Switzerland), 100 U/mL penicillin, and 100 µg/mL streptomycin. Once 
confluent, the transfected CHO-K1 cells were treated with culture medium containing 1 µM 
kifunensine (Cayman Chemical, MI) for 2 days. The medium was discarded and replaced by 
culture medium containing 5 µM kifunensine. Conditioned culture medium was collected 
weekly. 
 
The following primers were used for amplification of E-selectin* cDNA: 
SELE_koz_fw with EcoRI restriction site and Kozak consensus sequence 
5’–GCGAATTCGCCGCCACCATGGGAATTGCTTCACAGTTTCTCTCAG–3’ 
SELE_SCR2_rv with two stop codons and an EcoRV restriction site 
5’-GCGATATCCTATTAAGCTTTACACGTTGGCTTCTC-3’ 
 
Protein purification 
 
A purification column with the functional anti-E-selectin antibody 7A9 coupled to sepharose 
was prepared as previously described.9 Affinity chromatography was performed with a 
functional anti-E-selectin antibody (7A9) column with loading buffer (50 mM Tris/HCl, pH 
7.6, 150 mM NaCl, and 0.05% v/v Tween-20), washing buffer (5 mM NH4OAc/CH3COOH, 
pH 5.0), and elution buffer (0.5 M CH3COOH/NH4OAc, pH 3.4). Protein samples were 
adjusted to neutral pH upon elution with 2.5 M Tris and concentrated by ultrafiltration (10 
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kDa cut-off, Millipore, MA). Approximately 5 mg high-mannosylated E-selectin was 
obtained per liter medium. 
Concentrated high-mannosylated E-selectin (10-20 mg/mL) was deglycosylated with 
endoglycosidase Hf (New England Biolabs, MA) according to the recommendation of the 
manufacturer using 10 U/µg protein for 3 h at 37 °C under non-reducing conditions. The 
deglycosylation yielded protein with a single GlcNAc moiety attached to each N-linked 
glycosylation site. The deglycosylation progress was checked with standard SDS-
PAGE/Coomassie analysis. When required, deglycosylation was extended with additional 5 
U EndoHf per µg protein for 1 h. Deglycosylated protein was re-purified over the functional 
anti-E-selectin antibody (7A9) column and concentrated to 50 mg/mL in 10 mM Tris-HCl, 
pH 7.4, 5 mM CaCl2. 
 
Figure S1. SDS-PAGE (12%) of E-selectin* expressed CHO cells in absence (lane 1) or presence (lane 2) of 
kifunensine, and endoglycosidase H treated protein (lane 3). 
 
Activity assays 
 
To verify the activity of E-selectin upon deglycosylation, the affinity towards biotinylated-
polyacrylamide (PAA) functionalized with sLex (Neu5Ac(α2-3)Gal(β1-4)[Fuc(α1-
3)]GlcNAc) and its isoform sLea (Neu5Ac(α2-3)Gal(β1-3)[Fuc(α1-4)]GlcNAc) was 
determined similarly as previously described.9 Briefly, fully glycosylated E-selectin 
expressed in absence of kifunensine, high-mannosylated E-selectin, and endoglycosidase H 
treated E-selectin were coated at a concentration of 0.2 µM on polystyrene dishes 
(Immunoplate II MaxiSorpTM 96-well microtiter plates, Nunc, Denmark) at 4 °C overnight in 
assay buffer (10 mM Tris/HCl, pH 7.4, 150 mM NaCl, 1 mM CaCl2) and blocked with 
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bovine serum albumin (2% w/v in assay buffer). After washing with assay buffer, serial 
dilutions of sLex-PAA or sLea-PAA were applied, which were co-incubated with 
streptavidin-peroxidase (200 U/mL, Roche Applied Science, Rotkreuz, Switzerland) prior to 
the assay. Control wells without protein were treated in the same fashion. Carbohydrate-PAA 
binding was detected by colorimetric reaction with 2,2’-azino-di-(3-ethylbenzthiazoline)-6-
sulfonic acid (Bio-Rad, Reinach BL, Switzerland), which was stopped with 2% (w/v) oxalic 
acid. The optical density was measured at 415 nm. Measured values were subtracted with the 
control wells and curve fitting was performed with the Prism software (GraphPad Software 
Inc., CA). A four-parameter fit for minimum, maximum, logEC50 and slope was used. The 
EC50 values correspond to the half-maximal effective concentration (Figure S2). 
 
 EC50 (ng/mL) 
sLex-PAA 
EC50 (ng/mL) 
sLea-PAA 
Fully glycosylated 762 243 
Kifunensine treated 292 132 
EndoH 267 92 
 
Figure S2. Activity assays as described above of fully glycosylated, high-mannosylated, and deglycosylated E-
selectin* with sLex-polyacrylamide (PAA) and sLea-PAA. 
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Protein-ligand co-crystallization 
 
Deglycosylated E-selectin* was co-crystallized with sLex-OTMSE or glycomimetic 1 in a 
sitting drop vapor diffusion setup. Initial crystals were obtained in equal volumes of 23.5% 
(w/v) polyethylene glycol 8000, 0.1 M 3-(N-morpholino)propanesulfonic acid pH 6.2, 0.2 M 
CaCl2 with protein (25 mg/mL) containing each ligand (final concentration 25 mM sLex or 10 
mM glycomimetic 1). Diffraction quality crystals were obtained in 12.5-13.5 % PEG8000, 
MOPS 0.1 M pH 6.2, 0.2 M CaCl2 after microseeding within 48 h. Plate-like crystals 
appeared within one day. The drops were covered with perfluoropolyether (Hampton 
Research, CA) prior to flash cooling in liquid nitrogen. Diffraction data were collected at the 
PXI beamline at the Swiss Light Source, Paul Scherrer Institute, Villigen, Switzerland. Data 
were processed with the XDS software.10 
 
Structure determination and refinement 
 
The structure of E-selectin*/1 was determined by molecular replacement using PHASER11 
within the CCP4 software package12 with the P-selectin/PSGL-1 (PDB code 1G1S)13 
structure for the Lec- and EGF domains, human mannose-binding lectin-associated serine 
protease-1 (PDB code 3GOV)14 for the first SCR, and human CD55 (PDB code 1H0415) for 
the second SCR. The E-selectin*/sLex structure was determined with the E-selectin*/1 
structure. Refinement was performed with the BUSTER16 software and model building was 
performed with COOT.17 Restraints for the ligands were generated using PRODRG.18 
Modeling of the TMSE protecting group of the sLex ligand was omitted due to poor density 
of this flexible group. Parts of the SCR2 domain in the E-selectin*/sLex structure were 
modeled on the basis of the E-selectin*/1 structure due to weak density. In the E-
selectin*/sLex structure, 15 residues are within the allowed Ramachandran region (2.7%) and 
11 are outliers (2.0%). In the E-selectin*/1 structure, 14 residues are within the allowed 
region (2.9%) and 7 are outliers (1.4%). Data collection and refinement statistics are listed in 
Table S1. Root-mean-square deviations (rmsd) for the Lec- and EGF domains were 
calculated with the DALI server.19 Figures were generated with the Visual Molecular 
Dynamics (VMD) software.20 
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 Table S1. Data collection and refinement statistics. 
 
 E-selectin/sLex E-selectin/1 
PDB Entry 4CSY 4C16 
   
Data collection   
Wavelength (Å) 0.99985 0.99987 
Space group P1 P1 
Cell dimensions   
    a, b, c (Å) 52.3, 58.7, 58.9 52.6, 56.9, 59.7 
    α, β, γ (°)  76.1, 86.3, 86.3 74.4, 87.1, 88.3 
Molecules in the 
asymmetric unit 2 2 
Resolution (Å)* 28.3-2.40 (2.53-2.40) 57.4-1.93 (2.03-1.93) 
Rmerge* 0.043 (0.317) 0.040 (0.257) 
I / σI* 8.8 (2.0) 9.3 (2.0) 
Completeness (%)* 95.4 (90.2) 92.5 (91.0) 
Redundancy* 1.8 (1.8) 1.8 (1.7) 
   
Refinement   
Resolution (Å)* 28.3-2.40 (2.50-2.40) 15.2-1.93 (1.98-1.93) 
No. reflections* 25130 (2538) 46243 (3357) 
Rwork / Rfree % 21.7 / 25.3 18.3 / 23.2 
No. atoms   
    Protein 4387 4571 
    Ligand/ion 312 280 
    Water 127 525 
B-factors   
    Protein 78.2 39.7 
    Ligand/ion 101.1 52.8 
    Water 63.2 48.3 
RMS deviations   
    Bond lengths (Å) 0.010 0.010 
    Bond angles (°) 1.22 1.16 
RMS indicates root mean square. Single crystals were used. 
*Values in parentheses are for highest-resolution shell. 
 
Small angle X-ray scattering 
 
Small-angle X-ray scattering (SAXS) measurements were conducted at the X12SA-cSAXS 
beamline (Swiss Light Source) with a sample to detector (Pilatus 2M) distance of 7.0 m and 
ten measurements of 0.5 s exposure time. Deglycosylated E-selectin* was diluted to 10 
mg/mL and measured either in presence or absence of 3 mM glycomimetic 1. Buffer samples 
(10 mM Tris/HCl, pH 7.4, 5 mM CaCl2) alone were measured as reference. A control 
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measurement with 3 mM glycomimetic 1 without protein showed no difference to the buffer 
control. Integrated data were background subtracted with the PRIMUS software.21 
Experimental and theoretical scattering curves were evaluated with the CRYSOL software.22 
A model for the E-selectin* bent conformation was generated using the coordinates of the 
Lec-EGF domains of the apo-E-selectin (PDB code 1ESL)23 structure combined with the 
coordinates of the two SCR domains from E-selectin*/1. Data evaluation and fitting 
parameters are given in Table S2. 
 
Table S2. SAXS parameters for data validation and interpretation. 
 
 E-selectin, ligand absent E-selectin, ligand present 
Fit Model E-selectin bent E-selectin extended E-selectin bent E-selectin extended 
Goodness of fit (χ2) 0.622 0.702 0.891 0.758 
q-range 0.007 - 0.500 Å-1 0.007 - 0.500 Å-1 0.007 - 0.500 Å-1 0.007 - 0.500 Å-1 
Rg (guinier plot) 37.84 Å 37.84 Å 41.80 Å 41.80 Å 
Rg model 40.07 Å 41.02 Å 40.07 Å 41.02 Å 
Dmax experimental 132.43 Å 132.43 Å 147.56 Å 147.56 Å 
Dmax model 137.23 Å 143.58 Å 137.23 Å 143.58 Å 
q = 4πsin(θ)/λ 
Dmax indicates the maximum particle size. 
Rg indicates the radius of gyration as calculated with the AutoRG software using globular fitting parameters. 
 
Molecular dynamics simulations 
 
The Protein Preparation Wizard24 was used to convert the extended and bent (PDB code 
1G1T)13 E-selectin crystal structures to all-atom protein models. A rigid receptor grid was 
generated from the crystal structure 1G1T, using the OPLS 2005 force field.25,26 An initial 
protein-ligand complex of glycomimetic 1 docked to 1G1T was obtained through flexible 
docking using Glide.27 The best docking pose was selected interactively considering the 
proposed binding mode already known from existing structures and similar ligands. 
Molecular dynamics simulations were carried out with Desmond28 using the OPLS 2005 
force field, as implemented in the Schrödinger 2012 suite.24 Each system was solvated using 
an orthorhombic, TIP3P water box29 with a minimum distance of 10 Å from the complex. 
Counterions (Na+ and Cl-) were added to neutralize the charges and account for physiological 
salt concentration (0.15 M). Long-range electrostatic interactions were handled using the 
particle mesh Ewald summation.30 All systems were equilibrated using the default relaxation 
protocol and simulated over the span of 48 ns with a time step of 2.0 fs. The SHAKE 
algorithm31 was applied to all heavy atom-bound hydrogens. Production runs were carried out 
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in the Martyna-Tobias-Klein isothermal-isobaric ensemble (NPT)32 using the Nose-Hoover 
barostat to maintain a constant temperature of 300 K.33 Energetic and structural data were 
recorded in 4.8 ps intervals. To assess the stability of the MD simulations, energetic and 
structural data was analyzed over the course of the entire simulation time (Table S3). 
Table S3. Energetic and structural values of the MD simulations. 
Conformation Ligand Average total energy [kcal/mol] Slope* [ps
-1] Average backbone RMSD  
Bent sLex -68804 ± 250 0.018 0.473 ± 0.019 
Bent Glycomimetic 1 -70675 ± 215 0.015 0.481 ± 0.019 
Extended sLex -69939 ± 367 0.026 0.486 ± 0.019 
Extended Glycomimetic 1 -70557 ± 289 0.020 0.507 ± 0.017 
* The slope denotes the change of the total energy over time. 
 
From the collected MD frames, every tenth frame (1000 frames in total) was used to calculate 
the average ∆G applying the molecular mechanics generalized Born surface area (MM-
GB/SA) method implemented in Prime34 (Table S4). 
 
Table S4. Calculated interaction energies of sLex and glycomimetic 1 to both E-selectin conformations. 
Conformation Ligand Average ∆G [kcal/mol] 
Scaled ∆G 
[kcal/mol] 
Bent sLex -45.1 ± 5.2 -3.36 
Bent Glycomimetic 1 -38.3 ± 5.0 -2.86 
Extended sLex -56.1 ± 6.0 -4.18 
Extended Glycomimetic 1 -58.7 ± 6.8 -4.38 
 
The observed high ∆G energies as well as the high dynamic range in comparison to published 
experimental data9 is due to limitations of the MM-GB/SA method. Protein desolvation 
energies, enthalpy–entropy compensation, or overestimation of electrostatic interactions as 
described by Guimarães et al.35,36 are causes of energy overestimation with this method. For a 
more realistic representation of the binding energies, we scaled the calculated results by a 
factor of 13.4 based on published ITC measurements of sLex.9 
Chapter 2.3. – Manuscript 1 
 74 
SCR comparison  
Table S5. List of SCR domain structures solved by X-ray crystallography deposited on the PDB. 
 
PDB Entry No. of SCR 
domains 
No. of disulfide 
bonds per SCR Ref 
This publication 2 3 - 
1C1Z 4 2 37 
1QUB   38 
1CKL 2 2 39 
1H2P (= 1H2Q, 
1H03, 1H04, 
1UOT) 
2 2 15 
   1LY2 2 2 40 
1OJV (= 1OJW, 
1OJY, 1OK1, 
1OK2, 1OK3, 
1OK9) 
3 2 41 
1ZJK 2 2 42 
2W80 (= 2W81) 1 2 43 
2XRD 3 2 44 
2UWN (= 2V8E) 2 2 45 
 
 
 
 
Figure S3. Alignment of E- (SELE), L- (SELL), and P-selectin (SELP) short consensus repeat domains (SCR). 
The disulfide bonds are connected in red. The stabilizing loop glycine interaction with the linker region is 
marked in blue. Residues marked red are potential N-linked glycosylation sites. Sequence alignment was 
performed with the ClustalW2 server.46 
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Lec-EGF comparison  
 
 
 
Figure S4. Sequence alignment of E- and P-selectin Lec (residues 1-120) and EGF-like (residues 121-157) 
domains. Underlined residues are involved in ligand binding and/or Ca2+ coordination in the extended 
conformation (taken from PDB code 1G1S for P-selectin)13. Residues marked red are potential N-linked 
glycosylation sites. 
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The family of selectins with the three members E-, P-, and L-selectin, are key players in 
leukocyte trafficking in physiological and pathophysiological processes.[1] All selectins are 
membrane bound C-type (i.e. calcium dependent) lectins that mediate the initial adhesion of 
leukocytes to endothelial cells. The carbohydrate binding site is located in the N-terminal 
lectin (Lec) domain, which is followed by the epidermal growth factor-like (EGF-like) 
domain, a variable number of short consensus repeats (SCR), a transmembrane region, and a 
C-terminal cytoplasmic tail.[2] The three selectins share a common minimal binding motif, [3] 
namely the tetrasaccharide sialyl Lewisx (1, sLex, (Neu5Ac(α2-3)Gal(β1-4)[Fuc(α1-
3)]GlcNAc), Figure 1), which is presented on cell-surface glycoproteins (e.g. P-selectin 
glycoprotein ligand-1[4] and E-selectin ligand-1[5]). 
Dysregulation of E-selectin presentation on postcapillary venules leads to excessive 
leukocyte recruitment and extravasation that may cause numerous pathophysiological 
situations, e.g. stroke, asthma, psoriasis, or rheumatoid arthritis.[6] Several drug discovery 
programs aiming at selectin inhibition have been launched in the past.[7] In search of drug-
like antagonists for selectin-mediated diseases, sLex (1) has become the lead structure. These 
efforts have resulted in the development of several clinical candidates, e.g. CY-1503,[8] 
TBC-1269[9], or GSC-150[10], and recently GMI-1070, a pan-selectin antagonist with a 
glycomimetic core,[11] which is currently in phase 2 clinical trials for the treatment of sickle 
cell crisis. 
The structural elucidation of the E-selectin Lec and EGF-like domains in absence of ligand[12] 
and the soaked E-selectin/sLex (1) structure[13] enhanced the understanding of the interaction 
on a molecular level. The comparison of both structures revealed no significant changes to 
the binding site residues in presence or absence of the ligand. The two moieties L-fucose 
(L-Fuc) and D-galactose (D-Gal) on sLex (1), as well as the carboxylate group of N-acetyl-D-
neuraminic acid (D-Neu5Ac) form direct contacts to the protein and the Ca2+ ion within the 
binding site. The D-GlcNAc moiety and most of the D-Neu5Ac are solvent exposed. By 
replacing these portions of sLex (1) with hydrophobic moieties, structurally simplified and 
more drug-like antagonists such as CGP69669 (2)[14] with fifteenfold improved affinity, as 
determined by isothermal titration calorimetry (ITC),[15] were developed (Figure 1). Further 
investigations on substituents on the cyclohexane-diol moiety led to the closely related 
antagonist 3, which exhibited a further sixfold improvement in affinity over 2 by optimizing 
the spatial orientation of the L-Fuc and D-Gal moieties.[16] Finally, the introduction of a 
benzoyl group in the 2-hydroxyl position of D-Gal in antagonist 4, further increased affinity 
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fivefold compared to 3.[16] However, the benefits in affinity that arise from benzoylation 
could not be rationalized since any substituent on the 2-hydroxyl group of D-Gal is expected 
to protrude into the solvent assuming an identical binding mode as observed in 
E-selectin/sLex (1) crystal structure.[13] In this report, we provide insights on how D-Gal 
benzoylation increases ligand affinity by aiding the pre-organization of the carboxylic acid 
using a combination of molecular modeling, surface plasmon resonance (SPR), ITC, and 
protein-ligand crystallography. 
 
Figure 1. Series of E-selectin antagonists investigated in this study. The minimal carbohydrate 
binding epitope sialyl Lewisx (sLex, 1) and related glycomimetics CGP69669 (2), 3 and 4. For all sLex 
mimics, D-Neu5Ac was replaced by (S)-cyclohexyl lactic acid. D-GlcNAc has been replaced by (R,R)-
cyclohexane-1,2-diol (→2) or (1R,2R,3S)-3-methyl cyclohexane-1,2-diol (→3, 4). Antagonist 4 is 
additionally benzoylated in the 2-hydroxyl position of D-Gal. KD values from isothermal titration 
calorimetry (KD ITC) for compounds 1-3 are taken from Binder et al.[15] Steady-state KD values from 
surface plasmon resonance (KD SPR) data for compounds 2-4 are taken from Schwizer et al.
[16] 
Two dihedral angles have previously been identified to describe the spatial organization of 
the pharmacophores of sLex (1). The core conformation describes the spatial arrangement of 
L-Fuc and D-Gal, while the acid orientation describes the orientation of the carboxylic acid 
group relative to the Lex core (Figure 2).[14b] These two torsion angles have previously been 
determined for sLex (1) in its protein-bound state by transferred nuclear Overhauser-NMR 
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(trNOE-NMR).[17] In its bioactive conformation, the core conformation of sLex (1) ranges 
between -30° and -55°, and the acid conformation between 105° and 130°.[18] These angles 
were confirmed in the E-selectin structure soaked with sLex (1).[13] Using molecular dynamic 
(MD) simulations, we calculated the two torsion angles in a solvated environment for sLex 
(1), and the three E-selectin antagonists (2-4). As shown in Figure 2, both, the core 
conformation and the acid orientation are well defined for sLex (1), since the angles are 
highly populated within the experimental window. This is thought to be a consequence of the 
exo-anomeric effect,[19] and additionally of intramolecular hydrogen bonds and steric effects 
which limit the movements of the entire tetrasaccharide. The replacements of D-GlcNAc and 
D-NeuNAc by smaller, hydrophobic and unsubstituted residues in compound 2, while greatly 
improving affinity, lead to a small offset in the core conformation as described by Schwizer 
et al.,[16] and additionally introduced flexibility of carboxylic acid. While the introduction of 
the methyl group in the 3-position of cyclohexane-diol in compound 3 counteracted the 
deficit in core conformation, thus leading to improved affinity, the flexibility of the 
carboxylic acid remained similar. The introduction of the bulky benzoate in 2-position of D-
Gal in compound 4 restored the pre-organization of the acid orientation to the position as 
determined for sLex (1).  
With ligand preorganization in the bioactive conformation, two benefits are apparent: i) The 
association rate of binding (kon) is increased since the ligand does not need to reorganize prior 
to binding. Indeed, the association rate of the E-selectin ligand-1 (ESL-1), a glycoprotein 
bearing the pre-organized sLex (1) motif, has a rapid association rate of 7.4⋅104 M-1s-1.[20] ii) 
A restrained ligand usually has decreased entropic costs compared its flexible counterpart, 
since the flexibility is limited prior to complex formation with the protein. We have recently 
shown that sLex (1) binding to E-selectin is an entropy driven process with unfavorable 
enthalpy, an unusual feature for carbohydrate-lectin interactions.[21]  
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"
Figure 2. The acid orientation is a measurement of the carboxylic acid position relative to the Lex 
core. The core conformation describes the spatial arrangement of the core itself. These torsion angles 
were calculated in solution for the ligands 1–4 in absence of protein with 9.6 ns MD simulations. A 
darker shading correlates with higher population in the respective conformation. The red rectangle 
encloses experimental trNOE-NMR data of sLex (1) bound to E-selectin.[17] The measured angles 
from crystallographic structures for E-selectin soaked with sLex (1, cyan, PDB code 1G1T),[13] and the 
co-crystallized compounds (1, magenta; 2, orange; 3, green; 4, yellow) are given. The blue arrow 
indicates the small offset in core-conformation of antagonist 2. 
To address binding kinetics, the association and dissociation constants for antagonists 2–4 
were determined with SPR (Table 1). The dissociation constants (koff) for all three antagonists 
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were similarly rapid, which translated in short half-lives (t1/2) of 0.5–0.8 s. The improvements 
in affinities therefore arise from increasing association constants. The offset in both, the core 
conformation and the acid orientation in compound 2 requires the ligand to adopt an 
energetically unfavored core conformation and freezing of the carboxylic. The pre-
organization of the modified Lex core in antagonist 3 lead to a tenfold faster association rate 
(kon). Finally, the association rate was further enhanced fourfold for compound 4, in which 
both, the core conformation and acid orientation are pre-organized. These observations give 
reason to believe that optimal orientation of the pharmacophores in sLex mimetics greatly 
enhance ligand association, while ligand unbinding remains unaltered. 
Table 1: Binding kinetics of the glycomimetic E-selectin antagonists 2–4 as determined by SPR. 
Ligand KD eq [a] [µM] kon [105 M-1 s-1] koff [s-1] t1/2 [b] [s] 
2 50.4 0.2 1.0 0.7 
3 6.5 2.0 1.3 0.5 
4 1.5 8.5 0.9 0.8 
[a] The KD was derived from steady-state response fit to a single binding site model. 
[b] The half-life (t1/2) was calculated with t1/2=ln2/koff. 
To investigate whether stabilization of the acid orientation translates into the expected 
benefit in entropy, we determined the thermodynamic profile of antagonist 4 by ITC (Table 
2). As previously reported, the Lex core stabilization (2→3) lead an improvement in both, 
enthalpy (ΔΔH = –0.4 kJ mol-1) and, more significantly, in entropy (–TΔΔS = –2.4 kJ mol-1). 
The introduction of the benzoate moiety (3→4) unexpectedly enhanced binding by improving 
enthalpy (ΔΔH = –6.6 kJ mol-1), while showing an unexpected compensation in entropy       
(–TΔΔS = +2.9 kJ mol-1).  
Table 2: Thermodynamic profile of sLex (1) and the glycomimetic antagonists 2–4 as determined by 
ITC.[a] 
Ligand KD [µM] 
ΔG  
[kJ mol-1] 
ΔH  
[kJ mol-1] 
-TΔS 
[kJ mol-1] N 
ΔCp 
[kJ mol-1 K-1] 
1[15] 878 ± 93 –17.5 ± 0.2 +5.4 ± 0.7 -23.0 ± 1.0 1 –0.06 
2[15] 59 ± 4 –24.2 ± 0.2 –5.3 ± 0.4 –18.9 ± 0.6 0.93 ± 0.08 –0.11 
3[15] 19 ± 2 –27.1 ± 0.2 –5.8 ± 0.1 –21.3 ± 0.4 0.97 ± 0.01 n.d. 
4 4.0 ± 0.3 –30.8 ± 0.2 –12.4 ± 0.6 –18.4 ± 0.8 1.00 ± 0.07 –0.16 
[a] ITC data of compounds 1-3, except for the ΔCp values, are taken from Binder et al.[15] KD, ΔH, and 
the stoichiometry N for antagonist 4 were determined by ITC, while ΔG and TΔS were calculated 
using following equation: ΔG = ΔH – TΔS = RTlnKD. Changes in heat capacity ΔCp for compounds 1, 
2, and 4 were determined from measurements at three temperatures (283.15, 298.15K, and 310.15 
K). ΔCp was calculated with following equation: ΔCp = ΔHT2 – ΔHT1 (T2 – T1)-1. 
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Since the overall entropy term, as determined by ITC, is the sum of not only conformational 
entropy, but also solvation entropy of both the protein and the ligand (ΔStot = ΔSconfL + ΔSconfP 
+ ΔSsolvL + ΔSsolvP), it is conceivable that the introduction of a hydrophobic aromatic group in 
antagonist 4 might alter the solvation properties of the ligand. However, the benzoate moiety 
in the 2-position of D-Gal is expected to be solvent exposed after binding and is therefore not 
likely to undergo desolvation upon binding. Changes in heat capacity, ΔCp, are commonly 
referred to as parameter for solvent reorganization, especially of hydrophobic interactions.[22] 
A negative ΔCp value correlates with a burial of non-polar surfaces. To assess changes in heat 
capacity for E-selectin antagonists, we determined the thermodynamic parameters of 
compounds 1, 2 and 4 at three different temperatures (283.15, 298.15K, and 310.15 K). As 
commonly observed for carbohydrate-lectin interactions,[21a, 23] the changes in heat capacity 
for sLex (1) of –0.06 kJ mol-1 K-1 were small and negative. This observation was also 
consistent after introducing hydrophobic portions in antagonists 2 (–0.11 kJ mol-1 K-1) and 4 
(–0.16 kJ mol-1 K-1). These slight differences were within the experimental range. The small 
increase in ΔCp indicate that there was a minimally increase in burial of hydrophobic surfaces 
from sLex (1) to antagonists 2 and 4. 
For further insights into E-selectin-ligand interactions, especially of antagonist 4 in relation to 
antagonist 3, we co-crystallized compounds 1–4 with E-selectin consisting of the four 
N-terminal domains (lectin domain, EGF-like domain, and first two short consensus repeats). 
Compared to the previously reported crystallographic structures of E-selectin without ligand 
or soaked with sLex (1), we have recently demonstrated with sLex (1) and antagonist 3, that 
E-selectin-ligand co-crystallization reveals an alternative overall conformation of the 
protein.[Manuscript 1] We further showed that small-molecule–ligand interactions lead to an 
induced fit of the protein in solution and an overall extension of the protein, which involves 
rearrangements over the entire length of the lectin domain to the EGF-like domain interface 
(Figure 2). This extension is described by a 30° increase in the angle from the Ca2+ ion to 
Trp1Cα at the pivot to Cys144Cα within the EGF-like domain (Figure 2a). Three major 
changes in the direct vicinity of the ligand were identified: i) The loop consisting of the 
amino acid residues 81–89 was entirely rearranged and lead to a constriction around the Ca2+ 
ion an the L-Fuc moiety. Additional direct hydrogen bonds between the 2-hydroxyl group of 
L-Fuc and Gln85 and Glu88 were formed. ii) Rearrangement also allowed for Glu107 to form 
a hydrogen bond with the 3-hydroxyl group of L-Fuc. iii) Co-crystallization of antagonist 3 
showed that Pro46 and its neighboring residues shift towards the D-Gal moiety, allowing for 
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a water-mediated interaction to the 6-hydroxyl group of D-Gal. Overall, these three 
modifications upon an induced fit allowed for a more “pocket-like” binding site topology 
compared to the soaked E-selectin/sLex (1) structure.[12] While the protein underwent 
significant alterations when co-crystallized, the binding mode and the general orientation of 
pharmacophores of sLex (1) and antagonist 3 remained similar to the soaked structure. Here 
we report crystallographic structures of antagonists 2 and 4. Antagonist 2 crystallized in 
similar conditions as sLex (1) as the mimic 3, and showed similar overall conformation of the 
protein. For antagonist 4 however, different crystallization conditions were required to yield 
diffraction quality crystals, which resulted in alternative crystal packing. Nonetheless, the 30° 
increase in the Ca2+–Trp1Cα–Cys144Cα angle as observed in co-crystallized structures with 
ligands 1–3 was conserved. Furthermore, the specific alterations regarding the protein 
backbone surrounding the binding site were also in agreement (Figure 2b). The unexpected 
loss in entropy upon pre-organization (3→4) can therefore not be attributed to a different 
binding mode of antagonist 4 or major differences in the conformation of E-selectin.  
 
Figure 2. Structures of E-selectin soaked with sLex (1, cyan, PDB code 1G1T)[13] or co-crystallized 
(cc) with sLex (1) (magenta), antagonists 2 (orange), 3 (green), and 4 (yellow). The Ca2+ ion is 
depicted as purple sphere. a) Overall conformation of the E-selectin structures. The Ca2+–Trp1Cα–
Cys144Cα angle is marked red and was consistently increased by ~30° for all co-crystallized 
structures compared to the soaked structure. b) Superposition of the protein backbone surrounding 
the ligand. Regions involved in major alterations from the soaked to the co-crystallized structure are 
marked by an arrow. The Lex core of sLex (1) is well aligned between the soaked and co-crystallized 
structure, as well as for antagonists 2–4. Flexibility of the D-Neu5Ac/(S)-cyclohexyl lactic acid is 
apparent. 
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Detailed inspection of the (S)-cyclohexyl lactic acid moiety and the side-chain rotamers of 
amino acid residues within the binding site, however, revealed significant alterations. While 
most binding site residues, especially those interacting with the L-Fuc and D-Gal moieties, 
have identical orientations (Figure 3a), significant changes are observed for the two residues 
Glu98 and Lys99 (Figure 3b). The benzoate on D-Gal in antagonist 4 provides for sigma-pi 
interactions to the cyclohexane moiety with a distance of 3.7 Å of the closest heavy atom to 
the centre of the aromatic ring. This intramolecular interaction shifts the cyclohexane moiety 
into a slightly different position, as indicated by the arrow in Figure 3b. The absence of the 
aromatic benzoyl group allows for more flexibility of the (S)-cyclohexyl lactic acid in 
antagonists 2 and 3. Indeed, comparing the crystallographic b-factors, which give an 
indication for thermal motion of the cyclohexyl moiety for antagonists 3 and 4 to their 
respective modified Lex core, the values are significantly higher in antagonist 3, while being 
similar to the modified Lex core in antagonist 4. This is also true for b-values for the 
carboxylic acid, which are also increased in compound 3. Thermodynamically speaking, a 
more steady orientation of the carboxylic acid might allow for higher quality and 
energetically improved interactions of the carboxylic acid to Tyr48 and Arg97 and might 
therefore account for some of the increase in enthalpy. The interplay of the cyclohexane ring 
and the benzoate in compound 4 prior to binding that leads to rigidification of the molecule is 
expected lead to beneficial entropy. Concerning the binding site, differences in the side-chain 
orientation of Glu98 and Lys99 were observed, while being conserved along the backbone. 
The side-chain atoms of these two residues in the structure of antagonist 3 exhibit greater b-
values compared to their backbone atoms, suggesting flexibility. With compound 4, the b-
values of Glu98/Lys99 side-chain atoms are, again in comparison to their respective 
backbone atoms, not increased to the extent observed with antagonist 3. Furthermore, 
different side-chain rotamers are adopted that allowed the cyclohexane ring to be 
accommodated between the two residues. This provided for hydrophobic interactions, as 
indicated by distances of the cyclohexane ring of 3.7 Å and 3.9 Å to Glu98Cγ and Lys99Cγ, 
respectively. These interactions might benefit from the slight reorientation and stabilization 
of the cyclohexane moiety, which is likely caused by the intramolecular sigma-pi interaction. 
By interacting with the cyclohexane moiety in antagonist 4, their flexibility is limited which 
might account for loss in entropy. Furthermore, such hydrophobic interactions require highly 
ordered water molecules surrounding the surfaces to be released into bulk water upon 
binding, a process that is accompanied by a large gain in entropy.[24] These classical 
hydrophobic interactions are accompanied by small favorable enthalpic contributions that are 
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strongly temperature dependent (ΔCp). In contrast, non-classical hydrophobic interactions are 
largely driven by enthalpic contributions.[22b] Here, water molecules surrounding hydrophobic 
surfaces form strong interactions to bulk water upon desolvation,[22c] especially for water 
molecules in hydrophobic cavities, where they are not well ordered. Such a non-classical 
hydrophobic behavior has previously been observed for ligands of increasing 
lipophilicity.[22c, 25] However, no data on surface-exposed binding sites exist. 
 
Figure 3. E-selectin co-crystallized with the flexible antagonists 3 (green), and the pre-organized 
antagonist 4  (yellow). a) Comparison of binding site residues in direct or water-mediated (Pro46) 
contact to the ligands (transparent). All residues are in identical orientations, except for Glu89 and 
Lys99 side-chains. The water mediating an interaction to Pro46 is shown as green or yellow sphere. 
The Ca2+ ion is depicted as purple sphere. b) Comparison of crystallographic b-values in blue (low 
b-value), white (average), and red (high). For the Glu98 and Lys99 side-chains, the b-values were 
normalized against their backbone atoms. For each ligand, the b-values of the (S)-cyclohexyl lactic 
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acid were normalized against the modified Lex core. The arrow indicates the shift of the cyclohexane 
ring orientation. c) Water clustering surrounding the benzoate moiety of antagonist 4 and the Arg84 
side-chain. Connected lines are drawn for distances up to 3.2 Å. Water molecules with near-identical 
positions in the structures with antagonist 3 or 4 are marked by arrows. 
Finally, the Arg84 residue, belonging to the 81–89 loop involved in the induced fit, is shifted 
towards ligand without directly contributing to binding.[Manuscript 1] In the co-crystal structure 
with antagonist 3, the Arg84 side-chain adopts various rotamers, thus suggesting flexibility. 
With antagonist 4, however, the Arg84 is in a well defined orientation, and is surrounded by a 
cluster of water molecules which extend to the carboxylic oxygen of the benzoate moiety 
(Figure 3c). This water cluster might lead to a stabilization of the guanidinium moiety of 
Arg84, thus further being detrimental for entropy. However, the importance of such effects 
that propagate over several water molecules are difficult to quantify. 
The above observations regarding the flexibility of (S)-cyclohexyl lactic acid, Arg84, Glu98, 
and Lys99 were also observed in the structure with antagonist 2 (not shown), further 
suggesting that these effects are indeed a direct consequence of D-Gal benzoylation. 
In summary, we provide kinetic, thermodynamic, and crystallographic insights for a series of 
glycomimetic E-selectin antagonists. sLex (1) is a rigid carbohydrate with optimal core 
conformation and rigid acid orientation. Substitution of D-GlcNAc and D-Neu5Ac with 
(1R,2R)-cyclohexane-1,2-diol and (S)-cyclohexyl lactic acid (→ 2), respectively, results in 
improved affinity due to alteration of solvation properties.[15] However, this antagonist suffers 
from an offset in core conformation and from flexibility of the acid orientation.[16] 
Methylation of the 3-position of cyclohexane-diol (→ 3) corrects the deficit in core 
conformation, while the acid orientation remains flexible. Finally, we propose that 
benzoylation of the 2-position of D-Gal (→4), pre-organizes the acid orientation by forming 
sigma-pi interactions with the cyclohexane ring. While ligand pre-organization lead to the 
expected increase in association kinetics, comparison of the thermodynamic profiles of 
antagonist 3 → 4 revealed a significant increase in enthalpy accompanied by an unexpected 
loss in entropy. Such paradox entropic behavior has previously been reported for the flexible 
and constrained ligands to the SH2 domain of the growth factor receptor-bound protein 2 
(Grb2),[26] where more interactions and closer contact of the protein with the pre-organized 
ligands were observed. Based on co-crystallization of E-selectin antagonists 2–4, we 
observed that: i) intramolecular interactions in antagonist 4 lead to a more rigid orientation of 
the acid orientation, ii) the two residues Glu98 and Lys99 are rigidified and form 
Chapter 2.4. – Manuscript 2 
 91 
hydrophobic interactions, and iii) water clustering occurs surrounding the benzoate group. 
While quantitative dissection of each of these observations is troublesome, we provide a 
qualitative explanation for the entropic paradox of ligand pre-organization of antagonist 4. 
The fact that E-selectin undergoes an induced fit upon binding also needs to be taken into 
consideration. Higher ligand affinity could lead to a more stable adoption of the induced fit 
conformation, which might also be reflected in the thermodynamic profile. Also such effects 
are difficult to quantify and are largely elusive.  
Regarding kinetics of glycomimetic small-molecule E-selectin antagonists, the major future 
challenge is to improve half-lives (t1/2), since this often can be directly translated into 
compound efficacy.[27] With structural information on the induced-fit conformation of the 
lectin domain, rational drug design can now move forward towards high-affinity antagonists 
with long half-lives. 
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1. MD simulations of solution conformations 
The mixed torsional/low-mode sampling algorithm implemented in MacroModel[S1] (version 
9.8107) in conjunction with the OPLS 2005 force-field[S2] was used to find the global minima 
of ligands in implicit solvent conditions (GB/SA, water). The global minimum conformation 
was then positioned in the center of an orthorhombic periodic boundary system extending by 
12.0 Å beyond the ligand structure in each (x, y, z) direction and surrounded by the TIP3P 
water molecules. Sodium counterions were added in order to neutralize total charge of the 
system to zero. The system was then minimized using Desmond simulation software 
(provenance 2.3.4.1).[S3]  Simulated annealing (SA) at constant volume was employed in 
order to provide the compounds an option to readjust their conformation as well as to 
organize surrounding solvent molecules for optimal interaction. SA setup details (Desmond): 
for the initial period of 30 ps the system was equilibrated at 0 K. From 30 to 300 ps the 
temperature was gradually increased to 400 K, from 300 to 500 ps maintained at 400 K and 
from 500 to 1000 ps the system was slowly cooled down to 300 K followed by the final 
equilibration from 1000 to 1200 ps. After this preparatory step a 9.6 ns long production phase 
molecular dynamics (MD) simulation was then performed in Desmond. Snapshots of the 
system were taken every 2.4 ps, thus overall 4000 frames were saved from the production 
phase. For each saved frame the two most important structural descriptors – the core 
conformation and the acid orientation of the ligand – were evaluated. The distribution of the 
to descriptor values was plotted in a gradient-colored histogram. 
2. Synthesis of antagonists 2-4 
Antagonist {(1R,2R)-2-[(α-L-Fucopyranosyl)oxy]-cyclohex-1-yl} 3-O-[sodium (1S)-1-
carboxy-2-cyclohexyl-ethyl]-β-D-galactopyranoside (2) was synthesized according to Kolb 
and Ernst.[S4] Antagonists {(1R,2R,3S)-2-[(α-L-Fucopyranosyl)oxy]-3-methyl-cyclohex-1-yl} 
3-O-[sodium (1S)-1-carboxy-2-cyclohexyl-ethyl]-β-D-galactopyranoside (3) and 
{(1R,2R,3S)-2-[(α-L-Fucopyranosyl)oxy]-3-methyl-cyclohex-1-yl} 2-O-benzoyl-3-O-
[sodium (1S)-1-carboxy-2-cyclohexyl-ethyl]-β-D-galactopyranoside (4) were synthesized 
described by Schwizer et al.[S5] 
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3. Protein expression and purification 
Human E-selectin consisting of the lectin domain, the EGF-like domain and the six short 
consensus repeats fused to the Fc-part of human IgG1 (E-selectinLEC6-IgGFc) was expressed 
an purified according to Binder et al.[S6] This construct was used for ITC and SPR 
experiments. For co-crystallization, a deglyosylated monomeric construct consisting of the 
lectin domain, EGF-like domain and the first two short consensus repeats (E-selectinLEC2) 
was expressed and purified according to Preston et al.[Manuscript 1]  
4. Surface plasmon resonance (SPR) 
SPR measurements of antagonists 2–4 were performed as previously described.[S5] Briefly, a 
research grade CM5 sensor chip (GE Healthcare, Freiburg, Germany) was functionalized 
with polyclonal anti-human IgGFc antibody (Sigma Aldrich GmbH, Buchs, Switzerland) via 
amine coupling according to the protocol of the manufacturer and subsequently with 
E-selectinLEC6-IgGFc. A reference cell was not functionalized with E-selectin. Ligands were 
injected in HBS-P buffer (10 mM HEPES, pH 7.4, 150 mm NaCl, 0.002% v/v surfactant 
P20) supplemented with 20 mM CaCl2 and 2.5 % DMSO. Steady-state KD, association (kon) 
and dissociation constants (koff) were determined with the Scrubber 2.0a software (BioLogic 
Software). All experiments were run on a Biacore 3000 instrument (Biacore, Uppsala, 
Sweden). Half-life values (t1/2) were calculated with equation S1. 
€ 
t1/ 2 = ln(2 /koff )  Eq. S1 
5. Isothermal titration calorimetry (ITC) 
ITC measurements of compound 4 were performed and analyzed at 298.15 K as previously 
reported.[S6] The measurement was performed in tripcliate with protein (E-eslectinLEC6-IgGFc) 
concentrations between 30–45 µM, and ligand concentrations of 475–1000 µM. For 
measurements of heat capacities (ΔCp) of compounds 1, 2, and 4, measurements were 
performed at 283.15 K and 310.15 K. Together with data from measurements at 298.15 K, 
the enthalpy (ΔH) was calculated using equation S2. 
  
€ 
ΔCp =
ΔH°T2 − ΔH°T1
(T2 −T1)
  Eq. S2 
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6. E-selectin co-crystallization with compounds 2 and 4 
E-selectinLEC2 was expressed in kifunensine-treated Chinese hamster ovary (CHO) cells, 
which yielded active, high-mannosylated protein as previously described.[Manuscript 1] The high-
mannose N-linked glycans were cleaved with endoglycosidase Hf and concentrated in 10 mM 
Tris-HCl, 5 mM CaCl2 to approximately 50 mg/mL. E-selectin-ligand co-crystals were grown 
at 20 °C in sitting-drop vapor diffusion. Initial crystals for E-selectin/2 were obtained at 25 
mg/ml protein with tenfold molar excess (10 mM) of antagonist 2 in 23 % v/v PEG8000, 0.1 
M MOPS pH 6.2, and 0.2 M CaCl2 within 24 hours. Final crystals for diffraction 
measurements were grown in decreased precipitation concentrations (13.5 % PEG8000) 
under the same conditions after microseeding. For antagonist 4 co-crystallization, E-
selectinLEC2 (25 mg/ml) was incubated with a 10 mM precipitated solution of the ligand at 37 
°C for 2 h. Remaining ligand precipitation was removed by brief centrifugation. With the 
same conditions as for antagonist 3, antagonist 4 yielded only thin and bent crystals. Initial 
co-crystals with antagonist 4 were grown in 20 % PEG8000, 0.1 M Tris-HCl pH 8.0, and 0.2 
M LiCl within 48 hours. Crystal conditions were optimized with microseeding to 15 % 
PEG8000, 0.1 M glycine pH 9.5, and 1.0 M LiCl. Both, co-crystals with antagonist 2 and 4 
were flash cooled to 100 K with perfluoropolyether (Hampton Research, CA) as 
cryoprotectant. Data was collected with synchrotron radiation (λ = 0.99987 Å for antagonist 
3, λ = 1.00000 Å for antagonist 4) at the PXI (3) or PXIII (4) beamline at the Swiss Light 
Source, Switzerland. 
7. Structure determination and refining 
Diffraction images were indexed, processed, and scaled with the XDS package.[S7] The 
structures were solved by molecular replacement with PHASER[S8] using the structure of 
E-selectin/3.[Manuscript 1] The structures were refined with the BUSTER software[S9] and 
adjusted with the COOT software.[S10] Geometric restraints of antagonists 2 and 4 were 
generated with the PRODRG server.[S11] In the E-selectin/3 co-crystal, 10 (1.82 %) residues 
are Ramachandran outliers, while 28 (5.1 %) are in the allowed region. In the E-selectin/4 co-
crystal structure, 12 residues (2.3 %) are Ramachandran outliers, while 10 (1.9 %) are in the 
allowed region. The statistics are given in Table S1. Figures were generated with the Visual 
Molecular Dynamics (VMD) software.[S12] 
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Table S1. Data collection and refinement statics. 
 E-selectin/2 E-selectin/4 
Data collection   
Space group P1 P1 
Cell dimensions   
    a, b, c (Å) 52.3, 58.9, 59.2   51.0, 58.2, 65.7 
    α, β, γ (°)  75.9, 86.9, 86.5 83.3, 80.9, 90.4 
Resolution (Å) 23.58– 2.05 (2.10–2.05) 29.92–1.90 (1.95–1.90) 
CC (1/2) 99.9 (91.4) 99.8 (76.7) 
I / σI 15.1 (2.1) 12.1 (2.2) 
Completeness (%) 92.4 (92.4) 96.3 (91.9) 
Redundancy 1.8 (1.8) 3.4 (3.2) 
   
Refinement   
Resolution (Å) 23.58– 2.05 (2.10–2.05) 29.92–1.90 (1.95–1.90) 
No. reflections 39578 56270 
Rwork / Rfree 22.4 / 25.6 19.1 / 23.3 
No. atoms   
    Protein 4380 4455 
    Ligand/ion 469 855 
    Water 191 599 
B-factors   
    Protein 62.8 30.6 
    Ligand/ion 79.4 42.8 
    Water 58.4 36.6 
R.m.s. deviations   
    Bond lengths (Å) 0.010 0.010 
    Bond angles (°) 1.24 1.19 
Single crystals were used for structure determination. Values in parentheses are for highest-resolution 
shell. 
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The C-type lectin E-selectin mediates the rolling of circulat-
ing leukocytes on vascular endothelial cells during the in-
ﬂammatory process. In numerous studies, the S128R
mutation of the E-selectin was associated with cardiovascu-
lar and autoimmune diseases. There is evidence that the
S128R E-selectin mutation leads to a loss in ligand speciﬁ-
city, thus increasing leukocyte recruitment. Apart from the
natural tetrasaccharide ligand sialyl Lewisx (sLex), it has
previously been proposed that non-fucosylated carbohy-
drates also bind to S128R E-selectin. To evaluate the thera-
peutic potential of the antagonism of the E-selectin mutant,
ligand speciﬁcity was reinvestigated on a molecular basis.
We determined the ligand speciﬁcity of wild-type and
S128R E-selectin in a target-based competitive assay, a
glycan array screen and cell-based binding assays under
static and ﬂow conditions. Regarding ligand-speciﬁcity, the
binding properties of S128R E-selectin were identical to
those of wt E-selectin, i.e., no mutant-speciﬁc binding of
3′-sialyl-N-acetyllactosamine, heparin, fetuin and K562
cells was observed. Additionally, the binding afﬁnities of
glycomimetic E-selectin antagonists were identical for wt
and S128R E-selectin. Overall, the previous reports on
carbohydrate ligand promiscuity of S128R E-selectin could
not be conﬁrmed.
Keywords: E-selectin / selectin antagonists / single-nucleotide
polymorphism / sLex mimic / S128R
Introduction
In case of inﬂammation, the human body possesses a highly
sophisticated defense line. At the initial stage, the members of
the selectin family, E-, P- and L-selectin, play an important role
by recruiting leukocytes to the inﬂammatory site (Kansas
1996). However, excessive extravasation of leukocytes leads to
tissue damage being deleterious for numerous diseases with an
inﬂammatory component (Ernst and Magnani 2009). Blocking
selectins with selectin antagonists is, therefore, regarded as a
promising anti-inﬂammatory treatment.
Selectins are C-type (calcium dependent) lectins consisting
of a C-terminal cytoplasmic domain followed by a transmem-
brane region, variable numbers of short consensus repeats
(SCRs), an epidermal growth factor-like (EGF-like) domain
and an N-terminal lectin domain. Their physiological ligands
such as the P-selectin glycoprotein ligand-1 (PSGL-1) (McEver
and Cummings 1997; McEver 2001) and E-selectin ligand-1
(ESL-1) (Steegmaier et al. 1995) contain the common tetrasac-
charide epitope sialyl Lewisx (sLex, NeuNAcα2-3Galβ1-4
(Fucα1-3)GlcNAc; Figure 1A) as part of O-glycosylated glyco-
proteins. The structural analysis of E- and P-selectin soaked
with sLex revealed the central role of the L-fucose moiety,
which coordinates the Ca2+ ion with its 3- and 4-hydroxyl
groups (Somers et al. 2000).
In recent years, several case–control studies have suggested a
correlation of a single-nucleotide polymorphism (SNP) in exon
4 of the E-selectin encoding gene with an early onset, increased
susceptibility and severity of various, mainly cardiovascular
and immune diseases. These include myocardial infarction
(Yoshida et al. 2003; Stepień et al. 2011), severe recurrent
venous thromboembolism (Jilma et al. 2005, 2006) and the for-
mation of colon metastasis (Alessandro et al. 2007). The SNP
causes a mutation of serine 128 to arginine (S128R) and is
present in 10–15% of the Caucasian population (Wenzel et al.
1994). The mechanism by which the S128R mutation alters the
physiological function of E-selectin at molecular level is still
unclear, since the mutation is located in the EGF-like domain
and not in the carbohydrate recognition domain (CRD) of the
lectin. Based on the crystal structure of E-selectin (lectin and
EGF-like domain), a direct or indirect involvement of the
Ser128 in ligand binding is unlikely (Figure 1B and C) (Graves
et al. 1994; Somers et al. 2000).
All previous reports on the binding properties of the S128R
E-selectin mutant are summarized in Table I. First, Revelle et al.
showed a 2- to 3-fold increased adherence of S128R E-selectin to
HL60 cells compared with wt E-selectin (Revelle et al. 1996).
Furthermore, only S128R E-selectin was capable of binding to
heparin and to K562 cells, a cell line lacking fucosyltransferase
VII required for sLex biosynthesis (Snapp et al. 1997). They also
showed that the binding of heparin and K562 cell to the S128R
E-selectin mutant was reversed by the sLex precursor 3′-sialyl-
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N-acetyllactosamine (3′SLN, NeuNAcα2-3Galβ1-4GlcNAc) or
3′-sialyllactose (3′SL, NeuNAcα2-3Galβ1-4Glc) (Figure 1A), in-
dicating that the presence of the L-fucose moiety was no longer
required. Furthermore, Revelle et al. (1996) demonstrated that the
binding of HL60 cells (which express the sLex epitope) was abol-
ished with soluble sLex or an anti-sLex antibody for wt E-selectin,
Fig. 1. (A) The natural ligand of E-selectin is sialyl Lewisx (sLex). The proposed S128R E-selectin speciﬁc trisaccharide 3′sialyllactose lacks the L-fucose moiety.
(B) The crystal structure of the wt E-selectin/sLex complex. The residues 135–139 form interactions with the lectin domain (Lec), EGF (epidermal growth factor
like domain). (C) The side chain of the Ser128 residue forms a hydrogen bond to the backbone carbonyl of Lys152. This area is rigidiﬁed by two disulﬁde bonds
(Cys144-Cys153 and Cys127-Cys142).
Table I. Summary of the reported binding properties of the S128R E-selectin mutant
Revelle et al. (1996) Wenzel et al. (1999) Rao et al. (2002) Yoshida et al. (2003) This publication
Assay type Protein–cell Cell–cell Cell–cell Cell–cell Protein–ligand/cell
Assay conditions Static Static Flow Flow Static
wt and S128R
E-selectin constructs
Soluble Lec-EGF-CR2/IgG Full length on COS Full length on CHO Full length on
HUVEC
Soluble Lec-EGF-CR2/IgG
HL60 Higher binding of S128R than wt;
S128R not inhibited by sLex or
anti-sLex-Ab
Lower binding of
S128R than wt
Higher binding of
S128R than wt
Higher binding of
S128R than wt
Equal binding of wt and
S128R
K562 S128R binding not inhibited by
anti-sLex-Ab
n.d. Binding only of
S128R
n.d. No binding of S128R
3′SL/3′SLN Inhibition of S128R binding to
K562 and fetuin
n.d. n.d n.d. No binding of S128R
Heparin Binding only of S128R n.d. No binding of
S128R
n.d. No binding of S128R
Bovine fetuin Binding only of S128R n.d. n.d. n.d. No binding of S128R
sLex/sLea n.d. n.d. n.d. n.d. Equal binding of wt
and S128R
n.d., not determined.
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but did not affect binding of S128R E-selectin. Finally, the S128R
E-selectin mutant showed speciﬁc binding to bovine fetuin, a
glycoprotein lacking fucosylated glycans (Green et al. 1988),
further suggesting a shift in ligand speciﬁcity.
In contrast, Wenzel et al. (1999) reported cell-based assays
under static conditions that showed diminished adhesion
of HL60 cells to a COS cell monolayer bearing the S128R
E-selectin mutant compared with the wt E-selectin counterpart.
Later, Rao et al. (2002) observed that only chinese hamster
ovarian cells (CHO) cells displaying the S128R E-selectin mutant
were able to tether K562 cells under ﬂow conditions, an effect
that was not observed with wt E-selectin. However, no inhibitory
effect of heparin for S128R E-selectin as suggested by Revelle
et al. (1996) was observed. Since neuraminidase or O-sialogly
coprotein endopeptidase treatment of the K562 cells was not
deleterious for their tethering toward S128R E-selectin expres-
sing CHO cells, Neu5Ac- as well as O-linked glycoprotein-
independent binding to the S128R mutant was implied.
Finally, Yoshida et al. (2003) reported increased attachment
of HL60 cells toward human umbilical vein cells (HUVECs)
displaying S128R E-selectin compared with those displaying
wt E-selectin.
Since the S128R E-selectin polymorphism is correlated with
numerous diseases, we aimed to re-evaluate its binding speciﬁ-
city at molecular level and additionally determine the potency
of E-selectin antagonists which were originally designed for
the wt E-selectin. We used a cell-free, target-based assay, which
is routinely applied for screening of E-selectin antagonists
(Weitz-Schmidt et al. 1996; Thoma et al. 1997). In addition, in
a cell-based assay setup, we investigated the binding of HL60
and K562 cells under static and ﬂow conditions.
Results
Characterization of wt and S128R E-selectin
For the afﬁnity determination of three E-selectin antagonists and
for further functional analyses, we recombinantly expressed a wt
E-selectin construct containing the lectin domain, the EGF-like
domain and the ﬁrst two SCRs and the corresponding S128R
mutant as IgG chimera. The binding properties of the proteins
were evaluated in a cell-free, target-based assay and additionally
in a cell-based assay under static and ﬂow conditions.
The proteins were expressed in CHO cells followed by
functional puriﬁcation with the functional monoclonal anti-E-
selectin antibody 7A9 (see experimental part). The fact that the
7A9-antibody bound S128R E-selectin suggests correct folding
of the protein. The sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) analysis showed a similar appar-
ent molecular weight of 100 kDa, suggesting equal glycosyla-
tion of the wt and the mutant E-selectin (Figure 2A). The
presence of the mutation was conﬁrmed by DNA sequencing
and at protein level by liquid chromatography-tandem mass
spectrometry analysis (data not shown).
For the evaluation of protein activity, we determined the
binding afﬁnities of the natural carbohydrate ligands sLex and
sLea to wt and S128R E-selectin as shown in Figure 2B. For wt
E-selectin, the EC50 values for biotinylated sLe
x- and sLea-poly-
acrylamide polymer (sLex- PAA, sLea-PAA) were 119.5 ± 17.1
ng/mL and 26.2 ± 1.3 ng/mL, respectively. The higher afﬁnity of
sLea compared with sLex for recombinant E-selectin has previous-
ly been reported with a comparable assay (Weitz-Schmidt et al.
1996; Thoma et al. 1997). Similar afﬁnities were also obtained
with S128R E-selectin, with EC50 values of 93.8 ± 13.1 ng/mL
for sLex-PAA and 27.2 ± 1.2 ng/mL for sLea-PAA. Using concen-
trations of the biotinylated 3′SL-polyacrylamide polymer (3′
SL-PAA) of up to 3 µg/mL, no binding was observed for both wt
and S128R E-selectin, suggesting no or very low afﬁnity. The
evaluation of higher concentrations of 3′SL-PAAwas not possible,
as the background signal increased signiﬁcantly.
SLex glycomimetics are efﬁcacious for S128R E-selectin
The binding afﬁnities of three previously reported E-selectin
antagonists for wt and S128R E-selectin are shown in Figure 2C.
In all the three of these sLex mimics, the Neu5Ac moiety has
been exchanged with (S)-cyclohexyl lactic acid. For antagonist 1
(Norman et al. 1998), GlcNAc has been replaced with (1R,2R)-
cyclohexane-1,2-diol and for antagonist 2 and 3 (Schwizer et al.
2012), with (1R,2R,3S)-3-methylcyclohexane-1,2-diol. For an-
tagonist 3, the 2-hydroxyl group of D-galactose is additionally
benzoylated. The half-maximal inhibitory concentration (IC50)
values of all three ligands were similar for the wt as well as
S128R E-selectin. In agreement with previously reported results
(Schwizer et al. 2012), the afﬁnities of compounds 2 and 3 were
approximately 4- and 14-fold higher than that of antagonist 1, re-
spectively. The absolute IC50 values obtained here are, however,
weaker than previously reported due to the presence of only two
SCR domains instead of six SCR domains, which is known to
reduce E-selectin afﬁnity (Li et al. 1994).
Evaluation of putative S128R E-selectin ligands
According to Revelle et al. (1996), bovine fetuin and heparin dir-
ectly interact with S128R E-selectin, and 3′SLN interferes with
the mutant binding to K562 cells. For the evaluation of their afﬁn-
ities (see experimental part) single concentrations of the carbohy-
drate ligands (3′SLN: 10 mM, bovine fetuin: 10 mg/mL, heparin;
10 mg/mL) were used to enable clear inhibition. As a result, the
binding of sLex-PAA to wt and S128R E-selectin was not inhib-
ited by any of the three substances (Figure 3A). In a control ex-
periment, the assay was also performed with wt P-selectin, for
which heparin is a known ligand (Nelson et al. 1993; Wang and
Geng 2003). As shown in Figure 3A, sLex-PAA binding to wt
P-selectin was completely abolished in the presence of heparin.
In addition to the target-based assays, further investigations
of the binding properties of S128R E-selectin were performed
with a cell-based assay under static and ﬂow conditions. In
the static assay, the adhesion of HL60 and K562 cells to wt
and S128R E-selectin was determined. Revelle et al. (1996)
reported that under static conditions the sLex-presenting HL60
cells adhere to both wt and mutant E-selectin, whereas the
sLex-deﬁcient K562 cells selectively bind S128R E-selectin. In
our assay, ﬂuorescently labeled HL60 and K562 cells were
allowed to bind to E-selectin coated on microtiter plates (see
Figure 3B). HL60 cells bind to both forms of E-selectin and
since the addition of the functional anti-E-selectin antibody
7A9 inhibited binding entirely, both interactions are clearly
E-selectin dependent. For the K562 cells, however, no binding
to either form of E-selectin was observed, albeit the high
number of applied cells. In the ﬂow assay, adhesion of HL60
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cells was studied at physiologic shear stress (Figure 3C). Again,
the number of initially tethered and consequently rolling cells
was similar for wt and S128R E-selectin. While at low shear
stress (1 dyne/cm2) the highest number of cells tethered and
rolled on wt and mutant E-selectin coated surfaces, decreased
tethering was observed when higher shear forces were applied
(2 and 3 dynes/cm2). At 5 dynes/cm2, tethering was entirely
abolished. Addition of EDTA completely abolished HL60 cells
from binding to both forms of E-selectin, thus conﬁrming the
calcium-dependent binding (data not shown).
Glycan array screening
To identify potential novel ligands of S128R E-selectin, a glycan
array screening was performed at the Core H facilities of the Con-
sortium for Functional Glycomics. In this analysis, 465 glycan
structures (version 4.1) were tested, including the tetrasaccharides
sLea and sLex and derivatives thereof such as 3′SLN, Lea and
Lex. For comparison, wt and S128R E-selectin were analyzed in
parallel. Binding of the E-selectin constructs was detected with
Alexa Fluor® 488 labeled anti-IgG antibody and was quantiﬁed
by measuring ﬂuorescence intensities as shown in Figure 4.
The results clearly indicate that both proteins preferentially
bind to glycan structures bearing sLea and sLex, thus conﬁrm-
ing the result of the competitive binding assays. In addition,
binding to 3-sulfated Lewisa and Lewisx was also observed for
both E-selectin constructs. Finally, the S128R mutant did not
exhibit any afﬁnity for 3′SLN or any other non-fucosylated
glycan. For both proteins, the ten best binding glycan structures
contain a fucose moiety. This result underlines the importance
of the fucose moiety for the binding of wt E-selectin and the
corresponding mutant S128R E-selectin.
Discussion
A SNP of E-selectin in which the serine residue at position 128
is substituted by arginine was shown to correlate with various
cardiovascular and immune diseases (Yoshida et al. 2003;
Fig. 2. (A) SDS-PAGE analysis of recombinant wt and S128R E-selectin puriﬁed by afﬁnity chromatography on a 7A9-Sepharose column as described in the
Materials and methods section. M, molecular weight marker. (B) Determination of the EC50 values for sLe
x-, sLea- and 3′SL-PAAwith wt E-selectin (B, upper
panel) and S128R mutant (B, lower panel). For this assay microtiter plates were coated overnight with either wt or S128R E-selectin (3 µg/mL), blocked with BSA
(2%) and incubated with increasing concentrations of sLex-PAA. The bound polymer was detected by colorimetric reaction at 415 nm. The assay was repeated three
times, each in duplicate as described in the Materials and methods section. (C) Competitive binding assay for the determination of IC50 for antagonists 1-3 with wt
and S128R E-selectin. The assay was performed as described in the Materials and methods section.
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Jilma et al. 2006; Alessandro et al. 2007). The mutation is
located in the EGF-like domain of E-selectin, which is neces-
sary for, but not directly involved in, ligand binding (Erbe et al.
1992). Revelle et al. (1996) reported that the regular physio-
logical E-selectin ligand, the tetrasaccharide sLex was no
longer required for S128R E-selectin to interact with HL60 and
K562 cells.
In competition assays with K562 cells or heparin, 3′SL and
3′SLN were identiﬁed as ligands for S128R E-selectin.
Furthermore, the glycoproteins heparin and bovine fetuin were
shown to interact only with S128R E-selectin and not with wt
E-selectin. Interestingly, the E-selectin R84A mutation, which
is located adjacent to the carbohydrate-binding site, showed
identical binding behavior as the S128R mutant. Binding of
E-selectin-R84A to fetuin, however, was not observed in a pre-
vious publication, notably with the identical assay (Kogan et al.
1995). In contrast, Rao et al. (2002) reported that heparin did
not inhibit S128R E-selectin binding to K562 cells. As stated
above, the adverse effects of the S128R mutation were
investigated in a number of case–control studies for a variety of
diseases, indicating that the loss of ligand speciﬁcity is possibly
correlated with an increased leukocyte recruitment which in
turn leads to pathophysiological situations.
Selectin antagonists have unequivocally been shown to inter-
fere with excessive recruitment of leukocytes upon inﬂammation
in vivo (Mulligan et al. 1993; Norman et al. 1998; Ridger et al.
2005). For the development of such antagonists, functional and
structural information on the target protein are a prerequisite. For
this purpose and due to the controversial reports on the binding
properties of the S128R mutant, we decided to express the
S128R mutant and the corresponding wt E-selectin as secreted
IgG forms. Using cell-free target-based and cell-based binding
assays, we assessed the binding properties of S128R E-selectin
in comparison with the wild-type (wt). For wt and mutant
E-selectin, no signiﬁcant difference in the afﬁnity for sLea and
sLex was observed, indicating that the carbohydrate-binding site
of the E-selectin mutant is not altered.
Fig. 3. Evaluation of the binding of 3′SLN (10 mM), heparin (Hep) (10 mg/mL) and bovine fetuin (Fet) (10 mg/mL) to wt E-selectin and S128R mutant (A).
Microtiter plates were coated with either wt or S128R E-selectin (3 µg/mL), blocked with BSA (2%) and incubated with a ﬁxed concentration of sLex-PAA (20 ng/
mL), either in the presence or in the absence of Hep and Fet. As positive control wt P-selectin was co-incubated with sLex-PAA (20 ng/mL) and heparin (10 mg/mL).
(B) Cell-based static binding assay with HL60 and K562 cell lines. Microtiter plates were coated with either wt or S128R E-selectin (10 µg/mL), blocked with BSA
(2%) and incubated with the ﬂuorescently labeled cells (2 × 105 cells/well), in the presence or absence of anti-E-selectin antibody 7A9 (20 µg/mL). Bound cells
were measured by ﬂuorescence measurements at 492 nm excitation and 517 nm emission wavelengths. The assay was repeated twice, each in duplicate as described
in the Materials and methods section. (C) Cell-based ﬂow binding assay with HL60 cells at physiological shear stress. Flow chambers were coated with protein
A (50 µg/mL) and subsequently with wt or S128R E-selectin (50 µg/mL). The HL60 cells (1 × 106 cells/mL) were perfused at given shear stress (1–5 dynes/cm2).
Cells were counted after 10 min at three points along the ﬂow chamber. The error bars correspond to the standard error of the mean of the three points.
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To investigate a potential treatment of patients carrying the
S128R E-selectin polymorphism, binding afﬁnities of three
E-selectin antagonists were determined (Figure 2C). We dem-
onstrate that regardless of the S128R mutation, binding afﬁn-
ities for all antagonists were similar when compared with wt
E-selectin. This further conﬁrmed that carbohydrate-binding
site of S128R E-selectin was intact and suggests a possible ap-
plication of such sLex mimics in the treatment of affected
patients. Regarding the speciﬁcity of S128R E-selectin, direct
binding of the 3′SL polymer was not observed even at high
concentrations. To further evaluate the promoted speciﬁc
ligands for S128R E-selectin, inhibition assays with sLex
Fig. 4. Glycan array screening (version 4.1) of wt and S128R E-selectin. Binding was detected by a second incubation with Alexa Fluor® labeled anti-IgG antibody
as described in the Materials and methods section. The values of the RFUs are given the average of 6 measurements of which the lowest and highest values were
removed.
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polymer in competition with the 3′SLN trisaccharide, heparin
and bovine fetuin were performed. Even at high concentrations,
none of these three compounds showed inhibition of the sLex
polymer binding to S128R E-selectin (Figure 3A). These results
suggest similar binding phenotypes of wt and S128R E-selectin.
Finally, to investigate the binding of S128R E-selectin to leuko-
cytes, we performed cell-based assays (Figure 3B and C). The
sLex bearing HL60 cell line bound wt and S128R E-selectin to
the same degree under static and physiological ﬂow conditions
and in an E-selectin dependent manner. Again, no difference
in binding speciﬁcity was observed for S128R E-selectin.
Furthermore, unlike previously reported, no speciﬁc binding
of K562 cells was measured. Therefore, no interaction between
S128R E-selectin and an unknown carbohydrate or non-
carbohydrate ligand on K562 occurred. Finally, to characterize
the binding phenotype with another cell-free assay, a glycan
array screening was performed at the Consortium for Functional
Glycomics (Figure 4). The binding of wt and S128R E-selectin
to 465 different mammalian glycan structures was evaluated.
The results conﬁrmed the similar binding proﬁles for wt and
S128R E-selectin. The 10 best binding glycan structures all con-
tained a fucose moiety. The RFU values of glycans lacking the
fucose moiety such as 3′SLN showed signals on background
level for both proteins. Additionally, no speciﬁc ligand for the
S128R E-selectin mutant was detected, and thus, its binding
properties do not differ from those of the wt. As in the EC50
determinations of sLea and sLex, an augmented binding of sLea
over sLex was also observed which is reﬂected by the higher
RFU values for sLea. Although high E-selectin concentrations
(1 mg/mL) were applied for the glycan array, the resulting RFU
values were rather low. This was most likely due to the low afﬁn-
ity of E-selectin for its tetrasaccharide ligands (Schwizer et al.
2012). The reason why S128R E-selectin showed eightfold
lower maximal RFU values compared with wt E-selectin is not
clear, since in the polymer-based activity assays, the afﬁnity
(EC50) of both proteins for sLe
x- and sLea-PAAwere comparable
(equal maximal OD415nm values). However, glycan array screen-
ings provide for qualitative and not quantitative measurements.
Our results suggest similar binding speciﬁcities of wt and
S128R E-selectin under static and ﬂow conditions. This is to be
expected from a visual inspection of the E-selectin crystal struc-
ture in complex with sLex (Somers et al. 2000). It was shown
that only the amino acids 135–139 from the EGF-like domain
form a direct contact with the lectin domain by hydrogen
bonding and van der Waals interactions (Graves et al. 1994).
The distance between the Ser128 Cα atom and Ca2+ in the
binding site is 43 Å. The Ser128 side chain forms a hydrogen-
bond with the backbone carbonyl of Lys152, an interaction
found in all selectin crystal structures. This hydrogen bond
would be lost in case of the S128R mutation. The fact that the
amino acid sequence Ser126-Cys127-Ser128 is conserved in all
the three selectins and throughout several species implies that
this region is indeed important for the proper function of the
selectins. However, the region surrounding the mutation is ri-
gidiﬁed by three disulﬁde bonds (Cys122–Cys133, Cys127–
Cys142 and Cys144–Cys153) within a 10 Å radius of Ser128
Cα atom (Figure 1C).
In conclusion, as the S128R E-selectin displayed unaltered
binding speciﬁcity under static and ﬂow conditions as wt
E-selectin, we conclude that glycomimetic E-selectin antagonists
are also effective antagonists of the mutant. According to our
studies, the reported correlation of a SNP in the E-selectin en-
coding gene with an increased susceptibility and severity of
various, mainly cardiovascular and immune, diseases is there-
fore not related to altered binding properties of wt and mutant
E-selectin. Further investigations, e.g., structural and biophysic-
al protein characterization, as well as functional in vivo assays
are necessary to shed light on possible therapeutic opportunities
based on the S128R E-selectin mutant.
Materials and methods
Materials and reagents
The E-selectin primers lec-fw (5′-GGCC GAATTC GTG GTC
TTA CAA CAC CTC CAC GGA A-3′) and cr2_rev (5′-GGCC
GATATC GAA GCT TTA CAC GTT GGC TTC TCG TT-3′)
containing the restriction sites EcoRI and EcoRV (underlined),
respectively, and the mutation primers egf_s128r_fw (5′-AAT
ACATCC TGC AGA GGC CAC GGT-3′) and egf_s128r_rev
(5′-ACC GTG GCC TCT GCA GGA TGT ATT-3′) were pur-
chased from Microsynth (Balgach, Switzerland). The restriction
enzymes EcoRI and EcoRVand the glycosidase PNGaseF were
obtained from New England BioLabs (Allschwil, Switzerland).
The pFUSE-hIgG2-Fc2 expression vector and the antibiotic
Zeocin™ were purchased from Invivogen (Toulouse, France).
Tissue culture ﬂasks and MaxiSorp™ 96-well microtiter plates
were from Nunc (Roskilde, Denmark). Ham’s Nutrient Mixture
F-12 medium, Roswell Park Memorial Institute (RPMI-15)
medium, fetal calf serum (FCS) and the horseradish peroxidase
substrate 2,2′-azino-di(3-ethylbenzthiazoline-6-sulfonic acid)
(ABTS) were purchased from Invitrogen (Lucerne, Switzer-
land). Penicillin (10,000 U/mL)/streptomycin (10 mg/mL),
cyanogen bromide-activated-Sepharose® 4B, bovine fetuin and
heparin sodium salt were obtained from Sigma-Aldrich (Basel,
Switzerland). The FuGENE® HD transfection reagent and the
streptavidin-peroxidase (streptavidin-POD)were purchased from
Roche Applied Science (Rotkreuz, Switzerland). Amicon®
ultraﬁltration tubes (50 kDa cut-off) were obtained from
Millipore (Zug, Switzerland). The ion exchange column
UnoQ6 was purchased from Bio-Rad (Reinach BL, Switzer-
land). Protein A-Sepharose® was obtained from BioVision
(Mountain View, CA). Protein G-Sepharose® was purchased
from Amersham Pharmacia (GE Healthcare, Pistcataway, NJ).
3-SL, sLex- and sLea-polyacrylamide (PAA)-biotin were fromGly-
coTech (Gaithersburg, MD). The Alexa Fluor® 488 labeled
anti-human-IgG(Fc) antibody and the Microscanarray XL4000
scanner were from Invitrogen (Carlsbad, CA) and PerkinElmer
Life Sciences (Waltham, MA), respectively. Trypsin sequen-
cing grade was obtained from Promega (Dübendorf, Switzer-
land). The trapping 300SB C-18 column (0.3 × 50 mm) was
purchased from Agilent Technologies (Basel, Switzerland), the
Magic 300 Å C18 reverse-phase material (5 µm particle size)
from Michrom Bioresources, Inc. (Auburn, CA), the Orbitrap
FT hybrid instrument from Thermo Finnigan (San Jose, CA)
and the Rheos 2200 pump from (Flux Instruments, Basel,
Switzerland). The cell line HL60 was purchased from LGC
Standards (Molsheim, France) and K562 cells from the
German Collection of Microorganisms and Cell Cultures
(DSMZ, Braunschweig, Germany). The BioFlux™ system was
purchased from Fluxion (San Francisco, CA).
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Molecular cloning
Genomic DNA from wild-type human E-selectin [Lec-EGF-
CR6/hIgG1(Fc)] expressing CHO-K1 cells (Schefﬂer et al. 1995)
was used for polymerase chain reaction (PCR) ampliﬁcation of
the cDNA encoding for the human E-selectin lectin domain (bp
1–360), the EGF-like domain (bp 361–471) and the ﬁrst two con-
sensus repeat domains (bp 472–840). The forward primer lec_fw
and the reverse primer cr2_rev containing EcoRI and EcoRV re-
striction sites were used. The restricted insert was ligated into the
corresponding cloning site of the pFUSE-hIgG2-Fc2 expres-
sion vector. The resulting construct containing the N-terminal
interleukine-2 secretion signal and the Fc part of human IgG2
at C-terminus was transformed into chemocompetent Escherichia
coli DH5α. After single clone selection and DNA-minipreparation,
the correctness of the construct was conﬁrmed by DNA double-
strand sequencing (Microsynth, Balgach, Switzerland).
Site-directed mutagenesis was employed for the thymine-
to-adenine substitution at cDNA position 384, shifting the ex-
pression from a serine to an arginine at amino acid position 128.
The standard overlap extension PCR method was used (Ho et al.
1989). In a ﬁrst step, two overlapping DNA fragments were gen-
erated separately, using wild-type E-selectin cDNA as template.
The ﬁrst fragment was ampliﬁed with the lec_fw primer and the
internal reverse primer egf_s128r_rev and the second fragment
was ampliﬁed using cr2_rev and the internal forward primer
egf_s128r_fw. The two internal primers contained a mismatch
for the site-directed base substitution. In a second step, both
overlapping DNA fragments were elongated to the full-length
insert, containing the single point mutation. The cloning into the
pFUSE-hIgG2-Fc2 expression vector and sequence veriﬁcation
were performed as described above for the wt construct.
Cell transfection and expression of wt E-selectin,
wt P-selectin and S128R E-selectin
CHO-K1 cells (American Type Culture Collection No.
CCL-61™) were cultivated in tissue culture ﬂasks in Ham’s
Nutrient Mixture F-12 medium supplemented with 2 mM
L-glutamine, 10% (v/v) FCS, 100 U/mL penicillin and 100 µg/
mL streptomycin. The cells were transfected with either the wt or
the S128R construct using the FuGENE® HD transfection
reagent according to the instructions of the supplier (Roche).
The selection of stably transfected CHO-K1 cells was achieved
by treatment with 500 µg/mL Zeocin™ and single clones
were obtained by limiting dilution. Culture medium containing
the secreted E-selectin [Lec-EGF-CR2/hIgG2(Fc)] chimera was
harvested weekly and sterile ﬁltered (0.22 µm). The medium was
used immediately for protein puriﬁcation or stored at −20°C.
For control experiments P-selectin [Lec-EGF-CR6/hIgG1
(Fc)] wt expressed in CHO-K1 cells was used (Fritz et al. 1998).
Expression and puriﬁcation of anti-E-selectin antibody 7A9
Mouse hybridoma cells expressing the mouse monoclonal anti-
E-selectin antibody 7A9 (American Type Culture Collection No.
HB-10135™) were cultivated in RPMI-15 medium supplemen-
ted with 15% (v/v) FCS, 100 U/mL penicillin and 100 µg/mL
streptomycin. Antibodies were puriﬁed from the culture medium
by protein G-Sepharose®. The column was attached to a fast
protein liquid chromatography apparatus (Bio-Rad, Reinach BL,
Switzerland) and equilibrated with loading buffer (50 mM Tris–
HCl (pH 7.6), 150 mM NaCl and 0.05% v/v Tween-20). The
culture medium was ﬁltrated (0.22 µm) diluted with loading
buffer and then loaded onto the protein G-Sepharose® column
followed by two washing steps, ﬁrst with loading buffer and then
with washing buffer (5 mM NH4OAc, pH 5.0). The protein was
ﬁnally eluted with elution buffer (0.5 M NH4OAc, pH 3.4) and
the eluate was immediately neutralized to pH 7–7.5 with a 2.5 M
Tris solution. The protein concentration was determined by high-
performance liquid chromatography (HPLC) (Mesch et al.
2012). Approximately 5 mg of puriﬁed 7A9 antibody were
coupled to 1 mL of cyanogen bromide-activated-Sepharose® 4B
according to the manufacturer’s protocol.
Puriﬁcation of wt E-selectin, wt P-selectin and S128R
E-selectin
The culture medium containing E-selectin was diluted (1:1, v/v)
with loading buffer, ﬁltrated (0.22 µm) and puriﬁed with the
7A9-Sepharose® column using the same protocol and buffers as
for the puriﬁcation of the 7A9 antibody (see above). The puriﬁed
protein was concentrated by ultraﬁltration (50 kDa cut-off).
P-selectin was puriﬁed in two steps. The ﬁrst step was per-
formed on a protein A-Sepharose® column using the same pro-
cedure and buffers as described above. The second step was
performed with anion exchange chromatography using a
UnoQ6 column and the buffer A (20 mM Tris–HCl, pH 7.4)
for column equilibration and loading and buffer B (20 mM
Tris–HCl, pH 7.4, 1 M NaCl) for protein elution.
Protein purity was conﬁrmed by SDS-PAGE analysis fol-
lowed by Coomassie Brilliant Blue G-250 staining. The protein
concentration was determined by HPLC as previously reported
(Mesch et al. 2012).
Activity binding assay
Biotinylated sLex-, sLea- and 3′SL-polyacrylamide polymers
(sLex-PAA, sLea-PAA and 3′SL-PAA, purchased from Glyco-
Tech, Gaithersburg, MD 20879) were coupled to streptavidin-
β-peroxidase (POD) by incubation of 20 µL (100 µg/mL)
polymer, 80 µL (500 U/mL streptavidin-POD conjugate), 10 µL
FCS and 80 µL assay buffer (20 mM HEPES pH 7.4, 150 mM
NaCl, and 10 mM CaCl2) for 2 h at 37°C. The complexes were
stable for several weeks when stored at 4°C.
MaxiSorp™ 96-well microtiter plates were coated with
100 µL/well of wt or S128R E-selectin at 3 µg/mL in assay
buffer overnight at 4°C in a humidiﬁed chamber. Control wells
were coated with assay buffer without protein for subsequent
background signal subtraction. The wells were washed three
times with 150 µL/well of assay buffer and blocked with 150 µL/
well of 3% w/v bovine serum albumin (BSA) in assay buffer for
3 h at 4°C. The wells were then washed three times with 150 µL/
well assay buffer before adding 100 µL/well of a serial dilution
(0–3 µg/mL) of a sLex-, sLea- or 3′SL-PAA solution. Each con-
centration was applied in duplicate. After incubation for 3 h at
25°C and 250 rpm, the wells were carefully washed with 150 µL/
well assay buffer. Carbohydrate-PAA binding was detected by
addition of 100 µL/well of ABTS-substrate. The colorimetric re-
action was allowed to develop for 10 min and then stopped by
the addition of 2% aqueous oxalic acid before the optical density
(OD) was measured at 415 nm on a microplate reader. The
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OD415 nm values were background subtracted and the EC50
values were calculated using the Prism software (GraphPad
Software, Inc., La Jolla). The assays were repeated three times on
separate days. The EC50 value deﬁnes the glycopolymer concen-
tration corresponding to 50% of the maximum binding to the
protein.
Competitive binding assay
For the evaluation of the proposed ligands for S128R E-selectin
and the afﬁnity measurements of the sLex mimics, polyacryl-
amide polymer-based competitive binding assay was performed.
The trisaccharide 3′-sialyl-N-acetyllactosamine (3′SLN) was
synthesized in-house as reported in the Supplementary data.
Antagonists 1-3 were prepared as previously described (Schwi-
zer et al. 2012). MaxiSorp™ 96-well microtiter plates were
coated with a solution of E- or P-selectin (3 µg/mL, 100 µL/
well) and blocked for 3 h with 150 µL/well of BSA (3%, w/v).
The wells were subsequently co-incubated with 50 µL of
sLex-PAA (40 ng/mL) and 50 µL of 3′SLN (10 mM ﬁnal con-
centration), bovine fetuin (10 mg/mL) or heparin sodium salt
(10 mg/mL). Inhibition of sLex-PAA binding to wt P-selectin by
heparin sodium salt served as positive control. For compounds
1-3, 25 µL of serial dilutions were mixed with 25 µL of
sLea-PAA polymer (40 ng/mL). All other assay steps were per-
formed similar to the activity binding assay. For 3′SLN, the
assay was repeated twice on separate days and for bovine fetuin
and heparin three times on separate days. The sLex mimics were
tested a single time in duplicate. IC50 values were calculated
using the Prism software. The IC50 deﬁnes the molar concentra-
tion of the test compound that reduces the maximal speciﬁc
binding of sLex/a-PAA to E/P-selectin by 50%.
Cell-based static assay
The protein coating, washing and blocking steps of the cell-based
binding assay were performed similar to the activity binding
assay, with an increase in wt or S128R E-selectin concentration
to 10 µg/mL. HL60 and K562 cells were cultivated in suspension
in RPMI 1640 culture medium supplemented with 10% FCS, 2
mM L-glutamine, 10% (v/v) FCS, 100 U/mL penicillin and
100 µg/mL streptomycin. The cell suspension was harvested at
5 × 105–1 × 106 cells/mL by centrifugation at 1500 rpm and 4°C.
The cells were washed twice with PBS, resuspended to 1 × 106
cells/mL and labeled with 5 µM carboxyﬂuorescein succinimidyl
ester) for 8 min at room temperature. The reaction was stopped
with FCS (2%, v/v) and the cells were washed twice with
assay buffer containing FCS (2%, v/v). Final concentrations of
2 × 105 cells/well and 20 µg/mL 7A9 antibody were used. After
incubation for 1 h at 37°C and 250 rpm, the wells were washed
three times with assay buffer. Fluorescent intensities were mea-
sured at 492 nm excitation and 517 nm emission with a ﬂuores-
cence plate reader. The cell-based assays were performed in
duplicate and repeated twice on separate days. Cell viability was
>95% at all times as judged by trypan blue staining.
Cell-based ﬂow assay
Flow chamber assays were performed with a BioFlux™
system. The ﬂow chambers were coated over night at 4°C with
50 µg/mL soluble protein A in bicarbonate buffer (pH 9.6).
After washing with assay buffer, the chambers were perfused
with wt or S128R E-selectin (50 µg/mL) and incubated for 2 h
at 4°C. The chambers were subsequently blocked with 2% w/v
BSA in assay buffer. HL60 cells were prepared as described
above, resuspended to 1 × 106 cells/mL and perfused at physio-
logical shear forces between 1 and 5 dynes/cm2. Rolling cells
were determined at three points along the chamber after 10 min
perfusion with a Nikon inverted-stage phase-contrast micro-
scope with 20 ×magniﬁcation. Shutter speed was set according
to shear stress for correct distinction of adherent and free
ﬂowing cells.
Glycan array screening
The glycan array screening (version 4.1) was performed at the
Core H facilities of the Consortium for Functional Glycomics
as previously described (Blixt et al. 2004). Brieﬂy, the wt
and S128R E-selectin samples were diluted to 1 mg/mL in
Tris-buffer [20 mM Tris–HCl (pH 7.4), 150 mM NaCl, 2 mM
CaCl2, 2 mM MgCl2] supplemented with 0.05% Tween 20
and 1% BSA. An aliquot of 70 µL was applied to the slides
containing the covalently linked glycans, each glycan in repli-
cate of six. The slides were coverslipped and incubated in a
humidiﬁed chamber protected from light for 1 h at room tem-
perature and subsequently incubated with Alexa Fluor® 488
labeled anti-human-IgG(Fc) antibody at a concentration of 5
µg/mL in Tris-buffer. After washing and drying the slides, the
ﬂuorescence was measured with the Microscanarray XL4000
scanner. The relative ﬂuorescence units (RFUs) were then cal-
culated as the average of the six replicates of each glycan
structure, of which the lowest and the highest values were
ignored.
Supplementary data
Supplementary data for this article is available online at http://
glycob.oxfordjournals.org/.
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1. Synthesis of the trisaccharide 3’-sialyl-N-acetyllactosamine (3’SLN, 6) 
 
 
Scheme S1. a) BzCl, DMAP, pyridine, r.t., 4 h, 40%; b) Me3N⋅BH3, AlCl3, THF, H2O, r.t., 5 h, 79%; 
c) DMTST, CH2Cl2, MS 4 Å, r.t., 5 d, 39%; d) (i) H2, Pd(OH)2/C, dioxane, H2O, r.t., 2 d; (ii) NaOH, 
MeOH, H2O, r.t., 20 h, 77%. 
 
General Methods: NMR spectra were recorded on a Bruker Avance DMX-500 (500 MHz) 
spectrometer. Assignment of 1H and 13C NMR spectra was achieved using 2D methods 
(COSY, HSQC, HMQC, HMBC). Chemical shifts are given in ppm and were assigned in 
relation to the solvent signals on the δ-scale[S1] or to tetramethylsilane (0 ppm) as internal 
standard. Coupling constants J are given in Hertz (Hz). Multiplicities were specified as 
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follows: s (singlet), d (doublet), dd (double doublet), t (triplet), q (quartet), m (multiplet). For 
assignment of resonance signals to the appropriate nuclei the following abbreviations were 
used: Gal (galactose), GlcNAc (N-acetylglucosamine), Sia (N-acetyl neuraminic acid, sialic 
acid). Reactions were monitored by TLC using glass plates coated with silica gel 60 F254 
(Merck) and visualized by using UV light and/or by charring with a molybdate solution (a 
0.02 M solution of ammonium cerium sulfate dihydrate and ammonium molybdate 
tetrahydrate in aqueous 10% H2SO4). Column chromatography was performed using 
automated systems (RediSep Companion or RediSep Rf) from Teledyne Isco with normal 
phase RediSep columns from the same manufacturer or reversed-phase columns containing 
LiChroprep RP-18 (40-63 µm) from Merck KGaA, Darmstadt, Germany. Size exclusion 
chromatography was performed with Bio-Gel® P-2 Gel (45-90 mm) from Bio-Rad. Solvents 
were purchased from Sigma-Aldrich or Acros. Solvents were dried prior to use where 
indicated. Tetrahydrofurane (THF) was dried by refluxing with sodium/benzophenone and 
distilled immediately before use. Dichloromethane (CH2Cl2) was dried by filtration over 
Al2O3 (Fluka, type 5016 A basic). Methanol (MeOH) was dried by distillation from sodium 
methoxide, dimethyl formamide (DMF) by distillation from calcium hydride. Optical 
rotations were measured using a Perkin-Elmer Polarimeter 341. Electron spray ionization 
mass spectra (ESI-MS) were obtained on a Waters micromass ZQ. Compound purity was 
determined on an Agilent 1100 HPLC; detector: ELS, Waters 2420; column: Waters Atlantis 
dC18, 3 µm, 4.6 x 75 mm; eluents: A: water + 0.1% TFA; B: 90% acetonitrile + 10% water + 
0.1% TFA; linear gradient: 0-1 min 5% B; 1-20 min 5 to 70% B; flow: 0.5 mL/min. 
 
Abbreviations: BzCl, benzoyl chloride; DMAP, 4-dimethylaminopyridine; DMTST, 
dimethyl (methylthio)sulfonium triflate; MS, molecular sieves; Gal, galactose; GlcNAc, N-
acetylglucosamine; Sia, N-acetyl neuraminic acid/sialic acid; TMSE, 2-(trimethylsilyl)ethyl. 
 
2-(Trimethylsilyl)ethyl 2-acetamido-3-O-benzoyl-4,6-O-benzylidene-2-deoxy-β-D-gluco-
pyranoside (2). Benzoyl chloride (0.060 mL, 72 mg, 0.52 mmol) and DMAP (cat.) were 
added to a solution of 1[S2] (50 mg, 0.12 mmol) in anhydrous pyridine (0.5 mL) and stirred at 
r.t. under argon for 4 h. The reaction was quenched with H2O (20 mL) and the mixture was 
extracted with CH2Cl2 (3 x 15 mL). The combined organic layers were dried (Na2SO4) and 
concentrated. Column chromatography of the residue on silica (petroleum ether/EtOAc) gave 
2 (25 mg, 40%) as white solid. 
[α]20D -73.9 (c 1.68, CHCl3); 1H NMR (500.1 MHz, CDCl3): δ = 8.11-7.27 (m, 10H, 2 C6H5), 
6.52 (d, J = 9.2 Hz, 1H, NHCOCH3), 5.67 (t, J = 10.0 Hz, 1H, H-3), 5.52 (s, 1H, CHPh), 4.57 
(d, J =  8.4 Hz, 1H, H-1), 4.35 (m, 1H, H-2), 4.29 (dd, J = 4.9, 10.2 Hz, 1H, H-6a), 3.92-3.84 
(m, 2H, H-4, OCH2), 3.80 (t, J = 10.2 Hz, H-6b), 3.68 (dt, J = 4.9, 10.2 Hz, H-5), 3.41 (m, 
1H, OCH2), 1.86 (s, 3H, NHCOCH3), 1.00-0.84 (m, 2H, CH2Si), 0.00 (s, 9H, Si(CH3)3); 13C 
NMR (125.8 MHz, CDCl3): δ = 170.3 (NHCOCH3), 167.3 (COC6H5), 137.2, 133.6, 130.0, 
129.4, 129.0, 128.6, 128.2, 126.1 (12C, 2 C6H5), 101.6 (C-1), 101.3 (CHPh), 79.2 (C-4), 73.3 
(C-3), 68.8 (C-6), 67.6 (OCH2), 66.2 (C-5), 54.5 (C-2), 23.4 (NHCOCH3), 18.1 (CH2Si), -1.3 
(3C, Si(CH3)3); MS (ESI): m/z: Calcd for C27H36NNaO7Si [M+Na]+: 536.2, found: 536.2. 
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2-(Trimethylsilyl)ethyl 2-acetamido-3-O-benzoyl-6-O-benzyl-2-deoxy-β-D-glucopyrano-
side (3). To a solution of 2 (300 mg, 0.58 mmol) in anhydrous THF (12 mL) were added 
Me3N⋅BH3 (170 mg, 2.3 mmol) and anhydrous AlCl3 (470 mg, 3.5 mmol) with stirring under 
argon at r.t. After all reagents were dissolved, H2O (0.01 mL) was added and the mixture was 
stirred for 5 h.[S3] The reaction was quenched by addition of H2O (6 mL) and 1 N aq HCl (6 
mL) and extracted with EtOAc (3 x 25 mL). The organic layers were washed with brine, dried 
over Na2SO4, and concentrated. Column chromatography of the residue on silica gel 
(petroleum ether/EtOAc, 7:3 to 1:1) gave 3 (238 mg, 0.46 mmol, 79%) as white foam. 
1H NMR (500.1 MHz, CDCl3): δ = 8.06-7.26 (m, 10H, 2 C6H5), 5.81 (d, J = 8.0 Hz, 1H, 
NHCOCH3), 5.36 (dd, J = 9.6, 10.6Hz, 1H, H-3), 4.63-4.61 (m, 2H, H-1, CH2Ph), 4.58 (B of 
AB, J = 11.9 Hz, 1H, CH2Ph), 4.08 (m, 1H, H-2), 3.98 (m, 1H, OCH2), 3.87 (t, J = 9.6 Hz, 
1H, H-4), 3.82 (m, 2H, H-6a, H-6b), 3.65 (dt, J = 4.8, 9.6 Hz, 1H, H-5), 3.56 (m, 1H, OCH2), 
1.85 (s, 3H, NHCOCH3), 1.05-0.85 (m, 2H, CH2Si), 0.00 (s, 3H, Si(CH3)3); 13C NMR (125.8 
MHz, CDCl3): δ = 170.4 (NHCOCH3), 167.7 (COC6H5), 137.8, 133.6, 130.1, 129.4, 128.6, 
128.0, 127.9 (12C, 2 C6H5), 100.6 (C-1), 77.2 (C-3), 76.4 (C-5), 74.3 (CH2Ph), 73.9 (C-4), 
71.3 (C-6), 70.6 (OCH2), 54.3 (C-2), 23.5 (NHCOCH3), 18.1 (CH2Si), -1.3 (3C, Si(CH3)3); 
MS (ESI): m/z: Calcd for C27H37NNaO7Si [M+Na]+: 538.2, found: 538.2. 
 
2-(Trimethylsilyl)ethyl (benzyl 5-acetamido-4,7,8,9-tetra-O-acetyl-3,5-dideoxy-D-
glycero-α-D-galacto-2-nonulopyranosynate)-(2→3)-2,4-di-O-acetyl-6-O-benzoyl-β-D-
galactopyranosyl-(1→4)-2-acetamido-3-O-benzoyl-6-O-benzyl-2-deoxy-β-D-glucopyra-
noside (5). Compounds 3 (200 mg, 0.39 mmol) and 4[S4] (190 mg, 0.20 mmol) were dissolved 
in anhydrous CH2Cl2 (5.0 mL) under argon. Activated molecular sieves 4 Å (0.5 g) were 
added and the mixture was stirred at r.t. for 4 h. Subsequently, a suspension of DMTST (130 
mg, 0.50 mmol) and activated molecular sieves 4 Å (0.1 g) in anhydrous CH2Cl2, that had 
been stirred under argon at r.t. for 4 h, was added. After 5 d, the reaction mixture was diluted 
with CH2Cl2 (10 mL), filtered through a pad of celite, and washed with satd. aq. NaHCO3 (20 
mL) and brine (20 mL). The aqueous layers were extracted with CH2Cl2 (3 x 20 mL) and the 
combined organic layers were dried over Na2SO4 and concentrated. Column chromatography 
of the residue on silica (petroleum ether/EtOAc/MeOH, 8:5:0.5 to 8:5:0.9) gave 5 (109 mg, 
0.08 mmol, 39%) as white solid. 
1H NMR (500.1 MHz, CDCl3): δ = 8.13-7.21 (m, 20H, 4 C6H5), 5.68 (d, J = 9.4 Hz, 1H, 
GlcNAc-NHCOCH3), 5.55 (ddd, J = 2.7, 5.9, 8.8 Hz, 1H, Sia-H8), 5.39 (dd, J = 8.3, 9.5 Hz, 
1H, GlcNAc-H3), 5.30 (dd, J = 2.7, 8.8 Hz, 1H, Sia-H7), 5.25 (A of AB, J = 12.0 Hz, 1H, 
CH2Ph), 4.99-4.94 (m, 2H, Gal-H2, Gal-H4), 4.91-4.78 (m, 4H, Gal-H1, Sia-H4, Sia-
NHCOCH3, CH2Ph), 4.64-4.59 (m, 2H, CH2Ph), 4.58 (dd, J = 3.5, 10.0 Hz, 1H, Gal-H3), 4.51 
(d, J = 7.5 Hz, 1H, GlcNAc-H1), 4.32 (dd, J = 2.7, 12.4 Hz, 1H, Sia-H9a), 4.23-4.11 (m, 2H, 
GlcNAc-H2, GlcNAc-H4), 4.05-3.94 (m, 3H, Sia-H5, Sia-H9b, OCH2), 3.88-3.65 (m, 6H, 
Gal-H5, Gal-H6a, Gal-H6b, GlcNAc-H5 GlcNAc-H6a, GlcNAc-H6b), 3.56 (m, 1H, OCH2), 
3.45 (dd, J = 2.7, 10.7 Hz, Sia-H6), 2.56 (dd, J = 4.6, 12.7 Hz, Sia-H3eq), 2.13, 2.10, 2.03, 
2.02, 1.97, 1.93, 1.87, 1.82 (8 s, 24H, 8 COCH3), 1.65 (m, 1H, Sia-H3ax), 1.02-0.90 (m, 2H, 
CH2Si), 0.01 (s, 9H, Si(CH3)3); 13C NMR (125.8 MHz, CDCl3): δ = 170.7, 170.4, 170.2, 
170.1, 170.0, 169.7 (8C, 8 COCH3), 167.5 (Sia-C1), 166.4, 165.4 (2 COC6H5), 138.5, 134.8, 
133.4, 133.3, 130.1, 129.9, 129.8, 128.9, 128.8, 128.7, 128.6, 128.5, 128.4, 127.6 (24C, Ar-
C), 100.9 (Gal-C1), 100.7 (GlcNAc-C1), 96.9 (Sia-C2), 75.4 (GlcNAc-C4), 75.0 (GlcNAc-
C5), 73.7, 73.6 (GlcNAc-C3, CH2Ph), 72.2 (Sia-C6), 71.6 (Gal-C3), 70.7, 70.6 (Gal-C2, Gal-
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C5), 69.4 (Sia-C4), 68.8 (Gal-C6), 68.5 (CH2Ph), 67.8 (Sia-C8), 67.2, 67.1, 66.8 (Sia-C7, 
Gal-C4, OCH2), 62.6 (Sia-C9), 61.0 (GlcNAc-C6), 53.6 (GlcNAc-C2), 49.0 (Sia-C5), 37.5 
(Sia-C3), 23.4, 23.3, 21.5, 21.1, 20.9, 20.9, 20.9, 20.7 (8 COCH3), 18.2 (CH2Si), -1.3 (3C, 
Si(CH3)3); MS (ESI): m/z: Calcd for C70H86N2NaO27Si+ [M+Na]+: 1437.5, found: 1437.8. 
 
2-(Trimethylsilyl)ethyl (sodium 5-acetamido-3,5-dideoxy-D-glycero-α-D-galacto-2-
nonulopyranosynate)-(2→3)-β-D-galactopyranosyl-(1→4)-2-acetamido-2-deoxy-β-D-
glucopyranoside (6). Pd(OH)2/C (15 mg, 10% Pd) was added to a solution of 5 (100 mg, 
0.07 mmol) in dioxane/H2O (4:1, 5.0 mL) and the resulting mixture was hydrogenated (1 bar 
H2) at r.t. After 2 d, the reaction mixture was filtered, concentrated, and the residue was 
redissolved in MeOH (1.0 mL) and aq. 1.0 M NaOH (5.0 mL). After stirring for 20 h at r.t., 
the solution was neutralized with aq. 1.0 M HCl and concentrated. Size exclusion 
chromatography of the residue, followed by reversed phase chromatography (RP-18, 
H2O/MeOH) gave 6 (43 mg, 0.54 mmol, 77%) as white foam. 
[α]20D -14.1 (c 0.99, MeOH); 1H NMR (500.1 MHz, D2O/CD3OD): δ  = 4.55 (d, J = 7.9 Hz, 
2H, Gal-H1, GlcNAc-H1), 4.11 (dd, J = 3.1, 9.9 Hz, 1H, Gal-H3), 4.04 (td, J = 4.9, 10.4 Hz, 
1H, OCH2), 3.99 (dd, J = 2.1, 12.3 Hz, GlcNAc-H6a), 3.95 (d, J = 3.1 Hz, 1H, Gal-H4), 3.92-
3.54 (m, 16H, OCH2, Gal-H2, Gal-H5, Gal-H6a, Gal-H6b, GlcNAc-H2, GlcNAc-H3, 
GlcNAc-H4, GlcNAc-H6b, Sia-H4, Sia-H5, Sia-H6, Sia-H7, Sia-H8, Sia-H9a, Sia-H9b), 2.76 
(dd, J = 4.6, 12.1 Hz, 1H, Sia-H3eq), 2.03, 2.02 (2 s, 6H, 2 COCH3), 1.80 (t, J = 12.1 Hz, 1H, 
Sia-H3ax), 1.05-0.80 (m, 2H, CH2Si), 0.00 (s, 9H, Si(CH3)3); 13C NMR (125.8 MHz, 
D2O/CD3OD): δ = 176.0 (Sia-C1), 175.3, 174.8 (2 COCH3), 103.5 (Sia-C2), 101.3 (GlcNAc-
C1), 100.8 (Gal-C1), 79.3 (GlcNAc-C3), 76.5 (Gal-C3), 76.1 (GlcNAc-C5), 75.8 (Gal-C5), 
73.9, 73.7, 72.7, 70.4, 69.3, 69.3, 69.1 (Gal-C2, Sia-C4, Sia-C6, Sia-C7, Sia-C8, GlcNAc-C4, 
OCH2), 68.5 (Gal-C4), 63.6 (Sia-C9), 62.0 (Gal-C6), 61.0 (GlcNAc-C6), 56.0 (GlcNAc-C2), 
52.7 (Sia-C5), 40.6 (Sia-C3), 23.2, 23.0 (2 COCH3), 18.1 (CH2Si), -1.5 (3C, Si(CH3)3); HR-
MS (ESI): m/z: Calcd for C30H54N2NaO19Si [M+H]+: 797.2982, found: 797.2983; HPLC 
purity: > 99.5%. 
 
2. LC-MS/MS analysis of E-selectin  
To confirm the mutation at the amino acid level, purified wt and S128R E-selectin were 
submitted to LC-MS/MS analysis. Prior to the analysis, the proteins were deglycosylated with 
PNGaseF under denaturing conditions according to the manufacturers protocol (New England 
BioLabs). 
The protein band was reduced prior to digestion with 10 mM dithiothreitol for 2 h at 37 °C 
and alkylated with iodoacetamide at 50 mM final concentration for 15 min at r.t. in the dark. 
The gel piece was digested with 125 ng trypsin (sequencing grade) for 18 h at 37 °C. The 
peptides in the supernatant were collected and the gel piece was extracted with aqueous 
solution of 0.1% acetic acid / 50% acetonitrile and the extract was pooled with the tryptic 
peptides. The digest was dried in a SpeedVac and redissolved in 0.1% acetic acid / 2% 
acetonitrile.  
The trypsin digests were analyzed by capillary liquid chromatography tandem MS (LC-
MS/MS) using a set up of a trapping 300SB C-18 column (0.3 x 50 mm) and a separating 
column (0.1 mm x 10 cm) that had been packed with Magic 300 Å C-18 reversed-phase 
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material (5 µm particle size). The columns were connected on line to an Orbitrap FT hybrid 
instrument. A linear gradient from 2 to 80% solvent B (0.1% acetic acid and 80% acetonitrile 
in water) in solvent A (0.1% acetic acid and 2% acetonitrile in water) was delivered with a 
Rheos 2200 pump at a flow rate of 100 µL/min during 85 min. A pre-column split was used to 
reduce the flow to approximately 100 nL/min. 10 µL of peptide digest were injected with an 
autosampler thermostatted to 4 °C. The eluted peptides were ionized at 1.7 kV. The mass 
spectrometer was operated in a data-dependent fashion. The precursor scan was done in the 
Orbitrap set to 60,000 resolution, while the fragment ions were mass analyzed in the LTQ 
instrument. A top five method was run so that the five most intense precursors were selected 
for fragmentation. The MS/MS spectra were then searched using TurboSequest software.[S5] 
The data were searched against the protein itself with Bioworks version 3.3.1. SP1 by setting 
the precursor ion tolerance to 10 ppm, while the fragment ion tolerance was set to 0.5 Da. 
Cleavage rules were set to fully enzymatic-cleaves at both ends, allowing 2 missed cleavages. 
Post filtering was set to the following parameters: ΔCN, 0.1; Xcorr versus charge state was 
1.50 (1+), 2.00 (2+), 2.50 (3+); peptide probability, 0.01; protein probability 0.01 
Fragment with the sequence K.KLALCYTAACTNTSCR.G or K.LALCYTAACTNTSCR.G 
were found which correspond to the S128R mutation. 
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Abstract 
E-selectin is a human cell-adhesion molecule which is involved in leukocyte recruitment 
during inflammation. Dysregulation of E-selectin may, however, lead to pathological 
situations, e.g. ischemic stroke, asthma, or psoriasis. Glycomimetic E-selectin antagonists 
based on the natural ligand sialyl Lewisx (sLex) have been developed to prevent E-selectin 
mediated leukocyte recruitment. Such antagonists have been developed under guidance of in 
vitro target- and cell-based assays with the human form of E-selectin. For the approval of 
clinical studies, in vivo efficacy needs to be demonstrated. For selectin-related diseases, 
various mouse models exist, but the affinity of E-selectin antagonists towards murine 
E-selectin was never investigated in vitro to date.  
In this study we compared binding affinities of the natural ligand sLex and the isoform sLea to 
recombinantly expressed and purified human and murine E-selectin. Furthermore, we 
compared binding of N-glycolyl-sLex (1), the natural ligand for E-selectin in mice. Finally, 
we assessed binding affinities of three sLex (2–4) mimetics to murine E-selectin.  
For sLex, a three-fold higher affinity was observed for murine E-selectin when compared to 
the human counterpart, while sLea and N-glycolyl-sLex (1) showed comparable affinites. All 
three sLex glycomimetics (2–4) were capable of binding to murine E-selectin and exhibited 
three- to five-fold increased affinity compared to human E-selectin. 
We therefore confirm that mouse models are suitable for the evaluation of E-selectin 
antagonists in vivo. However, the effect of these antagonists may be overestimated, since 
generally higher affinities for murine E-selectin were measured. 
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Introduction 
The family of selectins with its three members E-, P- and L-selectin are transmembrane 
calcium dependent lectins. They act as vascular cell-adhesion molecules that are responsible 
for leukocyte trafficking.[1] Being part of the innate immune system, E- and P-selectin appear 
on post-capillary venules upon cytokine stimulation upon tissue injury and form the initial 
contact to leukocytes circulating in the blood stream. This leukocyte tethering is the initial 
step of an entire chain of events, leading to rolling of leukocytes along endothelial 
vasculature, firm adhesion, and transmigration into the surrounding tissue where leukocytes 
counteract the cause of inflammation. To allow tethering and rolling, the selectins interact 
with carbohydrates that are presented on the cell surface of leukocytes. The presence of the 
tetrasaccharide sialyl Lewisx (sLex, Neu5Ac(α2-3)Gal(β1-4)[Fuc(α1-3)]GlcNAc) on 
glycoproteins is an absolute necessity for selectin mediated interaction in humans. Unlike 
most species, humans are not capable of converting N-acetyl-neuraminic acid (Neu5Ac) into 
N-glycolyl-neuraminic acid (Neu5Gc) during sialic acid biosynthesis. This is a result of a 
deletion of the CMAH gene in humans that encodes the cytidine monophosphate-N-
acetylneuraminic acid hydroxylase.[2] Therefore, N-glycolyl-sLex (1) is the natural ligand for 
E-selectin in most species, also for mice.  
While the presentation of E-selectin on vascular endothelial cells is strictly regulated on the 
transcription level in healthy tissue, dysregulation of immune processes can lead to locally 
excessive leukocyte accumulation. The massive influx of leukocytes and their release of 
cytotoxic agents can subsequently lead to leukocyte-inflicted tissue damage. Such an 
inadequate immune response over a prolonged time period can lead to various diseases, e.g. 
atherosclerosis, reperfusion injury, stroke and psoriasis. By targeting the initial adhesion step 
with selectin antagonists, the emergence of selectin-mediated diseases can be prevented. 
Efforts in drug discovery to target selectins have lead to therapeutic antibodies,[3] 
recombinant glycoprotein fragments,[4] or small-molecule antagonists, e.g. glycomimetics 
that are based on sLex as lead structure.[5] For therapeutic use of small-molecule antagonists, 
their safety and efficacy are required to be assessed in pre-clinical trials, which involves 
proof-of-concept studies in animal models. For glycomimetic E-selectin antagonists, 
leukocyte rolling and the inhibition thereof is investigated by intravital microscopy in 
C57BL/6 mice.[5a] This mouse model requires the induction of selectin presentation which is 
achieved by injection of tumor necrosis factor-α.[6] For vascular occlusion models, sickle cell 
disease mice are generated by bone marrow transplants from sickle cell mice into irridiated 
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C57BL/6 mice.[5b] In vitro analysis of glycomimetic E-selectin antagonists are performed 
with a set of techniques, such as flow chamber assays,[7] target-based polymer-binding 
assays,[5e, 7-8] surface plasmon resonance,[5d] and isothermal titration calorimetry.[9] In these 
assays, human E-selectin expressing cells (human umbilical vein cells) or recombinantly 
expressed and purified human E-selectin is employed. Therefore, a correlation of affinity data 
originating from in vitro studies using human E-selectin and in vivo mouse models with 
murine E-selectin as target might not be straight forward.  
In this study we assessed the affinity of glycomimetic E-selectin antagonist binding to murine 
E-selectin in comparison to human E-selectin in vitro. While the terminal residue in sLex in 
mice is either Neu5Ac or Neu5Gc, it is exclusively Neu5Ac in humans. It is therefore 
conceivable that human E-selectin has adapted to the N-acetyl form of sLex and that 
modifications of sLex based mimics, especially of the Neu5Ac portion, might exhibit 
differential impact on murine E-selectin in comparison to human E-selectin. The distinction 
of the two sialic acids has previously been studied on Siglec-1, a sialic acid binding member 
of the immunoglobulin family, where the human protein strongly prefers Neu5Ac over 
Neu5Gc.[10] 
 
Figure 1. Sequence alignment of the lectin domain (residues 1–120) and the EGF-like domain (residues 121–
156) of human and murine E-selectin. Asparagin residues marked green are potential N-linked glycosylation 
sites (as determined by NetNGlyc v1.0). Residues marked in red are involved in ligand binding as observed in 
the crystal structure of human E-selectin in complex with sLex (PDB code 1G1T).[11] The lectin domains share 
83% sequence identity, while the EGF-like domains share 77% identity. 
Human and murine E-selectin share an identical overall structure, with an N-terminal lectin 
(Lec) domain containing the carbohydrate binding site, an epidermal growth factor-like 
(EGF) domain, six short consensus repeats (SCR), a transmembrane region, and a 
cytoplasmic domain. The sequence homology across all domains is 73%. The Lec and EGF 
domains, which together provide the minimal requirement for carbohydrate binding, are more 
conserved with 82% sequence similarity (Figure 1). The amino acid residues in direct contact 
81.5% identity in 157 residues overlap; Score: 743.0; Gap frequency: 0.0%
Human E-selectin   1 WSYNTSTEAMTYDEASAYCQQRYTHLVAIQNKEEIEYLNSILSYSPSYYWIGIRKVNNVW
Murine E-selectin  1 WYYNASSELMTYDEASAYCQRDYTHLVAIQNKEEINYLNSNLKHSPSYYWIGIRKVNNVW
                     * ** * * ***********  ************* **** *  ****************
Human E-selectin  61 VWVGTQKPLTEEAKNWAPGEPNNRQKDEDCVEIYIKREKDVGMWNDERCSKKKLALCYTA
Human E-selectin  61 IWVGTGKPLTEEAQNWAPGEPNNKQRNEDCVEIYIQRTKDSGMWNDERCNKKKLALCYTA
                      **** ******* ********* *  ******** * ** ******** **********
Human E-selectin 121 ACTNTSCSGHGECVETINNYTCKCDPGFSGLKCEQIV
Human E-selectin 121 SCTNASCSGHGECIETINSYTCKCHPGFLGPNCEQAV
                      *** ******** **** ***** *** *  *** *
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with sLex or the Ca2+ ion, as determined by X-ray crystallography of the human 
E-selectin/sLex complex,[11] are fully conserved in murine E-selectin. However, two residues 
in close proximity to Neu5Ac are not conserved. The Tyr44 and Glu98 in human E-selectin 
are exchanged by a His44 and Thr98 in murine E-selectin (Figure 2). 
 
Figure 2. Surface representation of human E-selectin in complex with sLex (PDB code 1G1T).[11] Residues 
colored in blue are conserved in human and murine E-selectin, while residues colored in red mark non-
conserved residues. The Ca2+ ion is depicted as green sphere. While most of the binding site is well conserved, 
two residues near the D-Neu5Ac moiety differ. 
Results and Discussion 
To compare human and murine E-selectin in vitro, we expressed the Lec (L), EGF (E) and 
the first two SCRs (C2) of both types of E-selectin as IgGFc constructs in Chinese hamster 
ovary cells. Both proteins were purified to homogeneity (Figure 3A). While the human 
E-selectinLEC2-IgGFc construct shows an apparent molecular weight of 95 kDa, murine 
E-selectinLEC2-IgGFc exhibits a lower apparent molecular weight of 80 kDa. This suggests 
different glycosylation patterns of human and murine E-selectin. Indeed, while human 
E-selectin is predicted to possess seven potential N-linked glycosylation sites in the first four 
domains (predicted by NetNGlyc v1.0, threshold = 0.5), murine E-selectin has only five 
potential sites. The position of four N-linked glycosylation sites are conserved in the first four 
domains (Asn4, Asn124, Asn178, and Asn244).  
The affinity of the natural ligands sLex and its isoform sLea 
(Neu5Acα2→3Galβ1→3(Fucα1→4)GlcNAc), also an E-selectin ligand,[12] was compared in 
a target-based binding assay with peroxidase-conjugated carbohydrate polyacrylamide 
(sLex-PAA/sLea-PAA) as shown in Figure 3B.[8a, 8b] For human E-selectinLEC2-IgGFc, the 
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EC50 value of sLex-PAA was 315 ± 63 ng/mL, whereas sLea-PAA showed a threefold 
improved affinity of 112 ± 5 ng/mL. The higher affinity for sLea compared to sLex for human 
E-selectin has previously been observed in in vitro assays.[8a, 13] For murine E-selectinLEC2-
IgGFc, the EC50 value of sLex (105 ± 8 ng/mL) was similar to that of sLea (96 ± 9 ng/mL). 
Therefore, sLex-PAA exhibited a threefold higher affinity to murine E-selectin than to the 
human form. For sLea-PAA the affinities were similar for both, human and murine E-selectin. 
Human E-selectin is therefore capable of distinguishing α1→3 and α1→4 linkage of L-Fuc, 
while murine E-selectin binds both isoforms with similar affinities. 
 
Figure 3. (A) SDS-PAGE analysis of purified human and murine E-selectinLEC2IgGFc. (B) Binding of 
sLex- and sLea-polyacrylamide-peroxidase (PAA) to immobilized human and murine E-selectin. 
Signals were obtained after color reaction with a peroxidase substrate. EC50 values are the 
concentration of carbohydrate-PAA at which half-maximal binding was observed. Errors given are 
standard deviations from two independent measurements, each run in duplicate wells. 
We assessed the affinity of N-glycolyl-sLex (1), which is the natural ligand to E-selectin in 
mice, with a competitive inhibition assay (Figure 4). Since sLea-PAA exhibited a similar 
affinity for the human and murine form of E-selectin, this ligand was chosen as reporter in 
the competitive binding assays. Binding of N-glycolyl-sLex (1) to human E-selectin was in 
the millimolar range (IC50 = 1.7 mM), similar as observed for N-acetyl-sLex.[14] The affinity 
of N-glycolyl-sLex (1) to murine E-selectin (IC50 = 1.4 mM) was similar as observed for the 
human counterpart. Murine E-selectin is therefore not adapted to the Neu5Gc form of sLex. 
Since no interactions of Neu5Ac are observed in the E-selectin/sLex crystal structure except 
for the carboxylic acid, it is not surprising that the exchange of an acetyl to glycolyl group 
does not influence binding. It is noteworthy, however, that murine E-selectin/IgG bound 
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N-acetyl-sLex-PAA three-fold better than the human counterpart and that this appears not to 
be the case for N-glycolyl-sLex, albeit being in the α1→3 configuration for L-Fuc. 
 
Figure 4. Binding affinites of the natural ligand for murine E-selectin (N-glycolyl-sLex, 1) and the three sLex 
mimetics 2-4. Binding affinities were measured in a target-based competitive binding assay with a dilution 
series of each compound. Compounds 1 and 2 were measured a single time in duplicate wells. The errors for 
compound 3 and 4 are standard deviations of two independent measurements. 
To evaluate the efficacy of sLex derived glycomimetics with murine E-selectin, selected 
compounds were tested in the target-based inhibition assay. Three glycomimetic compounds 
that cover a wide range of affinities (20–1500 µM) were tested for their affinity.[5d, 9] In 
compound 2, D-GlcNAc and D-Neu5Ac are replaced by (1R,2R)-cyclohexane-1,2-diol and 
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(S)-phenyl lactic acid, respectively.[5a, 15] Compound 2 previously exhibited a 4.5-fold weaker 
affinity than compound 3 in a target-based inhibition assay.[8c] In compound 3 
(CGP69669A), Neu5Ac has been exchanged with (S)-cyclohexyl lactic acid, while otherwise 
being identical to compound 2. The affinity of compound 3 to human E-selectinLEC6IgGFc 
was shown to be 12-fold improved over sLex.[5d] The glycomimetic compound 4 consists of 
the same replacement for D-Neu5Ac as compound 3. Furthermore, the D-GlcNAc moiety is 
replaced by (1R,2R,3S)-3-methylcyclohexane-1,2-diol, and the D-Gal moiety is additionally 
benzoylated in the 2’-position. Compound 4 was shown to be 15 to 20-fold more potent than 
compound 3.[5d] 
For the human E-selectinLEC2IgGFc construct, similar relative IC50 values were obtained as 
reported in the literature. Compared to compound 3 (236 ± 58 µM), compound 4 was 13-fold 
more potent (19 ± 2 µM), while compound 2 was 5-fold weaker (1131 µM). However, the 
absolute values were higher than previously reported. For example, the IC50 value of 
compound 3 to E-selectinLEC6IgGFc is reported to be 80 µM, whereas a value of 236 ± 58 µM 
was measured with the E-selectinLEC2IgGFc construct. The difference in affinities is a 
consequence of the reduced number of SCR domains, which has been shown to influence E-
selectin activity, but not its selectivity.[16] The glycomimetic compounds were also able of 
inhibiting sLea-PAA binding to murine E-selectin. A similar ranking of the compounds was 
observed. In relation to compound 3 (52 ± 17 µM), compound 4 was 14-fold more potent (3.8 
± 0.8 µM), and compound 2 was 6-fold weaker (310 µM). In direct comparison, the affinities 
of all glycomimetics were 3.5–5-fold improved for murine E-selectin than for human 
E-selectin. However, the differences in affinities was consistent with the comparison of the 
EC50 values of the sLex-PAA, where murine E-selectin exhibited 3-fold increased binding 
potency. In that regard, the augmented affinity to murine E-selectin is not surprising since the 
tested glycomimetics are based on sLex and therefore all posses α1→3 linked L-Fuc moieties. 
Conclusion and Summary 
In summary, we show that sLex glycomimetics designed against human E-selectin are also 
capable of binding to murine E-selectin. This piece of information is important since in vivo 
efficacy studies are routinely performed in mice. Based on the herein presented data, mouse 
studies with E-selectin antagonists are suitable for proof-of-concept studies. However, since 
the affinity of antagonists was approximately three-fold higher for murine E-selectin 
compared to human E-selectin, this must be taken into consideration when correlating dosage 
for human application. 
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Material and Methods 
Protein expression and purification 
CHO-K1 cells expressing human E-selectin expressing Lec-EGF-SCR2 domains fused to the 
Fc-part of human IgG2 was generated as previously reported.[17] Protein was purified with a 
protein A-Sepharose® column and by an anti-human E-selectin antibody (7A9) as previously 
described.[9] CHO-K1 cells expressing murine E-selectin Lec-EGF-SCR2 domains fused to 
the Fc-part of murine IgG1 were a generous gift from Prof. Dr. Vestweber (Max Planck 
Institute for Molecular Biomedicine, Münster, Germany). The cells were grown as 
monolayers at 37 °C and 5% CO2 in Ham’s Nutrient Mixture F-12 medium supplemented 
with 2 mM L-glutamine, 10% (v/v) fetal calf serum, 100 U/mL penicillin, and 100 µg/mL 
streptomycin. Once confluent, culture medium was collected weekly. Murine E-selectin was 
initially purified with a protein A-sepharose® according to the human counterpart. The 
protein was subsequently purified to homogeneity by anion exchange chromatography with a 
UnoTM Q6 column (Bio-Rad, Reinach BL, Switzerland) and buffers A (20 mM Tris/HCl, pH 
8.8) and B (20 mM Tris/HCl, pH 8.8, 1 M NaCl). Protein was concentrated by ultrafiltration 
(50 kDa cut-off, Millipore AG, Zug, Switzerland). 
 
Target-based binding assays 
The target-based binding assays were performed similar as previously reported.[17] Briefly, 20 
µL biotinylated sLex- and sLea-PAA (100 µg/mL, GlycoTech, Gaithersburg, MD) was 
incubated together with 80 µL streptavidinidase (200 U/mL, Roche Applied Science, 
Rotkreuz, Switzerland), 10 µL fetal calf serum and 80 µL assay buffer (20 mM 
HEPES/NaOH pH 7.4, 150 mM NaCl, and 1 mM CaCl2) at 37 °C for 2 h. Human and murine 
E-selectin/IgG diluted to 3 µg/mL in assay buffer was passively coated on Immunoplate II 
MaxiSorpTM 96-well microtiter plates (100 µL/well, Nunc, Roskilde, Denmark) overnight at 4 
°C. Wells were washed with assay buffer (150 µL/well) and blocked with 2% BSA in assay 
buffer (200 µL/well). For EC50 assays, serial dilutions (3 ng/mL–3 µg/mL) of the 
carbohydrate-PAA was incubated for 3 h at 25 °C while shaking (300 rpm). For competitive 
inhibition assays, serial dilutions of the compounds (1–4) were prepared with 10% DMSO 
(v/v) and diluted 1:1 with sLea-PAA (200 ng/mL) prior to incubating on the protein-coated 
wells. After washing and removal of excess carbohydrate-PAA, 2,2’-azino-di-(3-
ethylbenzthiazoline)-6-sulfonic acid (100 µL/well, Invitrogen, Lucerne, Switzerland) was 
added for colorimetric reaction and stopped by addition of 2% oxalic acid (w/v, 100 µL/well) 
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after 1–2 minutes. The optical density was measured at 415 nm. EC50 and IC50 values were 
determined with the Prism software (GraphPad Software Inc., La Jolla, CA). A four-
parameter fit for minimum, maximum, logIC50/logEC50 and slope was used. 
 
Synthesis of compounds 
Compounds 1-4 were synthesized as described previously.[5d, 8c, 18] 
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3.1. Introduction to FimH 
3.1.1. Urinary Tract Infections 
A urinary tract infection (UTI) is a bacterial infection, with involvement of the bladder, the 
urethra, or even the kidneys. The major cause of UTIs are gram-negative uropathogenic 
Escherichia coli (UPEC) that are responsible in 80 % of the cases, thus being the most 
prominent species1-3. Staphylococcus saprophyticus has been identified as the second most 
common species in UTIs with a proportion of 10–20 % of the cases4. UTIs are a common 
infection disease, since each year millions of people suffer from such an infection, causing 
major costs in diagnosis and treatment. Approximately 50 % of all women endure at least one 
symptomatic UTI during their lifetime. Further risk factors are diabetes5, spinal cord 
injuries6, age (menopause7), suppressed immune system8, sexual activity and use of 
contraceptives (diaphragm9). 
A cystitis, commonly referred to as a bladder infection, is a UTI that only affects the lower 
parts of the urinary tract, i.e. the urethra and the bladder. The typical symptoms are pain 
during micturition (dysuria), frequent urination (polyuria), and blood traces in the urine 
(haematuria). When left untreated, a cystitis may lead to a pyelonephritis, an infection of the 
upper urinary tract involving the kidneys. A pyelonephritis poses a serious health risk, as it 
may lead to sepsis, kidney failure, and finally death3. A major problem of UTIs is its 
reoccurrence. One in four women who have experienced an initial UTI will suffer a second 
UTI regardless of antibiotic treatment within six moths10. 
3.1.2. The Infection Cycle and Virulence Factors 
UPECs undergo a well defined infection cycle within the host (Figure 3-1). The adherence of 
the bacteria to epithelial cells in the lower urinary tract is the first and one of the most crucial 
steps. This is mediated by the interaction of bacterial type 1 pili, which contains the lectin 
FimH, and oligosaccharides presented on the glycocalix on bladder epithelial cells. The cell-
surface glycoprotein uroplakin-Ia (UPIa), which contains high-mannosylated glycan 
structures, has been identified as an important ligand for UPECs11,12. Once adhered to the 
urothelium, UPECs are protected from clearance by the flow of urine and can invade the host 
cells within hours13, finally leading to a UTI14,15. The host defends against UPECs by 
exfoliation of the outer cell lining and by activating the immune response accompanied by a 
massive influx of leukocytes16. By forming biofilm-like intracellular bacterial communities 
(IBC), in which bacteria are in a quiescent state, and by penetrating deeper into the host 
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tissue, UPECs can evade the host immune response. Especially the IBCs pose a major 
challenge for the host immune system and for the treatment of UTIs. The bacteria therein are 
embedded in an extracellular polysaccharide matrix, which binds and inactivates almost any 
external agents17-19. UPECs can remain in IBCs for long periods after which the bacteria can 
re-emerge and infect neighboring epithelial cells, a mechanism associated with the high 
reoccurrence of UTIs. 
 
Figure 3-1. Infection cycle of uropathogenic E. coli (UPECs) in the lower urinary tract (adapted 
from20). The urethra is the entry point of UPECs from which they colonize within the bladder. Initial 
adhesion (1) is mediated by type 1 pili binding to mannosylated glycoproteins (e.g. uroplakin Ia) 
presented on urothelial cells. UPECs consequently invade into the urothelium (2), in which they are 
able to form intracellular bacterial communities (3). Within these communities, the UPECs are 
protected from the host immune response and from antibiotics. UPECs are released as filamentous 
structures upon exfoliation of bladder epithelial cells (4) and are able either to penetrate deeper into 
the tissue or to infect surrounding urothelial cells (5). 
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UPECs have acquired a specific set of virulence factors to adhere to and invade host cells, 
and to form IBCs. These virulence factors are activated at the various stages of infection: 
• Adhesins, which are required for attachment to epithelial cells14. The mannose 
specific type I fimbriae are involved in initial attachment; galabiose specific P pili are 
required for ascending infections. 
• Toxins such as the lipoprotein α-haemolysin (HylA), which facilitate bacterial entry 
over mucosal barriers and damage immune cells21. 
• Siderophores in the iron acquisition systems, which allows survival in nutrient poor 
environtment22. 
• Further virulence factors such as proteases23, lipopolysaccharides, and the 
polysaccharide capsule, which are involved in IBC formation22. 
3.1.3. Type I pili – Structure, Assembly and Expression 
Type I pili are long, multimeric filamentous rods that protrude from the bacterial cell 
wall24,25. Each pili is approximately 7 nm wide, 1-3 µm in length and is composed of ~300-
5000 of FimA subunits, followed by one of each FimF, FimG, and FimH that form the tip of 
the pili (see Figure 3-2). The subunits are connected by high-affinity, non-covalent 
interactions providing stability and rigidity26,27. Each subunit has an incomplete 
immunoglobulin-like fold, with a missing C-terminal beta strand. During assembly in the 
periplasmic space, the subunits are bound to FimC, a chaperone protein which donates the 
missing beta strand and stabilizes the subunits28,29. Upon delivery to FimD, an usher protein 
in the outer cell membrane, the subunit is released from FimC and is linked to the next 
subunit, which itself donates the missing beta strand. At the same time, FimD translocates the 
growing pilus rod through the outer cell membrane. A similar chaperone/usher pathway for 
pilus assembly is also used for the biosynthesis of other pili30,31. 
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Figure 3-2. Left: Schematic representation of type 1 pili and their assembly27. Pilus subunits are 
assembled via “donor strand complementation”, in which the immunoglobulin-like fold is completed by 
the insertion of an anti-parallel beta-sheet of the following subunit. The bacterial lectin FimH is located 
on the tip of each pili. Right top: The fim operon encodes all type 1 pili subunits as well as the 
chaperone FimC and the regulators FimB and FimE. The fim operon is regulated by an invertible 
element that regulates pilus expression. Right bottom: Electron micrograph of the UTI89 strain 
expressing type 1 pili (kindly provided by Dr. Meike Scharenberg and Deniz Eris, Institute of Molecular 
Pharmacy, University of Basel). 
The genes for type I pili are located on the fim gene operon. Besides the genes encoding for 
the pili subunits, two regulatory genes are encoded (fimB and fimE). FimB and FimE are 
recombinases and are able to influence the direction of the invertible element, a 314 bp long 
region in the fim operon. In its off-state, the invertible element prevents mRNA transcription 
of the downstream fimA, fimC, fimD, fimF, fimG, and fimH genes. When switched to the on-
state, transcription takes place and type I pili are expressed32,33. The regulation of type I pili 
expression is also referred to as phase-variation. The two recombinases are influenced by 
external factors, e.g. pH, osmolarity, and motion. However, the exact mechanism is still 
elusive33,34. While FimB is able to switch the invertible element in both directions (on-to-off 
and off-to-on), FimE can only promote expression silencing (on-to-off)35,36. To prevent 
simultaneous expression of multiple pilus types, cross-talk between the various systems 
occur. For example, when the fim operon is in the on-state, the pap operon (encoding P pili) 
is suppressed37. This strategy is important for the pathogenicity, as it allows specific pili 
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expression, depending on the surroundings of the bacteria. In the lower urinary tract, type I 
pili expression is preferred, while in the upper urinary tract, during the course of an ascending 
infection, P pili expression is beneficial. 
3.1.4. The Bacterial Lectin FimH 
The terminal FimH subunit on type I pili is responsible for the bacterial adherence, as it 
contains the mannose binding site24,38. The 29 kDa protein with 279 amino acid residues 
consists, unlike the other Fim subunits, of two immunoglobulin-like domains: the lectin 
domain (FimHLD, residues 1–156) at the N-terminus, which contains the CRD, and the 
C-terminal pilin domain (FimHPD, residues 160–279), which connects FimH to the pilus rod 
(see Figure 3-3). The two domains are linked via three amino acid residues (amino acids 
157–159). While the lectin domain alone is stable, the entire FimH protein consisting of both 
domains is not due to the missing beta-strand of the following subunit in the pilin domain. 
Therefore, full length FimH in solution is only stable in presence of FimC. The FimC-FimH 
complex was the first structure to be solved in 199938. Three years later Hung et al. reported 
the first FimC-FimH structure in presence of a mannoside ligand, which gave important 
insight into the binding site39. Later, the structures of the FimH lectin domain alone40 and in 
complex with oligomannose-341 were published. An elegant crystal structure of FimHLD and 
FimHPD together with FimG, two FimF, and FimC subunits was reported by LeTrong et al. in 
201042. This structure revealed significant differences of the overall fold of FimH as 
discussed in section 3.1.7. Finally, several structures of the lectin domain with various 
mannoside ligands were recently published43. 
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Figure 3-3. Left: Structure of FimHLD-FimHPD-FimC in complex with D-mannose (PDB code 1KLF)39. 
FimH (blue) is wedged apart by FimC (red), which provides the donor strand (magenta). The 
carbohydrate binding site is located at the very tip of FimH. Right: Structure of the fimbrial tip (PDB 
code 3JWN)42 with both domains of FimH (blue), FimG (magenta), and FimC (red) wedged between 
two FimF domains (green). 
3.1.5. Natural Ligands to FimH 
As stated in section 3.1.1., type I pili dependent bacterial adhesion to the urothelium is 
mediated by the interaction of FimH to oligomannosides presented on cell surfaces. 
Therefore, FimH binds to any cell type presenting mannose, e.g. yeast cells (yeast mannan) 
and erythrocytes44. On mammalian cells, mannose is presented on high-mannose N-linked 
glycans, consisting of five (Man5-GlcNAc2) to nine mannose (Man9-GlcNAc2) residues 
attached to two GlcNAc moieties (see Figure 3-4). FimH affinity strongly depends on the 
connectivity of the terminal mannose residues. For Man9-GlcNAc2, all terminal mannose 
moieties are α1-2 linked, while for Man5-GlcNAc2, they are α1-3 or α1-6 linked. FimH shows 
strongest affinity towards α1-3 linked mannose, followed by the α1-6 and weakest binding to 
α1-2 configuration45. 
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Figure 3-4. The natural ligand of FimH is presented on high-mannose N-linked glycans. These are 
presented on urothelial cells as part of the glycoprotein uroplakin Ia. While FimH binds weakly to full 
high-mannose N-linked glycans (Man9-GlcNAc2, red/blue/green), affinity towards truncated glycans 
(Man5-GlcNAc2, blue/green) is augmented. 
Apart from mannose and mannosylated glycoproteins, FimH has been shown to bind non-
carbohydrate structures as well. For example, the naturally occurring S62A mutation in the 
FimHLD allows it to bind to type I and type IV collagen46. Furthermore, FimH has been 
shown to bind fibronectin and peptide fragments thereof47,48. The binding mechanism of these 
non-carbohydrate ligands has not been determined to date. 
3.1.6. The Mannose Binding Site 
From the crystal structure of FimHLD with α-D-mannose (PDB code 1KLF)39, the binding 
mode and the involved residues were identified. The mannose binding site consists of a deep, 
negatively charged pocket with a hydrophobic entrance. The residues Phe1, Asn46, Asp47, 
Asp54, Gln133, Asn135, Asp140, and Phe142 provide an extensive hydrogen bond network 
to the hydroxyl groups of mannose. All oxygen atoms of D-mannose are involved, except for 
the one at the anomeric center. The hydrophobic entrance, termed “tyrosine-gate”, is formed 
by Ile52, and the two aromatic residues Tyr48 and Tyr137. FimH has also been crystallized 
with n-butyl α-D-mannopyranoside (1UWF40, see Figure 3-5), which sparked the 
development of α-D-mannopyranosides with hydrophobic aglycons as FimH antagonists (see 
Section 3.1.9.)40. 
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Figure 3-5. Schematic representation of the binding site of n-butyl α-D-mannopyranoside according to 
X-ray crystallography (PDB code 1UWF)40. Relevant pharmacophores are marked in blue. Amino acid 
residues involved in binding are marked in red. 
3.1.7. Catch-Bonds in FimH 
Similar to the selectins, FimH also exhibits catch-bond binding behavior, i.e. an increased 
bond lifetime under tensile force49. This has independently been observed under 
hydrodynamic force in flow chamber assays50-53 and in AFM studies54. The structural 
mechanism by which the catch-bonding is regulated in FimH has been structurally 
elucidated42. FimH is able to adopt two distinct conformations, a high- and a low-affinity 
conformation. The low affinity conformation, which is the preferred conformation in absence 
of force or ligand, is stabilized by interdomain interactions between FimHLD and FimHPD 
with various loops (insertion-, swing-, and linker loop). These interdomain interactions twist 
the beta-sandwich fold of the FimHLD, thus allosterically auto-inhibiting FimH by widening 
the binding pocket and not providing a suitable mannose binding site (see Figure 3-6). Upon 
transition into the high-affinity state by force along the FimHLD-FimHPD axis, interactions 
between the domains are disrupted, consequently relaxing and untwisting the FimHLD. The 
interaction between the two domains for the low-affinity conformations are absolutely 
necessary to stabilize this conformation. Therefore, the FimHLD expressed alone is always in 
the high-affinity state. This is also true for FimH-FimC co-expression, because FimC is 
wedged at the interdomain region, consequently forcing the two domains apart38. 
Furthermore, mannose-based ligands can induce the switch from the low- to the high-affinity 
state, possibly by contracting the ligand binding site upon interaction49. 
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It is assumed that the UPECs exploit the catch-bond function to have mobility in the bladder 
while avoiding clearance from the urinary tract under hydrodynamic force, as it occurs during 
micturition. Furthermore, lower affinity under static conditions prevents UPECs from 
clearance by natural soluble antagonists, such as the Tamm-Horsfall protein55. 
 
Figure 3-6. Comparison of the binding site in both states of FimH. Left: The low-affinity state, which is 
adopted without ligand and in absence of FimC (PDB code 3JWN)42. Right: D-mannose bound in the 
high-affinity state binding site (PDB code 1KLF)39. In the high-affinity state, a deep pocket surrounding 
the ligand is formed, while being a shallow groove in the low-affinity state. 
3.1.8. Variation of FimH 
E. coli have a relatively high mutation rate of 1 in every 108 base pair during replication56. As 
a consequence, UPECs genetically adapt to support optimal pathogenicity, a process, which 
also involves the fimH gene. The primary sequence of FimH was determined in several 
UPEC isolates from the intestine and from patients suffering from UTI57,58. A number of 
single nucleotide point mutations were found, some of which alter the binding phenotype of 
FimH. Compared to non-pathogenic E. coli from the intestine, the mutations determined in 
UPECs usually lead to an enhanced affinity of FimH to mannose. Some of these mutations 
are found with a high frequency in UPECs, e.g. the A27V or the S62A mutation. Judging 
from the crystal structures of FimH, the functional implications of the mutations were 
rationalized: No mutation is located within the mannose binding pocket, which remains 
highly conserved throughout all investigated E. coli strains. All mutations are located in or 
near to the interdomain region of FimHLD and FimHPD. Therefore, it was assumed that these 
mutations influence the stability of the high- and low-affinity conformation, by disrupting the 
stabilizing interdomain bonds53. Indeed, this was confirmed by Tchesnokova et al., who 
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identified an antibody specific for a ligand induced binding site (LIBS)49. The LIBS epitope 
is exposed only in the high-affinity state of FimH, while it is obstructed in the low-affinity 
conformation. By thorough analysis of many FimH mutants, the LIBS antibody binding was 
correlated with the mannose binding affinity. The higher the affinity towards mannose, the 
greater the binding of the LIBS antibody, which for the first time corroborated the allosteric 
link between ligand affinity and the conformational state. 
The mutations leading to the destabilization of the allosteric autoinhibition by interfering 
with interdomain interactions, even under low shear or static conditions as found in the upper 
urinary tract, have evolved under positive selection due to their enhanced virulence as shown 
in in vivo studies59.  
3.1.9. FimH Antagonists 
The first-line treatment for uncomplicated UTIs are a three-day antibiotic treatment with a 
combination of trimethoprim and sulfamethoxazole or with a fluoroquinolone (e.g. 
ciprofloxacin)60,61. However, in clinical practice the emergence of bacterial resistance due to 
overuse of antibiotics poses a serious problem62. In a recently published study in which 
UPEC resistance in association with antibiotic treatment was monitored between 2000– 2010, 
a dramatic increase in bacterial resistance was observed63. To tackle the resistance problem, 
new strategies for UTI treatment are required. The inhibition of initial bacterial adherence by 
FimH antagonists is a promising approach. These anti-adhesive compounds must however 
fulfill a set of requirements besides being efficacious: they must be orally available, 
inexpensive, and safe. Furthermore, bacterial resistance mechanism should not be induced. 
Since FimH antagonists are neither bacteriolytic nor bacteriostatic, a reduced potential of 
bacterial resistance is expected.  
Over recent years, numerous assays for the affinity determination of FimH antagonists have 
been reported. Initially, cell-based assays were employed in which the inhibition of 
aggregation of E. coli with guinea pig erythrocytes64,65 or yeast cells66-68 was determined. 
Furthermore, sophisticated cell-based assays using an immortalized urothelial cell line were 
developed69. After successful cloning, expression and purification of FimH, target-based 
assays were developed. With competitive ELISA-based assays, high-throughput methods 
were established70,71. Surface plasmon resonance studies yielded first equilibrium 
dissociation constants (KD)40, however, due to the assay setup, no association or dissociation 
constant could be determined. Isothermal titration calorimetry (ITC) provided further insights 
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into the thermodynamic aspects of FimH antagonist binding72-74. When comparing affinity 
data from various assays, variation in the assay setup must be considered. In target-based 
assays, usually the FimHLD is employed, which is locked in the high-affinity state. In cell-
based assays, however, FimH is can switch between the low- and high-affinity conformation. 
Furthermore, E. coli expressing different variants of FimH are employed, leading to a further 
diversification on the degree of high- and low-affinity FimH investigated in assays. 
Since methyl α-D-mannopyranoside (1) has been shown to inhibit bacterial adhesion in the 
1970s66 with micro-40,71,75 to millimolar64,67 affinity, most drug discovery programs have 
focused on improving affinity by modifications on the aglycone portion at the anomeric 
center. Bouckaert and co-workers identified alkyl α-D-mannosides as potent FimH 
antagonists. A length of seven carbon atoms, as in n-heptyl α-D-mannopyranoside (2), proved 
to be the optimal length of the alkyl chain40. Further hydrophobic aglycones were designed in 
order to reach the hydrophobic rim at the binding site entrance. Aromatic aglycons were 
introduced, e.g. p-nitrophenyl α-D-mannopyranoside67 (3, p-NPMan), which has a 30-fold 
increase in the relative inhibitory potential over methyl α-D-mannopyranoside70. Extension of 
aromatic moieties lead to biphenyl aglycons modified with carboxylic acids (4–9)76,77 or 
other bulky substituents (6–8)73,77. Indolinylphenyl derivatives (10) have proven to be 
beneficial for in oral availability, while maintaining affinity78. Squaric acid derivatives (11) 
represent a class of FimH antagonists with affinities in the low nanomolar range70. This was 
initially attributed to covalent binding of protein and ligand, a notion that was not 
confirmed79. Further development was focused on the pharmacokinetic aspects of FimH 
antagonists to address oral availability. The efficacy of monovalent mannosides was 
determined in several in vivo mouse treatment studies41,78,80,81. To reduce polarity and thus 
increase oral uptake by passive intestinal absorption, an ester prodrug approach was 
successfully employed77. Indolinylphenyl proved to be successful candidates for oral 
application, since they were as effective as antibiotic treatment with ciprofloxacin78. A 
representative set of the most important FimH antagonists are summarized in Figure 3-7.  
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Figure 3-7. List of the most important FimH antagonists with their relative inhibitory potential (rIP). 
The rIPs were calculated either to compound 1 or 2 as noted in the brackets. 
All mannosides with extended hydrophobic aglycons have improved affinity over α-D-
mannose or methyl α-D-mannopyranoside due to hydrophobic interactions of the aglycone 
with the tyrosine gate. However, their binding mode can differ. For example, the aglycones 
of alkyl mannosides reside between Tyr48 and Tyr13740. This binding mode is termed the 
“in-binding mode” (see Figure 3-8)82. The more bulky aromatic aglycons on the other hand, 
adopt a different conformation, in which π-π stacking only occurs exclusively with Tyr48 as 
shown in X-ray crystal structures76. This binding mode is termed “out-binding mode”. 
However, recently published structures show aromatic aglycons, e.g. propinyl biphenyl α-D-
mannopyranoside also binding in the in-docking mode43. When discussing ligand poses in the 
crystal structures, one needs to take crystal packing effects into account. Binding site residues 
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form numerous crystal contacts in most published FimH structures, which might influence 
the location of certain residues and the ligand itself.!!
!
Figure 3-8. Two distinct binding modes of FimH antagonists. Left: The “in-binding mode” as observed 
in the FimH structure in complex with n-butyl α-D-mannopyranoside (PDB code 1TR7)40. Right: The 
“out-binding mode” as observed with the biphenyl substituted α-D-mannopyranoside (9) (PDB code 
3MCY)83. By courtesy of Adam Zalewski, University of Basel. 
Finally, multimeric FimH antagonists were developed in which mannose moieties are 
attached to a scaffold. Hartmann and Lindhorst have summarized the recent development of 
multimeric FimH antagonists in their review84. While the affinity of mannose multimers is 
high due to avidity and their ability to bind multiple FimH molecules simultaneously, such 
antagonists are most likely not orally available due to their size and polarity. !
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ABSTRACT 
 
Urinary tract infections (UTIs), predominantly caused by uropathogenic Escherichia coli 
(UPEC) belong to the most prevalent infectious diseases worldwide. The attachment of UPEC 
to host cells is mediated by FimH, a mannose-binding adhesin at the tip of bacterial type 1 pili. 
To date, UTIs are mainly treated with antibiotics, leading to the ubiquitous problem of 
increasing resistance against most of the currently available antimicrobials. Therefore, new 
treatment strategies are urgently needed. Here, we describe the development of an orally 
available FimH antagonist. Starting from the carboxylate substituted biphenyl α-D-mannoside 
9 affinity as well as the relevant pharmacokinetic parameters (solubility, permeability, renal 
excretion) were substantially improved by a bioisosteric approach. With 3’-chloro-4’-(α-D-
mannopyranosyloxy)-biphenyl-4-carbonitrile (10j) a FimH antagonist with an optimal in vitro 
PK/PD profile was identified. Orally applied, 10j was effective in a mouse model of UTI by 
reducing the bacterial load in the bladder by over 1000-fold. 
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INTRODUCTION 
 
Urinary tract infection (UTI) is one of the most frequent infectious diseases worldwide and 
affects millions of people every year.1 In more than 70% of the reported cases, uropathogenic 
Escherichia coli (UPEC) is the causal pathogen.2 Acute, uncomplicated lower urinary tract 
infection, commonly referred to as cystitis, requires an antibiotic treatment for symptom relief 
(i.e. reduction of dysuria, frequent and urgent urination, bacteriuria, pyuria) and for prevention 
of more devastating or even life threatening complications like pyelonephritis and urosepsis.3,4 
However, the repeated use of antibacterial chemotherapeutics provokes antimicrobial 
resistance leading to treatment failure.5 Hence, a new approach for the prevention and 
treatment of UTI with orally applicable therapeutics is urgently needed.6 
 
UPEC undergo a well-defined infection cycle within the host.7 The key step in pathogenesis is 
bacterial adhesion to the epithelial cells in the lower urinary tract.8 This interaction prevents 
UPEC from clearance by the bulk flow of urine and enables the bacteria to colonize the 
epithelial cells. The adhesion is mediated by the virulence factor FimH located at the tip of 
bacterial type 1 pili.9,10 FimH consists of two immunoglobulin-like domains: the N-terminal 
lectin domain and – connected by a short linker – the C-terminal pilin domain.11 The lectin 
domain encloses the carbohydrate recognition domain (CRD) that binds to the 
oligomannosides of the glycoprotein uroplakin Ia on the epithelial cell surface.12 The pilin 
domain anchors the adhesin to the pilus and regulates the switch between two conformational 
states of the CRD with high and low affinity for mannosides, respectively. 
 
More than three decades ago, Sharon and co-workers described various oligomannosides and 
aryl α-D-mannosides as potential antagonists of the FimH-mediated bacterial adhesion.13,14 
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However, only weak interactions in the milli- to micromolar range were observed. In recent 
years, several high-affinity monovalent mannose-based FimH antagonists with various 
aglycones like n-alkyl,15 phenyl,16 dioxocyclobutenylaminophenyl,17 umbelliferyl,16 
biphenyl,18-22 indol(in)ylphenyl,23 triazolyl24 and thiazolylamino25 have been reported. In 
addition, different multivalent presentations of the mannose have been synthesized26-32 and a 
heptavalent presentation of n-heptyl α-D-mannoside (1) tethered to β-cyclodextin proved  to 
be highly effective when applied together with the UTI89 bacterial strain through a catheter 
into the bladder of C3H/HeN mice.32 Importantly, adverse side effects resulting from non-
selective binding of FimH antagonists - they are all α-D-mannopyranosides - to mannose 
receptors of the human host system have recently been ruled out.33 
 
The high affinities of the monovalent α-D-mannopyranosides are based on optimal interactions 
with the main structural features of the CRD.34-37 First, the mannose binding pocket 
accommodating the mannose moiety by means of an extended hydrogen bond network and, 
second, the entrance to the binding site composed of three hydrophobic amino acids (Tyr48, 
Tyr137, and Ile52) and therefore referred to as ‘tyrosine gate’ hosting aliphatic and aromatic 
aglycones. As an example, n-heptyl α-D-mannopyranoside (1) exhibits nanomolar affinity due 
to hydrophobic contacts of the alkyl aglycone with the hydrophobic residues of the tyrosine 
gate.15 Furthermore, aromatic aglycones, such as present in mannosides 2 & 3 (Figure 1), 
provide strong π-π stacking interactions with the tyrosine gate. This interaction is further 
favored by the addition of an electron withdrawing substituent on the terminal ring of the 
biaryl portion (→ 4).18,19 
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Figure 1. Monovalent FimH antagonists 1-4 acting as reference compounds and 5-8 which have been orally 
explored in in vivo disease models. 
 
Recent in vivo PK studies in mice proved the high potential of the biphenyl α-D-mannosides 5-
8 for an oral treatment, although high doses (≥ 50 mg/kg) were necessary to achieve the 
minimal concentrations required for the anti-adhesive effect in the urinary bladder.19-21 
Moreover, the therapeutic effect could only be maintained for a few hours, i.e. four hours for a 
po (per os) single-dose application of 7 (50 mg/kg), because of rapid elimination by glomerular 
filtration and low reabsorption from the primary urine in the renal tubules.19 
 
To date, the physicochemical properties affecting the rate of renal excretion, i.e. lipophilicity 
and plasma protein binding (PPB), or metabolic liabilities promoting non-renal elimination 
pathways have been barely investigated for FimH antagonists. The goal of the present study 
was to optimize the biphenyl α-D-mannoside with respect to oral bioavailability and renal 
excretion. Starting from antagonist 919 (Figure 2), we synthesized new biphenyl derivatives, 
characterized their affinity to the CRD, structurally investigated their binding mode, and 
determined physicochemical and pharmacokinetic parameters predictive for intestinal 
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absorption and renal elimination. Furthermore, we determined in vivo PK (pharmacokinetics) 
of the most promising new antagonists in a mouse model. After oral administration, the 
compound with the best PK profile proofed effective in reducing the bacterial loads upon 
bladder infection in a mouse model of UTI. 
 
RESULTS AND DISCUSSION 
 
As previously reported, the carboxylate substituent present in the biphenyl mannoside 9 – its 
electron withdrawing potential being essential for an enhanced drug target interaction – 
strongly decreases the lipophilicity of the antagonist (log D7.4 < -1.519) in comparison to the n-
heptyl (→ 1, log P = 1.719) or the unsubstituted biphenyl aglycone (→ 3, log P = 2.122). Since 
low lipophilicity is a major reason for low intestinal absorption and rapid renal excretion of the 
systemically available antagonist,19,23 we aspired to improve oral bioavailability as well as 
renal excretion by replacing the carboxylate in 9 with various bioisosteric groups39 (Figure 2). 
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Figure 2. Bioisosteric replacement of the carboxylic acid substituent of biphenyl α-D-mannopyranoside 9. 
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Synthesis. Iodide 11 was prepared from peracetylated mannose and 4-iodophenol in the 
presence of BF3·Et2O.22 In a palladium-catalyzed Miyaura-Suzuki coupling40 with the boronic 
acid or boronate derivatives 12a-g, the biphenyl derivatives 13a-g were obtained in good to 
excellent yields. Final deprotection yielded the test compounds 10a-g. Utilizing microwave-
assisted reaction conditions,41 the conversion of arylnitrile 13g to tetrazole 14 proceeded 
rapidly and with good yield. After deprotection of 14 using Zemplén conditions, the test 
compound 10h was obtained (Scheme 1). 
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Scheme 1. a) Pd(Cl2)dppf·CH2Cl2, K3PO4, DMF, 80 °C, 4 h (13a-g, 44-99%); b) NaOMe, MeOH, rt, 4 h (10a-h, 
29-86%); c) TMSN3, Bu2Sn(O), DME, 150 °C, µW, 10 min (81%). 
 
The cyanobenzamide derivative 10i (Scheme 2) was obtained from 9 by peracetylation (→ 15) 
followed by conversion of the carboxylic acid into its acid chloride with 1-chloro-N,N,2-
trimethyl-1-propenylamine.42 Without isolation, the acid chloride was reacted with sodium 
hydrogen cyanamide in DMF followed by deacetylation under Zemplén conditions to yield the 
test compound 10i. 
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Scheme 2. a) i) Ac2O, DMAP, pyridine, 0 °C to rt, overnight; ii) satd. NaHCO3 aq., DCM, rt, 2 h (15, 53%); b) 1-
chloro-N,N,2-trimethyl-1-propenylamine, toluene, 0 °C to rt, 2 h; c) NaH, NH2CN, DMF, 0 °C to rt, overnight; d) 
NaOMe, MeOH, rt, 4 h (10i, 21% for three steps). 
 
Finally, to further improve the pharmacokinetic properties of mannoside 10g18 (see Table 3), a 
chloride substituent was introduced to the ortho-position of the aromatic ring adjacent to the 
anomeric oxygen. For its synthesis, peraceylated α-D-mannose (16) was coupled with 2-
chloro-4-iodophenol (17) using BF3⋅Et2O as promotor (→ 18, 76%). After the introduction of 
the second aromatic ring by Miyaura-Suzuki coupling (→ 19, 75%), deprotection yielded 
mannoside 10j (Scheme 3). 
OAc
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Scheme 3. a) BF3⋅Et2O, CH2Cl2, 40 °C (76%); b) Pd(Cl2)dppf·CH2Cl2, K3PO4, DMF, 80 °C (75%); c) NaOMe, 
MeOH, rt, 4 h (48%). 
 
Binding Affinity. The binding affinity of heptyl mannoside 1, the biphenyl mannosides 3, 9, 
20,18 and the bioisosteres 10a-j was determined in a competitive fluorescence polarization 
assay (FP-assay) and with isothermal titration calorimetry (ITC). A protein construct 
consisting of the CRD with a C-terminal His-tag with a thrombin cleavage site (FimH-CRD-
Th-His6) was used for all experiments.43 
 
Chapter 3.2. – Manuscript 4 
 
 160 
Competitive Fluorescence Polarization Assay. For the rapid evaluation of binding affinity, 
we established a competitive binding assay based on fluorescence polarization (FP). Similar 
formats have been applied before for the detection of carbohydrate-lectin interactions.18,44 In 
this assay, the antagonist of interest displaces a fluorescently labeled competitor from the 
binding site, thereby causing a reduction in fluorescence polarization.45 To identify the optimal 
competitor, fluorescein isothiocyanate (FITC) was connected to the FimH ligand 21 by three 
linkers of different lengths (→ 22-24, Scheme 4). For optimal sensitivity and signal-to-noise 
ratio, three main parameters need to be considered: (i) the affinity of the competitor should not 
be impaired by the fluorescent label, (ii) the conformational flexibility of the label upon 
binding of the competitor to the CRD should be low and (iii) the fluorescence properties of the 
label should not be affected by the connected ligand.46-48 A change in fluorescence properties 
was observed for reporter ligand 22 in which the label was linked to the biphenyl agylcone by 
an amide bond. The absorption spectrum revealed a lack of the characteristic fluorescein 
absorption peak at 494 nm (Scheme 4), likely due to an extension of the conjugated system to 
the biphenyl moiety of the ligand. The elongated saturated spacer groups in competitors 23 and 
24 ensured that the expected spectral properties of the dye were retained (Scheme 4). 
Chapter 3.2. – Manuscript 4 
 
   161 
 
 
Scheme 4. a) 1-[(1-(Cyano-2-ethoxy-2-oxoethylideneaminooxy)-dimethylamino-morpholinomethylene)] 
methanaminium hexafluorophosphate (COMU), NEt3, fluoresceinamine, DMF, rt, 7 h (22, 19%); b) i. DIC, NHS, 
N-Boc-ethylenediamine, DMF, rt, 12 h; ii. TFA, DCM, rt, 10 min (68% over two steps), iii. fluorescein 
isothiocyanate (FITC), NEt3, DMF, rt, 3 h (23, 48%); c) i. DIC, NHS, N-Boc-PEG2-NH2, DMF, rt, 14 h; ii. TFA, 
DCM, rt, 30 min (62% over two steps); iii. FITC, DMF, rt (24, 65%). 
 
For the determination of their binding affinity, fixed concentrations of the reporter ligands 23 
and 24 were incubated for 24 h with a linear dilution of the FimH-CRD (0-100 nM). FP was 
measured using a plate reader, with polarized excitation at 485 nm, and emission at 528 nm 
measured through appropriately oriented polarizers. Fitting the single-site binding function of 
Cooper49 to the observed FP data resulted for compound 23 in a dissociation constant (KD = 1.7 
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nM, Figure 3A) similar to that of the unlabeled parent compound 21,19 whereas 24 showed a 
five-fold lower affinity (9.9 nM) (Scheme 4). Therefore, the reporter ligand 23 fulfills all 
characteristics as an optimal competitor and was used for the FP assay. 
 
 
Figure 3. A) Direct binding curve of the labeled competitor 23 obtained by adding a linear dilution of FimH-CRD 
(0-100 nM) and a constant concentration of competitor 23 (5 nM). The KD was determined by fitting the 
experimental data to a single-site binding fit that accounts for ligand depletion. In three FP based direct binding 
experiments the KD of competitor 23 was determined to be 1.7 nM. B) Inhibition curve of n-heptyl mannoside (1) 
from the competitive FP assay. The IC50 value was determined by nonlinear least-squares fitting to a standard 4-
parameter equation. A modified Cheng-Prusoff equation45 was used to calculate the corresponding KD value (KD = 
28.3 nM). 
 
For the test compounds 1, 3, 9, 20, and 10a-j, a 24 h incubation time was applied before FP 
was measured due to the long residence time of FimH antagonists (t1/2 > 3.5 h, Figure 3B50). 
The 24 h incubation period was empirically determined to be necessary to reach equilibrium 
between reporter ligand and compound of interest. IC50 values were obtained by nonlinear 
least-squares regression (standard four-parameter dose response curve) and converted to KD 
values using a modified Cheng-Prusoff equation.45 This equation accounts for the ligand 
depletion effect in competitive titrations involving high-affinity interaction partners present in 
similar concentrations. Under these conditions, the free concentration of an interacting species 
cannot be assumed to equal the total concentration. 
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The KD values determined for the test compounds 1, 3, 9, 20, and 10a-j are summarized in 
Table 1. Against our expectations, the biphenyl mannosides 3 and 9 exhibit similar affinities 
(Table 1), despite the presence of an electron withdrawing carboxylate substituent in 
antagonist 9. According to the crystal structure of FimH co-crystallized with the sulfonamide 
derivative 10e (Figure 4A), the outer aromatic ring of the biphenyl aglycone forms π-π 
interactions with the electron rich Tyr48, which is part of the tyrosine gate of FimH.15 A 
reduction of electron density of the aglycone by the electron withdrawing carboxylate was 
expected to enforce these π-π stacking interactions and lead to improved affinity. However, 
this beneficial effect might be compensated by an entropic penalty originating from the 
improved π-π stacking to Tyr48 that might lead to the reduced flexibility of both protein and 
antagonist. Furthermore, a beneficial enthalpy effect might be partially compensated by an 
enthalpy penalty originating from the desolvation of the charged carboxylate in 951 (see also 
experimental part). Although this substituent is solvent exposed, at least a partial desolvation 
may be necessary upon antagonist binding. To prove this assumption, we replaced the 
carboxylate by the corresponding methyl ester (→ 20)19 in order to reduce the desolvation 
penalty and, as predicted by the Hammett constant σp,52 to further improve the π-π stacking. 
Indeed, a six-fold improvement in affinity was achieved. However, since the methyl ester 
undergoes rapid enzyme-mediated hydrolysis in vivo,19 it will not be available at the place of 
action in the urinary bladder. The methyl ester was therefore replaced by metabolically stable 
bioisosteres39 exhibiting comparable electron withdrawing properties52 (Table 1, entries 5-13). 
The most potent derivatives 10d, 10e and 10g showed affinities in the low nanomolar range. 
 
As previously reported,22 a chloro substituent in the ortho-position of the aromatic ring 
adjacent to the anomeric oxygen is favorable for affinity and improves the physicochemical 
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properties relevant for oral bioavailability. Indeed, the corresponding antagonist 10j was the 
most potent compound tested in this study. 
 
Table 1. Affinities (KD) of FimH antagonists to FimH-CRD-Th-His6; dissociation constants (KD) were determined 
in a competitive fluorescence polarization assay. 
 
Entry Compd 
OR
OHO
OH
HO
OH
 
Affinity 
KD [nM] 
1 1 O  28.3 ± 5.0  
2 3 
O
 
15.1 ± 2.2 
3 9 
O
OH
O  
17.9 ± 1.5 
4 20 
O
OMe
O  
3.6 ± 0.9  
5 10a 
O
O
NH2
 
2.8 ± 0.3 
6 10b 
O
O
NHMe
 
2.9 ± 0.5 
7 10c 
O
O
N
O
 
3.0 ± 0.1 
8 10d 
O
S
Me
O O  
1.7 ± 0.2 
9 10e 
O
S
NHMe
O O  
2.7 ± 0.4 
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10 10f 
O
F
OH
F  
3.7 ± 0.2 
11 10g 
O
CN  
2.0 ± 0.6 
12 10h 
O
HN N
N
N
 
5.7 ± 0.1 
13 10i 
O
NHCN
O  
8.4 ± 0.3 
14 10j 
O
CN
Cl
 
< 1a) 
 
a) The KD value of 10j was approximated to be in the subnanomolar range. The IC50 value obtained in the 
competitive FP assay was equal to the lowest value that can be resolved by the assay, indicating stoichiometric 
titration of 10j due to its high affinity. Consequently, its KD must be below the KD of competitor 23. 
 
Isothermal Titration Calorimetry (ITC). To further confirm our hypothesis regarding π-π 
stacking and desolvation, we performed ITC experiments with the reference compound 1, the 
unsubstituted biphenyl mannoside 3, the carboxylic acid 9, and the bioisosteres 10b-e, g and j 
(Table 2). ITC allows the simultaneous determination of the stoichiometry (N), the change in 
enthalpy (∆H) and the dissociation constant (KD) for ligand-protein binding.53,54 The reliable 
determination of these three parameters requires well-defined sigmoidal titration curves 
characterized by the dimensionless Wiseman parameter c (c = Mt(0) KD-1, where Mt(0) is the 
initial macromolecule concentration).55 To be sure that data can be fitted with confidence, the 
c-value should be between 1 and 1,000 (ideally between 5 and 500),56 which could be achieved 
for the antagonists 3 and 9. For titrations involving low micromolar Mt(0) and interactions in 
the low nanomolar or picomolar range, as suggested for the bioisosteres 10b-j, c-values above 
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1,000 were expected. Since these conditions lead to steep titration curves that do not allow the 
determination of the curve slope representing 1/KD, we applied an alternative, competitive 
format referred to as displacement assay.57,58 First, FimH-CRD-Th-His6 was pre-incubated 
with the low affinity antagonist n-heptyl 2-deoxy-α-D-mannopyranoside (25, for synthesis see 
supporting information). The high-affinity bioisosteres of interest were titrated into the protein-
ligand complex giving well-defined sigmoidal titration curves. 
 
Table 2. Thermodynamic parameters from ITC for selected FimH-antagonists binding to FimH-CRD-Th-His6; n, 
stoichiometric correction factor; CI, confidence interval from fitting.  
 
Entry Compd 
OR
OHO
OH
HO
OH
 
KD[a] 
[nM] 
ΔG 
[kJ/mol] 
ΔH[a] 
[kJ/mol] 
-TΔS 
[kJ/mol] 
n 
Type of 
measurement 
1 1[b,c] O  
28.9 
(25.8 – 32.3) 
-43.0 
-50.3 
(-50.2 – -50.7) 
7.3 1.00 direct 
2 3[b] 
O
 
17.7 
(14.1 – 22.3) 
-44.2 
-45.0 
(-44.5 – -45.6) 
0.8 1.07 direct 
3 9 
O
OH
O  
15.0 
(13.4 – 16.7) 
-44.7 
-48.7 
(-48.4 – -49.0) 
4.0 1.05 direct 
4 10b 
O
O
NHMe
 
4.3 
(3.2 – 5.6) 
-47.8 
-54.5 
(-54.1 – -54.9) 
6.7 1.02 
competitive 
vs. 25 
5 10c 
O
O
N
O
 
5.0 
(3.8 – 6.6) 
-47.4 
-54.5 
(-54.1 – -54.8) 
7.1 0.97 
competitive 
vs. 25 
6 10d 
O
S
Me
O O  
3.0 
(2.1 – 4.2) 
-48.7 
-52.3 
(-51.5 – -53.1) 
3.6 0.99 
competitive 
vs. 25 
7 10e 
O
S
NHMe
O O  
3.5 
(2.9 – 4.3) 
-48.2 
-52.2 
(-51.6 – -52.8) 
3.9 1.06 
competitive 
vs. 25 
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8 10g 
O
CN  
2.8 
(2.3 – 3.3) 
-48.8 
-58.2 
(-57.8 – -58.6) 
9.4 1.00 
competitive 
vs. 25 
9 10j 
O
CN
Cl
 
1.3 
(1.1 – 1.6) 
-50.7 
-60.9 
(-60.4 – -61.4) 
10.1 1.01 
competitive 
vs. 25 
10 25 
O
OHO
OH
HO
 
9’386 
(8’555 – 
10’287) 
-28.7 
-19.5 
(-19.1 – -20.0) 
-9.1 1.00 direct 
 
[a] 95% confidence interval from fitting in parentheses; [b] Global fit including two direct titration measurements; 
[c] ITC data were previously published with an n-value of 0.82.37 
 
The resulting KD values (Table 2) correspond well with the data obtained from the FP assay 
(Table 1). A comparison of the thermodynamic fingerprints of antagonists 3 and 9 reveals that 
the more favorable enthalpic contribution resulting from facilitated π-π stacking leads to a net 
enthalpy gain (ΔΔH: -3.7 kJ/mol). However, an even greater increase in enthalpy is likely 
countered by the enthalpy costs for desolvation of the electron withdrawing carboxylate. 
 
The gain in enthalpy is in turn compensated by an unfavorable entropy (-TΔΔS: 3.2 kJ/mol) as 
a result of the reduced flexibility of both the antagonist and the Tyr48 side-chain caused by the 
improved interaction. This is not entirely outweighed by the beneficial entropy contribution 
related to the partial desolvation of the carboxylate and the related release of water into the 
bulk. Added together, the enthalpy and entropy contributions of antagonists 3 and 9 result in 
similar affinities (KD: 17.7 and 15.0 nM, respectively).  
 
In contrast, the replacement of the carboxylate group by various neutral bioisosteres (entries 4-
7) reduces the enthalpy costs for desolvation (see calculated free energies of desolvation, 
experimental part) and therefore leads to a markedly improved enthalpy (ΔΔH: -3.5 to -5.8 
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kJ/mol). As a result, an up to fivefold improvement of the KD values was achieved. Finally, 
with a cyano substituent (entries 8 & 9), the enthalpy term was further improved (ΔΔH: -3.7 
kJ/mol) due to a reduced desolvation penalty and improved π-π stacking interactions. 
However, this beneficial component is again partially compensated by a decrease in entropy. 
This can be attributed, first, to the loss of flexibility of the tightly bound ligand (Figure 4B) 
and, second, to the smaller surface area of the cyano substituent compared to amide, 
sulfonamide and sulfone, which results in a smaller number of water molecules being released 
to bulk upon binding. 
 
X-ray Crystallography. To determine the binding poses of the bioisosters, we co-crystallized 
the compounds 10e and 10j with the FimH-CRD (Figure 4). Atomic resolution crystal 
structures were obtained at 1.07 Å (10e) and 1.10 Å (10j). As observed in previous mannoside 
co-crystal structures,15,18,36 the mannose moiety forms an extensive hydrogen bond network to 
the well-defined binding site with all of its hydroxyl groups. The biphenyl aglycone is located 
between the tyrosine gate residues (Tyr48/Tyr137). The π-π stacking of the second aromatic 
ring of the aglycone to the side chain of Tyr48 contributes most to the interaction energy of the 
aglycone moiety. Interactions to the Tyr137 side-chain on the other hand are only limited. 
Whereas a previously published crystal structure of a biphenyl mannoside in complex with 
FimH-CRD suffers from crystal contacts of binding site residues (Tyr48 side-chain to 
backbone oxygen of Val27) possibly causing the distortion of the binding site,18 the binding 
site of our structures are mostly solvent exposed. This revealed the flexibility of the aglycone 
in the FimH-CRD/10e structure, since the electron density towards the solvent-exposed 
sulfonamide indicates that there is not one single orientation. Therefore, the aglycone was 
modeled in two distinct poses. In contrast, in the FimH-CRD/10j structure the amino acid side 
chain of Y48 can be modeled in two distinct rotamers, suggesting flexibility also of the 
receptor. 
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Figure 4. Ligand binding poses determined by X-ray co-crystallization with compounds 10e resolved to 1.07 Å 
(A) and 10j resolved to 1.10 Å (B). The electron density surrounding the aglycone of 10e indicates flexibility of 
the aglycone and was modeled in two poses. Both compounds bind in a similar pose with a well-defined hydrogen 
network surrounding the mannose moiety and π-π stacking interactions between the second aromatic ring and 
Tyr48 side-chain (A). In contrast, in the FimH-CRD/10j structure the amino acid side chain of Y48 can be 
modeled in two distinct rotamers, suggesting flexibility also of the receptor (B). 
 
Physicochemical Properties and In Vitro Pharmacokinetics. Intestinal absorption and renal 
excretion are prerequisites for a successful oral treatment of UTI with FimH antagonists. 
Furthermore, reabsorption of antagonist from the renal ultrafiltrate is desirable for maintaining 
the minimal anti-adhesive concentration in the target organ, namely the bladder, over an 
extended period of time. To estimate the influence of the bioisostere approach on oral 
bioavailability and the rate of renal excretion, we determined lipophilicity by means of the 
octanol-water distribution coefficient (log D7.4),59 aqueous solubility, and membrane 
permeability in the artificial membrane permeability assay (PAMPA)60 and the colorectal 
adenocarcinoma (Caco-2) cell monolayer model.61 
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Table 3. Physicochemical and in vitro pharmacokinetic parameters. 
Compd pKaa) log D7.4b) 
Solubility 
[µg/mL] / pHc) 
PAMPA log Pe 
[cm/s] / pHd) 
Caco-2 Papp, 
[10-6 cm/s]e) PPB fb [%]f) 
Metabolic 
stability t1/2 
[min]g) a→b b→a 
1 --- 1.65 > 3000 -4.89 7.0 ± 0.6 9.4 ± 0.2 81 13 
3 --- 2.1 ± 0.1 21 ± 1 / 7.4 -4.7 ± 0.1 / 7.4 10.0 ± 0.9 19.0 ± 1.2 93 ± 1 n.d. 
20 --- 2.14 33.8 / 6.51 -4.7 4.23 n.d. 93 1.0 
9 3.88 < -1.5 > 3000 / 6.61 no permeation n.d. n.d. 73 > 60 
10a --- 0.5 ± 0.1 12 ± 1 / 7.4 -6.8 ± 0.3 / 7.4 0.12 ± 0.01 0.61 ± 0.03 n.d. n.d. 
10b --- 0.8 ± 0.0 122 ± 13 / 7.4 -9.2 ± 1.4 / 7.4 1.10 ± 0.82 0.87 ± 0.15 n.d. n.d. 
10c --- 0.2 ± 0.1 > 250 / 7.4 -7.8 ± 0.3 / 7.4 0.18 ± 0.07 1.30 ± 0.03 48 ± 2 > 60 
10d --- 0.4 ± 0.0 246 ± 17 / 7.4 -7.2 ± 0.0 / 7.4 0.36 ± 0.01 1.76 ± 0.12 99 ± 1 > 60 
10e --- 0.7 ± 0.1 > 250 / 7.4 -8.6 ± 0.2 / 7.4 0.28 ± 0.23 1.82 ± 0.14 > 99 > 60 
10f 6.5 1.1 ± 0.0 
> 150 / 3.0 
> 150 / 7.4 
-7.7 ± 0.8 / 5.0 
-8.8 ± 0.1 / 7.4 
0.40 ± 0.02 1.90 ± 0.17 n.d. n.d. 
10g --- 1.4 ± 0.0 186 ± 4 / 7.6 -5.7 ± 0.0 / 7.4 2.0 ± 0.1 13.2 ± 2.1 99 ± 0 > 60 
10h 3.7 -1.4 ± 0.1 
11 ± 0 / 3.0 
273 ± 2 / 7.4 
-9.3 ± 1.4 / 5.0 
-8.8 ± 1.4 / 7.4 
0.17 ± 0.00 0.22 ± 0.01 n.d. n.d. 
10i 2.5 -1.1 ± 0.1 
> 150 / 3.0 
> 150 / 7.4 
-6.8 ± 0.2 / 5.0 
-7.0 ± 0.1 / 7.4 
0.22 ± 0.14 0.29 ± 0.03 n.d. n.d. 
10j --- 2.1 ± 0.0 192 ± 5 / 7.4 -5.2 ± 0.0 / 7.4 2.2 ± 0.4 22.1 ± 1.5 89 ± 1 > 60 
 
a) pKa values were determined by NMR spectroscopy; b) Octanol-water distribution coefficients (log D7.4) were 
determined by a miniaturized shake-flask procedure at pH 7.4, values represent the mean ± SD of sextuplicate 
measurements;59 c) Kinetic solubility was measured in a 96-well format using the µSOL Explorer solubility 
analyzer at the indicated pH in triplicate; d) Pe = effective permeability: passive permeation through an artificial 
membrane was determined by the parallel artificial membrane permeation assay (PAMPA), values represent the 
mean ± SD of quadruplicate measurements performed at the indicated pH;60 e) Papp = apparent permeability: 
permeation through a Caco-2 cell monolayer was assessed in the absorptive (a→b) and secretory (b→a) directions 
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in triplicate;61 f) Plasma protein binding (PPB) was determined by equilibrium dialysis in triplicate;62 g) 
Metabolic stability was determined by incubating the compounds (2 µM) with pooled rat liver microsomes (RLM, 
0.5 mg/mL) in presence of NADPH (1 mM, compounds 1, 9, 10c-e, g, j) or without NADPH (compound 20);63 
n.d. = not determined. 
 
Oral Bioavailability. Oral bioavailability of a compound relies on solubility, permeation 
through the membranes lining the intestine, and stability against first pass metabolism.64,65 As 
discussed by Lipinski66 and Curatolo,67 dose and permeability define the minimum aqueous 
solubility required for oral administration. Thus, a dose of 1 mg/kg of a moderately permeable 
compound requires a solubility of at least 52 µg/mL. Whereas sufficient aqueous solubility (> 
3000 µg/mL) was reported for n-heptyl α-mannopyranoside (1),19 the unsubstituted biphenyl 
α-D-mannopyranoside 3 as well as the antagonists bearing a methylcarboxylate, carboxamide, 
or tetrazole substituent (compounds 20, 10a and 10h) were found to be scarcely soluble.22 As 
proposed by Ishikawa,68 a possible reason is the apolar and planar aglycone. By contrast, the 
polar carboxylic acid moiety present in antagonist 9 or the substituents in the bioisosteres 10b-
j enhance solubility to 122-273 µg/mL, a level sufficient for in vivo PK studies. For in vivo 
disease studies, however, dosages of up to 10 mg/kg were foreseen (see below), requiring a 
solubility of 520 µg/mL.66,67 For this reason, surfactant Tween 80 (1%) had to be added. 
 
Furthermore, permeability data derived from PAMPA69 and the Caco-2 model70 suggest 
moderate to high permeation of the moderately lipophilic antagonists 1, 3 and 20 (log D7.4 > 
1.6) through the intestinal membranes. The bioisosteres 10a-f, h, i, although slightly more 
permeable than the strongly hydrophilic carboxylic acid derivative 9, show only low values of 
permeability compared to n-heptyl α-D-mannopyranoside (1) or the unsubstituted biphenyl 
mannoside 3. However, the para-cyanobiphenyl derivatives 10g and 10j display elevated log 
D7.4 and effective permeability (log Pe) in the range for successful intestinal absorption. 
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Regarding both, sufficient aqueous solubility and elevated membrane permeability, the para-
cyano substituted bioisosteres 10g and 10j are thus the most promising candidates for oral 
absorption. Moreover, combining the bioisosteric replacement with the addition of a chloro 
substituent in the ortho-position of the aromatic ring adjacent to the anomeric oxygen (→ 
10j)22 resulted in the most advantageous physicochemical profile for oral bioavailability. 
 
Renal Excretion. The rate of renal excretion depends on the rate of glomerular filtration and 
the propensity to tubular secretion and reabsorption of an antagonist.71 Only the fraction that is 
not bound to plasma proteins is expected to enter the glomerular filtrate.72 Plasma protein 
binding (PPB) data indicating the fraction bound (fb) are listed in Table 2.62 The biphenyls 9 
and 10c were identified as moderate binders to plasma proteins (fb ≤ 65%), which suggests a 
low impact of PPB on antagonist filtration. The fb values of the antagonists 1, 3, 20 and 10j 
were between 80 and 93%, whereas the bioisosteres 10d, e and g showed particularly high 
protein binding (fb ≥ 99%) implying slow compound entry into the primary urine. However, 
the kinetic aspects of PPB, that is, association and dissociation rate constants, remain to be 
determined to quantify precisely the influence of PPB on filtration.73 
 
Furthermore, log D7.4 was identified as key determinant of tubular reabsorption.74-76 
Accordingly, lipophilic compounds are predominantly reabsorbed from the renal filtrate. Given 
that renal clearance is the major route of elimination, this will result in a slow but steady 
excretion into the bladder. In contrast, hydrophilic compounds are poorly reabsorbed and thus 
quickly renally eliminated, which leads to high initial compound levels in the urine but 
narrows the time range where the minimal anti-adhesive concentration is maintained. 
Consequently, low log D7.4 as shown for the antagonists 9, 10h and 10i implies low tubular 
reabsorption and rapid elimination of the filtered molecules by the urine. Otherwise, log D7.4 
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between 0.2 and 0.7, such as determined for the bioisosteres 10a-e, suggests increasing 
propensity to tubular reuptake, whereas log D7.4 > 1 as shown for heptyl mannoside 1 and the 
biphenyl mannosides 3, 20, 10g, 10f and 10j is optimal for tubular reabsorption from the 
glomerular filtrate and thus for slow renal clearance. 
 
Metabolic Stability. Increasing lipophilicity is usually paralleled by increasing susceptibility 
to metabolism.77 Liabilities towards metabolic clearance pathways which prevent the intact 
antagonist from reaching the target in the bladder were therefore of interest. To assess their 
propensity to cytochrome P450 (CYP450)-mediated metabolism, heptyl mannoside 1, the 
carboxylic acid derivative 9, and the bioiosteres 10c-e, g, j were incubated with rat liver 
microsomes (RLM, 0.5 mg/mL) in presence of the cofactor β-nicotinamide adenine 
dinucleotide phosphate (NADPH).63 To confirm the high propensity of the methyl ester present 
in antagonist 20 to carboxylesterase (CES)-mediated hydrolysis, this antagonist was incubated 
with RLM only. The profiles of unchanged compound versus time revealed high susceptibility 
of heptyl mannoside 1 to CYP450-mediated metabolism (t1/2 = 13 min) and rapid hydrolysis of 
the ester 20 by the hepatic CES (t1/2 = 1.0 min). Otherwise, the bioisosteres 10c-e, g & j were 
stable against enzyme-mediated bioconversion (t1/2 > 60 min) suggesting lower propensity to 
metabolic, non-renal elimination pathways. 
 
Considering PPB, lipophilicity, and metabolic stability data, we therefore expected (i) a steady 
release of compounds 10d, e, g, j into the bladder because of high PPB decelerating glomerular 
filtration (10d, e, g) and/or high log D7.4 supporting tubular reabsorption (10g, j), (ii) a fast 
excretion of antagonists 9 and 10c via the urine due to low PPB and low log D7.4, and (iii) a 
rapid clearance of heptyl mannoside 1 from the body by renal and metabolic pathways. 
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Compounds featuring high propensity to renal excretion as major route of elimination (10c, 
10e and 10j) were selected for in vivo PK studies in a mouse model. 
 
Pharmacokinetic Studies in C3H/HeN Mice. This first part of our study explored the 
predicted effects of lipophilicity, PPB, and metabolic stability on antagonist disposition and 
elimination upon a single dose iv application (50 mg/kg) of compounds 10c and 10e. The PK 
parameters of these applications and those of the previously published carboxylate 9 are 
summarized in Table 4. The Table also contains the results of the iv administration of 
compound 10j (0.625 mg/kg). 
 
Table 4. Pharmacokinetic parameters determined after a single iv application of compounds 9, 10c, 10e and 10j 
in female C3H/HeN mice. Values were calculated using PKSolver.78 C0, initial concentration; Vz, volume of 
distribution in terminal phase; AUC, Area under the curve; CLtot, total clearance; Cmax, maximal concentration. 
Compd Plasma Urine 
 C0 (µg/mL) Dose (mg/kg) Vz (mL) t1/2 (h) AUC0-inf (µg x h/mL) CLtot (mL/h) Cmax (µg/mL) 
9 40 50 25.2 0.33 23.5 53.1 300 
10c 109.7 50 28.3 0.4 25.3 49.4 4611 
10e 151.6 50 19.5 1.9 175.1 7.1 387 
10j 0.36 0.625 52.8 0.17 0.07 218 10 
 
In contrast to the fast plasma clearance of antagonists 9 and 10c (Figure 5A), the methyl 
sulfonamide bioisostere 10e attained higher initial concentration in plasma (C0) and lower total 
clearance (CLtot). Therefore, it could be detected until 6 h post application, resulting in 
markedly higher plasma AUC. The observed high C0 of compound 10e may be attributed to a 
small volume of distribution (Vz) resulting from the high PPB (fb ≥ 99%).72 In urine (Figure 
5B), the carboxylic acid 9 and the morpholinomethanone 10c displayed high levels 
immediately following administration and a rapid concentration decrease within the first two 
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hours, reflecting the rapid elimination from plasma. Fast renal excretion as major route of 
elimination can be rationalized by the physicochemical properties of the antagonists 9 and 10c, 
that is, moderate PPB and log D7.4, as well as high metabolic stability. Otherwise, the methyl 
sulfonamide bioisostere 10e showed sustained compound levels in urine over a period of 2 h 
and subsequent slow decrease until 6 h post administration. This sustained renal excretion is a 
result of the interplay of the antagonist’s elevated PPB and log D7.4. 
 
Figure 5. Antagonist concentrations in (A) plasma and (B) urine after a single iv application of 9, 10c, and 10e 
(50 mg/kg).  
 
In a second study, the para-cyano bioisostere 10j, characterized by a high oral absorption 
potential, was administered as a single dose iv (0.625 mg/kg) and po (1.25 mg/kg). The plasma 
concentration curve upon iv dosing displays a steep decline within the first hour post 
application, while the po curve shows a prolonged period where absorption and elimination are 
in equilibrium (Figure 6A). The urine concentration profiles (Figure 6B) parallel the plasma 
curves obtained by the two modes of application, i.e. high plasma clearance upon iv bolus 
injection led to high initial antagonist levels in urine and a rapid concentration decline. By 
contrast, sustained plasma concentrations upon po administration resulted in prolonged urine 
levels. 
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As a result, urine concentrations exceed the minimum level required for the anti-adhesive 
effect as estimated from the in vitro cell infection model79 (minimal anti-adhesion 
concentration23, MAC90, 0.094 µg/mL) for more than eight hours upon oral single-dose 
administration (Figure 6B). 
Figure 6. Antagonist concentrations in (A) plasma and (B) urine after a single iv and po application of compound 
10j (iv: 0.625 mg/kg; po: 1.25 mg/kg). MAC90, minimal anti-adhesive concentration to inhibit 90% adhesion 
(0.094 µg/mL). 
 
Infection study in C3H/HeN Mice. Based on the promising PK profile of 10j, six mice were 
inoculated with UTI89 following an oral application of 10j (1.25 mg/kg) 40 min prior to 
infection. Three hours after inoculation, the animals were sacrificed and bladder and kidneys 
were removed. Organs were homogenized and analyzed for bacterial counts. The effect of the 
FimH antagonist was compared to a 8 mg/kg dose of ciprofloxacin (CIP) subcutaneously (s.c.) 
applied, used as standard antibiotic therapy against UTI89.80 The median reduction in bacterial 
counts of the mice treated with 10j and CIP compared to the control group are displayed in 
Figure 7. 
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Figure 7. Treatment efficacy in the UTI mouse model 3 h after infection. The bars depict the median bacterial 
load with the interquartile range in the different study groups. Shown are the results of the untreated control group 
and the intervention groups with applications of either 1.25 mg/kg 10j, 10 mg/kg 10j p.o. or 8 mg/kg CIP s.c. 
(representing the murine dose equivalent to a human standard dose).81 10j in a dose of 10 mg/kg results in a 
median reduction of over 3 log10 CFU/ml of bacterial counts in the bladder. 
The median value in the untreated control group showed bacterial counts of 6.6 log10 colony 
forming units (CFU) in the bladder and 6 log10 CFU in the kidneys. After oral application of 
1.25 mg/kg of 10j, bacterial loads in the bladder decreased by 1.7 log10 CFU and 1.08 log10 
CFU in the kidneys. The lower reduction in the kidneys is most likely due to the differing 
adhesion mechanisms between bladder and kidneys (type 1 pili vs P-pili), which is not targeted 
by 10j.82 With CIP (8 mg/kg s.c.) a substantial reduction in both, bladder and kidneys (median 
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reductions of 2.44 log10 and 2.47 log10, respectively) was observed. Despite the low oral dose 
of 10j (1.25 mg/kg), the approximately 100-fold reduction of CFU in the bladder promised an 
even higher effect upon dose increase to 10 mg/kg. However, solubility of 10j for this 
increased dose is to low (192 µg/mL), therefore we used surfactants as solubilizer (Tween 80, 
1%) to enhance solubility. When 10 mg/kg were applied, bacterial loads in the bladder 
decreased by 3.4 log10 CFU/mL, exceeding the effect of CIP, but only 0.5 log10 CFU in the 
kidneys. Based on this large reduction after an oral application of 10 mg/kg, 10j has a large 
potential for further development. 
 
SUMMARY AND CONCLUSION 
 
Recently, numerous monovalent alkyl and aryl α-D-mannopyranosides have been described as 
potent FimH antagonists. However, most of them suffer from insufficient pharmacokinetic 
properties, i.e. modest bioavailability and short duration of the therapeutic effect in the 
bladder, their site of action. As a consequence, high doses at short intervals are required to 
achieve anti-adhesive effects over an extended period of time. Therefore, the goal of the 
present study was an appropriate optimization of the pharmacokinetic profile of biphenyl α-D-
mannopyranosides while keeping their high affinity to the CRD of FimH. The starting point 
was the biphenyl-carboxylate 9 where the critical carboxylate was replaced by bioisosteres.39,83 
With a series of bioisosteres a three- to fivefold improvement of affinity was achieved 
compared to 9. Although binding necessitates only partial desolvation of the carboxylate and 
its bioisosteric replacements, a reduction of the enthalpy penalty for desolvation51 was 
identified as the source of the improved affinity exhibited by the bioisosteres. Thermodynamic 
evaluation of antagonists 10b-e revealed almost identical enthalpy contribution to binding. 
However, for antagonists with the para-cyano substituent (10g & 10j) an enhancement of up to 
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-8.7 kJ/mol was observed, indicating a reduced desolvation penalty and an improved stacking 
as derived from the crystal structure of 10j co-crystallized with the CRD of FimH (Figure 4B). 
On the other hand, higher affinity originating from a reduction of conformational flexibility of 
ligand and protein resulted in a concomitant entropy penalty of up to 6.5 kJ/mol. 
 
In addition to the improved pharmacodynamics, the relevant pharmacokinetic parameters 
(solubility, permeability, renal excretion) could also be substantially improved. With 3’-
chloro-4’-(α-D-mannopyranosyloxy)-biphenyl-4-carbonitrile (10j), a FimH antagonist with an 
optimal in vitro PK/PD profile was identified. The para-cyano substituent conferred 
lipophilicity and high binding to plasma proteins, which slowed down the rate of renal 
excretion. Despite higher lipophilicity, antagonist 10j was insusceptible to CYP450-mediated 
metabolism, and therefore predominantly eliminated via the renal pathway. In vivo 
experiments confirmed the excellent PK-profile of 10j with steady renal excretion for more 
than 8 h after oral application, suggesting a long-lasting anti-adhesive effect. Finally, orally 
applied 10j (10 mg/kg) was effective in a mouse model of UTI by reducing the bacterial load 
in the bladder by over 1000-fold. Improvement of solubility, enabling the application of higher 
dosages of 10j, will possibly lead to an even higher bacterial reduction, which will be the 
subject of future investigations. 
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EXPERIMENTAL SECTION 
 
Synthesis 
 
The synthesis of compounds 10a-d, 10f, 10g, 10i, 13a-d, 13f, 13g, 15, 18 and 25, including 
compound characterization data, can be found in the Supporting Information. 
 
General methods. NMR spectra were recorded on a Bruker Avance DMX-500 (500.1 MHz) 
spectrometer. Assignment of 1H and 13C NMR spectra was achieved using 2D methods 
(COSY, HSQC, HMBC). Chemical shifts are expressed in ppm using residual CHCl3, 
CHD2OD or HDO as references. Optical rotations were measured using Perkin-Elmer 
Polarimeter 341. Electron spray ionization mass spectra (ESI-MS) were obtained on a Waters 
micromass ZQ. The LC/HRMS analysis were carried out using a Agilent 1100 LC equipped 
with a photodiode array detector and a Micromass QTOF I equipped with a 4 GHz digital-time 
converter. Microwave-assisted reactions were carried out with a CEM Discover and Explorer. 
Reactions were monitored by TLC using glass plates coated with silica gel 60 F254 (Merck) and 
visualized by using UV light and/or by charring with a molybdate solution (a 0.02 M solution 
of ammonium cerium sulfate dihydrate and ammonium molybdate tetrahydrate in aqueous 
10% H2SO4). MPLC separations were carried out on a CombiFlash Companion or Rf 
(Teledyne Isco) equipped with RediSep normal-phase or RP-18 reversed-phase flash columns. 
LC-MS separations were done on a Waters system equipped with sample manager 2767, pump 
2525, PDA 2525 and micromass ZQ. All compounds used for biological assays are at least of 
95% purity based on HPLC analytical results. Commercially available reagents were 
purchased from Fluka, Aldrich, Alfa Aesar or abcr GmbH & Co. KG (Germany). Solvents 
were purchased from Sigma-Aldrich or Acros and were dried prior to use where indicated. 
Methanol (MeOH) was dried by refluxing with sodium methoxide and distilled immediately 
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before use. Dimethoxyethane (DME) was dried by filtration over Al2O3 (Fluka, type 5016 A 
basic). 
 
4’-(2,3,4,6-Tetra-O-acetyl-α-D-mannopyranosyloxy)-N-methyl-biphenyl-4-sulfonamide 
(13e). A Schlenk tube was charged with aryl iodide 1122 (116 mg, 0.21 mmol), 4-(N-
methylsulfamoyl)-phenylboronic acid (12e, 50 mg, 0.23 mmol), Pd(dppf)Cl2⋅CH2Cl2 (5 mg, 
0.006 mmol), K3PO4 (67 mg, 0.32 mmol) and a stirring bar. The tube was closed with a rubber 
septum and was evacuated and flushed with argon. This procedure was repeated once, and then 
anhydrous DMF (1 mL) was added under a stream of argon. The mixture was degassed in an 
ultrasonic bath and flushed with argon for 5 min, and then stirred at 80 °C overnight. The 
reaction mixture was cooled to rt, diluted with EtOAc (50 mL), and washed with water (50 
mL) and brine (50 mL). The organic layer was dried over Na2SO4 and concentrated in vacuo. 
The residue was purified by MPLC on silica gel (petroleum ether/EtOAc) to afford 13e (105 
mg, 84%) as a white solid. [α]D20 +56.4 (c 0.50, MeOH); 1H NMR (500 MHz, CDCl3): δ = 
7.92-7.90 (m, 2H, Ar-H), 7.70-7.68 (m, 2H, Ar-H), 7.57-7.55 (m, 2H, Ar-H), 7.21-7.19 (m, 
2H, Ar-H), 5.60-5.57 (m, 2H, H-1, H-3), 5.48 (dd, J = 1.8, 3.4 Hz, 1H, H-2), 5.40 (t, J =10.0 
Hz, 1H, H-4), 4.38 (dd, J = 5.4, 10.8 Hz, 1H, NH), 4.30 (dd, J = 4.9, 12.3 Hz, 1H, H-6a), 4.13-
4.08 (m, 2H, H-5, H-6b), 2.72 (d, J = 5.4 Hz, 3H, NCH3), 2.22, 2.07, 2.05, 2.04 (4 s, 12H, 4 
COCH3); 13C NMR (126 MHz, CDCl3): δ = 170.55, 170.06, 170.03, 169.75 (4 CO), 155.97, 
144.81, 137.16, 134.09, 128.62, 127.85, 127.39, 117.01 (Ar-C), 95.78 (C-1), 69.34 (C-5), 
69.31 (C-2), 68.81 (C-3), 65.86 (C-4), 62.07 (C-6), 29.44 (NHCH3), 20.92, 20.74, 20.72 (4C, 4 
COCH3); ESI-MS: m/z: Calcd for C27H31NNaO12S [M+Na]+: 616.1, found: 616.1. 
 
4’-(α-D-Mannopyranosyloxy)-N-methyl-biphenyl-4-sulfonamide (10e). To a solution of 
13e (40 mg, 0.07 mmol) in dry MeOH (5 mL) was added freshly prepared 1 M NaOMe/MeOH 
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(0.1 eq) under argon. The mixture was stirred at rt until the reaction was complete (monitored 
by TLC), then neutralized with Amberlyst-15 (H+) ion-exchange resin, filtered and 
concentrated in vacuo. The residue was purified by MPLC on silica gel (DCM/MeOH, 10:1-
7:1) to afford 10e (22 mg, 76%) as white solid. [α]D20 +105.7 (c 0.30, MeOH); 1H NMR (500 
MHz, CD3OD): δ = 7.90-7.88 (m, 2H, Ar-H), 7.80-7.79 (m, 2H, Ar-H), 7.66-7.64 (m, 2H, Ar-
H), 7.26-7.25 (m, 2H, Ar-H), 5.58 (d, J = 1.7 Hz, 1H, H-1), 4.06 (dd, J = 1.8, 3.3 Hz, 1H, H-2), 
3.96 (dd, J = 3.4, 9.5 Hz, 1H, H-3), 3.79-3.74 (m, 3H, H-4, H-6a, H-6b), 3.63 (ddd, J = 2.5, 
5.2, 9.7 Hz, 1H, H-5), 2.57 (s, 3H, NHCH3); 13C-NMR (126 MHz, CD3OD): δ = 158.34, 
146.13, 138.67, 134.55, 129.53, 128.82, 128.21, 118.29 (Ar-C), 100.09 (C-1), 75.53 (C-5), 
72.42 (C-3), 71.96 (C-2), 68.32 (C-4), 62.68 (C-6), 29.31 (NHCH3); HRMS: m/z: Calcd for 
C19H23NNaO8S [M+Na]+: 448.1037, found: 448.1038. 
 
5-(4’-(2,3,4,6-Tetra-O-acetyl-α-D-mannopyranosyloxy)-biphenyl-4-yl)-1H-tetrazole (14). 
A Schlenk tube was charged with 13g (30 mg, 0.06 mmol), trimethylsilyl azide (16 µL, 0.12 
mmol), dibutyltin oxide (2 mg, 0.006 mmol), DME (1 mL) and a stirring bar. The mixture was 
heated to 150 °C for 10 min by microwave irradiation. The reaction mixture was cooled to rt, 
and then concentrated in vacuo. The residue was purified by MPLC on silica gel 
(DCM/MeOH, 9:1-8:1) to afford 14 (26 mg, 81%) as colorless oil. [α]D20 +56.1 (c 0.3, 
MeOH); 1H NMR (500 MHz, CDCl3): δ = 8.25-8.15 (m, 2H, Ar-H), 7.75-7.65 (m, 2H, Ar-H), 
7.60-7.55 (m, 2H, Ar-H), 7.20-7.17 (m, 2H, Ar-H), 5.64-5.55 (m, 2H, H-1, H-3), 5.49 (dd, J = 
1.7, 3.3 Hz, 1H, H-2), 5.40 (t, J = 10.1 Hz, 1H, H-4), 4.31 (dd, J = 5.3, 12.4 Hz, 1H, H-6a), 
4.17-4.06 (m, 2H, H-5, H-6b), 2.22, 2.07, 2.06, 2.05 (4 s, 12H, 4 COCH3); 13C NMR (126 
MHz, CDCl3): δ = 170.67, 170.14, 170.11, 169.81 (4 CO), 155.61, 128.36, 127.84, 127.49, 
116.93 (Ar-C), 95.78 (C-1), 69.36 (C-5), 69.26 (C-2), 68.90 (C-3), 65.89 (C-4), 62.12 (C-6), 
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20.92, 20.76, 20.73 (4 COCH3); ESI-MS: m/z: Calcd for C27H28N4NaO10 [M+Na]+: 591.2, 
found: 591.1. 
 
5-(4’-(α-D-Mannopyranosyloxy)-biphenyl-4-yl)-1H-tetrazole (10h). Prepared according to 
the procedure described for 10e from 14 (26 mg, 0.03 mmol). Yield: 18 mg (quant.) as a white 
solid. [α]D20 +112.1 (c 0.1, MeOH/H2O, 2:1); 1H NMR (500 MHz, CD3OD): δ = 7.98-7.96 (m, 
2H, Ar-H), 7.72-7.71 (m, 2H, Ar-H), 7.58-7.54 (m, 2H, Ar-H), 7.16-7.13 (m, 2H, Ar-H), 5.46 
(d, J = 1.7 Hz, 1H, H-1), 3.94 (dd, J = 1.9, 3.5 Hz, 1H, H-2), 3.83 (dd, J = 3.4, 9.5 Hz, 1H, H-
3), 3.68-3.61 (m, 3H, H-4, H-6a, H-6b), 3.52 (ddd, J = 2.5, 5.4, 9.7 Hz, 1H, H-5); 13C NMR 
(126 MHz, CD3OD): δ = 158.19, 145.07, 134.97, 129.29, 128.74, 128.55, 118.26 (Ar-C), 
100.13 (C-1), 75.52 (C-5), 72.42 (C-3), 71.98 (C-2), 68.33 (C-4), 62.69 (C-6); HRMS: m/z: 
Calcd for C19H21N4O6 [M+H]+: 401.1456, found: 401.1450. 
 
4’-(2,3,4,6-Tetra-O-acetyl-α-D-mannopyranosyloxy)-3’-chloro-biphenyl-4-carbonitrile 
(19). Prepared according to the procedure described for 13e from aryl iodide 1823 (79 mg, 
0.135 mmol), 12g (22 mg, 0.15 mmol), Pd(dppf)Cl2⋅CH2Cl2 (3.3 mg, 4 µmol) and K3PO4 (57 
mg, 0.27 mmol). Yield: 57 mg (75%) as a white solid. [α]D20 +77.7 (c 0.5, CHCl3); 1H NMR 
(500 MHz, CDCl3): δ = 7.72 (d, J = 8.3 Hz, 2H, Ar-H), 7.63 (m, 3H, Ar-H), 7.43 (dd, J = 2.2, 
8.6 Hz, 1H, Ar-H), 7.27 (d, J = 8.6 Hz, 1H, Ar-H), 5.64-5.59 (m, 2H, H-1, H-2), 5.54 (dd, J = 
1.9, 3.2 Hz, 1H, H-3), 5.41 (t, J = 10.1 Hz, 1H, H-4), 4.28 (dd, J = 5.2, 12.3 Hz, 1H, H-6a), 
4.17 (ddd, J = 2.1, 5.1, 10.0 Hz, 1H, H-5), 4.10 (dd, J = 2.2, 12.3 Hz, 1H, H-6b), 2.21 (s, 3H, 
COCH3), 2.12- 2.00 (m, 9H, 3 COCH3); 13C NMR (126 MHz, CDCl3): δ = 170.54, 170.08, 
169.90, 169.84, (4C, CO) 151.67, 143.61, 135.29, 132.87, 129.41, 127.53, 126.60, 125.20, 
118.79, 117.36, 111.47 (Ar-C, CN), 96.72 (C-1), 70.00 (C-5), 69.39 (C-3), 68.82 (C-2), 65.86 
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(C-4), 62.16 (C-6), 20.98, 20.81, 20.79, 20.78 (4 COCH3); ESI-MS: m/z: Calcd for 
C27H26ClNNaO10 [M+Na]+: 582.1, found: 582.1. 
 
3’-Chloro-4’-(α-D-mannopyranosyloxy)-biphenyl-4-carbonitrile (10j). Prepared according 
to the procedure described for 10e from 19 (36 mg, 0.06 mmol). Yield: 12 mg (48%) as a 
white solid. [α]D20 +109.4 (c 0.23, MeOH); 1H NMR (500 MHz, CD3OD): δ = 7.80-7.72 (m, 
5H, Ar-H), 7.59 (dd, J = 2.2, 8.6 Hz, 1H, Ar-H), 7.48 (d, J = 8.7 Hz, 1H, Ar-H), 5.62 (d, J = 
1.4 Hz, 1H, H-1), 4.12 (dd, J = 1.8, 3.3 Hz, 1H, H-2), 4.00 (dd, J = 3.4, 9.5 Hz, 1H, H-3), 3.83-
3.68 (m, 3H, H-4, H-6a, H-6b), 3.63 (ddd, J = 2.3, 5.4, 9.6 Hz, 1H, H-5); 13C NMR  (126 MHz, 
CD3OD): δ = 153.65, 145.15, 135.42, 133.86, 129.82, 128.53, 127.87, 125.47, 119.70, 118.59 
(Ar-C), 111.97 (CN), 100.66 (C-1), 76.05 (C-5), 72.39 (C-3), 71.80 (C-2), 68.20 (C-4), 62.65 
(C-6); IR (KBr), ν = 3400 (OH), 2227 (C≡N), 1606, 1487 (Ar-C=C) cm-1; HRMS: m/z: Calcd 
for C19H18ClNNaO6 [M+Na]+: 414.0715, found: 414.0721. 
 
3'-Chloro-N-(3',6'-dihydroxy-3-oxo-3H-spiro[isobenzofuran-1,9'-xanthen]-5-yl)-4'-(α-D-
mannopyranosyloxy)-biphenyl-4-carboxamide (22). Compound 21 (10.0 mg, 0.024 mmol), 
fluoresceinamine isomer I (12.7 mg, 0.037 mmol) and COMU (20.9 mg, 0.049 mmol) were 
dissolved in dry DMF (1 mL), then NEt3 (10 µL, 0.073 mmol) was added and the mixture was 
stirred at rt for 7 h. 1 N HCl in DMF was added until acid reaction on pH paper and the 
mixture was concentrated. The residue was dissolved in DCM/MeOH (3:1) and loaded onto a 
silica gel column. The complex mixture of compounds was only partially resolved. The 
fractions containing the product were collected, concentrated and purified by preparative 
HPLC (gradient H2O/MeCN, +0.2% HCO2H), to afford compound 22 (5 mg, 19%). [α]D20 
+21.1 (c 0.10, MeOH); 1H NMR (500 MHz, CD3OD): δ = 8.26 (d, J = 8.4 Hz, 2H, Ar-H), 
7.88-7.74 (m, 3H, Ar-H), 7.66 (dd, J = 2.2, 8.6 Hz, 1H, Ar-H), 7.51 (d, J = 8.7 Hz, 1H, Ar-H), 
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7.29 (dd, J = 1.9, 5.3 Hz, 2H, Ar-H), 7.19 (dd, J = 2.1, 8.3 Hz, 1H, Ar-H), 7.08-6.99 (m, 2H, 
Ar-H), 6.95 (d, J = 8.7 Hz, 1H, Ar-H), 6.72 (dd, J = 5.5, 10.6, Hz, 2H, Ar-H), 6.61 (dd, J = 2.3, 
8.7 Hz, 1H, Ar-H), 5.65 (s, 1H, H-1), 4.15 (dd, J = 1.8, 3.2 Hz, H-2), 4.03 (dd, J = 3.4, 9.5, Hz, 
H-3), 3.87-3.72 (m, 3H, H-4, H-6a, H-6b), 3.65 (m, 1H, H-5); 13C NMR (126 MHz, CD3OD): 
δ = 137.50, 136.01, 131.90, 130.24, 130.20, 129.87, 129.24, 128.03, 127.91, 125.79, 125.46, 
124.73, 118.99, 118.76, 118.65 (Ar-C), 100.73 (C-1), 76.06 (C-5), 72.42 (C-3), 71.85 (C-2), 
68.24 (C-4), 62.69 (C-2); ESI-MS: m/z: Calcd for C39H31ClNO12 [M+H]+: 740.2, found: 740.2. 
 
3'-Chloro-N-(2-(3-(3',6'-dihydroxy-3-oxo-3H-spiro[isobenzofuran-1,9'-xanthen]-5-yl)-
thioureido)ethyl)-4'-(α-D-mannopyranosyloxy)-biphenyl-4-carboxamide (23). To a stirred 
solution of compound 21 (25 mg, 0.061 mmol) in dry DMF (1 mL), NHS (21 mg, 0.183 mmol) 
was added, followed by DIC (9.2 mg, 0.073 mmol). The mixture was stirred at rt for 2 h, then 
N-Boc-ethylendiamine (10.7 mg, 0.067 mmol) was added and the reaction was stirred for 10 h. 
It was then cooled down to 0 °C, diluted with water and concentrated. Chromatography on 
silica gel (DCM/MeOH) yielded 23 mg (0.042 mmol, 68%) of tert-butyl (3’-chloro-4’-(α-D-
mannopyranosyloxy)-biphenyl-4-yl-carboxamido)ethyl)carbamate. This product was dissolved 
in DCM (3 mL) and TFA (1 mL) was added. The solid dissolved during addition of TFA. 
After 10 min the reaction was complete. The mixture was evaporated and excess TFA was 
removed in high vacuum. The intermediate N-(2-aminoethyl)-3'-chloro-4'-(α-D-manno-
pyranosyloxy)-biphenyl-4-carboxamide TFA salt (23 mg, 0.042 mmol, quant.) was used 
directly in the next step. It was dissolved in dry DMF (0.5 mL) and NEt3 (12.8 mg, 0.127 
mmol) was added. The mixture was cooled to 0 °C, then FITC (14.8 mg, 0.038 mmol) was 
added and the mixture was stirred for 3 h in the dark. The mixture was then co-evaporated with 
water, taken up in MeOH/10% aq. acetic acid and evaporated. Chromatography on silica gel 
(DCM/MeOH) yielded compound 23, contaminated with triethylammonium acetate. The 
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compound was then re-dissolved in MeOH, and 0.5 N HCl in MeOH was added. The mixture 
was evaporated and chromatographed on silica gel, to yield pure 23 (15 mg, 47%). [α]D20 
+12.1 (c 0.30, MeOH); 1H NMR (500 MHz, CD3OD): δ = 8.12 (s, 1H), 7.92 (d, J = 8.3 Hz, 
2H, Ar-H), 7.70 (dd, J = 5.0, 13.1 Hz, 2H, Ar-H), 7.64 (d, J = 8.3 Hz, 2H, Ar-H), 7.54 (dd, J = 
2.2, 8.6 Hz, 1H, Ar-H), 7.46 (d, J = 8.7 Hz, 1H, Ar-H), 7.09 (d, J = 8.2 Hz, 1H, Ar-H), 6.74 (s, 
2H), 6.69 (d, J = 1.4 Hz, 2H, Ar-H), 6.55 (d, J = 8.4 Hz, 2H, Ar-H), 5.63 (d, J = 1.3 Hz, H-1), 
4.15 (dd, J = 1.8, 3.1 Hz, H-2), 4.03 (dd, J = 3.4, 9.5 Hz, H-3), 3.94 (s, 2H, CH2), 3.86-3.64 
(m, 6H, H-4, H-5, H-6, CH2); 13C NMR (126 MHz, CD3OD): δ = 153.21, 143.84, 136.41, 
129.66, 129.18, 127.76, 127.70, 125.37, 118.64, 103.62 (Ar-C), 100.75 (C-1), 76.00 (C-5), 
72.41 (C-3), 71.86 (C-2), 68.24 (C-4), 62.69 (C-6), 40.76 (CH2); ESI-MS: m/z: Calcd for 
C42H37ClN3O12S [M+H]+: 842.2, found: 842.2. 
 
3'-Chloro-N-(2-(2-(2-(3-(3',6'-dihydroxy-3-oxo-3H-spiro[isobenzofuran-1,9'-xanthen]-5-
yl)thioureido)ethoxy)ethoxy)ethyl)-4'-(α-D-mannopyranosyloxy)-biphenyl-4-
carboxamide (24). Compound 21 (280 mg, 0.68 mmol) was dissolved in dry DMF (5 mL) 
under argon, then NHS (235 mg, 2.04 mmol) was added, followed by DIC (0.12 mL, 0.78 
mmol) and the mixture was stirred at rt for 4 h, then Boc-PEG2-NH2 (186 mg, 0.75 mmol) was 
added, and the mixture was stirred at rt under argon for 10 h. It was then slowly diluted with 
water and concentrated. The residue was purified by chromatography on silica gel 
(DCM/MeOH) to give tert-butyl (2-(2-(2-(3'-chloro-4'-(α-D-mannopyranosyloxy)-biphenyl-4-
ylcarboxamido)ethoxy)ethoxy)ethyl)carbamate (300 mg, 0.468 mmol, 69%). Then, the 
carbamate was suspended in DCM (3 mL) and TFA (1 mL) was added dropwise at rt. After 30 
min, the solvents were evaporated and the crude mixture was dissolved in CHCl3/MeOH (6:4, 
+ 0.5% conc. NH4OH) and transferred to a silica gel column, eluting with the same solvent 
mixture, to yield N-(2-(2-(2-aminoethoxy)ethoxy)ethyl)-3'-chloro-4'-(α-D-mannopyranosyl-
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oxy)-biphenyl-4-carboxamide (228 mg, 90 %). A fraction of the amine (10 mg, 0.018 mmol) 
was dissolved in dry DMF (0.5 mL) and cooled to 0 °C. FITC (6.5 mg, 0.017 mmol) was 
added and the mixture was stirred for 1 h. The mixture was concentrated and the residue was 
purified by chromatography on silica (DCM/MeOH), to yield 24 (10 mg, 65%). 1H NMR (500 
MHz, CD3OD): δ = 8.21 (d, J = 1.4 Hz, 1H, Ar-H), 7.88 (d, J = 8.3 Hz, 2H, Ar-H), 7.68 (d, J = 
2.2 Hz, 2H, Ar-H), 7.63 (d, J = 8.3 Hz, 2H, Ar-H), 7.53 (dd, J = 2.2, 8.6 Hz, 1H, Ar-H), 7.43 
(d, J = 8.7 Hz, 1H, Ar-H), 7.09 (d, J = 8.2 Hz, 1H, Ar-H), 6.68 (d, J = 2.3 Hz, 2H, Ar-H), 6.65 
(dd, J = 2.6, 8.6 Hz, 2H, Ar-H), 6.53 (dd, J = 1.6, 8.7 Hz, 2H, Ar-H), 5.61 (d, J = 1.3 Hz, 1H, 
H-1), 4.14 (dd, J = 1.8, 3.2, Hz, 1H, H-2), 4.03 (dd, J = 3.4, 9.5 Hz, 1H, H-3), 3.93-3.53 (m, 
16H), 3.37 (s, 2H, NCH2), 1.30 (s, 2H, CH2); 13C NMR (126 MHz, CD3OD): δ = 170.01 (CO), 
153.17, 143.72, 136.37, 134.37, 130.39, 129.69, 129.04, 127.78, 127.73, 125.35, 118.60, 
103.60 (Ar-C), 100.72 (C-1), 75.97 (C-5), 72.41 (C-3), 71.86, 71.40, 70.59 (5C, C-2, OCH2), 
68.23 (C-4), 62.64 (C-6), 49.88, 45.49, 40.97 (CH2);  ESI-MS: m/z: Calcd for C46H45ClN3O14S 
[M+H]+: 930.2, found: 930.4. 
 
Competitive Fluorescence Polarization Assay 
 
Expression and purification of CRD of FimH. A recombinant protein consisting of the CRD 
of FimH linked to a 6His-tag via a thrombin cleavage site (FimH-CRD-Th-His6) was 
expressed in E. coli strain HM125 and purified by affinity chromatography as previously 
described.43 
 
KD determination of FITC-labeled ligands. The functionalized ligands (23, 24) were 
prepared as a 10 mM stock solution in pure DMSO (Sigma Aldrich, Buchs, Switzerland). All 
further dilutions of compounds and FimH-CRD-Th-His6 protein were prepared in assay buffer 
(20 mM HEPES, 150 mM NaCl, 50 µg/mL BSA, pH 7.4). BSA was added to the assay buffer 
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to prevent non-specific binding of protein to the plastic surface. Binding isotherms for the 
fluorescent ligands were obtained in direct binding studies by adding a constant concentration 
of ligand (final concentration 5 nM) and a linear dilution of protein (final concentration 0-100 
nM) to a final volume of 200 µL in 96-well, black, flat bottom NBSTM plates (Corning Inc., 
Corning, NY, USA). After incubating the plate for 24 h at rt with gentle shaking, the 
fluorescence polarization was measured with the SynergyTM H1 Hybrid Multi-Mode 
Microplate Reader (BioTek Instruments Inc., Winooski, VT, USA) with polarized excitation at 
485 nm and emission measured at 528 nm through polarizing filters parallel and 
perpendicularly oriented to the incident polarized light. KD values were determined by plotting 
the FP readout as a function of the protein concentration and applying the following single-site 
binding equation (Equation 1) that accounts for ligand depletion: 
 
€ 
Sobs = SF + (SB − SF ) ⋅ (
CP + CL + KD − (CP +CL + KD )
2 − 4CPCL
2CL
) (1) 
where Sobs is the observed signal from the ligand, SF is the signal from free ligand, SB is the 
signal from bound ligand, CP is the total concentration of protein, and CL is the total 
concentration of ligand.49 
 
KD Determination of FimH Antagonists. The fluorescently labeled ligand 23 was used for 
the competitive fluorescence polarization assay. A linear dilution of non-labeled FimH 
antagonist with final concentrations ranging from 0-10 µM was titrated into 96-well, black, flat 
bottom NBSTM plates (Corning Inc.) to a final volume of 200 µL containing a constant 
concentration of protein (final concentration 25 nM) and FITC-labeled ligand which was fixed 
at a higher concentration in competitive binding assays than in direct binding experiments to 
obtain higher fluorescence intensities (final concentration 20 nM). Prior to measuring the 
fluorescence polarization, the plates were incubated on a shaker for 24 h at rt until the reaction 
reached equilibrium. The IC50 value was determined with Prism (GraphPad Software Inc., La 
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Jolla, CA, USA) by applying a standard four-parameter IC50 function. The obtained IC50 values 
were converted into their corresponding KD values using the derivation of the Cheng-Prusoff 
equation.45 This variation of the Cheng-Prusoff equation is applied to competition assays with 
tight-binding inhibitors, and includes terms to correct for ligand depletion effects. However, 
the KD for antagonists having a higher affinity towards FimH than the labeled ligand could not 
be accurately determined.45 
 
Isothermal Titration Calorimetry (ITC) 
 
All ITC experiments were performed with the FimH-CRD-Th-His6 protein using a VP-ITC 
instrument from MicroCal, Inc. (Malvern Instruments, Worcestershire, UK) with a sample cell 
volume of 1.4523 mL. The measurements were performed with 0 to 5% DMSO at 25 °C, a 
stirring speed of 307 rpm, and 10 µcal s-1 reference power. The protein samples were dialyzed 
in assay buffer prior to all experiments. Due to the high protein consumption of ITC, only the 
experiments for the reference compounds (1, 3 and 25) were measured in duplicates. 
Compounds 1, 3, 9, and 25 were measured in a direct fashion by titration of ligand (100-2,000 
µM) into protein (8.6-55 µM) with injections of 3-8 µL at intervals of 10 min to ensure non-
overlapping peaks. The quantity c = Mt(0) KD–1, where Mt(0) is the initial macromolecule 
concentration, is of importance in titration microcalorimetry. The c-values of the direct 
titrations were below 1,000 and thus within the reliable range. For the compounds 10b-e, 10g 
and 10j additional competitive ITC experiments were performed due to their high affinity 
resulting in c-values above 1,000 for direct titrations. These ligands (600 µM) were titrated 
into protein (30 µM), which was preincubated with compound 25 (300 µM) resulting in 
sigmoidal titration curves. Due to slow reaction kinetics, titration intervals of 20 min were 
used. 
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Baseline correction and peak integration was performed using the Origin 7 software  
(OriginLab, Northampton, MA, USA). An initial 2 µL injection was excluded from data 
analysis. Baseline subtraction and curve-fitting with the three variables N (concentration 
correction factor), KD (dissociation constant), and ∆H° (change in enthalpy) was performed 
with the SEDPHAT software version 10.40 (National Institute of Health).84 A global fitting 
analysis was performed for the competition titration (compounds 10b-e, 10g or 10j competing 
for the protein binding site with compound 25) and the direct titration of the competitor 
(compound 25 binding to protein) to fit for KD. ∆H° and N were fitted from direct titrations of 
compounds 10b-e, 10g or 10j into protein. For the compounds 3, 9 and 25 binding to protein 
all variables could be determined from a global analysis of the direct titration. 
 
The thermodynamic parameters were calculated with the following equation (Equation 2): 
  (2) 
where ∆G°, ∆H°, and ∆S° are the changes in free energy, enthalpy, and entropy of binding, 
respectively, T is the absolute temperature, and R is the universal gas constant (8.314 J mol-1 
K-1). The 95 %-confidence intervals of the measurements were calculated for the two variables 
KD and ∆H° with the 1-dimensional error surface projection within the SEDPHAT software. 
 
Calculation of the Free Energy of Desolvation. The three dimensional representation for 
each of the aglycons (4-methoxy biphenyl scaffold, Figure 7) was built in the Maestro85 
modeling environment and the global minimum conformation was identified by performing 
500 iterations of the mixed torsional/low-mode conformational sampling in combination with 
the OPLS-2005 force-field and the implicit solvent model (water) as implemented in the 
Macromodel 9.9.86 The global minimum structures were used as input for the AMSOL 7.1 
program87 to obtain the free energy of desolvation ΔGdes (Table 5) with the SM5.4A solvation 
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model88 and the AM189 level of theory (used keywords “AM1 SM5.4A SOLVNT=WATER 
TRUES”). 
RO
 
Figure 7. The 4-methoxy biphenyl scaffold of aglycons. 
Table 5. Aqueous free energy of desolvation.    
R ΔGdes [kJ/mol] 
neutral  
H 15.6 
CONHCH3 39.9 
COOCH3 23.0 
SO2NHCH3 65.5 
SO2CH3 56.4 
4-morpholine amide 45.3 
CN 22.0 
  
deprotonated  
COO- 298.2 
SO2-N--Me 342.0 
 
Determination of the MAC90 by flow cytometry 
 
The MAC90 was determined in principle as in the previously published flow cytometry assay,79 
but with some modifications. The human epithelial bladder carcinoma cell line 5637 (DSMZ, 
Braunschweig, Germany) was grown in RPMI 1640 medium, supplemented with 10% fetal 
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calf serum (FCS), 100 U/mL penicillin and 100 µg/mL streptomycin at 37 °C, 5% CO2. All 
solutions were purchased from Invitrogen (Basel, Switzerland). The cells were subcultured 1:6 
twice per week [using Trypsin/EDTA (Sigma-Aldrich) for the detachment]. Two days before 
infection, 1.8 × 105 cells were seeded in each well of a 24-well plate in RPMI 1640 containing 
10% FCS without antibiotics. The cell density was approximately 3-5 × 105 cells/well at the 
assay day. 
 
For infection, the GFP-expressing clinical E. coli isolate UTI8990 (UTI89 wt) and the GFP-
expressing FimA-H knock-out strain UTI89 ∆fimA-H were used (strains were provided by 
Prof. Urs Jenal, Biocenter, University of Basel, Switzerland).79 Bacteria were cultivated at 37 
°C in 10 mL Luria-Bertani (LB) broth (Becton, Dickinson and Company) overnight, harvested 
by centrifugation (3,800 rpm, 10 min) and washed three times in phosphate buffered saline 
(PBS, Sigma-Aldrich) and a bacterial solution of OD600 of 0.75 in RPMI + 10% FCS was 
prepared. For the determination of the MAC90 value, the IC90, linear dilutions of the FimH-
antagonist were prepared in 5% DMSO and PBS. Bacteria and antagonists were pre-incubated 
for 10 min at 37 °C, before cells were infected with either only 200 µL bacterial solution of 
UTI89 or UTI89 ∆fimA-H (positive and negative controls), or 225 µL of the pre-incubated 
bacteria-antagonist mixture. Infection lasted for 1.5 h, during this time infected cells were 
incubated at 37 °C. Then, cells were washed with PBS and detached from wells by the addition 
of 150 µL trypsin and incubation at 37 °C for 10 min, before flushing from wells PBS 
containing 2% FCS and transferred to tubes. To dilute the trypsin, cells were centrifuged at 
13000 rpm, 1 min, 600 µL of the supernatant was discarded and the pellet was re-suspended in 
the remaining 300 µL PBS containing 2% FCS. Samples were stored on ice until 
measurement. Before analysis with the flow cytometer (Becton Dickinson, FACSCanto II), the 
samples were gently mixed and filtered using a 35 µm nylon mesh (Corning Life Sciences) to 
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prevent cellular aggregation. Cells were gated with linear scaling for side scatter (SSC) and 
forward scatter (FSC) and GFP intensity of live cells was evaluated. IC90 values were 
determined by plotting the concentration of the antagonist in a logarithmic mode versus the 
mean fluorescence intensity (MFI) of living cells and by fitting a dose response curve (variable 
slope, four parameters) with the prism software (GraphPad Prism). 
 
X-ray analysis of the antagonists 10e and 10j co-crystallized with FimH-CRD 
 
FimH-CRD-10e co-crystallization. Initial FimH-CRD (18 mg/mL in 20 mM HEPES pH 7.4) 
crystals were obtained in complex with 4-(5-nitroindolin-1-yl)phenyl α-D-mannopyranoside (5 
mM).23 Crystals were grown in sitting-drop vapor diffusion at 20 °C with 200 nL of protein-
antagonist mixture together with 200 nL precipitant solution in well D3 (0.2 M sodium 
phosphate monobasic monohydrate, 20% w/v PEG 3,350) of the PEG/Ion HTTM screen 
(Hampton Research, CA, USA). Cubic crystals appeared within one week, which served as 
cross-seeding crystals. A solution of FimH-CRD (20 mg/mL) and 10e (5 mM) was mixed with 
0.2 M sodium phosphate monobasic monohydrate, 20% w/v PEG 400 with 0.5 µL of each 
solution. Streak-seeding was performed after one day of incubation. Cubic FimH-CRD-10e 
crystals formed within 24 h. Crystals were flash cooled to 100 K with perfluoropolyether cryo 
oil (Hampton Research, CA, USA) as cryoprotectant. Data was collected with synchrotron 
radiation (λ = 0.99999 Å) at the PXIII beamline, Swiss Light Source, Switzerland. 
 
FimH-CRD-10j co-crystallization. Co-crystals were initially grown in sitting-drop vapor 
diffusion at 20 °C with 0.5 µL of a mixture of FimH-CRD (20 mg/mL) and 10j (5 mM) 
together with 0.5 µL of 0.1 M HEPES pH 7.5, 2 M ammonium sulfate. Plate-like crystals 
formed within two weeks and were used as seeds for subsequent crystallization. Diffraction 
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quality crystals were grown by streak-seeding in 0.5 µL of FimH-CRD (10 mg/mL) with 10j 
(2.5 mM) and 0.5 µL of 0.1 M HEPES pH 7.5, 1.25 M ammonium sulfate. The drops were 
covered with perfluoropolyether cryo oil prior to flash cooling to 100 K. Data was collected 
with synchrotron radiation (λ = 1.00003 Å) at the PXIII beamline, Swiss Light Source, 
Switzerland. 
 
Structure Determination and Refinement. Data were indexed and integrated with the XDS 
package91 for the FimH-CRD-10e co-crystal structure, and with mosflm92 for the FimH-CRD-
10j co-crystal structure. Scaling was performed with XDS and SCALA included in the CCP4 
suite, respectively.93 Structures were solved by molecular replacement with PHASER94 using 
the FimH-CRD-butyl α-D-mannopyranoside complex  (PDB code 1UWF) as search model. 
The structures were iteratively built using the COOT software95 and refined with the PHENIX 
software.96 Geometric restraints for 10e and 10j were generated with PRODRG.97 The models 
were validated using molprobity.98 Residues 113-115 were not modeled in the 10e structure 
due to disorder. Furthermore, the ligand was modeled in two possible conformations. For both 
ligands, electron density is reduced on the second aromatic ring due to flexibility of the ligand. 
 
Table 6. Data Collection and Refinement Statistics for FimH-CRD-10e and FimH-CRD-10j co-crystals. 
 FimH-CRD-10e FimH-CRD-10j 
PDB code 4CSS 4CST 
Space group P 21 21 21 P 21 21 21 
No. of molecules in the asymmetric unit 1 1 
Cell dimensions 
a, b, c (Å) 48.38, 56.23, 61.59  48.84, 55.89, 61.00 
     a, b, c (°)  90, 90, 90 90, 90, 90 
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Data Collection 
Beamline Swiss Light Source PXIII Swiss Light Source PXIII 
Resolution range (Å)a 30.0 - 1.07 (1.13 – 1.07) 23.5 – 1.10 (1.12 – 1.10) 
Unique observationsa 72000 (9354) 66470 (2500) 
Average multiplicitya 10.9 (3.7) 5.4 (2.4) 
Completeness (%) 96.1 (78.0) 97.2 (76.5) 
Rmergea 0.056 (0.57) 0.051 (0.305) 
Mean I / σ(I)a 21.5 (2.22) 15.5 (2.9) 
Refinement 
Resolution range (Å) 15.7 – 1.07 23.5 – 1.10 
R, Rfree 11.2, 13.2 11.4, 13.0 
Rms deviation from ideal bond length (Å) 0.010 0.010 
Rms deviation from ideal bond angle 
(deg) 
1.170 1.420 
 
aValues in parentheses are for highest-resolution shell. 
 
Physicochemical and in vitro pharmacokinetic studies. 
 
Materials. Dimethyl sulfoxide (DMSO), 1-propanol, 1-octanol, Dulbecco’s Modified Eagle’s 
Medium (DMEM) - high glucose, L-glutamine solution, penicillin-streptomycin solution, 
Dulbecco’s Phosphate Buffered Saline (DPBS), trypsin-EDTA solution, magnesium chloride 
hexahydrate, and reduced nicotinamide adenine dinucleotide phosphate (NADPH) were 
purchased from Sigma-Aldrich. MEM nonessential amino acid (MEM-NEAA) solution, fetal 
bovine serum (FBS), and DMEM without sodium pyruvate and phenol red were bought from 
Invitrogen (Carlsbad, CA, USA). PRISMA HT universal buffer, GIT-0 Lipid Solution, and 
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Acceptor Sink Buffer were ordered from pIon (Woburn, MA, USA). Human plasma was 
bought from Biopredic (Rennes, France) and acetonitrile (MeCN) and methanol (MeOH) from 
Acros Organics (Geel, Belgium). Pooled male rat liver microsomes were purchased from BD 
Bioscience (Franklin Lakes, NJ, USA). Tris(hydroxymethyl)-aminomethane (TRIS) was 
obtained from AppliChem (Darmstadt, Germany). The Caco-2 cells were kindly provided by 
Prof. G. Imanidis, FHNW, Muttenz, and originated from the American Type Culture 
Collection (Rockville, MD, USA).  
 
pKa. The pKa values were determined as described elsewhere.99 In brief, the pH of a sample 
solution was gradually changed and the chemical shift of protons adjacent to ionizable centers 
was monitored by 1H nuclear magnetic resonance (NMR) spectroscopy. The shift was plotted 
against the pH of the respective sample, and the pKa was read out from the inflection point of 
the resulting sigmoidal curve. 
 
Log D7.4. The in silico prediction tool ALOGPS100 was used to estimate log P values of the 
compounds. Depending on these values, the compounds were classified into three categories: 
hydrophilic compounds (log P below zero), moderately lipophilic compounds (log P between 
zero and one) and lipophilic compounds (log P above one). For each category, two different 
ratios (volume of 1-octanol to volume of buffer) were defined as experimental parameters 
(Table 7). 
 
Table 7. Compound classification based on estimated log P values. 
Compound type log P ratio (1-octanol / buffer) 
hydrophilic < 0 30:140, 40:130 
moderately lipophilic 0 - 1 70:110, 110:70 
lipophilic > 1 3:180, 4:180 
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Equal amounts of phosphate buffer (0.1 M, pH 7.4) and 1-octanol were mixed and shaken 
vigorously for 5 min to saturate the phases. The mixture was left until separation of the two 
phases occurred, and the buffer was retrieved. Stock solutions of the test compounds were 
diluted with buffer to a concentration of 1 µM. For each compound, six determinations, that is, 
three determinations per 1-octanol/buffer ratio, were performed in different wells of a 96-well 
plate. The respective volumes of buffer containing analyte (1 µM) were pipetted to the wells 
and covered by saturated 1-octanol according to the chosen volume ratio. The plate was sealed 
with aluminum foil, shaken (1,350 rpm, 25 °C, 2 h) on a Heidolph Titramax 1000 plate-shaker 
(Heidolph Instruments GmbH & Co. KG, Schwabach, Germany) and centrifuged (2,000 rpm, 
25 °C, 5 min, 5804 R Eppendorf centrifuge, Hamburg, Germany). The aqueous phase was 
transferred to a 96-well plate for analysis by LC-MS. 
 
The log D7.4 coefficient was calculated from the 1-octanol/buffer ratio (o:b), the initial 
concentration of the analyte in buffer (1 µM), and the concentration of the analyte in buffer 
(cB) with Equation 3: 
 
€ 
logD7.4 = log
1µM − cB
cB
×
1
o :b
$ 
% 
& 
' 
( 
) 
 (3) 
 
Aqueous Solubility. Solubility was determined in a 96-well format using the µSOL Explorer 
solubility analyzer (pIon, version 3.4.0.5). For each compound, measurements were performed 
at pH 3.0 and 7.4 in triplicates. For this purpose, six wells of a deep well plate, that is, three 
wells per pH value, were filled with 300 µL of PRISMA HT universal buffer, adjusted to pH 
3.0 or 7.4 by adding the requested amount of NaOH (0.5 M). Aliquots (3 µL) of a compound 
stock solution (10-50 mM in DMSO) were added and thoroughly mixed. The final sample 
concentration was 0.1-0.5 mM, the residual DMSO concentration was 1.0% (v/v) in the buffer 
Chapter 3.2. – Manuscript 4 
 
 198 
solutions. After 15 h, the solutions were filtrated (0.2 µm 96-well filter plates) using a vacuum 
to collect manifold (Whatman Ltd., Maidstone, UK) to remove the precipitates. Equal amounts 
of filtrate and 1-propanol were mixed and transferred to a 96-well plate for UV/Vis detection 
(190 to 500 nm, SpectraMax 190). The amount of material dissolved was calculated by 
comparison with UV/Vis spectra obtained from reference samples, which were prepared by 
dissolving compound stock solution in a 1:1 mixture of buffer and 1-propanol (final 
concentrations 0.017-0.083 mM). 
 
Parallel Artificial Membrane Permeation Assay (PAMPA). Effective permeability (log Pe) 
was determined in a 96-well format with the PAMPA.60 For each compound, measurements 
were performed at pH 5.0 and 7.4 in quadruplicates. Eight wells of a deep well plate, that is, 
four wells per pH-value, were filled with 650 µL of PRISMA HT universal buffer adjusted to 
pH 5.0 or 7.4 by adding the requested amount of NaOH (0.5 M). Samples (150 µL) were 
withdrawn from each well to determine the blank spectra by UV/Vis-spectroscopy (190 to 500 
nm, SpectraMax 190). Then, analyte dissolved in DMSO was added to the remaining buffer to 
yield 50 µM solutions. To exclude precipitation, the optical density was measured at 650 nm, 
with 0.01 being the threshold value. Solutions exceeding this threshold were filtrated. 
Afterwards, samples (150 µL) were withdrawn to determine the reference spectra. Further 200 
µL were transferred to each well of the donor plate of the PAMPA sandwich (pIon, P/N 
110163). The filter membranes at the bottom of the acceptor plate were infused with 5 µL of 
GIT-0 Lipid Solution, and 200 µL of Acceptor Sink Buffer was filled into each acceptor well. 
The sandwich was assembled, placed in the GutBoxTM, and left undisturbed for 16 h. Then, it 
was disassembled and samples (150 µL) were transferred from each donor and acceptor well to 
UV-plates for determination of the UV/Vis spectra. Effective permeability (log Pe) was 
calculated from the compound flux deduced from the spectra, the filter area, and the initial 
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sample concentration in the donor well with the aid of the PAMPA Explorer Software (pIon, 
version 3.5). 
 
Colorectal Adenocarcinoma (Caco-2) Cell Permeation Assay. Caco-2 cells were cultivated 
in tissue culture flasks (BD Biosciences) with DMEM high glucose medium, containing L-
glutamine (2 mM), nonessential amino acids (0.1 mM), penicillin (100 U/mL), streptomycin 
(100 µg/mL), and fetal bovine serum (10%). The cells were kept at 37 °C in humidified air 
containing 5% CO2, and the medium was changed every second day. When approximately 
90% confluence was reached, the cells were split in a 1:10 ratio and distributed to new tissue 
culture flasks. At passage numbers between 60 and 65, they were seeded at a density of 5.3 × 
105 cells per well to Transwell 6-well plates (Corning Inc.) with 2.5 mL of culture medium in 
the basolateral and 1.8 mL in the apical compartment. The medium was renewed on alternate 
days. Permeation experiments were performed between days 19 and 21 post seeding. Prior to 
the experiment, the integrity of the Caco-2 monolayers was evaluated by measuring the 
transepithelial electrical resistance (TEER) with an Endohm tissue resistance instrument 
(World Precision Instruments Inc., Sarasota, FL, USA). Only wells with TEER values higher 
than 250 Ω cm2 were used. Experiments were performed in the apical-to-basolateral 
(absorptive) and basolateral-to-apical (secretory) directions in triplicates. Transport medium 
(DMEM without sodium pyruvate and phenol red) was withdrawn from the donor 
compartments of three wells and replaced by the same volume of compound stock solution (10 
mM in DMSO) to reach an initial sample concentration of 62.5 µM. The Transwell plate was 
then shaken (600 rpm, 37 °C) on a Heidolph Titramax 1000 plate-shaker. Samples (40 µL) 
were withdrawn from the donor and acceptor compartments 30 min after initiation of the 
experiment and the compound concentrations were determined by LC-MS (see below). 
Apparent permeability (Papp) was calculated according to Equation 4: 
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€ 
Papp =
dQ
d t ×
1
A × c0
 
 (4) 
where dQ/dt is the compound flux (mol s-1), A is the surface area of the monolayer (cm2), and 
c0 is the initial concentration in the donor compartment (mol cm-3).60 After the experiment, 
TEER values were assessed again for each well and results from wells with values below 250 
Ω cm2 were discarded. 
 
Plasma Protein Binding (PPB). PPB was determined in a 96-well format using a high 
throughput dialysis block (HTD96b; HTDialysis LCC, Gales Ferry, CT, USA). For each 
compound, measurements were performed in triplicate. Dialysis membranes (MWCO 12-14 K; 
HTDialysis LCC) were hydrated according to the instructions of the manufacturer and placed 
into the dialysis block. Human plasma was centrifuged (5,800 rpm, 5 °C, 10 min), the pH of 
the supernatant (without floating plasma lipids) was adjusted to 7.4 by adding the requested 
amount of HCl (4 M), and analyte was added to yield a final concentration of 10 µM. Equal 
volumes (150 µL) of plasma containing the analyte or TRIS-HCl buffer (0.1 M, pH 7.4) were 
transferred to the compartments separated by the dialysis membrane. The block was covered 
with a sealing film and left undisturbed (5 h, 37 °C). Afterwards, samples (90 µL) were 
withdrawn from the buffer compartments and diluted with plasma (10 µL). From the plasma 
compartments, samples (10 µL) were withdrawn and diluted with TRIS-HCl buffer (90 µL). 
The solutions were further diluted with ice-cooled MeCN (300 µL) to precipitate the proteins 
and centrifuged (3600 rpm, 4 °C, 10 min). The supernatants (50 µL) were retrieved, and the 
analyte concentrations were determined by LC-MS (see below). The fraction bound (fb) was 
calculated as follows (Equation 5): 
 
€ 
fb = 1−
cb
cp
 (5) 
Chapter 3.2. – Manuscript 4 
 
   201 
where cb is the concentration of the analyte withdrawn from the buffer compartment before 
dilution and cp is the concentration in the plasma compartment. The values were accepted if the 
recovery of analyte was between 80 and 120% of the initial amount. 
 
Cytochrome P450-mediated metabolism. Incubations consisted of pooled male rat liver 
microsomes (0.5 mg microsomal protein/mL), test compound (2 µM), MgCl2 (2 mM), and 
NADPH (1 mM) in a total volume of 300 µL TRIS-HCl buffer (0.1 M, pH 7.4) and were 
performed in a 96-well plate on a Thermomixer Comfort (Eppendorf). Compounds and 
microsomes were preincubated (37 °C, 700 rpm, 10 min) before NADPH was added. Samples 
(50 µL) at t = 0 min and after an incubation time of 5, 10, 20, and 30 min were quenched with 
150 µL of ice-cooled MeOH, centrifuged (3,600 rpm, 4 °C, 10 min), and 80 µL of supernatant 
was transferred to a 96-well plate for LC-MS analysis (see below). The metabolic half-life 
(t1/2) was calculated from the slope of the linear regression from the log percentage remaining 
compound versus incubation time relationship. Control experiments without NADPH were 
performed in parallel. 
 
LC-MS measurements. Analyses were performed using an 1100/1200 Series HPLC System 
coupled to a 6410 Triple Quadrupole mass detector (Agilent Technologies, Inc., Santa Clara, 
CA, USA) equipped with electrospray ionization. The system was controlled with the Agilent 
MassHunter Workstation Data Acquisition software (version B.01.04). The column used was 
an Atlantis® T3 C18 column (2.1 × 50 mm) with a 3 µm particle size (Waters Corp., Milford, 
MA, USA). The mobile phase consisted of eluent A: H2O containing 0.1% formic acid (for 
10a-f, h-i), or 10 mM ammonium acetate, pH 5.0 in 95:5, H2O/MeCN (for 10g, j); and eluent 
B: MeCN containing 0.1% formic acid. The flow rate was maintained at 0.6 mL/min. The 
gradient was ramped from 95% A/5% B to 5% A/95% B over 1 min, and then hold at 5% 
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A/95% B for 0.1 min. The system was then brought back to 95% A/5% B, resulting in a total 
duration of 4 min. MS parameters such as fragmentor voltage, collision energy, polarity were 
optimized individually for each analyte, and the molecular ion was followed for each 
compound in the multiple reaction monitoring mode. The concentrations of the analytes were 
quantified by the Agilent Mass Hunter Quantitative Analysis software (version B.01.04). 
 
In Vivo Pharmacokinetic Studies. 
 
Materials. DMSO and PBS were purchased from Sigma-Aldrich. The 96-well plates were 
bought from Agilent Technologies (0.5 mL, polypropylene). The gavage was obtained from 
Fine Science (Heidelberg, Germany) and the syringes (BD Micro Fine, U-100 Insuline, 30 G) 
and needles (BD Microlance 3, 25 G) from Becton Dickinson (USA, Ireland) and Henke Sass 
Wolf in Germany (Soft-Ject, 1 mL syringes). 
 
Animals. Female C3H/HeN mice weighing between 19 and 25 g were obtained from Charles 
River Laboratories (Sulzfeld, Germany) and were housed three or four per cage. The mice 
were kept under specific pathogen-free conditions in the Animal House of the Department of 
Biomedicine, University Hospital of Basel, and animal experimentation guidelines according 
to the regulations of the Swiss veterinary law were followed. After 7 d of acclimatization, 9-10 
week old mice were used for the studies. Animals had free access to chow and water at any 
time and were kept in a 12h/12h light/dark cycle. For administration volumes and sampling the 
good practice guidelines were followed.101 
 
Pharmacokinetic studies. The single-dose studies for the first experiment set were performed 
by intravenous application of FimH antagonists at a dosage of 50 mg/kg body weight, followed 
by plasma and urine sampling. Antagonists were diluted in PBS for injection into the tail vein. 
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Blood and urine samples (10 µL) were taken at 6 and 30 min, and 1, 2, 4, 6, and 8 h after 
injection. For the PK studies with 10j, the antagonist was dissolved in PBS with 5 % DMSO 
and injected into the tail vain (0.625 mg/kg) or given orally (1.25 mg/kg) using a gavage. 
Blood and urine were sampled (10 µL) after 7, 13, 20, 30, 45 min, and 1, 1.5, 2, 2.5, 3, 4, 6, 8, 
and 24 h. Both, blood and urine samples, were directly diluted after sampling with MeOH to 
precipitate the proteins and centrifuged for 11 min at 13,000 rpm. The supernatants were 
transferred to a 96-well plate and the analyte concentrations were determined by LC-MS (see 
above). 
 
Infection study. For all infection studies, the drinking water of the mice was replaced by water 
containing 5% glucose (monohydrate from AppliChem, BioChemica), three days before the 
start of the experiment. 10j was dosed at 1.25 mg/kg (in 5% DMSO and PBS) and 10 mg/kg 
(5% DMSO in PBS containing 1% Tween 80) applied orally to 6 and 4 mice, respectively, as 
described in the pharmacokinetic studies, 40 min prior to infection. Ciprofloxacin was dosed 
with 8 mg/kg, which would correspond to a human dose of 400 mg,81 subcutaneously 10 min 
prior to infection with UTI89 to 4 mice. Control values resulted from the infection of 11 mice. 
Before infection, remaining urine in the bladder was expelled by gentle pressure on the 
abdomen. Mice were anaesthetised in 2.5 vol% isoflurane/oxygen mixture (Attane, Minrad 
Inc, Buffalo, NY, USA) and placed on their back. Infection was performed transurethrally 
using a polyethylene catheter (Intramedic polyethylene tubing, inner diameter 0.28 mm, outer 
diameter 0.61 mm, Beckton Dickinson, Allschwil, Switzerland), on a syringe (Hamilton 
Gastight Syringe 50 µL, removable 30G needle, BGB Analytik AG, Boeckten, Switzerland). 
After gentle insertion of the catheter into the bladder, 50 µL of bacterial suspension of UTI89 
(5.5 × 109 to 2.25 × 1010 CFU/mL) was slowly injected. This corresponded to approximately 
107-108 CFU per mouse. Mice were killed by CO2 three hours after inoculation and bladder 
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and kidneys were aseptically removed. Organs were homogenized in 1 mL PBS using a tissue 
lyser (Retsch, Haan, Germany). Serial dilutions of bladder and kidneys were plated on Levine 
Eosin Methylene Blue Agar plates (Beckton Dickinson, France) and CFU were counted after 
overnight incubation at 37 °C. 
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Urinary tract infections caused by uropathogenic E. coli are among 
the most prevalent infectious diseases. The mannose-specific lectin 
FimH mediates the adhesion of the bacteria to the urothelium 
enabling host cell invasion and recurrent infections. An attractive 
alternative to antibiotics treatment is the development of FimH 
antagonists that mimic the physiological ligand. A large variety of 
candidate drugs have been developed and characterized using in 
vitro studies and animal models. Here we present the X-ray co-crystal 
structures of FimH with four antagonist classes for three of which 
structural data were unavailable to date. We used NMR spectroscopy 
to further characterize FimH-antagonist interactions by chemical shift 
perturbation. The analysis allowed a clear determination of the 
conformation of the tyrosine gate motif that is crucial for interaction 
with aglycone moieties and was not obvious from X-ray structural 
data alone. Finally, ITC experiments provided insight into the 
thermodynamics of antagonist binding. In conjunction with the 
structural information from X-ray and NMR experiments the results 
suggest a mechanism for the often-observed enthalpy-entropy 
compensation of FimH antagonists that may play a role in fine-tuning 
of the interaction. 
 
Introduction 
Urinary tract infection (UTI) is one of the most frequent infectious 
disease affecting millions of people every year.[1] Women have a 
50% risk experiencing at least one symptomatic UTI during their 
lifetime. The large majority of UTIs is caused by uropathogenic 
Escherichia coli (UPEC) that are able to invade the urothelial cells 
in the bladder, form biofilms and cause recurrent infections.[2] To 
date, UTIs are mainly treated with antibiotics leading to the 
ubiquitous problem of increasing antimicrobial resistance.[3] 
Therefore, new treatment strategies are urgently needed. 
Adherence of UPEC to the urothelial surface is mediated via 
the mannose-specific lectin FimH located at the tip of bacterial 
type 1 pili.[4] FimH therefore represents a major virulence factor of 
UPEC. It consists of two immunoglobulin-like domains: the N-
terminal lectin domain and – connected by a short linker – the C-
terminal pilin domain. The lectin domain encloses the 
carbohydrate recognition domain (CRD). The pilin domain 
anchors the adhesin to the pilus and regulates the switch 
between the two conformational states of the CRD with high and 
low affinity for mannosides, respectively.[5] Most in vitro studies on 
the interaction of FimH with FimH-antagonists have been 
performed with only the lectin domain FimH-CRD that is trapped 
in the high-affinity state.[6] The cellular ligand for FimH is the 
mannosylated glycoprotein uroplakin Ia present on urothelial 
cells.[7] Mannose-based FimH antagonists compete with the 
interaction and prevent the bacterial adhesion and hence the 
infection. A substantial advantage of this anti-adhesion therapy 
over antibiotics treatment is the reduced risk of resistance 
development, since no direct selection pressure is imposed on 
the pathogen.[8] The first successful demonstration of the anti-
adhesion strategy was the protective effect of methyl α-D-
mannoside in a UTI mouse model.[9] Since then, great progress 
has been made in the optimization of FimH antagonists with 
affinities in the low nanomolar range.[10] In part, these 
modifications are the result of rational drug design based on X-
ray crystal structures of FimH bound to α-D-mannosides.[10c, 11] 
The mannose moiety is tightly bound and involved in an 
extended hydrogen bond network. A promising perspective for 
optimizing binding is offered by a rim of hydrophobic residues 
cresting the entrance to the mannose pocket. This so-called 
tyrosine gate, consisting of Tyr48 and Tyr137 with Ile52 
positioned in between, is involved in the interaction with 
oligomannosides as revealed from the X-ray crystal structure of 
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FimH-CRD with oligomannose-3.[12] For drug design, the tyrosine 
gate was exploited for hydrophobic stacking interactions with 
suitable aglycones. In particular the finding that hydrophobic aryl 
and alkyl aglycones show stronger affinities led to many 
promising drug candidates. Through binding studies with a series 
of alkyl mannosides, n-heptyl α-D-mannoside (1) was identified 
as the most efficient non-aromatic FimH binder.[10c] For aryl and 
heteroaryl derivatives a large diversity of antagonists differing in 
the number of aromatic rings and substituents, and the type of 
linkers exist. Chemically easy accessible aromatic derivatives 
such as 4-nitrophenyl and 4-methylumbelliferyl mannosides have 
been discovered quite early.[10a, 10c] They were followed by 
derivatives of squaric acid,[10d, 10j] biphenyls and other diaryls,[10e, 
10f, 10k, 10m] triazoles[10g] and indolines [10h] among others. 
In our group, we routinely test new candidates for in vitro 
binding to FimH-CRD[10f-j, 13] and to UPEC[14] as well as for efficacy 
in a UTI mouse model.[15] A special focus is placed on the PK/PD 
properties for oral bioavailability.[10m] The ideal FimH antagonist 
for UTI treatment needs to be balanced between a reasonable 
solubility for effective dosage and a certain degree of lipophilicity 
for efficient membrane permeation during oral absorption. Despite 
the availability of structural information, rational design of FimH 
antagonists not always led to the expected improvement in 
binding affinities. Specifically, thermodynamic profiles from 
isothermal titration calorimetry (ITC) frequently revealed enthalpy-
entropy compensations,[10i, 10m] the reasons of which are not yet 
fully understood. 
In this study, we analyzed the binding of a representative set 
of FimH antagonists to FimH-CRD through a combination of high-
resolution X-ray crystal structures and NMR chemical shift 
perturbation (CSP) experiments. NMR spectroscopy allows the 
study of protein-carbohydrate interactions in solution, thus 
maintaining the molecule’s natural dynamics behavior.[16] In 
contrast, X-ray crystallography provides structural information 
from a “static” crystal with limited flexibility of the protein. Both 
methods are therefore highly complementary. The potential of 
NMR spectroscopy to contribute to the drug design process has 
been widely acknowledged.[17] The chemical shifts of protein 
resonances are highly sensitive to the chemical environment e.g. 
to hydrogen bonds and aromatic ring currents.[18] CSP effects 
hence identify residues in direct proximity to a bound ligand, and 
in addition indicate conformational changes in allosteric sites. We 
used 1H-15N-HSQC experiments of 15N-enriched FimH-CRD in the 
presence of various antagonists to monitor the CSP effects on the 
backbone amide groups. Previous NMR studies of methyl α-D-
mannoside[6] and n-heptyl α-D-mannoside[19] binding to FimH-
CRD only noted a general match of the CSP maps and the ligand 
binding interface identified from X-ray co-crystal structures. With 
our analysis we demonstrate that NMR and X-ray structural data 
can be combined to characterize FimH-antagonist complex 
formation at unprecedented detail. In addition to the structural 
information, ITC experiments were performed to quantify the 
thermodynamics of antagonist binding to FimH-CRD. 
Results and Discussion 
FimH antagonist classes studied in this work. 
In this study we examined FimH antagonists that are composed 
of an α-D-mannosyl residue linked to an aliphatic or aromatic 
aglycone (Table 1). n-Heptyl α-D-mannoside (1)[10c] is the only 
non-aromatic antagonists with a similar affinity (low nanomolar 
range) as the aromatic antagonists 2 to 7 (Table 1 and Table 2). 
Although its pharmacokinetic properties render 1 ineffective for 
oral administration, it is often used as a reference compound in 
screening studies. Biphenyl mannoside 2[10e] was rationally 
designed to make aromatic stacking interactions with the side 
chains of Tyr48 and Tyr137 in the tyrosine gate. Later on, the aryl 
moieties were derivatized to optimize this interaction as reported 
by our group and others.[10e, 10i, 10k] An impressive example hereof 
is biphenyl mannoside 4 that carries an ortho-chlorine on the 
inner aromatic ring and a cyano group in the para-position of the 
outer ring as a bioorthogonal replacement of the carboxyl group 
present in antagonist 3.[10m] Both ring substituents of 4 reduce the 
electron density in the aglycone and thereby enhance the π-π 
interaction leading to a more than 10-fold affinity improvement in 
comparison to the unsubstituted antagonist 2 (Table 2). Besides 
the biphenyls 2 to 4, three other compound classes with multiple 
aromatic rings in non-planar arrangements have been tested: 5 
features a 5-nitroindolinyl moiety N-linked to an inner phenyl 
ring;[10h] 6 extends an ortho-chlorophenyl by squaric acid and N-
methyl-piperazine;[10j] and in 7 (see supporting information for 
synthesis) an amide bond is inserted between two phenyl rings 
with ortho-chlorine and para-carboxyl substituents. 
In addition to high affinity antagonists, we studied methyl α-D-
mannoside (8), n-butyl α-D-mannoside (9) and 1,5-
anhydromannitol (10). Finally, the 4-deoxy-4-fluoro derivate 11 
(see supporting information for synthesis) exhibits a dramatically 
reduced affinity compared to 1 emphasizing the importance of the 
hydrogen bond network in the mannose binding pocket. 
X-ray crystal structures of FimH with antagonists. 
We obtained high-resolution X-ray structures of FimH-CRD co-
crystallized with antagonists 2 and 5-7 with a resolution between 
1.00 and 1.65 Å (Table 1 and Table S1) and compared them to 
the known structures with antagonists 1 and 4.[10m] Unfortunately, 
biphenyl mannoside 3 could not be crystallized with FimH-CRD 
under the tested conditions. FimH-CRD comprises eleven mainly 
antiparallel beta strands and two short helices (Figure 1). 
Superposition of the six protein structures reveals a high 
structural similarity with a backbone RMSD around 0.5 Å between 
any two structures. In all six structures the ligand is bound within 
the mannoside binding pocket. The mannosyl moieties form 
hydrogen bonds to the side chains of residues Asp54, Gln133, 
Asn135 and Asp140 and to the backbone of Phe1 and Asp47 
(Figure S1). Tyr48 is involved in stacking interactions with the 
outer aromatic ring of the aglycones or in case of 1 with the alkyl 
chain of the ligands (Figure 1). Tyr137 stabilizes the loop 
containing Tyr48 by hydrophobic interaction with Ile52. In case of 
6 and 7, the side chain hydroxyl group of Tyr137 may form a 
hydrogen bond with the oxygen atoms of the squaric acid and the 
amide bond, respectively. Moreover, the backbone amides of 
Tyr137, Asn138 and Asp140 and the side chains of Asn135, 
Asn138 and Asp140 form a complex hydrogen bond network 
within the loop and with the 3- and 4-position of the mannosyl 
residue of the ligand. 
Noteworthy, the tyrosine gate residues Tyr48 and Tyr137 
nearly perfectly overlap in all six structures. The position of their 
side chains corresponds to the closed conformation of the 
tyrosine gate as described previously.[10c, 10e, 10i, 20] The closed 
conformation was also observed in co-crystal structures of FimH-
CRD with n-butyl α-D-mannoside (9) (PDB ID: 1UWF)[10c] or with 
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a biphenyl mannoside with a methylcarboxylate group in meta-
position of the outer aromatic ring (PDB ID: 3MCY).[10e] 
 
Table 1. FimH antagonists analyzed for binding to FimH-CRD using X-ray 
crystallography and/or CSP NMR experiments (indicated with +). For already 
published X-ray structures, the reference and PDB IDs are given. 
Compd Structure X-ray NMR 
1 
 
+ 
(4BUQ)  + 
2 
 
+ 
(ID) + 
3 
 
n.d. + 
4 
 
+ 
(4CST) + 
5 
 
+ 
(ID) + 
6 
 
+ 
(ID) + 
7 
 
+ 
(ID) + 
8 
 
n.d. + 
9 
 + 
(1UWF, 
1TR7)[10c] 
+ 
10  n.d. + 
11 
 
n.d. + 
A significantly different orientation of the tyrosine gate termed 
the open conformation was observed in the crystal structure of 
the full-length FimH in complex with α-D-mannose stabilized by 
the chaperone FimC (PDB ID: 1KLF),[11] and of FimH-CRD with 
1,2-ethanediol in the mannose binding site (PDB ID: 4AUU).[20] 
The latter can be viewed as a “pseudo-apo” structure, although 
the bound 1,2,-ethanediol could still have an influence on the 
binding site. While the Tyr137 side chain in these structures 
remains in the orientation present in the closed conformation, the 
Tyr48 side chain is rotated towards the mannose pocket by ca. 
3.5 Å regarding the aromatic ring centers. This open conformation 
of FimH-CRD was also observed in the co-crystal structure with 
the native ligand epitope oligomannose-3, Manα1,3(Manα1,6) 
Manβ1,4GlcNAcβ1,4GlcNAc (PDB ID: 2VCO).[12] Here, the α1,3-
linked mannose at the nonreducing end is recognized in the 
orientation typical for all mannosides. This brings the first GlcNAc 
residue into a position where it would clash with Tyr48 in the 
closed conformation. Considering the limited conformational 
freedom around the glycosidic linkages it can be speculated that 
oligomannose-3 can only bind to FimH in the open conformation.  
In computational studies, FimH antagonists with flexible 
aglycones have been docked to FimH in both conformations of 
the tyrosine gate.[10c, 10i] As an experimental verification, n-butyl α-
D-mannoside (9)[10c] and several monoaryl antagonists[21] have 
been co-crystallized with FimH-CRD in both the open and closed 
form. Wellens et al. proposed that the open conformation 
represents the minimal energy conformer of FimH and the closed 
conformation is only stabilized by favorable interactions with 
hydrophobic aglycones, corresponding to a conformation 
selection process.[20] Nevertheless, an induced fit mechanism 
also seems possible. To conclude, Tyr48 can be regarded as a 
key element in ligand interaction and the knowledge of the Tyr48 
side chain conformation is critical to the discussion. Unfortunately, 
in many FimH-mannoside co-crystal structures the binding pocket 
residues or the ligand are involved in crystal contacts potentially 
affecting the binding pocket geometry.[20-21] Therefore, more 
experiments are needed to study the structure and dynamics of 
FimH-antagonist complex formation in solution. 
 
Figure 1. a), b) Superposition of X-ray co-crystal structures of 
FimH-CRD (grey, Tyr48 and Tyr137 shown as sticks) in complex 
with antagonists (shown as colored sticks in b) 1 (cyan), 2 (green), 
4 (orange), 5 (magenta), 6 (blue) and 7 (salmon). c) Beta sheet 
topology diagram of FimH-CRD according to [10c, 22]. 
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NMR experiments with FimH-CRD. 
We performed NMR experiments to obtain structural information 
on FimH-antagonist complexes in solution. This allows a full 
retention of the molecule dynamics and avoids potential distortion 
from crystal packing. The binding of antagonists to 15N-labeled 
FimH-CRD (173 residues) was monitored by CSP analysis of 1H-
15N-HSQC fingerprint spectra depicting the backbone amide 
groups. The protein contained a C-terminal 6His-tag for efficient 
affinity purification that does not influence mannoside binding.[13] 
A complete backbone resonance assignment was performed by 
measuring a set of triple resonance NMR spectra with a 13C,15N-
labeled FimH-CRD sample. The high chemical shift dispersion of 
the amide resonances allowed sequential backbone assignment 
mainly on the basis of HNCACB and CBCACONH spectra.[23] A 
total of 152 (94.4%) of 161 assignable residues could be 
assigned.[24] The 6His-tag remained unassigned. Three residues 
were absent in the 1H,15N-HSQC spectrum: the backbone and 
side chain signals of Asn96 and Arg98 which are located in a loop 
close to the binding pocket, as well as Gly79 located in an 
exposed loop ca. 20 Å away from the binding pocket. Carbon and 
proton signals of the side chains of these three residues were 
observed as (i-1) correlations of the succeeding residues 
suggesting that fast exchange with the solvent and not (solely) 
conformational exchange was responsible for the signal absence. 
The assignment matches that from a recently published study of 
FimH-CRD (BMRB entry: 19066)[19] that lacked a 6His-tag. The 
authors were able to observe and assign Gly79, Asn96 and 
Arg98 amide signals. This is likely due to different measuring 
conditions, in particular a lower pH of 6.0 [19] compared to pH 6.8 
(for assignment) and pH 7.0 (for CSP experiments) in this study. 
Chemical shift perturbation experiments. We subjected 
15N-labeled FimH-CRD to CSP experiments with antagonists 1 to 
11 (Table 1). Methyl (8) and n-heptyl α-D-mannoside (1) have 
been analyzed in similar studies before.[6, 19] With all compounds, 
separate signals for the bound and free form were observed in 
the 1H,15N-HSQC spectra at 500 MHz indicating slow exchange 
on the NMR time scale. The observation is in accordance with 
nanomolar to low micromolar affinities (Table 2) and with kinetic 
data obtained from surface plasmon resonance experiments.[25] 
Interestingly, even antagonist 11 that binds to FimH-CRD with a 
largely diminished affinity of 83 µM (Table 2) was found to be in 
slow or intermediate exchange. Slow exchange kinetics may be a 
hint to conformational rearrangements during complex formation. 
 
Figure 2. Chemical shift changes of FimH-CRD backbone amide signals upon addition of FimH antagonists. a) Absolute combined 
chemical shift changes ΔδAVG of 1, 8 and 10. b),c) Differential CSP effects ΔΔδAVG of aliphatic (b) and aromatic (c) ligands relative to 1,5-
anhydromannitol (10). Secondary structure elements are schematized on top. Residues missing from the chart are Phe1 (N-terminus), 
11 prolines (residues 12, 26, 49, 83, 85, 91, 102, 104, 111, 157 and 162), Gly79, Asn96 and Arg98 (not observed), Asp47, Tyr108 and 
Phe142 (overlap), Ser139 (exchange broadening), as well as the C-terminal 6His-tag (residues His168 to His173). 
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For the non-overlapping signals in the 1H,15N-HSQC spectra, 
combined chemical shift changes, ΔδAVG, with respect to the 
protein signals in absence of ligand were determined (Figure 2a). 
1,5-anhydromannitol (10) is the smallest structural motif that still 
shows specific binding to the mannose pocket of FimH-CRD. Its 
CSP effects were therefore used to calculate differential CSP 
effects, ΔΔδAVG, for the other ligands that should reflect mainly the 
influence of the aglycone moieties (Figure 2b,c). In presence of 
antagonists 1 to 11, FimH-CRD displayed chemical shift changes 
for residues around the known mannose binding site. Only minor 
CSP effects below 0.1 ppm were observed for residues distal 
from this site. Since proton chemical shifts are highly sensitive to 
changes in hydrogen bond length,[18] global conformational 
changes of FimH-CRD in response to antagonist binding can be 
excluded considering that the protein is comprised in large part of 
antiparallel beta sheets forming numerous hydrogen bonds.[22] 
The observation is in agreement with the high structural similarity 
of the X-ray co-crystal structures discussed above. In presence of 
the “core” motif 10, significant ΔδAVG values above 0.1 ppm were 
observed for (in order of decreasing ΔδAVG) Tyr48, Asn138, Thr53, 
Asn136, Asp54, Val56, Cys3, Tyr55, Asp47, Tyr95, Ile52, Ile13, 
Gly14, Thr134 and Asn46. Most of these residues are directly 
constituting the binding pocket, in particular residues from the 
loop regions between beta sheets A’ and A2 (Ile11 to Gly16), B2 
and C (Asn46 to Val56) as well as F and G (Arg132 to Phe144). 
Of these, Tyr48, Ile52 and Tyr137 form the tyrosine gate that is 
known to interact with the aglycone moieties of FimH antagonists. 
In addition, CSP effects were observed for residues Ala2 and 
Cys3 from the bottom of the binding pocket, and for Tyr95 that 
forms a hydrogen bond with the pocket residue Asp54. For most 
residues, only very small ΔΔδAVG values were observed . Larger 
deviations were observed for loop residues around Tyr137 in 
presence of 11 (see later discussion) and for loop residues 
around Tyr48. 
CSP data report on the Tyr48 side chain conformation. 
The strongest and most heterogeneous chemical shift changes of 
FimH-CRD with different antagonists were observed for the loop 
residues Tyr48, Glu50, Thr51, Ile52 and Thr53 (Figures 2 and 3). 
In the X-ray structures of FimH-CRD co-crystallized with 1, 2 and 
4 to 7, the Tyr48 side chain directly interacts with the aglycone 
moieties and adopts a significantly different orientation compared 
to that in the “pseudo-apo” X-ray structure[20] and in a recently 
solved NMR solution structure[19] (Figure S2). Apart from Tyr48, 
the conformation of the loop residues is remarkably conserved in 
all FimH-CRD crystal structures. This includes hydrogen bonds 
between Tyr48 HN and Asn46 Oδ1, between Glu50 HN and its side 
chain oxygen (stabilized by interaction with the guanidinium group 
of Arg98, Figure S3) and between Thr51 HN and Tyr48 O. We 
hypothesized that the observed backbone CSP effects of Tyr48 to 
Thr53 reflect mainly the conformational change of the Tyr48 side 
chain rather than direct ligand effects. In general, aromatic rings 
dramatically influence the chemical shifts of nearby nuclei through 
a local magnetic field induced by their delocalized π electrons. For 
protons located on the outside of the ring, the local magnetic field 
is parallel to the external field causing a downfield shift (higher 
ppm values). In contrast, protons located inside or above the ring 
experience an opposing field and hence an upfield shift. For 
Tyr48 and Glu50, we observed strong downfield shifts of both 
proton and 15N chemical shifts in presence of antagonists while 
Thr51 experienced a strong proton upfield shift up to 1 ppm and 
above (Figure 3). The shifts were larger for aromatic compared to 
aliphatic aglycones. In the open conformation seen in the 
“pseudo-apo” crystal structure[20] the Tyr48 ring is relatively far 
away from the loop residues. In the closed conformation, it is 
rotated towards the loop such that Glu50 HN comes closer and 
within 30° of the ring plane where it experiences a strong 
deshielding aromatic ring current. In contrast, Thr51 HN is pointing 
nearly directly into the ring in a T-shaped orientation where a 
strong shielding field causes upfield shifts.[26] Previous studies 
demonstrated that T-shaped N-H/π interactions can significantly 
contribute to ligand binding affinities.[27] Enhancement of the 
aromatic ring current effect by π-π stacking provides the 
explanation for the generally larger CSP effects observed for 
aromatic compared to aliphatic antagonists. Importantly, Glu50 
and Thr51 show nearly no shifts in presence of 10 strongly 
indicating that FimH-CRD remains in the unperturbed open 
conformation. 
 
Figure 3. Chemical shift changes of the binding loop residues 
Tyr48, Glu50, Thr51, Ile52 and Thr53 in presence of antagonists 
1 to 11. Spectra in absence of ligand are colored in green. 
Signals corresponding to Tyr48 conformations a and b in Figure 4 
are marked by dashed and solid line boxes, respectively. 
A more detailed analysis of the CSP effects with aromatic 
antagonists allows even further differentiation of the Tyr48 
orientation in the closed conformation. The signals of Glu50 and 
Thr51 group together for compounds 2, 3, 4, 6 and 7 (Figure 3, 
dashed line boxes). With antagonist 5, slightly different shifts 
were observed suggesting a different orientation of Tyr48. 
Aliphatic compounds 1 and 8-11 cannot be directly compared to 
the aromatic antagonists, since the aromatic ring current effect of 
Tyr48 as the main source of the shifts is drastically different. In 
good agreement with the NMR results, the high-resolution X-ray 
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structure of FimH-CRD in complex with 5 shows a distinct 
orientation of the Tyr48 ring that is tilted by ca. 40° compared to 
the co-crystal structures with compounds 1, 2, 6 and 7 (Figure 4, 
bottom). This tilt is likely the result of the unique geometry of the 
nonplanar indolinylphenyl moiety of 5 and the propensity of the 
system to optimize the stacking interaction. Interestingly, in the 
co-crystal structure with biphenyl derivate 4 the electron density 
clearly allows positioning of the Tyr48 ring in both conformations 
(Figure 4). We cannot find a confirmation for this in the NMR 
experiments, since only a single set of bound signals is observed 
with 3 and the CSP effects are very similar to that with 
compounds 2 and 6 with a single Tyr48 orientation in the crystal 
structure. Nevertheless it is conceivable that Tyr48 can retain a 
certain degree of flexibility in the bound state (see later 
discussion on ITC data). NMR chemical shifts of the binding loop 
residues thereby would show an average of fast exchanging 
Tyr48 orientations in the complex. 
 
Figure 4. Orientation of the Tyr48 side chain in FimH-CRD crystal 
structures. Top: Loop residues Tyr48 to Thr53 in the co-crystal 
structure with 1 (backbone in cyan, amides shown as spheres); 
Tyr48 side chain in the “pseudo-apo” structure[20] (green) and with 
1 (cyan), 2 (pale green), 6 (dark blue) and 7 (salmon). Bottom: 
Different Tyr48 orientations (a and b) with 2, 4 and 5. 
Water coordination in the FimH binding pocket. Some 
CSP effects are expected to be due to direct interactions of the 
protein with the mannosyl moiety. X-ray structural data implicate 
the formation of a direct hydrogen bond of Asp47 HN to Man OH6 
and of a water-mediated hydrogen bond of Gly14 HN to Man OH2 
(Figure 5). Against the expectation of a 1H downfield shift from 
deshielding upon hydrogen bond formation, both amide protons 
showed an upfield shift (Figure 5). This rather points to a 
weakening of an existing hydrogen bond. Although other more 
complex effects cannot be excluded, the results indicate that 
Gly14 and Asp47 coordinate water in absence of ligand that is 
replaced upon mannoside binding by the ligand’s polar groups in 
an effectively weaker hydrogen bond. The higher degree of 
freedom of water molecules may indeed allow hydrogen bonds 
with more ideal geometries compared to the ligand. In the X-ray 
co-crystal structures with antagonists 1, 2 and 4 to 7 the distance 
of the bridging water to Gly14 HN is 0.1 to 0.2 Å closer than in the 
“pseudo-apo” crystal structure in agreement with our hypothesis 
(Figure 5). Finally, molecular dynamics simulations confirmed the 
presence of a structural water molecule close to Gly14.[28] 
 
Figure 5. Water coordination in the FimH binding pocket. Top: X-
ray structures of “pseudo-apo” FimH-CRD (green sticks and 
transparent surface)[20] and in complex with 1 (yellow, asterisk 
indicates attachment point of aglycone); water molecules are 
shown as spheres; hydrogen bond lengths are given in Å. 
Bottom: Chemical shift changes of Asp47 (only assigned for non-
aromatic antagonists) and Gly14 (only subset of spectra shown). 
Hydrogen bond network in the binding loop with Tyr137. 
The loop residues Asn135 to Asp141 display similar CSP effects 
in presence of all tested antagonists except 11 (Figure 2). X-ray 
co-crystal structures revealed a complex interresidual hydrogen 
bond network between backbone and side chain atoms within this 
loop (Figure 6). For example, Asn138 HN forms a hydrogen bond 
to the side chain oxygen of Asn135. The strong deshielding of 
Asn138 HN in presence of ligand suggests a strengthening of this 
hydrogen bond (Figure 6). The shift could also result from a 
conformational change of the aromatic ring of Tyr137. However, 
Tyr137 HN displayed no or only very small shifts suggesting that 
its aromatic ring remains largely unchanged in agreement with 
very similar orientations in the X-ray structures. Furthermore, 
deshielding of Asp140 HN with all ligands except 1 and 9 indicate 
a slight shortening of the hydrogen bond to the side chain oxygen 
of Asn138 (Figure 6). In summary, mannoside coordination 
seems to induce subtle but specific conformational changes in the 
hydrogen bond network within the binding loop. The differences in 
the CSP effects of Asn135, Tyr137 and Asp141 with the 4-deoxy-
4-fluoro derivate 11 are hence causes by a different electronic 
environment of the fluorine atom that also compels a different 
loop arrangement through disruption of hydrogen bonds. The X-
ray structural data are not entirely conclusive on the effect of 
mannoside binding to the loop conformation. In all six co-crystal 
structures discussed above, the loop residues are well ordered, 
but hydrogen bonds in the loop are identical within error to that in 
the “pseudo-apo” structure. Apparently, very small conformational 
variations notably in an exposed loop cannot be resolved in the 
X-ray structures despite the relatively high resolution. 
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Figure 6. Hydrogen bond network in the binding loop with Tyr137. 
Top left: X-ray crystal structures of “pseudo-apo” FimH-CRD 
(green)[20] and in complex with 1 (yellow, attachment point of 
aglycone marked with an asterisk); observed hydrogen bonds: 
Asn135 Hδ22–Asn138 Oδ1, Tyr137 HN–Asn135 Oδ1, Asn138 HN–
Asn135 Oδ1, Asp140 HN–Asn138 Oδ1; with ligand: Man OH3–
Asp140 Oδ1, Asn135 Hδ21–Man O4. Bottom and right: Chemical 
shift changes of Asn138 and Asp140 with antagonists 1 to 11.  
Conformational changes in the pocket zipper motif. The 
CSP effects for Cys3 are unlikely to be caused by direct ligand 
effects considering its remote distance (>8.5 Å) from the bound 
mannose. In FimH-CRD, Cys3 is part of a highly structured and 
stable hydrogen bond network to neighboring beta strands further 
stabilized by a disulfide bond to Cys44 (Figure 7). This so-called 
“pocket zipper” motif is one of four regions that are suspected to 
play a key role in the conformational transition between the low 
and the high affinity states of in the full-length FimH.[6, 29] Upon 
transition to the high affinity state, the “pocket zipper” becomes 
tightly hydrogen bonded causing a constriction of the binding 
pocket.[6] The isolated lectin domain FimH-CRD is supposed to be 
locked in the high-affinity state. In the CSP experiments with 
FimH antagonists, we observed relatively uniform downfield shifts 
for Cys3 HN that forms a hydrogen bond to the backbone oxygen 
of Ile11 (Figure 7). A similar albeit smaller effect was seen for 
Ile11 HN that forms an adjacent hydrogen bond to the Cys3 
backbone oxygen. This suggests a strengthening of the hydrogen 
bonds, although a contribution of nearby aromatic rings, in 
particular of Phe144 (ca. 3 Å from Cys HN) seems also possible. 
In the six FimH-CRD crystal structures discussed above the 
hydrogen bond Cys3 HN–Ile11 O is 0.2 to 0.3 Å shorter than in 
the “pseudo-apo” structures in agreement with the CSP effects 
(Figure 7). It is again emphasized that such subtle differences are 
difficult to substantiate even from high-resolution X-ray structures. 
A strengthening of the “pocket zipper” upon ligand binding could 
point to a residual conformational transition of FimH-CRD. 
However, we observed no CSP effects in the other allosteric 
regions confirming that the isolated lectin domain is not 
undergoing significant conformational adaptions characteristic for 
the full-length protein. Corresponding NMR solution studies of 
full-length FimH would be highly desirable but have so far been 
hampered by limited protein yield and stability. 
 
Figure 7. Conformational changes in the pocket zipper motif. Left: 
Chemical shift changes of Cys3 and Ile11 in presence of 1 to 11. 
Right: X-ray crystal structures of “pseudo-apo” FimH-CRD 
(green,)[20] and in complex with 1 (yellow); hydrogen bond lengths 
are given in Å; aromatic residues in the vicinity are shown as lines. 
Thermodynamics data from ITC experiments 
FimH antagonists 1 to 11 have been subjected to ITC analysis 
with FimH-CRD (Table 2 and Table S2). To obtain reliable 
thermodynamics data, the high affinity of some of the compounds 
required the establishment of a competitive ITC assay[30] (see 
supporting information for details). The results indicate that all 
tested antagonists bind enthalpy-driven with mostly unfavorable 
entropic contributions in accordance with previous studies.[10i, 10m, 
20] The enthalpy term ΔH°obs=-42.9 kJ/mol of 1,5-anhydromannitol 
(10) contains the binding energies from van der Waals contacts 
and ten specific hydrogen bonds with the protein.[10c, 11] These 
favorable terms are partly compensated by enthalpic penalties 
from desolvation of ligand and protein. The enthalpic cost for 
desolvation of a single hydroxyl group had been estimated at 
29 kJ/mol.[31] On the protein side, X-ray and NMR data and 
molecular dynamics simulations found evidence for highly 
structured hydrogen-bonded water in the binding pocket that is 
replaced by the hydroxyl groups of the ligand. The classic 
hydrophobic effect predicts a strong entropic gain for the release 
of bound water upon complex formation.[32] However other studies 
also suggested an enthalpy-driven “non-classical” hydrophobic 
effect that is usually explained by water being forced into an 
enthalpically unfavorable configuration in the binding pocket.[33] 
The entropy term of 10 suggest that any entropic gain from the 
release of water into the bulk is overcompensated by unfavorable 
contributions such as the loss of rotational and translational 
entropy of the ligand (estimated at ca. 25 kJ/mol in aqueous 
solutions)[34] as well as conformational restriction of ligand and 
protein in the complex. Relevant for the latter is the formation of 
several hydrogen bonds that reduce the flexibility of the ligand’s 
hydroxyl groups and the involved protein residues. Quantification 
of the individual entropic contributions is cumbersome and in fact 
still represents a major obstacle in current research.[33, 35] 
The ITC data for methyl α-D-mannoside (8) reveal a less 
favorable enthalpy (ΔΔH°obs: 5.7 kJ/mol) and a smaller entropy 
penalty (-TΔΔS°obs: -5.5 kJ/mol) compared to 10. The additional 
methoxy group of 8 is supposed to increase the binding enthalpy 
through van der Waals interactions with the protein (Ile13, Asp47 
and Tyr48 within 4 Å). The effective enthalpy loss is likely due to 
an additional desolvation penalty for the methoxy group, while the 
entropy gain reflects the release of additional water molecules 
Chapter 3.3. – Manuscript 5 !
! 227 
 
into the bulk. From NMR CSP experiments we also expect a 
change in the Tyr48 side chain conformation for all mannosides 
with methyl or larger aglycones. The implications for the 
thermodynamics depend on whether the complex formation 
follows an induced fit mechanism or conformational selection or a 
mixture of both. In a recent solution NMR study of FimH-CRD, 15N 
relaxation and CPMG relaxation dispersion experiments of the 
backbone amides did not provide any indication for multiple 
conformations of Tyr48 in the apo protein neither for a significant 
change in the backbone flexibility in presence of 1.[19] The data 
therefore rather argue for an induced-fit mechanism of the 
tyrosine gate instead of conformational selection. Nevertheless, 
conformational equilibria of Tyr48 in the apo state may exist in a 
time scale not easily accessible by NMR experiments (µs to ms). 
Elongation of the aglycone from methyl (8) to butyl (9) and heptyl 
(1) led to significant improvement of the binding enthalpy due to 
the enhanced C-H/π interaction of the elongated alkyl chain with 
the Tyr48 ring. An expected improvement of the entropy term 
from the release of more water into the bulk is observed for 9 but 
not for 1 that even shows a loss of entropy compared to 8. We 
supposed that the stacking interaction of the heptyl chain of 1 
with Tyr48 leads to rigidification of both interaction partners and 
hence to significant entropic costs. For compound 11, the 4-
deoxy-4-fluoro analog of 1, a significantly smaller enthalpy term 
was observed as expected from the disruption of the hydrogen 
bonds in the 4-position. The CSP experiments also indicated 
structural changes in the binding loop containing Tyr137 that can 
translate into enthalpic costs. Interestingly, the entropy is 
improved by more than 9 kJ/mol in comparison to 1 likely due to 
the higher flexibility of the protein binding pocket and the ligand. 
For aromatic antagonists 2 to 7, strongly favorable enthalpy 
terms ranging from -45.0 to -71.8 kJ/mol were obtained. Again, an 
increase in enthalpy is always accompanied by an increase of 
entropic costs as becomes obvious in the enthalpy-entropy 
compensation plot (Figure S4). X-ray structure data indicate that 
the outer aromatic rings of antagonists 2 and 4-7 make parallel-
displaced π-π interactions with the Tyr48 ring in the closed 
conformation in analogy to the C-H/π interaction of the heptyl 
chain of 1. However, a direct comparison of the ITC data of 
aliphatic and aromatic antagonists is difficult in view of the large 
structural difference of the aglycones and because of the many 
contributing factors. The unsubstituted biphenyl mannoside 2 
displayed the smallest enthalpy term and likewise the smallest 
entropic penalty of all aromatic antagonists. For the substituted 
biphenyls 3 and 4 we observed a significant increase of the 
enthalpy by 11.2 and 15.9 kJ/mol, respectively, in comparison to 
2. First, the ortho-chloro substituent is assumed to enhance the 
binding enthalpy by favorable van der Waals interactions with the 
protein in a small pocket formed by Ile52, Tyr137 and Asn138.[10i] 
Second, the electron-withdrawing character of the substituents 
allows a stronger π-π interaction of the aglycones with the Tyr48 
ring. As already suggested for the comparison of 1 with 8, a 
stronger stacking interaction likely accounts for a reduced 
flexibility in both the Tyr48 side chain and the aglycone leading to 
compensating entropic penalties. For antagonist 5, the enthalpy is 
slightly better than for the best biphenyl compound 4. The entropy 
compensation is only partial resulting in the strongest dissociation 
constant of all tested antagonists. Compounds 6 and 7 display 
the most favorable enthalpies but also the highest entropic 
penalties. 6 could suffer from entropic costs for rigidification of 
additional rotatable bonds in the aglycone moiety. 7 is structurally 
very similar to biphenyl 3 apart from insertion of an amid bond 
linkage. The dramatically enhanced enthalpy (ΔΔH°obs: 
-15.6 kJ/mol) and entropic costs (-TΔΔS°obs: 17.0 kJ/mol) of 7 
compared to 3 can only be explained by a very efficient stacking 
interaction with Tyr48 and subsequent loss of conformational 
entropy in the complex. From comparison of all ITC data it 
becomes clear, that the antagonist with the highest enthalpic 
contribution presumably from the strongest stacking interaction 
with Tyr48 is not necessarily the strongest binder. Antagonist 5 
exhibits the best thermodynamic profile, although its enthalpy 
term is nearly 10 kJ/mol weaker than that of 7. From the NMR 
and X-ray data we deduced a distinct orientation of Tyr48 in 
presence of 5 likely as a result of the unique geometry of its 
indolinylphenyl aglycone. We assume that this complex 
conformation is optimal in terms of interaction efficiency and 
minimized compensating entropic penalties. However, with regard 
to the pharmacokinetic profiles of FimH-antagonists, biphenyl 
mannoside 4 was identified as the optimal lead compound for oral 
treatment of UTI as described in a separate publication.[10m] 
 
Table 2. Thermodynamics of FimH antagonists binding analyzed by ITC. 
Compd KD [nM] 
ΔG°obs 
[kJ/mol] 
ΔH°obs 
[kJ/mol] 
-TΔS°obs 
[kJ/mol] 
1[a] 28.9 (25.8 – 32.3) -43.0 -50.3 (-50.2 – -50.7) 7.3 
2[a] 17.7 (14.1 – 22.3) -44.2 -45.0 (-44.5 – -45.6) 0.8 
3[b] 3.5 (2.7 – 4.6) -48.3 -56.2 (-55.9 – -56.6) 8.0 
4[b] 1.3 (1.1 – 1.5) -50.7 -60.9 (-60.5 – -61.3) 10.1 
5[b] 1.0 (0.7 – 1.4) -51.3 -62.1 (-61.5 – -62.7) 10.8 
6[a] 14.0 (12.7 – 15.4) -44.8 -63.6 (-63.2 – -64.0) 18.8 
7[a] 6.2 (5.1 – 7.6) -46.8 -71.8 (-71.0 – -72.7) 25.0 
8[a] 1222 (1064 – 1403) -33.8 -37.2 (-36.4 – -38.0) 3.5 
9[a] 144 (127 – 163) -39.1 -39.1 (-38.6 – -39.7) 0.1 
10[a] 1125 (980 – 1292) -34.0 -42.9 (-42.1 – -43.8) 9.0 
11[a] 89990 (86140 – 94020) -23.1 -21.1 (-20.8 – -21.6) -2.0 
[a] Direct ITC assay format. 
[b] Competitive ITC assay format using a medium-affinity ligand. 
Conclusion 
We have combined NMR chemical shift perturbation (CSP) 
experiments with high-resolution X-ray structures to elucidate the 
interaction of the FimH lectin domain with antagonists in great 
detail. One advantage of NMR spectroscopy is the ability to 
identify even subtle conformational changes of the protein in 
solution. This is particularly helpful for the determination of ligand 
binding modes in cases where crystallization was unsuccessful or 
crystal packing effects may influence the protein and ligand 
conformation. We demonstrated that the CSP effects of FimH-
CRD can be used as an indicator for the conformation of the 
tyrosine gate motif in the binding pocket. The open conformation 
was observed in the apo protein and with 1,5-anhydromannitol 
(10), while antagonists with aliphatic or aromatic aglycones bound 
the closed conformation in agreement with X-ray structural data. 
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The CSP data even revealed slight differences in the Tyr48 
conformation as a result of different aglycone geometries. 
Furthermore, the NMR results report on the presence of highly 
structured water in the binding pocket of FimH-CRD. In 
combination with information from crystal structures and 
molecular modeling, CSP experiments therefore may help to 
analyze water coordination as an important contributor to the 
thermodynamics of ligand binding. 
We also performed ITC experiments to access full 
thermodynamic profiles of the antagonists. The results suggest 
enthalpy-entropy compensation in which enthalpically favorable 
stacking of hydrophobic aglycones with the Tyr48 side chain 
leads to conformational restriction of both the protein and the 
ligand and hence to unfavorable entropy. NMR relaxation 
experiments of the backbone amide signals of FimH-CRD did not 
show any changes in the backbone flexibility upon antagonists 
binding. However, we suppose that flexibility of the protein side 
chains, in particular of Tyr48, could play a pivotal role in the 
modulation of the thermodynamics of FimH-antagonist binding. 
These effects can be dissected by NMR relaxation experiments 
for side chain dynamics and incorporation of the results into 
rational design may lead to further improved FimH antagonists 
urgently needed for the therapy of UTI. 
Experimental Section 
Protein preparation: FimH-CRD from the E.coli K-12 strain was 
expressed with a C-terminal thrombin cleavage site and a 6His-tag 
(FimH-CRD-Th-6His, 173 residues) following a previously published 
protocol.[13] The clone containing the FimH-CRD construct was 
expressed in protease-deficient E.coli HM 125 at 30°C and 180 rpm in 
M9 minimal medium supplemented with 100 µg/mL ampicillin. The 
protein expression was induced by 1 mM IPTG at an OD600 of 0.8. 
The cells were further cultivated for 16 h, harvested by centrifugation 
for 20 min at 5000 rpm and 4°C. The pellet was resuspended in lysis 
buffer containing 50 mM Tris pH 7.4, 150 mM NaCl, 5 mM EDTA and 
1 mg/mL polymyxin B sulfate. The supernatant containing the 
periplasmic extract was dialyzed against sodium phosphate buffer 
and purified on Ni-NTA columns. For crystallization, the protein was 
dialyzed against 20 mM HEPES buffer pH 7.4. For production of 15N- 
and 13C,15N-labeled FimH-CRD-Th-6His for NMR experiments, E.coli 
HM 125 was cultivated in M9 minimal medium containing 1 g/L 
15NH4Cl or 1 g/L 15NH4Cl and 2 g/L 13C-glucose (Sigma, Switzerland ) 
as the only sources of nitrogen and carbon, respectively. The labeled 
proteins were purified as described above and dialyzed against 
25 mM phosphate buffer pH 6.8 (13C,15N-FimH-CRD) or 20 mM 
phosphate buffer pH 7.0 (15N-FimH-CRD). The purity of the proteins 
was verified by non-reducing SDS-PAGE analysis, and the 
concentration was determined by UV absorption (NanoDrop ND-1000, 
Thermo Scientific). The molecular weight was determined by mass 
spectrometry for 15N-FimH-CRD (18860.2 Da) and 13C,15N-FimH-CRD 
(19687.0 Da) demonstrating an isotope incorporation of > 99.9%. 
NMR spectroscopy: NMR assignment experiments were measured 
at 298 K on a Bruker Avance III 700 MHz NMR spectrometer 
equipped with a 5 mm QCI-P cryogenic probe. A set of triple 
resonance NMR spectra of a 600 µM sample of 13C,15N-FimH-CRD in 
25 mM phosphate buffer pH 6.8, 90%/10% H2O/D2O in a 5 mm 
Shigemi Tube (Shigemi Inc., USA) was recorded for backbone 
assignment: HNCA, HN(CO)CA, HNCO, HN(CA)CO, HNCACB and 
CBCA(CO)NH. Protein stability during data acquisition was tested via 
regular inspection of 1D 1H and 1H,15N-HSQC NMR spectra. Spectra 
were acquired and processed with Topspin 3.2 (Bruker BioSpin, 
Switzerland). CcpNmr Analysis (versions 2.2 and 2.3) was used for 
NMR resonance assignment.[36] The backbone assignment of FimH-
CRD has been deposited in the Biological Magnetic Resonance Data 
Bank (http://www.bmrb.wisc.edu). 
Chemical shift perturbation (CSP) experiments with FimH antagonists 
were performed with 100 to 200 µM 15N-FimH-CRD in 20 mM non-
deuterated phosphate buffer pH 7.0. FimH antagonists were solved in 
D2O at 2.5 to 100 mM stock concentrations. Biphenyl compound 4 
was solved at 6.3 mM in D2O with 40% of DMSO-d6 due to poor 
solubility. The antagonists were added at slight molar excesses to 
ensure complete saturation of the protein. NMR samples were 
prepared in 3 mm NMR tubes (Hilgenberg, Germany) with 5% D2O 
and d4-TSP ((3-(trimethylsilyl)-2,2’,3,3’-tetradeuteropropionic acid) 
added as internal reference. 1H,15N-HSQC spectra were measured on 
a Bruker Avance III 500 MHz spectrometer equipped with a BBO 
double resonance probe at 298 K. Spectra were acquired and 
processes with Topspin 2.1 and analyzed with CcpNmr Analysis 
(versions 2.2 and 2.3). All antagonists bound in the slow exchange 
regime and amide signals of the bound protein were assigned from 
chemical shift proximity and matching peak intensity. Combined 
chemical shift changes of FimH-CRD signals were calculated as 
weighted average of 1H and 15N chemical shift changes according to 
the equation ∆!!" = (∆!!!!)! + (0.2∆! !!" )!.[37] 
FimH-antagonists co-crystallization: For crystallization trials, FimH-
CRD (residues 1-158) at a final concentration of 18 mg/mL (ca. 1 mM) 
with a fivefold molar excess of ligand (5 mM) in 20 mM HEPES buffer 
pH 7.4 was used. Crystals were grown in sitting-drop vapor diffusion 
at 20°C as described before[10m] Precipitation solutions were 
determined by PEG/ION HT screen (Hampton Research, USA) and 
details for every crystal are given in the supporting information. In 
some cases streak seeding was performed with crystal seeds of 
FimH-CRD and compound 5 grown after one week. Crystals 
appeared within 24 h or in case of compound 6 after 4 weeks. 
Crystals were flash-cooled to 100 K with perfluoropolyether cryo oil 
(Hampton Research, USA). Data was collected with synchrotron 
radiation at the PXIII beamline of the Swiss Light Source (Paul 
Scherrer Institute, Switzerland). 
Structure determination and refining: Data was indexed, integrated 
and scaled with XDS.[38] Structures were solved by molecular 
replacement with PHASER[39] using the FimH-CRD-n-butyl  -D-
mannopyranoside complex (PDB ID: 1UWF[10c]) as search model. The 
structures were built using the COOT software[40] and periodically 
refined with the PHENIX software.[41] Geometric restraints for the 
ligands were generated with PRODRG.[42] Molprobity[43] was used to 
validate the available atomic coordinates and to add protons for 
distance calculation. The structures were submitted to the Protein 
Data Bank with PDB codes 4X50 (2), 4X5Q (5), 4X5R (6) and 4X5P 
(7). 
Isothermal titration calorimetry (ITC): All ITC experiments were 
performed with FimH-CRD-Th-6His using a MicroCal VP-ITC 
instrument (Malvern Instruments Ltd, Worcestershire, UK) with a 
sample cell volume of 1.4523 mL. Measurements were performed at 
25°C with a stirring speed of 307 rpm and 10 µcal/s reference power. 
The protein was dialyzed against assay buffer (10 mM HEPES, 
150 mM NaCl, pH 7.4). Injections of 3-12 µL ligand solution were 
added in 10 min intervals to the sample cell containing 5-50 µM 
protein. The c-values (c = Mt(0) KD–1, where Mt(0) is the initial protein 
concentration) were in a reliable range within 5 and 1’000 for 
compounds 1, 2 and 6-10. For compounds 3, 4, and 5 the c-values of 
the direct titrations were above 1’000 and therefore additional 
competitive ITC experiments were performed.[30] The ligands were 
titrated into protein preincubated with an 8 to 9-fold excess of 
compound 12 (structure and synthesis in supporting information) 
resulting in sigmoidal titration curves. For the low affinity compound 
11 the c-value was only 0.5, but reliable thermodynamics data could 
be extracted by fixing the stoichiometry to 1.0. Baseline correction 
and peak integration was performed using the Origin 7 software 
(OriginLab, USA). Baseline subtraction and curve fitting with the three 
variables N (concentration correction factor), KD (dissociation 
constant), and ∆H° (change in enthalpy) were performed with 
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SEDPHAT version 10.40 (National Institute of Health).[44] Global fitting 
to obtain KD values was performed for the competitive titrations of 
compound 12 with 3, 4 and 5 and for the direct titration of 12. ∆H° and 
N were then obtained from fitting of the direct titrations of 3, 4 and 5. 
For directly titrated compounds 1, 2 and 6-11 all three variables were 
determined from a global analysis. The 95 %-confidence intervals of 
KD and ∆H° were calculated with the 1-dimensional error surface 
projection. ∆G° and -T∆S° (change in entropy) were calculated using 
the equation ∆!° = ∆!° − !∆!° = −!"#$!! with T being the absolute 
temperature and R the universal gas constant (8.314 J mol-1 K-1). 
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Synthesis of compound 7 
!  
Scheme S1. a) H2 (1 atm), cat. PtO2, morpholine, MeOH, rt, 2 h (94%); b) cat. DMAP, pyridine, 0 °C 
to rt, 19 h (96%); c) i. NaOMe/MeOH, rt, 3 h; ii. NaOH, H2O/dioxane, rt, 16 h (56%). 
4-Amino-2-chlorophenyl 2,3,4,6-tetra-O-acetyl-α-D-mannopyranoside (15). A suspension of 14[S1] 
(2.00 g, 3.97 mmol), morpholine (200 µL) and PtO2 (100 mg) in MeOH (20 mL) was hydrogenated (1 
atm H2) for 2 h. Then the mixture was filtered and concentrated in vacuo. The residue was purified by 
MPLC on silica (petroleum ether/EtOAc) to yield 15 (1.76 g, 94%) as colorless foam. 1H NMR (500 
MHz, CDCl3): δ = 2.03, 2.06, 2.06, 2.18 (4 s, 12H, 4 COCH3), 4.10 (dd, J = 1.8, 11.7 Hz, 1H, H-6a), 
4.24 (ddd, J = 2.0, 5.4, 9.9 Hz, 1H, H-5), 4.28 (dd, J = 5.4, 11.8 Hz, 1H, H-6b), 5.36 (t, J = 10.0 Hz, 
1H, H-4), 5.39 (d, J = 1.7 Hz, 1H, H-1), 5.51 (dd, J = 1.9, 3.4 Hz, 1H, H-2), 5.58 (dd, J = 3.5, 10.0 Hz, 
1H, H-3), 6.69 (dd, J = 2.6, 8.7 Hz, 1H, Ar-H), 6.91 (d, J = 2.6 Hz, 1H, Ar-H), 7.01 (d, J = 8.8 Hz, 1H, 
Ar-H); 13C NMR (125 MHz, CDCl3): δ = 20.7, 20.7, 20.9 (4C, 4 COCH3), 62.2 (C-6), 65.9 (C-4), 68.8 
(C-3), 69.4 (C-2), 69.6 (C-5), 97.6 (C-1), 116.0, 118.7, 119.2, 125.6, 145.8 (6C, Ar-C), 169.8, 169.9, 
170.5 (4C, 4 CO); ESI-MS: m/z: Calcd for C20H25ClNO10 [M+H]+: 474.1, found: 474.1. 
 
Methyl 4-[(4-(2,3,4,6-tetra-O-acetyl-α-D-mannopyranosyloxy)-3-chlorophenyl)carbamoyl]-
benzoate (17). To a solution of 15 (200 mg, 0.422 mmol) and DMAP (10 mg) in pyridine (10 mL) was 
added methyl 4-chlorocarbonylbenzoate (16, 126 mg, 0.636 mmol) at 0 °C under argon. The mixture 
was stirred at rt for 19 h and then concentrated. The remains were dissolved in DCM (20 mL) and 
subsequently washed with 0.1 N aq. HCl (10 mL) and satd aq. NaHCO3 (10 mL). The organic layer 
was dried on Na2SO4, filtered and concentrated. The residue was purified by MPLC on silica 
(petroleum ether/EtOAc) to afford 17 (258 mg, 96%) as a colorless foam. [α]D +63.0 (c 1.38, CHCl3); 
1H NMR (500 MHz, CDCl3): δ = 2.02, 2.05, 2.06, 2.19 (4 s, 12H, 4 COCH3), 3.94 (s, 3H, OMe), 4.09 
(dd, J = 2.0, 12.1 Hz, 1H, H-6a), 4.20 (ddd, J = 2.0, 5.2, 9.9 Hz, 1H, H-5), 4.28 (dd, J = 5.3, 12.1 Hz, 
1H, H-6b), 5.38 (t, J = 10.1 Hz, 1H, H-4), 5.50 (s, 1H, H-1), 5.52 (dd, J = 1.7, 3.3 Hz, 1H, H-2), 5.58 
(dd, J = 3.4, 10.0 Hz, 1H, H-3), 7.15 (d, J = 8.9 Hz, 1H, C6H3), 7.53 (dd, J = 1.9, 8.9 Hz, 1H, C6H3), 
7.77 (d, J = 2.3 Hz, 1H, C6H3), 7.90 (d, J = 8.3 Hz, 2H, C6H4), 8.10 (d, J = 8.0 Hz, 2H, C6H4), 8.15 (s, 
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1H, NH); 13C NMR (125 MHz, CDCl3): δ = 20.6, 20.7, 20.8, 21.0 (4 COCH3), 52.5 (OMe), 62.1 (C-6), 
65.8 (C-4), 68.8 (C-3), 69.3 (C-2), 69.7 (C-5), 97.0 (C-1), 117.7, 119.8, 122.6, 124.8, 127.1, 130.0, 
133.1, 133.8, 138.3, 148.2 (12C, C6H3, C6H4), 164.8 (CONH), 166.1 (CO2Me), 169.7, 169.8, 170.0, 
170.6 (4 COCH3); ESI-MS: m/z: Calcd for C29H30ClNNaO13 [M+Na]+: 658.1, found: 658.1. 
 
Sodium 4-[(3-chloro-4-(α-D-mannopyranosyloxy)phenyl)carbamoyl]benzoate (7). To a solution 
of 17 (29.0 mg, 45.6 µmol) in MeOH (4 mL) was added 1 M NaOMe/MeOH (0.4 mL) under argon. The 
mixture was stirred at rt for 3 h and then concentrated in vacuo. The residue was dissolved in 
H2O/dioxane (4 mL, 1:1) and treated with 1 M aq. NaOH (0.4 mL) for 16 h. The mixture was 
neutralized with 1 M aq. HCl and evaporated. The residue was purified by preparative LC-MS (RP-18, 
H2O/MeCN + 0.2% HCO2H) to give the acid form of 17. The acid was dissolved in 0.1 M aq. NaOH (1 
mL) and re-purified by size-exclusion chromatography (P2 column, H2O) to yield 17 (11.5 mg, 56%) 
as a white powder after a final lyophilization from H2O. [α]D +63.8 (c 0.27, MeOH); 1H NMR (500 MHz, 
CD3OD): δ = 3.68 (ddd, J = 2.1, 5.4, 9.7 Hz, 1H, H-5), 3.73 (dd, J = 5.4, 11.8 Hz, 1H, H-6a), 3.76 (t, J 
= 9.6 Hz, 1H, H-4), 3.80 (dd, J = 2.1, 11.8 Hz, 1H, H-6b), 3.98 (dd, J = 3.4, 9.4 Hz, 1H, H-3), 4.11 (dd, 
J = 1.8, 3.3 Hz, 1H, H-2), 5.51 (d, J = 1.5 Hz, 1H, H-1), 7.37 (d, J = 9.0 Hz, 1H, C6H3), 7.56 (dd, J = 
2.5, 8.9 Hz, 1H, C6H3), 7.89 (d, J = 2.5 Hz, 1H, C6H3), 7.99 (d, J = 8.4 Hz, 2H, C6H4), 8.14 (d, J = 8.4 
Hz, 2H, C6H4); 13C NMR (125 MHz, CD3OD): δ = 62.7 (C-6), 68.3 (C-4), 71.9 (C-2), 72.4 (C-3), 75.9 
(C-5), 101.2 (C-1), 118.8, 121.7, 123.9, 124.9, 128.7, 130.9, 135.0, 135.1, 140.0, 150.2 (12C, C6H3, 
C6H4), 167.8, 168.9 (CONH, CO2); HR-MS: m/z: Calcd for C20H20ClNNaO9 [M+H]+: 476.0719, found: 
476.0725. 
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Synthesis of compound 11 
 
Scheme S2. a) DAST, pyridine, DCM, -30 °C to rt, overnight (66%); b) NaOMe/MeOH, rt, 3 h (97%); 
c) TBDPSCl, imidazole, DMF, 3.5 h (83%); d) Tf2O, pyridine, DCM, -18 to -10 °C, 1.5 h, then AcCl, -8 
°C to rt, 1 h (96%); e) CsOAc, 18-crown-6, toluene, reflux, 2.5 h (59%); f) 4% H2SO4/Ac2O, rt, 
overnight (98%); g) Me2NH/THF, rt, 3 h (70%); h) trichloroacetonitrile, NaH, DCM (91%); i) n-heptanol, 
TMSOTf, DCM, rt, 2 h (27: 25%, 28: 32%) ; j) NaOMe/MeOH, rt, overnight (92%). 
Methyl 2,3,6-tri-O-benzoyl-4-deoxy-4-fluoro-α-D-glucopyranoside (19).[S2] A solution of methyl 
2,3,6-tri-O-benzoyl-α-D-galactopyranoside (18,[S2] 5.06 g, 10.0 mmol) in dry DCM (10.0 mL) was 
added to a mixture of pyridine (2.5 mL) and DAST (1.7 mL) in dry DCM (25 mL) at -30 °C. After 
stirring at rt overnight, the reaction mixture was cooled to 0 °C, quenched with MeOH and 
concentrated. The residue was purified by MPLC on silica (petroleum ether/EtOAc, 15:1-9:1) to afford 
19 (3.36 g, 66%) as white foam. 1H NMR (500 MHz, CDCl3): δ = 3.47 (s, 3H, OCH3), 4.33 (m, 1H, H-
5), 4.63 (ddd, J = 1.0, 5.0, 12.0 Hz, 1H, H-6a), 4.72 (m, 1H, H-6b), 4.77 (dt, J = 9.5, 51.0 Hz, 1H, H-4), 
5.18 (t, J = 3.5 Hz, 1H, H-1), 5.21 (dd, J = 3.5, 10.0 Hz, 1H, H-2), 6.14 (ddd, J = 9.5, 10.0, 14.5 Hz, 
1H, H-3), 7.38 (m, 4H, Ar-H), 7.50 (m, 4H, Ar-H), 7.61 (m, 1H, Ar-H), 8.00 (m, 4H, Ar-H), 8.10 (m, 2H, 
Ar-H); 19F NMR (470 MHz, CDCl3): δ = -197.0. 
 
Methyl 4-deoxy-4-fluoro-α-D-glucopyranoside (20). To a suspension of 19 (3.36 g, 6.60 mmol) in 
dry MeOH (30 mL) was added 0.5 M NaOMe/MeOH (1.98 mL, 0.99 mmol) at rt. The reaction mixture 
was stirred at rt for 3 h, then neutralized with Amberlyst-15, filtered and concentrated. The residue 
was purified by MPLC on silica (DCM/MeOH, 20:1-9:1) to afford 20 (1.26 g, 97%) as a white solid, 
which was directly used in the next step. 
 
Methyl 6-O-tert-butyldiphenylsilyl-4-deoxy-4-fluoro-α-D-glucopyranoside (21). To a solution of 
20 (227 mg, 1.16 mmol) and imidazole (177 mg, 2.6 mmol) in dry DMF was added TBDPSCl (0.34 
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mL, 1.30 mmol) at rt. The reaction mixture was stirred for 3.5 h at rt under argon, then diluted with 
DCM, washed with 0.1 N HCl and brine, dried over Na2SO4, filtered and concentrated in vacuo. The 
residue was purified by MPLC on silica (DCM/MeOH, 15:1-9:1) to provide 21 (422 mg, 83%) as a 
colorless oil. [α]D +67.9 (c 1.80, CHCl3); 1H NMR (500 MHz, CDCl3): δ = 1.05 (s, 9H, C(CH3)3), 2.33 
(d, J = 9.0 Hz, 1H, 2-OH), 2.86 (m, 1H, 3-OH), 3.57 (td, J = 4.0, 9.5 Hz, 1H, H-2), 3.46 (s, 3H, OCH3), 
3.77 (m, 1H, H-5), 3.88 (m, 2H, H-6), 3.96 (m, 1H, H-3), 4.43 (dt, J = 9.5, 51.0 Hz, 1H, H-4), 4.80 (t, J 
= 3.5 Hz, 1H, H-1), 7.37-7.44 (m, 6H, Ar-H), 7.69 (m, 4H, Ar-H); 13C NMR (125 MHz, CDCl3): δ = 19.3 
(C(CH3)3), 26.7 (C(CH3)3), 55.3 (OCH3), 62.3 (C-6), 69.8 (d, J = 23.1 Hz, C-5), 72.2 (d, J = 7.8 Hz, C-
2), 73.2 (d, J = 17.4 Hz, C-3), 88.8 (d, J = 180.8 Hz, C-4), 98.7 (d, J = 1.3 Hz, C-1), 127.6, 127.7, 
129.7, 133.2, 133.2, 135.6, 135.6 (12C, Ar-C); 19F NMR (470 MHz, CDCl3): δ = -198.9; ESI-MS: m/z: 
Calcd for C23H31FNaO5Si [M+Na]+: 457.2, found: 457.1. 
 
Methyl 3-O-acetyl-6-O-tert-butyldiphenylsilyl-4-deoxy-4-fluoro-2-O-trifluoromethylsulfonyl-α-D-
glucopyranoside (22). To a solution of 21 (1.65 g, 3.79 mmol) and pyridine (1.23 mL, 15.2 mmol) in 
dry DCM (35 mL) was added trifluoromethanesulfonic anhydride (0.74 mL, 4.36 mmol) slowly at -18 
°C. The reaction mixture was stirred at -15 to -10 °C for 1.5 h, then acetyl chloride (0.323 mL) was 
added at -8 °C. The cooling bath was removed and the reaction mixture was stirred for 1 h at rt, then 
diluted with DCM, and washed with 5% NaHCO3 and brine. The organic layer was dried over Na2SO4 
and concentrated in vacuo. The residue was purified by MPLC on silica (petroleum ether/EtOAc, 15:1-
9:1)  to afford 22 (2.23 g, 96%) as a syrup.![α]D +64.5 (c 1.58, CHCl3);!1H NMR (500 MHz, CDCl3): δ = 
1.07 (s, 9H, C(CH3)3), 2.16 (s, 3H, COCH3), 3.47 (s, 3H, OCH3), 3.90 (m, 3H, H-5, H-6), 4.58 (dt, J = 
9.5, 50.5 Hz, 1H, H-4), 4.67 (dd, J = 3.5, 10.0 Hz, 1H, H-2), 4.99 (t, J = 3.5 Hz, 1H, H-1), 5.72 (dt, J = 
9.5, 13.5 Hz, 1H, H-3), 7.42 (m, 6H, Ar-H), 7.68 (m, 4H, Ar-H); 13C NMR (125 MHz, CDCl3): δ = 20.5 
(COCH3), 19.3 (C(CH3)3), 26.7 (C(CH3)3), 55.8 (OCH3), 61.7 (C-6), 68.9 (d, J = 21.3 Hz, C-3), 69.4 (d, 
J = 23.1 Hz, C-5), 80.9 (d, J = 7.9 Hz, C-2), 86.5 (d, J = 187.6 Hz, C-4), 96.5 (C-1), 127.7, 127.8, 
129.8, 132.9, 132.9, 135.6, 135.6 (12C, Ar-C), 169.4 (CO); 19F NMR (470 MHz, CDCl3): δ = -197.9, -
74.7; ESI-MS: m/z: Calcd for C26H32F4NaO8Si [M+Na]+: 631.1, found: 631.1. 
 
Methyl 2,3-di-O-acetyl-6-O-tert-butyldiphenylsilyl-4-deoxy-4-fluoro-α-D-mannopyranoside (23). 
A mixture of 22 (2.07 g, 3.39 mmol), CsOAc (977 mg, 5.08 mmol) and 18-crown-6 (1.34 g, 5.08 mmol) 
in dry toluene (20 mL) was refluxed for 2.5 h. After cooling to rt, toluene was removed in vacuo and 
the residue was dissolved in EtOAc, washed with water and brine, and dried over Na2SO4. The 
solvent was removed in vacuo and the residue was purified by MPLC on silica (petroleum 
ether/EtOAc, 9:1-6:1) to afford 23!(1.03 g, 59%) as a white solid. [α]D +27.3 (c 0.63, CHCl3);!1H NMR 
(500 MHz, CDCl3): δ = 1.10 (s, 9H, C(CH3)3), 2.09, 2.13 (2 s, 6H, 2 COCH3), 3.40 (s, 3H, OCH3), 3.84 
(m, 1H, H-5), 3.92 (m, 1H, H-6a), 3.99 (m, 1H, H-6b), 4.73 (s, 1H, H-1), 4.96 (dt, J = 9.5, 51.5 Hz, 1H, 
H-4), 5.29 (d, J = 1.5 Hz, 1H, H-2), 5.45 (ddd, J = 3.5, 9.5, 13.5 Hz, 1H, H-3), 7.41 (m, 6H, Ar-H), 
7.71-7.75 (m, 4H, Ar-H); 13C NMR (125 MHz, CDCl3): δ = 20.74, 20.82 (2 COCH3), 19.4 (C(CH3)3), 
26.7 (C(CH3)3), 55.1 (OCH3), 62.0 (C-6), 69.4 (d, J = 18.9 Hz, C-3), 70.4 (d, J = 8.4 Hz, C-2), 70.6 (d, 
J = 23.6 Hz, C-5), 84.8 (d, J = 179.9 Hz, C-4), 98.25 (C-1), 127.6, 127.7, 129.7, 129.7, 133.0, 133.4, 
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135.5, 135.7 (12C, Ar-C), 169.9, 170.0 (2 CO); 19F NMR (470 MHz, CDCl3): δ = -204.6; HR-MS: m/z: 
Calcd for C27H35FNaO7Si [M+Na]+: 541.2034, found: 541.2028. 
 
1,2,3,6-Tetra-O-acetyl-4-deoxy-4-fluoro-α-D-mannopyranoside (24). To a solution of 23 (940 mg, 
1.54 mmol) in acetic anhydride (8.0 mL) was added H2SO4 (95-97%, 0.35 mL) at 0 °C. The reaction 
mixture was stirred at rt overnight, then diluted with ethyl acetate and neutralized carefully with satd. 
aq. NaHCO3 at 0 °C. The aqueous layer was extracted twice with EtOAc, the combined organic layers 
were washed with brine and dried over Na2SO4. The solvent was removed in vacuo and the residue 
was purified by MPLC on silica (petroleum ether/EtOAc, 3:1-7:3) to afford 24! (530 mg, 98%) as a 
syrup. [α]D +27.2 (c 0.58, CHCl3);!1H NMR (500 MHz, CDCl3): δ = 2.07, 2.10, 2.14, 2.17 (4 s, 12H, 4 
COCH3), 4.10 (m, 1H, H-5), 4.29 (ddd, J = 1.0, 5.0, 12.0 Hz, 1H, H-6a), 4.38 (dt, J = 2.0, 12.5 Hz, 1H, 
H-6b), 4.74 (dt, J = 10.0, 51.5 Hz, 1H, H-4), 5.28 (dd, J = 3.0, 5.0 Hz, 1H, H-2), 5.42 (ddd, J = 3.5, 
9.5, 13.0 Hz, 1H, H-3), 6.04 (t, J = 3.0 Hz, 1H, H-1); 13C NMR (125 MHz, CDCl3): δ = 20.6, 20.6, 20.7, 
20.8 (4 COCH3), 62.1 (C-6), 68.7 (d, J = 18.9 Hz, C-3), 69.9 (d, J = 8.3 Hz, C-2), 70.0 (d, J = 23.8 Hz, 
C-5), 84.7 (d, J = 182.4 Hz, C-4), 90.3 (d, J = 0.5 Hz, C-1), 168.0, 169.5, 169.8, 170.5 (4 C=O); 19F 
NMR (470 MHz, CDCl3): δ = -204.5; HR-MS: m/z: Calcd for C14H19FNaO9 [M+Na]+: 373.0911, found: 
373.0904. 
 
2,3,6-Tri-O-acetyl-4-deoxy-4-fluoro-α-D-mannopyranoside (25). To a solution of 24 (530 mg, 1.51 
mmol) in dry THF (12.0 mL) was added Me2NH (1.51 mL, 2 M in THF, 0.89 mmol). The reaction 
mixture was stirred for 3 h at rt and then concentrated. The residue was purified by MPLC on silica 
(petroleum ether/EtOAc, 3:1-3:2) to afford 25 (326 mg, 70%) as a pale yellow solid. [α]D -7.9 (c 0.77, 
CHCl3);!1H NMR (500 MHz, CDCl3): δ = 2.08, 2.12, 2.14 (3 s, 9H, 3 COCH3), 3.49 (s, 1H, 1-OH), 4.29 
(m, 2H, H-5, H-6a), 4.44 (m, 1H, H-6b), 4.71 (dt, J = 10.0, 52.0 Hz, 1H, H-4), 5.21 (s, 1H, H-1), 5.30 
(d, J = 1.5 Hz, 1H, H-2), 5.50 (ddd, J = 3.5, 10.0, 13.5 Hz, 1H, H-3); 13C NMR (125 MHz, CDCl3): δ = 
20.7, 20.8, 20.8 (3 COCH3), 62.5 (C-6), 68.0 (d, J = 23.5 Hz, C-5), 68.7 (d, J = 18.9 Hz, C-3), 70.6 (d, 
J = 8.3 Hz, C-2), 85.2 (d, J = 181.9 Hz, C-4), 92.1 (C-1), 169.9, 169.9, 170.8 (3 CO); 19F NMR (470 
MHz, CDCl3): δ = -204.3; ESI-MS: m/z: Calcd for C12H17FNaO8 [M+Na]+: 331.1, found: 331.0. 
 
2,3,6-Tri-O-acetyl-4-deoxy-4-fluoro-α-D-mannopyranosyl trichloroacetimidate (26). To a solution 
of 25 (187 mg, 0.607 mmol) and trichloroacetonitrile (0.61 mL, 6.07 mmol) in dry DCM (5 mL) was 
added NaH (60%, 3.6 mg) at rt. The reaction mixture was stirred at rt for 1 h, then silica gel was 
added and the solvent was removed in vacuo. The residue was purified by MPLC on silica (petroleum 
ether/EtOAc, 9:1-3:1) to afford 26 (250 mg, 91%) as colorless syrup. [α]D +40.0 (c 0.29, CHCl3);! 1H 
NMR (500 MHz, CDCl3): δ = 2.09, 2.10, 2.18 (3 s, 9H, 3 COCH3), 4.26 (m, 1H, H-5), 4.31 (ddd, J = 
1.5, 5.0, 12.0 Hz, 1H, H-6a), 4.46 (dt, J = 1.5, 12.0 Hz, 1H, H-6b), 4.81 (dt, J = 9.5, 51.5 Hz, 1H, H-4), 
5.50 (m, 2H, H-2, H-3), 6.25 (s, 1H, H-1), 8.80 (s, 1H, NH); 13C NMR (125 MHz, CDCl3): δ = 20.6, 20.7 
(3C, 3 COCH3), 62.0 (C-6), 68.4 (d, J = 8.4 Hz, C-2), 68.7 (d, J = 18.9 Hz, C-3), 70.6 (d, J = 23.9 Hz, 
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C-5), 84.5 (d, J = 182.8 Hz, C-4), 94.3 (C-1), 159.7 (OCN), 169.5, 169.6, 170.5 (3 CO); 19F NMR (470 
MHz, CDCl3): δ = -204.5; ESI-MS: m/z: Calcd for C14H17Cl3FNNaO8 [M+Na]+: 474.0, found: 473.9. 
 
n-Heptyl 3,6-di-O-acetyl-4-deoxy-4-fluoro-α-D-mannopyranoside (27) and n-heptyl 2,6-di-O-
acetyl-4-deoxy-4-fluoro-α-D-mannopyranoside (28). To a mixture of 26 (116 mg, 0.265 mmol) and 
n-heptanol (75 µL, 0.53 mmol) in dry DCM (3 mL) was added TMSOTf (6.0 µL, 0.032 mmol) at rt. The 
reaction mixture was stirred at rt for 2 h, then neutralized with Et3N and concentrated to dryness. The 
residue was purified by MPLC on silica (petroleum ether/EtOAc, 6:1-2:1) to afford 27 (24 mg, 25%) 
and!28 (31 mg, 32%) as colorless oils. 27: [α]D +39.8 (c 1.13, CHCl3);!1H NMR (500 MHz, CDCl3): δ = 
0.88 (t, J = 7.0 Hz, 3H, H-7'), 1.28 (m, 8H, H-3', H-4', H-5', H-6'), 1.59 (m, 2H, H-2'), 2.10, 2.16 (2 s, 
6H, 2 COCH3), 2.27 (d, J = 3.5 Hz, 1H, 2-OH), 3.44 (m, 1H, H-1'a), 3.68 (m, 1H, H-1'b), 4.02 (m, 1H, 
H-5), 4.08 (s, 1H, H-2), 4.29 (dd, J = 4.5, 12.0 Hz, 1H, H-6a), 4.38 (d, J = 12.0 Hz, 1H, H-6b), 4.72 (dt, 
J = 10.0, 52.0 Hz, 1H, H-4), 4.81 (s, 1H, H-1), 5.33 (t, J = 12.0 Hz, 1H, H-3); 13C NMR (125 MHz, 
CDCl3): δ = 14.0 (C-7'), 20.8, 21.0 (2 COCH3), 22.6, 26.0, 29.0, 29.2, 31.7 (C-2', C-3', C-4', C-5', C-6'), 
62.6 (C-6), 67.8 (d, J = 23.4 Hz, C-5), 68.4 (C-1'), 70.0 (d, J = 8.0 Hz, C-2), 71.6 (d, J = 17.8 Hz, C-3), 
85.4 (d, J = 181.5 Hz, C-4), 99.4 (C-1), 169.8, 170.8 (2 CO); 19F NMR (470 MHz, CDCl3): δ = -205.7; 
ESI-MS: m/z: Calcd for C17H29FNaO7 [M+Na]+: 387.2, found: 387.1. 28: [α]D +35.9 (c 1.28, CHCl3);!1H 
NMR (500 MHz, CDCl3): δ = 0.88 (t, J = 7.0 Hz, 3H, H-7'), 1.28 (m, 8H, H-3', H-4', H-5', H-6'), 1.56 (m, 
2H, H-2'), 2.10, 2.13 (2 s, 6H, 2 COCH3), 2.53 (d, J = 4.0 Hz, 1H, 3-OH), 3.43 (m, 1H, H-1'a), 3.65 (m, 
1H, H-1'b), 3.94 (m, 1H, H-5), 4.23 (m, 1H, H-3), 4.28 (dd, J = 5.5, 12.0 Hz, 1H, H-6a), 4.38 (d, J = 
12.0 Hz, 1H, H-6b), 4.54 (dt, J = 9.5, 52.0 Hz, 1H, H-4), 4.79 (s, 1H, H-1), 5.14 (s, 1H, H-2);  13C NMR 
(125 MHz, CDCl3): δ = 14.0 (C-7'), 20.8, 20.9 (2 COCH3), 22.6, 26.0, 29.0, 29.2, 31.7 (C-2', C-3', C-4', 
C-5', C-6'), 62.7 (C-6), 67.6 (d, J = 23.4 Hz, C-5), 68.2 (d, J = 19.0 Hz, C-3), 68.4 (C-1'), 72.6 (d, J = 
9.0 Hz, C-2), 88.5 (d, J = 178.3 Hz, C-4), 97.3 (C-1), 170.6, 170.7 (2 CO); 19F NMR (470 MHz, 
CDCl3): δ = -204.5; HR-MS: m/z: calcd for C17H29FNaO7 [M+Na]+: 387.1795, found: 387.1796. 
 
n-Heptyl 4-deoxy-4-fluoro-α-D-mannopyranoside (11). To a mixture of 27 and 28! (118 mg, 0.324 
mmol) in dry MeOH (5 mL) was added 0.5 M NaOMe/MeOH (97 µL) at rt. The reaction mixture was 
stirred overnight, neutralized with Amberlyst-15, filtered and concentrated to dryness. The residue 
was purified by MPLC on silica (DCM/MeOH, 20:1) to afford 11 (83.4 mg, 92%) as a white solid. [α]D 
+61.5 (c 1.49, CHCl3);!1H NMR (500 MHz, CD3OD): δ = 0.91 (t, J = 7.0 Hz, 3H, H-7'), 1.34 (m, 8H, H-
3', H-4', H-5', H-6'), 1.60 (m, 2H, H-2'), 3.43 (m, 1H, H-1'a), 3.66-3.73 (m, 4H, H-5, H-6, H-1'b), 3.83 
(m, 1H, H-2), 3.91 (m, 1H, H-3), 4.51 (dt, J = 9.5, 52.5 Hz, 1H, H-4), 4.74 (s, 1H, H-1); 13C NMR (125 
MHz, CD3OD): δ = 14.4 (C-7'), 23.7, 27.3, 30.2, 30.6, 33.0 (C-2', C-3', C-4', C-5', C-6'), 62.1 (C-6), 
68.8 (C-1'), 70.8 (d, J = 17.5 Hz, C-3), 72.2 (d, J = 24.1 Hz, C-5), 72.9 (d, J = 9.1 Hz, C-2), 89.8 (d, J 
= 175.3 Hz, C-4), 101.5 (C-1); 19F NMR (470 MHz, CDCl3): δ = -206.5; HR-MS: m/z: Calcd for 
C13H25FNaO8 [M+Na]+: 303.1584, found: 303.1579. 
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Synthesis of compound 12 
 
Scheme S3. a) PhCH(OMe)2, p-TsOH, DMF, 50 °C, 5 h (48%); b) Bu2SnO, toluene, TBAB, BnBr, 
reflux (91%); c) TCDI, DCE, reflux, overnight (91%); d) Bu3SnH, toluene, reflux, 6 h (58%); e) i. 
HOAc/H2O (4:1), 80°C, 1 h; ii. H2 (4 bar), Pd(OH)2/C, rt, 5 h (46%). 
n-Heptyl 4,6-O-benzylidene-α-D-mannopyranoside (29). To a solution of 1 (527 mg, 1.89 mmol) in 
dry DMF (6.0 mL) were added benzylaldehyde dimethylacetate (0.56 mL) and p-TsOH (18 mg) at rt. 
The reaction mixture was stirred at 50 °C for 5 h, then diluted with DCM and washed with 5% aq. 
NaHCO3 and brine. The organic layer was dried over Na2SO4 and concentrated. The residue was 
purified by MPLC on silica (petroleum ether/EtOAc, 3:1-3:2) to yield 29 (650 mg, 94%) as a glassy 
solid. 1H NMR (500 MHz, CD3OD): δ = 0.91 (t, J = 7.0 Hz, 3H, H-7'), 1.36 (m, 8H, H-3', H-4', H-5', H-
6'), 1.62 (m, 2H, H-2'), 3.46 (dt, J = 6.5, 9.5 Hz, 1H, H-1'a), 3.41-3.76 (m, 2H, H-5, H-1'b), 3.81 (t, J = 
10.0 Hz, 1H, H-6a), 3.88 (m, 1H, H-2), 3.90-3.95 (m, 2H, H-3, H-4), 4.18 (dd, J = 4.5, 10.0 Hz, 1H, H-
6b), 4.77 (d, J = 1.0 Hz, 1H, H-1), 5.60 (s, 1H, CHPh), 7.33-7.37 (m, 3H, Ar-H), 7.49-7.51 (m, 2H, Ar-
H); 13C NMR (125 MHz, CD3OD): δ = 14.5 (C-7'), 23.7, 27.3, 30.2, 30.6, 33.0 (C-2', C-3', C-4', C-5', C-
6'), 65.3 (C-5), 68.8 (C-1'), 69.6 (C-4), 69.9 (C-6), 72.7 (C-2), 80.2 (C-3), 102.6 (C-1), 103.4 (CHPh), 
127.5, 129.0, 129.9, 139.3 (6C, Ar-C); ESI-MS: m/z: Calcd for C20H30NaO6 [M+Na]+: 389.2, found: 
389.1. 
 
n-Heptyl 3-O-benzyl-4,6-O-benzylidene-α-D-mannopyranoside (30). A mixture of 29 (152 mg, 
0.414 mmol) and dibutyltin oxide (112 mg, 0.456 mmol) in dry toluene (8 mL) was refluxed for 6 h and 
then concentrated to dryness under reduced pressure. The residue was dissolved in dry toluene (8 
mL) and tetrabutylammonium bromide (TBAB, 147 mg, 0.456 mmol) and benzyl bromide (59 µL, 0.50 
mmol) were added. The mixture was stirred at 95 °C overnight, concentrated to dryness, and the 
residue was purified by MPLC on silica (petroleum ether/EtOAc, 9:1-4:1) to give 30 (172 mg, 91%) as 
colorless oil. [α]D +34.2 (c 1.43, MeOH); 1H NMR (500 MHz, CDCl3): δ = 0.89 (t, J = 7.0 Hz, 3H, H-7'), 
1.29 (m, 8H, H-3', H-4', H-5', H-6'), 1.57 (m, 2H, H-2'), 2.64 (s, 1H, OH), 3.41 (m, 1H, H-1'a), 3.67 (m, 
1H, H-1'b), 3.82-3.88 (m, 2H, H-5, H-6a), 3.94 (dd, J = 3.0, 9.5 Hz, 1H, H-3), 4.06-4.14 (m, 2H, H-2, 
H-4), 4.27 (m, 1H, H-6b), 4.73 (d, J = 11.5 Hz, 1H, CH2Ph), 4.86 (m, 1H, H-1), 4.87 (d, J = 11.5 Hz, 
1H, CH2Ph), 5.62 (s, 1H, CHPh), 7.33-7.40 (m, 8H, Ar-H), 7.49-7.51 (m, 2H, Ar-H); 13C NMR (125 
MHz, CDCl3): δ = 14.1 (C-7'), 22.6, 26.0, 29.1, 29.4, 32.8 (C-2', C-3', C-4', C-5', C-6'), 63.2 (C-5), 68.0 
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(C-1'), 68.9 (C-6), 70.1 (C-2), 73.0 (OCH2Ph), 75.8 (C-3), 78.9 (C-4), 99.9 (C-1), 101.5 (CHPh), 126.0, 
127.8, 127.9, 128.2, 128.5, 128.9, 137.5, 138.1 (12C, Ar-C); HR-MS: m/z: Calcd for C27H36NaO6 
[M+Na]+: 479.2410, found: 479.2414. 
 
n-Heptyl 3-O-benzyl-4,6-O-benzylidene-2-O-(1H-imidazole-1-carbonothioyl)-α-D-manno-
pyranoside (31). A mixture of 30 (210 mg, 0.460 mmol) and N,N’-thiocarbonyldiimidazole (246 mg, 
1.38 mmol) in 1,2-dichloroethane (5 mL) was refluxed overnight, then the solution was concentrated 
in vacuo. The residue was dissolved in DCM and washed with 1N HCl and brine. The organic layer 
was dried over Na2SO4 and the solvent was removed in vacuo. The residue was purified by MPLC on 
silica (petroleum ether/EtOAc, 3:1-3:2) to afford 31 (238 mg, 91%) as a yellow oil. [α]D -9.8 (c 0.44, 
CH2Cl2); 1H NMR (500 MHz, CDCl3): δ = 0.90 (t, J = 7.0 Hz, 3H, H-7'), 1.31 (m, 8H, H-3', H-4', H-5', H-
6'), 1.61 (m, 2H, H-2'), 3.46 (dt, J = 6.5, 9.5 Hz, 1H, H-1'a), 3.69 (dt, J = 6.5, 9.5 Hz, 1H, H-1'b), 3.85 
(t, J = 10.0 Hz, 1H, H-6a), 3.94 (td, J = 4.5, 10.0 Hz, 1H, H-5), 4.04 (t, J = 10.0 Hz, 1H, H-4), 4.19 (dd, 
J = 3.5, 10.0 Hz, 1H, H-3), 4.31 (dd, J = 4.5, 10.0 Hz, 1H, H-6b), 4.73 (dd, J = 12.0 Hz, 2H, CH2Ph), 
5.01 (d, J = 1.5 Hz, 1H, H-1), 5.67 (s, 1H, CHPh), 5.90 (dd, J = 1.5, 3.5 Hz, 1H, H-2), 7.07 (d, J = 0.5 
Hz, 1H, Ar-H), 7.27-7.29 (m, 5H, Ar-H), 7.36-7.42 (m, 3H, Ar-H), 7.51 (dd, J = 2.5, 7.5 Hz, 2H, Ar-H), 
7.67 (s, 1H, Ar-H), 8.39 (s, 1H, Ar-H); 13C NMR (125 MHz, CDCl3): δ = 14.1 (C-7'), 22.6, 25.9, 29.0, 
29.2, 31.7 (C-2', C-3', C-4', C-5', C-6'), 63.7 (C-5), 68.5 (C-1'), 68.8 (C-6), 72.9 (OCH2Ph), 73.9 (C-3), 
78.8 (C-2), 79.2 (C-4), 97.2 (C-1), 101.8 (CHPh), 110.0, 126.1, 127.6, 127.8, 128.2, 128.4, 129.1, 
131.0, 137.2, 137.7 (15C, Ar-C), 183.6 (CS); HR-MS: m/z: Calcd for C31H38N2NaO6S [M+Na]+: 
589.2348, found: 589.2351. 
 
n-Heptyl 3-O-benzyl-4,6-O-benzylidene-2-deoxy-α-D-mannopyranoside (32). A solution of 31 
(238 mg, 0.419 mmol) in dry toluene (2 mL) was added dropwise over 10 min to a stirred solution of 
tributylstanne (0.169 mL, 0.63 mmol) in refluxing toluene (6 mL) under argon. After the reaction 
mixture was refluxed for 6 h, the solvent was removed in vacuo and the residue was purified by MPLC 
on silica (petroleum ether/EtOAc, 16:1-4:1) to afford 32 (107 mg, 58%) as a colorless oil.  [α]D +49.9 
(c 1.07, MeOH); 1H NMR (500 MHz, CDCl3): δ = 0.89 (t, J = 7.0 Hz, 3H, H-7'), 1.30 (m, 8H, H-3', H-4', 
H-5', H-6'), 1.58 (m, 2H, H-2'), 1.81 (ddd, J = 3.5, 11.5, 13.5 Hz, 1H, H-2a), 2.28 (ddd, J = 1.0, 5.0, 
13.5 Hz, 12H, H-2e), 3.35 (dt, J = 6.5, 9.5 Hz, 1H, H-1'a), 3.62 (dt, J = 6.5, 9.5 Hz, 1H, H-1'b), 3.70 (t, 
J = 9.0 Hz, 1H, H-4), 3.77 (t, J = 10.0 Hz, 1H, H-6a), 3.83 (m, 1H, H-5), 4.05 (ddd, J = 5.0, 9.0, 11.0 
Hz, 1H, H-3), 4.26 (dd, J = 4.5, 10.0 Hz, 1H, H-6b), 4.69, 4.86 (d, J = 12.0 Hz, 2H, OCH2Ph), 4.90 (d, 
J = 3.5 Hz, 1H, H-1), 5.63 (s, 1H, CHPh), 7.25-7.41 (m, 9H, Ar-H), 7.52 (dd, J = 2.5, 7.5 Hz, 1H, Ar-
H); 13C NMR (125 MHz, CDCl3): δ = 14.1 (C-7'), 22.6, 26.1, 29.1, 29.5, 31.8 (C-2', C-3', C-4', C-5', C-
6'), 36.6 (C-2), 62.9 (C-5), 67.7 (C-1'), 69.2 (C-6), 73.0 (CH2Ph), 73.1 (C-3), 84.0 (C-4), 97.9 (C-1), 
101.3 (CHPh), 126.0, 127.5, 127.6, 128.2, 128.3, 128.8, 137.6, 138.8 (12C, Ar-C); HR-MS: m/z: Calcd 
for C27H36NaO5 [M+Na]+: 463.2460, found: 463.2453. 
 
n-Heptyl 2-deoxy-α-D-mannopyranoside (12). A solution of 32 (66 mg, 0.15 mmol) in 80% aq. 
HOAc (1.25 mL) was stirred at 80 °C for 1 h and then concentrated to dryness. The residue was 
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purified by MPLC on silica (petroleum ether/EtOAc, 4:1-3:2) to afford the 3-O-benzylated intermediate. 
Hydrogenolysis of the intermediate was performed in MeOH (5 mL) in the presence of Pd(OH)2/C 
(10%, 5.2 mg) under hydrogen (4 bar) at rt for 5 h. The reaction suspension was filtered through celite 
and the filtrate was concentrated in vacuo. The residue was purified by MPLC on silica (DCM/MeOH, 
10:1) to provide 12 (18 mg, 46% over two steps) as a white solid. 1H NMR (500 MHz, CD3OD,): δ = 
0.91 (t, J = 7.0 Hz, 3H, H-7'), 1.32 (m, 8H, H-3', H-4', H-5', H-6'), 1.57-1.62 (m, 3H, H-2e, H-2'), 2.04 
(dd, J = 5.0, 13.0 Hz, 1H, H-2a), 3.23 (t, J = 9.5 Hz, 1H, H-4), 3.33 (m, 1H, H-1'a), 3.52 (m, 1H, H-5), 
3.66-3.70 (m, 2H, H-6a, H-1'b), 3.79-3.85 (m, 2H, H-3, H-6b), 4.87 (d, J = 2.5 Hz, 1H, H-1); 13C NMR 
(125 MHz, CD3OD,): δ = 14.4 (C-7'), 23.7, 27.4, 30.3, 30.7, 33.0 (C-2', C-3', C-4', C-5', C-6'), 39.0 (C-
2), 62.9 (C-6), 68.3 (C-1'), 70.0 (C-3), 73.3 (C-4), 74.0 (C-5), 98.6 (C-1); HR-MS: m/z: Calcd for 
C13H26NaO5 [M+Na]+: 285.1678, found: 285.1678. 
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Table S1. Statistics on X-ray diffraction data and refinement of FimH-CRD ligand complexes. 
 
 FimH-CRD/2 FimH-CRD/5 FimH-CRD/6 FimH-CRD/7 
Wavelength (Å) 1.00003 1.00000 0.97934 0.8000 
Resolution range 
(Å) 
24.69 - 2.00  
(2.04 - 2.00)* 
28.08 - 1.12  
(1.16 - 1.12) * 
42.15 - 1.65 
(1.709 - 1.65) * 
38.12 - 0.997 
(1.032 - 0.997) * 
Space group P 21 21 21 P 21 21 21 P 21 21 21 P 21 21 21 
Unit cell  63.3 69.3 95.9 48.8 56.2 61.5 53.3 96.9 97.9  48.8 55.9 61  
α, β, γ (°) 90 90 90 90 90 90 90 90 90 90 90 90 
Unique reflections 50818 (2906) 60363 (4211) 57603 (6056) 90597 (8175) 
Multiplicity 2.1 (2.0) 6.2 (4.6) 6.4 (6.3) 12.8 (12.4) 
Completeness (%) 93.1 (99.6) 92.42 (65.37) 93.27 (99.46) 98.87 (89.84) 
Mean I/sigma(I) 9.7 (3.9) 39.9 (7.1) 12.0 (2.1) 22.80 (2.06) 
Wilson B-factor 13.27 10.95 14.48 10.53 
R-meas 0.022 (0.21) 0.022 (0.21) 0.142 (1.05) 0.051 (0.97) 
CC1/2 0.99 (0.99) 0.99 (0.95) 0.99 (0.69) 0.99 (0.79) 
R-work 0.1745 (0.2418) 0.1077 (0.1201) 0.1696 (0.2639) 0.1236 (0.2280) 
R-free  0.2016 (0.2544) 0.1303 (0.1604) 0.2014 (0.2980) 0.1406 (0.2361) 
Number of atoms 2965 1625 4884 1631 
  macromolecules 2447 1291 3666 1294 
  ligands 24 30 104 31 
  water 518 300 1108 298 
Protein residues 316 158 474 158 
RMS(bonds) 0.004 0.012 0.004 0.014 
RMS(angles) 1.03 1.56 1.12 1.59 
Ramachandran 
 favored (%) 96.9 99.0 97.1 99.0 
Ramachandran 
 outliers (%) 0 0 0 0 
Clashscore 0.21 2.31 2.15 3.81 
Average B-factor 17.8 16 19.9 16.4 
  macromolecules 16.5 12.8 15.4 12.1 
  ligands 18.4 16.1 19.7 16.7 
  solvent 32.4 29.4 34.9 34.7 
 
* Values in parentheses are for highest resolution shell. 
In the refinement statistics, Friedel mates were merged. !! = Σ!Σ!!! ℎ − ! !!!!!!! ! , where i are the 
independent observations of reflection h. 
The Rfree factor was calculated from 5% of the data, which were removed at random before the 
refinement. 
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Figure S1. Comparison of the FimH antagonist binding site. The Mannose binding pocket of 
FimH cocrystal structures FimH-CRD/1 (PDB ID: 4BUQ) (a), FimH-CRD/2 (b), FimH-CRD/4 (PDB ID: 
4CST) (c), FimH-CRD/5 (d), FimH-CRD/6 (e) and FimH-CRD/7 (f). The antagonists (yellow) and 
residues of the binding site (grey) are shown in stick representation. 
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Figure S2. Trosine gate conformation in FimH-CRD X-ray and NMR solution structures. 
Superimposition of the “pseudo-apo” crystal structure of FimH-CRD with ethanediol in the binding site 
(green, PDB ID: 4AUU), the co-crystal structure with 1 (magenta, ligand not shown, PDB ID: 4BUQ) 
and the solution NMR structure of apo FimH-CRD published previously (grey, PDB ID: 3ZPD).[S3] The 
conformations of the Tyr48 sides chain are similar in the two apo structures while in presence of 
antagonist the Tyr48 ring is flipped towards the binding loop. Tyr137 has a similar orientation in all 
structures. 
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Figure S3. The side chain of Glu50 is stabilized by Arg98. FimH-CRD X-ray structures co-
crystallized with 1 (PDB ID: 4BUQ) (a) and as “pseudo-apo” protein with ethanediol in the binding 
pocket (PDB ID: 4AUU) (b). The Glu50 side chain is stabilized by hydrogen bonds with the 
guanidinium group of Arg98 in both structures. The orientation of Glu50 and Arg98 in the co-crystal 
structures with antagonists 2, 4, 5, 6 and 7 is similar to that with 1. 
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Figure S4. Enthalpy-entropy compensation of FimH antagonists. An enthalpy-entropy plot of 
FimH antagonists 1 to 11 obtained from ITC analysis is shown. A linear regression of all points (black 
line) suggests an average enthalpy gain of 1.6 kJ/mol for an entropy penalty of 1 kJ/mol. Grey 
diagonals indicate combinations of ΔH° and –TΔS° values resulting in the same ΔG° value. The grey 
arrow indicates increasing ΔG° values. 
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Summary 
 
Urinary tract infections (UTIs) are among the most prevalent infections worldwide resulting in 
considerable financial burden on society. Women have a 40-50% risk to experience at least one 
symptomatic UTI episode during their life. The disease is most frequently caused by uropathogenic 
Escherichia coli (UPEC). The type 1 pili tip FimH allows UPEC to bind specifically to the high-
mannosylated uroplakin-Ia glycoprotein on the bladder epithelium and thereby enables the invasion in 
the host cells. High affinity mannoside-based FimH antagonists that block the adhesion of UPEC are 
therefore considered as attractive anti-infective therapeutics. Alkyl- and aryl-functionalized FimH 
antagonists bind in the in-docking or out-docking mode respectively, as revealed by X-ray studies and 
supported by computer-based docking calculations. In the in-docking mode the alkyl-aglycone of the 
mannoside is hosted by two tyrosine residues (Y48 and Y137) located at the entrance of the binding 
site. In the out-docking mode, the bulky biphenyl aglycones form π-π interactions exclusively with 
the Y48 side chain, which account for higher affinity. To investigate the contribution of both tyrosine 
residues, the binding affinities and thermodynamic profiles of an alky- and an aryl substituted 
mannoside were assessed on wild type FimH-carbohydrate recognition domain (CRD) and the 
corresponding Y48A and Y137A mutants. Co-crystal structures of the three proteins with heptyl α-D-
mannopyranoside were also obtained.  
Different contributions of the tyrosine gate residues were observed, however not in a ligand-
dependent manner. In a competitive binding assay, the Y48A mutant exhibited similar binding 
affinities as the wild type for the alkyl- and aryl mannosides, whereas binding was reduced 6- to 8-
fold for the Y137A mutant. Thermodynamic profiling showed significant entropy-enthalpy 
compensation for the Y48A mutant, whereas only a partial compensation was observed for the 
Y137A mutant. Molecular modeling revealed a reorganization of the binding site upon Y137A 
mutation. The thermodynamic and structural data presented here improve our understanding of FimH-
mannoside interactions.  
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Introduction 
 
Urinary tract infections (UTIs) are the most common bacterial infections in human (1, 2). They are 
mainly caused by type 1-piliated uropathogenic Escherichia coli (UPEC) (3). The pili are 
proteinaceous hair-like appendages composed of four different subunits (FimH, FimG, FimF and 
FimA), which are assembled in the periplasmic space with the assistance of the chaperon-like FimC 
subunit via the conserved Usher pathway (4). The FimH subunit is located at the tip of the pili (5) and 
consists of two structural domains: (i) the N-terminal carbohydrate recognition domain (CRD), which 
binds specifically to mannose moieties displayed on the uroplakin complexes at the luminal surface of 
bladder epithelial cells (6-8), (ii) the pilin domain located at the C-terminus connects FimH to the core 
of the pili via FimG subunit. The attachment of bacteria to the bladder epithelium is followed by their 
internalization and subsequent biofilm formation inside the urothelial cells (9-11), which facilitate the 
persistence of UPEC within the urinary tract. FimH-mediated binding is enhanced under shear stress 
(12) whereas under static conditions the interactions between lectin and pilin domains increase at the 
expense of affinity towards the ligand (13).  
Antibiotics are the standard treatment for UTIs (14-16). However, their long-term use promotes the 
development of microbial resistance leading to recurrent infections (17,18), and thus accounting for 
significant morbidity and high medical costs (19). Therefore, anti-adhesion drugs, which ensure the 
clearance of UPEC from the urinary tract, exhibit a promising therapeutic potential as anti-infectives 
(20-28). In addition, such therapeutics are less likely to induce bacterial resistance, because their 
effect is neither bacteriostatic nor bacteriolytic.  
For the rational design of FimH antagonists, several 3D-structures are available. The first 
crystallographic structure of FimH was in complex with its chaperone FimC (29). The mannose-
binding site was occupied by one molecule of cyclohexylbutanoyl-N-hydroxyethyl-D-glucamide (C-
HEGA), an additive for the crystallization. The second structure of FimH-FimC bound to α-D-
mannopyranose was reported in 2002 (30). The ligand was located in a deep pocket in which the 
residues F1, N46, D47, D54, Q133, N135, D140 and F142 create an optimal hydrogen network with 
all the hydroxyl groups of α-D-mannopyranose, with the exception of the anomeric hydroxyl group. 
At the entrance of the mannose-binding pocket, the side chains of the tyrosine residues 48 and 137, in 
an almost parallel orientation, build the so-called “tyrosine gate”. In another crystallographic study a 
n-butyl α-D-mannopyranoside molecule originating from the culture medium (LB-medium) was 
found within FimH-CRD (31). The butyl aglcone was accommodated in a hydrophobic environment 
by van der Waals contacts within the tyrosine gate, with further participation of I52. The structure of 
FimH-CRD in complex with oligomannose-3 (32) illustrated the crucial role of the tyrosine gate for 
natural ligand binding, as the two residues allow for contacts to the hydrophobic face of the 
carbohydrates. Therefore, the binding-mode in which portions of the molecule are located within the 
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tyrosine 48 and tyrosine 137 side chains are termed the in-docking mode. In contrast, an out-docking 
mode where the biphenyl aglycone is not accommodated within the tyrosine-gate and forms 
interactions to Y48 exclusively was observed (23). In both binding modes favorable hydrophobic/π-π 
stacking interactions with Y48 account for higher ligand affinity (23, 31-33).  
 
To establish a detailed interaction profile and to rationalize binding affinities of various FimH 
antagonists we generated the tyrosine gate alanine mutants (Y48A and Y137A). In the first part of this 
project, we determined the experimental affinities and the thermodynamic binding profiles of selected 
mannosides. In the second part, we investigated the binding characteristics of FimH wt and mutants 
focusing on structures co-crystallized with n-heptyl α-D-mannopyranoside. The thermodynamic and 
structural data presented here improve considerably our understanding of FimH-mannoside 
interaction and guide for better design strategy of FimH antagonists. 
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Material and Methods 
 
Reagents 
 
Bacto-Yeast extract, Bacto-Agar, and Bacto-Tryptone were purchased from Becton Dickinson (Basel, 
Switzerland) and used for the preparation of LB (Luria-Bertani) culture medium. Isopropyl 1-thio-β-
D-galactopyranoside (IPTG) was obtained from Applichem (Darmstadt, Germany). Polymyxin B 
sulfate, Hepes (4-(2-hydroxyethyl)-piperazine-1-ethanesulfonicacid), oxalic acid, MgCl2, CaCl2, 
NaH2PO4, imidazole were purchased from Fluka (Buchs, Switzerland). Ampicillin, bovine serum 
albumin (BSA) and ethylenediaminetetraacetic acid (EDTA), amino acids and BME vitamin mix 
were obtained from Sigma (Buchs, Switzerland). 1,5-anhydro D-mannitol (1), n-heptyl α-D-
mannopyranoside (2) and 4-biphenyl α-D-mannopyranoside 3 were synthesized as described in (34, 
35 and 27). The biotinylated polyacrylamide (PAA) glycopolymer Manα1-3(Manα1-6)Manβ1-
4GlcNAcβ1-4GlcNAcβ-PAA-biotin (TM-PAA) containing 20 mol% sugar residues and 5 mol% 
biotin was purchased from Lectinity (Moscow, Russia). MaxiSorp 96-well microtiter plates were 
purchased from Nunc (Roskilde, Denmark). 
 
Cloning of tyrosine gate mutants 
 
FimH-CRD construct linked to the thrombin cleavage site (Th), and a 6His-tag (6His) was generated 
as described (36). The Y48A and AY137 mutants were generated by overlap extension PCR method 
(37) using the wild type (wt) encoding plasmid as template. The inserts were digested with HindIII 
and XbaI restriction enzymes, gel purified and subsequently ligated into the corresponding cloning 
site of pDsbA3 expression vector (36). The vectors were then transformed into E. coli DH5α chemo-
competent cells (Novagen, Lucerne, Switzerland). After plasmid isolation and restriction control, the 
correctness of the constructs was confirmed by DNA sequencing (Microsynth, Balgach, Switzerland). 
Finally, the vectors were transformed into the protease-deficient E. coli strain HM 125 (38) for 
protein expression. For protein crystallization a FimH-CRD construct (amino acids: 1-158), without 
any tag, was generated und purified by ion exchange chromatography as described (39). 
 
Protein expression and purification 
 
Bacterial clones were grown at 30 °C with vigorous shaking (300 rpm) in M9 minimal medium (40) 
supplemented with 2 mM MgSO4, 0.1 mM CaCl2, 20 % glucose, 10 µM of each amino acid, BME 
vitamin mix (Sigma, Buchs, Switzerland) and 100 µg/mL ampicillin. When an OD600 of 0.8 was 
reached, the cells were induced with 1 mM IPTG and further cultivated for 16 h at 30 °C and 300 
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rpm. Then the cells were cooled on ice for 5 min and harvested by centrifugation at 5,000 rpm for 20 
min at 4 °C. The pellet was suspended in a cold solution of 50 mM Tris/HCl, pH 7.5, 150 mM NaCl, 
5 mM EDTA, 1 mg/mL polymyxin B sulfate (lysis buffer) and stirred for 2 h at 4 °C. After 
centrifugation at 11,000 rpm for 20 min at 4 °C, the supernatant (periplasmic extract) was dialyzed 
overnight against 50 mM NaH2PO4, 300 mM NaCl, and 10 mM imidazole/NaOH, pH 8 (binding 
buffer), and applied to a Ni-NTA column (Sigma, Buchs, Switzerland) attached to a BioLogic fast 
protein liquid chromatography system (BioRad, Reinach BL, Switzerland). The column was washed 
with binding buffer and afterwards eluted with 50 mM NaH2PO4, 300 mM NaCl, and 250 mM 
imidazole/NaOH, pH 8 (elution buffer). The fractions containing FimH-CRD-Th-6His were pooled 
and dialyzed against water and then against 20 mM HEPES/NaOH, 150 mM NaCl, and 1 mM CaCl2, 
pH 7.4 (assay buffer). The purity of the protein was verified by SDS–PAGE analysis, and the amount 
was determined by HPLC (41) using BSA as standard. Aliquots of the proteins could be stored for up 
to 3 months at 4 °C. For long-term storage, the proteins were frozen at -80°C without additives. 
 
Circular dichroism analysis  
 
The far-UV region of a protein circular dichroism (CD) spectrum delivers spectral features that are 
directly relevant to the secondary structure of the protein (42, 43). To analyze the effect of the 
mutations on the secondary structure of FimH-CRD-Th-6His CD-spectrum profiles of the wild type 
and mutants were recorded. The proteins were diluted to 10 µM concentration in 10 mM sodium 
phosphate buffer at pH 7.4 and CD spectra were measured at 25°C using thermostat-controlled 0.1 cm 
cell. The spectra were recorded between 190 and 250 nm with 2 nm bandwith and 10 scans per 
sample on a Jasco J-720 spectrophotometer with temperature controller PFD-350S connected to the 
software program J-700. CD-spectra were corrected for background by subtracting buffer spectra and 
the CD signal was converted to residue ellipsity ([θ]MRW/deg.cm2 dmol-1). 
 
Fluorescence measurements 
 
The conformational stability was verified by monitoring the GdmCl-induced unfolding profiles (44) 
of the wild type and mutants. Prior spectroscopic measurements the samples (10 µM) were incubated 
with GdmCl concentrations ranging from 0 to 6 M for 24 h at 25°C. The effective GdmCl 
concentrations were determined via the refractive index of the samples (45). Fluorescence 
measurements were performed on a Hitachi F4500 fluorescence spectrometer at 25°C using an 
excitation slit of 2.5 nm and an emission slit of 5 nm. All samples were excited at λ = 280 nm and the 
spectra were recorded at a scan speed of 10 nm/min. The fluorescence emission for equilibrium 
unfolding experiments was followed at λ = 350 nm (tryptophan fluorescence). Fluorescence spectra 
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were corrected for background by subtracting buffer spectra. All transitions were evaluated according 
to a two-state model using the linear extrapolation method and normalized.   
 
Protein MS analysis 
 
The exact molecular weight of FimH-CRD wild type and mutants was verified by matrix-assisted 
laser desorption ionization mass spectrometry (MALDI-MS). To differentiate between Y48A and 
Y137A mutants the proteins were subjected to trypsin digestion followed by MS analysis. 
 
Competitive binding assay 
 
To evaluate the affinity of the mutants a competitive binding assay described previously (36) was 
applied. Microtiter plates (F96 MaxiSorp, Nunc) were coated with 100 µL/well of a 10 µg/mL 
solution of FimH-CRD-Th-6His in 20 mM HEPES/NaOH, 150 mM NaCl and 1 mM CaCl2, pH 7.4 
(assay buffer) overnight at 4 °C. The coating solution was discarded and the wells were blocked with 
150 µL/well of 3% BSA in assay buffer for 2 h at 4 °C. After three washing steps with assay buffer 
(150 µL/well), a serial dilution of the test compound (50 µL/well) in assay buffer containing 5% 
DMSO and streptavidin-peroxidase coupled TM-PAA polymer (50 µL/well of a 0.5 µg/mL solution) 
were added. The plates were incubated for 3 h at 25 °C and 350 rpm and then carefully washed four 
times with 150 µL/well assay buffer. After the addition of 100 µL/well of ABTS-substrate, the 
colorimetric reaction was allowed to develop for 4 min, then stopped by the addition of 2% aqueous 
oxalic acid before the optical density (OD) was measured at 415 nm on a microplate-reader 
(Spectramax 190, Molecular Devices, California, USA). The IC50 values of the compounds tested in 
duplicates were calculated with prism software (GraphPad Software, Inc., La Jolla, USA). The IC50 
defines the molar concentration of the test compound that reduces the maximal specific binding of 
TM-PAA polymer to FimH-CRD by 50%. The relative IC50 (rIC50) is the ratio of the IC50 of the test 
compound to the IC50 of n-heptyl α-D-mannopynoside. The relative IC50 (rIC50) was set to 1 for the 
wild type. 
 
Isothermal titration calorimetry 
 
The thermodynamic characterization of the interactions between FimH-CRD wild type, Y48A and 
Y137A and mannosides was measured by isothermal titration calorimetry (ITC) as previously 
described (27). The protein was dialyzed over night at 4 °C against assay buffer using Slide-A-Lyzer 
dialysis cassettes with 10 kDa cut-off (Thermo Fisher Scientific, Waltham, MA, USA). Final protein 
concentrations of 8-15 µM for the wild type and the Y48A mutant, and 17-23 µM for the Y137A 
mutant were used. The ligands 1,5-anhydro D-mannitol (1), n-heptyl α-D-mannopyranoside (2), and 
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4-biphenyl α-D-mannopyranoside (3) were diluted to 15-25 fold molar excess of the protein. Dilution 
enthalpy was determined by ligand in assay buffer titration. For the 4-biphenyl α-D-mannopyranoside 
(3), a final concentration of 2.5 % DMSO was required to dissolve the compound. For these 
measurements, DMSO was added to the protein samples (2.5 % final concentration). All 
measurements were performed with a MicroCalTM VP-ITC instrument (GE Healthcare, Northampton, 
MA, USA; sample cell volume of 1.4523 mL) at 25 °C, 307 rpm stirring speed, and 10 µcal/s 
reference power. The samples were preheated to 22 °C and degassed for 5 minutes prior to the 
measurements. Titration was started after steady baseline equilibration was reached with an initial 2 
µL injection, which was excluded from subsequent data analysis. Ligand was injected in 4-7 µL steps 
(38-66 injections in total) with a spacing of 10 minutes to ensure non-overlapping peaks. Sigmoidal 
binding curves with complete saturation at the end of each experiment were obtained. Baseline 
adjustments and peak integration were performed using the Origin 7 software (OriginLab, 
Northampton, MA, USA). The parameters KD (dissociation constant), N (stoichiometry), and ΔH° 
(change in enthalpy) were determined using non-linear least-square fitting in Microsoft Excel and the 
Solver add-in (Frontline Systems Inc., Incline Village, NV) according to Ziegler et al. (46). The 
thermodynamic parameters ΔG° (change in free energy) and TΔS° (change in enthalpy) were 
calculated using equation 1, 
ΔG° = ΔH° – TΔS° = RTlnKA = –RTlnKD   (Eq. 1) 
where T is the absolute temperature and R is the universal gas constant (8.314 J mol–1 K–1). The 
quantity c = Mt(0) KD-1, where Mt(0) is the initial macromolecule concentration, ranged between 10 
and 600 for all experiments, thus being in the reliable range (47). 
 
Molecular modeling 
 
For all experiments a 1.69 Å resolution crystal structure (PDB code 1UWF) of the FimH-CRD was 
used (31). Initial protein-ligand complexes were obtained through flexible docking using Glide 
(Glide, version 5.5, Schrödinger, LLC, New York, NY, 2009). Molecular dynamics (MD) simulations 
were carried out with Desmond (48) using the OPLS 2005 force field as implemented in the 
Schrödinger 2011 suite (Maestro, version 9.2, Schrödinger, LLC, New York, NY, 2011). Each system 
was solvated using an orthorhombic, TIP3P water (49) box with a minimum distance of 10 Å from the 
complex. Na+ and Cl- ions were added to neutralize the charges and account for physiological salt 
concentration (0.15 M). Long-range electrostatic interactions were handled using the particle mesh 
Ewald summation (50). All systems were equilibrated using the default relaxation protocol (Desmond 
2.2; Schrodinger, Inc., New York, NY) and simulated over the span 30 ns with a time step of 2.0 fs. 
The SHAKE algorithm (51) was applied to all heavy-atom bound hydrogens. Production runs were 
Chapter 3.4. – Manuscript 6 
 
  257 
carried out in the Martyna-Tobias-Klein isothermal-isobaric ensemble (NPT) (52) using the Nose-
Hoover barostat to maintain a constant temperature of 300 K (53). Energetic and structural data were 
recorded in 3.0 ps intervals. Trajectory clustering was performed based on ligand heavy atom RMSDs 
(1000 snapshots per simulation with 0.5 Å cutoff between clusters) using a hierarchical average-
linkage algorithm. Molecular mechanics-generalized Born surface area (MM-GBSA) calculations 
were performed on ensembles of 250 snapshots using the default settings implemented in Prime 
(Prime, version 3.0, Schrödinger, LLC, New York, NY, 2011). All images were generated using 
Maestro and PyMOL (54). 
 
Crystallization, data collection and refinement 
 
Crystallization of the FimH lectin was accomplished using the sitting drop vapor diffusion method 
(Hampton Research Crystal Screens I and II). Data were collected on Proxima I (SOLEIL, Saint-
Aubin, France) and PX14.2 (PSF BESSY, Berlin, Germany). The structure determination was 
performed using molecular replacement by the program PHASERi with apo-FimH (PDB entry code 
4AUU) as a model. The ligands were parametrised using the Prodrg server (55) and crystal structures 
were refined using Phenix (56). Data refinement and statistics are summarized in Table 6S 
(supplementary material). 
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Results 
Tyrosine gate mutants are conformationally stable 
For the treatment of UTIs, several FimH antagonists have been rationally designed, synthesized and 
evaluated (22-28). The interaction of the aryl aglycone of mannosides with the tyrosine gate (Y48 and 
Y137), have been shown to significantly improve the affinity. To experimentally evaluate the role of 
these residues we generated the corresponding alanine mutants (Y48A and Y137A). The proteins 
were expressed in the proteases deficient E. coli HM 125 and purified from the periplasmic space by 
chromatography on a Ni-NTA affinity matrix to homogeneity (Figure 1A). The mutations were 
confirmed at the protein level by ESI-MS (Figure S1). 
The stability of the mutants was preserved as verified in GdmCl unfolding experiments (Figure 1B). 
The conformational transition curves (Figure 1B) of the wild type and the mutants show 
superimposable profiles with similar transition mid-point values D1/2 (2.75 M GdmCl (wild type), 
2.77 M GdmCl (Y48A) and 2.73 M GdmCl (Y137A)). The data were evaluated according to the two-
state model yielding a free energy of folding 
€ 
ΔGH2O
°  of -50.00 ± 3.07 kJ mol-1 (wild type), -44.05 ± 
2.37 kJ mol-1 (Y48A) and -53.71 ± 4.53 kJ mol-1 (Y137A) and a folding cooperativity of 18.17 ± 1.11 
kJ mol-1, 15.95 ± 0.85 kJ mol-1 and 19.63 ± 1.64 kJ mol-1 for the wild type, Y48A and Y137A 
mutants, respectively. To evaluate whether the secondary structure of the proteins was altered upon 
the mutation, CD-spectra of the Y48A and Y137A mutants were recorded and compared to the 
corresponding CD-spectrum of the wild type (Figure 1C). The result shows identical spectrum 
profiles indicating that the mutants in native conformation retain secondary structure as the wild type.  
 
 
Figure 1. Characterization of FimH-CRD wild type and mutants: (A) Affinity-purified FimH-CRD wild type 
(WT) and tyrosine gate mutants Y48A and Y137A were subjected to SDS–PAGE under reducing conditions on 
a 16% gel. M, molecular weight marker. (B) GdmCl-dependent equilibrium unfolding profiles at 25 °C and pH 
7.4 were monitored by changes in fluorescence at 350 nm upon excitation at 280 nm. All transitions were 
evaluated according to a two-state model using the linear extrapolation method and normalized, red line (WT), 
blue line (Y48A) and green line (Y137A). (C) CD-spectra of FimH-CRD wild type (red line), Y48A (blue line) 
and Y137A (green line). All samples were measured at 10 µM concentration in 10 mM sodium phosphate buffer 
pH 7.4 and at 25°C using thermostat-controlled 0.1 cm cell as described in material and methods section. 
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Contributions of Y48 and Y137 to ligand binding 
 
The affinities of 1,5-anhydro D-mannitol (1), n-heptyl α-D-mannopyranoside (2) and the 4-biphenyl 
α-D-mannopyranoside (3) (Figure 2A) were evaluated with the wild type and the mutants in a 
competitive binding assay (36). The affinities are reported relative to 1 as rIC50 (Figure 2B). The 
mutation Y48A did not affect the binding properties of FimH-CRD, i.e. the rIC50 values for the tested 
mannosides were comparable to those obtained with the wild type. In contrast, the Y137A mutation 
resulted in a dramatic decrease in affinity towards n-heptyl α-D-mannopyranoside (2) and 4-biphenyl 
α-D-mannopyranoside (3), whereas the affinity to 1,5-anhydro D-mannitol (1) was only slightly 
decreased compared to the wild type. Compound 1 lacks the aglycone moiety and the anomeric 
oxygen and is therefore, not predicted to be affected by the mutations at the tyrosine gate. In wild type 
FimH-CRD, the aglycone of alkyl mannosides has been shown to interact with side chains of both 
tyrosine residues (Y48 and Y137, in-docking) (31), whereas in case of the bulky aromatic aglycone 
exclusively with Y48 (out-docking). It was therefore surprising hat the Y137A mutation, and not 
Y48A mutation, was detrimental for the binding of 4-biphenyl α-D-mannopyranoside (3).  
 
Figure 2. Structure and affinity of FimH ligands. (A) 1,5-anhydro D-mannitol (1), n-heptyl α-D-
mannopyranoside (2), and 4-biphenyl α-D-mannopyranoside (3). (B) The relative affinity of FimH-CRD wild 
type, Y48A and Y137A towards compounds 1, 2 and 3 was determined by the competitive binding assay (36).  
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Thermodynamic profiles of FimH mutants 
 
To gain further insights into the interaction of the antagonists 1, 2, and 3 with each of the FimH 
variants (wild type, Y48A and Y137A), direct binding affinity as well as the thermodynamic 
fingerprints were determined. Isothermal titration calorimetry (ITC) was employed for the 
measurements as described in material and methods section. The results are shown in Table 1 and 
Figure 3. The binding of the three compounds (1-3) was largely enthalpy driven, which is in 
agreement with previously reported results for other mono- and oligomannoside derivatives (33, 57) 
and for a series of biphenyl-mannosides (27). For the mannoside derivative 1,5-anhydro D-mannitol 
(1) KD values in the low micromolar range were obtained, which was expected since beneficial 
interactions between the aglycone moiety and the tyrosine-gate were missing. For this compound both 
mutants showed a 2.5 fold decrease in binding affinity compared to the wild type. This was due to a 
slightly decreased binding enthalpy, which was not entirely compensated by an increase in entropy. 
Such small effects might arise by slight modification of amino acid side chains or altered solvation 
properties. The n-heptyl α-D-mannopyranoside (2), expected to dock between the tyrosine gate 
residues, exhibited a KD of 31.3 nM for the wild type, which is in agreement with reported values 
measured by surface plasmon resonance (31). The Y48A mutant showed a two-fold decreased affinity 
(61.9 nM). Probably, the removal of the Y48 residue resulted in a loss in enthalpy (ΔΔH = +6.5 kJ 
mol-1), likely due to missing hydrophobic interactions of the alkyl moiety with the phenyl side chain. 
The increased flexibility in the alkyl moiety was partially compensated by beneficial entropy (-TΔΔS 
= -5.5 kJ mol-1), resulting in only a small net loss in binding free energy (ΔΔG = + 1.0 kJ mol-1). The 
Y137A mutant exhibited a similar beneficial entropic effect (-TΔΔS = -6.1 kJ mol-1) but suffered from 
a more pronounced loss in enthalpy (ΔΔH = +10.9 kJ mol-1), resulting in a seven-fold reduction of the 
affinity (ΔΔG = +4.8 kJ mol-1). The 4-biphenyl α-D-mannopyranoside (3) was expected to bind 
outside the tyrosine gate (23) and display little interaction with the residue Y137. This compound 
exhibited slightly improved overall binding affinity compared to compound 2, with a KD of 19.2 nM 
for FimH-CRD wild type. Similarly as observed for compounds 1 and 2, 4-biphenyl α-D-
mannopyranoside (3) showed a two-fold decreased affinity towards the Y48A mutant when compared 
to the wild type. The differences in enthalpy (ΔΔH = +4.4 kJ mol-1) and entropy (-TΔΔS = -2.9 kJ 
mol-1) contributions were however, not as pronounced as for compound 2. Considering the loss of π-π 
interactions with Y48 side chain, these changes are surprisingly small. Interestingly, the binding to 
Y137A showed a significant loss in enthalpy (ΔΔH = +12.1 kJ mol-1). This detrimental enthalpy was 
partially compensated by a beneficial entropy contribution (-TΔΔS = -8.4 kJ mol-1). While for 
compound 2, the entropy term was similar for Y48A and Y137A mutants (-8.4 kJ mol-1 vs. -9.0 kJ 
mol-1, respectively) there was a substantial gap for compound 3 (-2.5 kJ mol-1 vs. -8.0 kJ mol-1). This 
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suggests that the biphenyl-FimH interface retains greater mobility for the Y137A mutant, whereas 
compound 2 exhibits similar mobility regardless of the mutated tyrosine residue. 
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Figure 3. The thermodynamic fingerprint of the binding of 1,5-anhydro D-mannitol (1), n-heptyl α-D-
mannopyranoside (2), and 4-biphenyl α-D-mannopyranoside (3) to FimH-CRD wild type and mutants (Y48A & 
Y137A). The parameters ΔΔG, ΔΔH and -TΔΔS are plotted relative to compound 1. 
 
Table 1. Thermodynamic parameters of compounds 1, 2, and 3 binding to FimH-CRD wild type, Y48A, and 
Y137A mutants were determined by isothermal titration calorimetry. The dissociation constant (KD), the change 
in enthalpy (ΔH), and the molar ratio of protein and ligand (N) were determined from the non-linear least 
squares fitting as described in the material and methods section. The change in free binding energy (ΔG) and 
change in entropy (-TΔS) were calculated with equation 1 (ΔG = ΔH – TΔS).  
Compound Protein N rKD 
KD 
[nM] 
ΔG° 
[kJ mol-1] 
ΔH° 
[kJ mol-1] 
-TΔS° 
[kJ mol-1] 
1,5-Anhydro D-
mannitol (1) 
WT 1.07 1 943 -34.5 -36.6 2.1 
Y48A 1.05 2.6 2490 -32.0 -35.9 3.9 
Y137A 1.06 2.6 2476 -32.0 -35.2 3.2 
n-Heptyl α-D-
mannopyranoside (2)  
WT 1.00 1 31.3 -42.8 -39.9 -2.9 
Y48A 0.98 2.0 61.9 -41.8 -33.4 -8.4 
Y137A 1.05 7.1 220.7 -38.0 -29.0 -9.0 
4-Biphenyl α-D-
mannopyranoside (3)a 
WT 1.00 1 19.2 -44.0 -44.4 0.4 
Y48A 1.05 1.8 35.5 -42.5 -40.0 -2.5 
Y137A 1.04 4.5 87.3 -40.3 -32.3 -8.0 
a Measurement performed with 2.5 % DMSO for solubility reasons 
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Molecular modeling 
 
In both competitive binding assay and ITC the Y48A mutation has shown only a moderate effect on 
the affinity of FimH-CRD towards n-heptyl α-D-mannopynoside (2) and 4-biphenyl α-D-
mannopyranoside (3). This result was not expected, since the interaction between the mannoside 
aglycones, in both the in-docking and the out-docking, and the side chain of Y48 was no longer 
possible. Molecular modeling simulations were applied to elucidate the underlying reasons for this 
unexpected result. MM-GBSA binding free energy calculations performed on ensembles of ligand-
bound MD snapshots showed that the mutation Y48A resulted in diminished protein-ligand 
interaction energies (Tables S1 and S2). At the same time, visual inspection and clustering analyses of 
the simulations indicated that the removal of the bulky side chain allowed for increased ligand 
aglycone mobilities, especially in the case of n-heptyl α-D-mannopyranoside (2) (Figure 4A and 4C). 
Furthermore, given that the Y48 side chain is, upon binding, forced to adopt a single, mode-dependent 
rotamer, a corresponding increase in entropic costs are expected. In summary, these opposing effects 
result in an overall improvement of the entropy term. The flexibility of 4-biphenyl α-D-
mannopyranoside (3) however, remains similar (Figure 4B and 4D). This agrees with the 
thermodynamic profile of the binding of antagonist 3, which did not show an as pronounced enthalpy-
entropy compensation as observed for n-heptyl α-D-mannopynoside (2) with the Y48A mutant. 
Additional MD simulations for the apo wild type and mutant proteins coupled with detailed geometric 
and energetic analysis indicated significant deformation of the site (side chains only) in the Y137A 
mutant demonstrated by evident distortion of the Y48, Q133, and D135 conformations (Figure 5). 
Upon ligand binding, the original binding site topology needed to be reassumed and certain residues 
(e.g. D135) do not to fully reorient to their optimal positions.  
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Figure 4: Molecular dynamic simulation of FimH-CRD wild type and the Y48A mutants: Surface 
representation of the binding site of the wild type (A) with n-heptyl α-D-mannopyranoside (2), and (B) with 4-
biphenyl α-D-mannopyranoside (3) and Y48A (C) with n-heptyl α-D-mannopyranoside (2), and (D) with 4-
biphenyl α-D-mannopyranoside (3) in their most commonly occurring conformations as indicated by simulation 
frame clustering. Constrained bounds are indicated by an arrow. 
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Figure 5: Snapshots from molecular dynamics simulations of FimH-CRD and FimH-CRD bound to the 4-
biphenyl α-D-mannopyranoside (3) showing distortion of binding site residues in the Y137A mutant and the 
associated extra induced fit cost upon ligand binding. 
 
Crystallographic study 
 
In order to further confirm our findings, we obtained crystal structures of n-heptyl α-D-mannopyranoside 
in complex with the wild type, Y48A and Y137A FimH-CRD (Figure 6). Aside from Y48 side chain 
orientations impacted by crystal packing (as also reported for previous FimH-related studies in 
reference 31), the three structures supported our expectations regarding identical backbone and 
binding site conformations. The heptyl aglycones were found similarly oriented throughout all 
structures and interacting with both tyrosine side chains. For the Y48A mutant, alternative aglycone 
conformations could also be observed confirming increased ligand flexibility. Altogether the 
structures were found to closely resemble those obtained with molecular modeling and supported the 
corresponding predictions. 
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Figure 6: Co-crystal structures of FimH-CRD with n-heptyl α-D-mannopyranoside (2). FimH-CRD wild type 
(A), Y48A mutant (B) and Y137A mutant (C). 
         A       B    C 
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Discussion 
 
Previous studies suggested that the affinity of FimH-CRD towards ligands such as alky and aryl 
mannosides was significantly improved due to favorable hydrophobic/π-π interactions of the aglycone 
moiety with the phenyl rings of Y48 and Y137 residues (23,31). The n-butyl α-D-mannopyranoside 
was co-crystallized in an in-docking mode, where the butyl moiety interacts with both Y48 and Y137 
residues (31). In contrast, for a meta-carboxyl ester substituted biphenyl α-D-mannopyranoside co-
crystallized with the FimH-CRD, an out-docking mode was proposed (23). In this binding mode, π-π 
stacking of the outer aromatic ring of the biphenyl aglycone with Y48 was observed.  
The objective of this study was to assess the contributions of the Y48 and Y137 residues towards the 
binding of various mannosides. We have therefore generated the alanine mutants Y48A and Y137A 
of FimH-CRD and confirmed that the mutations did not affect the secondary structure, and stability of 
the proteins. We obtained the corresponding affinities and thermodynamic binding profiles for the 
1.5-anhydro D-mannitol (1), n-heptyl α-D-mannopyranoside (2) and the 4-biphenyl α-D 
mannopyranoside (3). For the Y48A mutation, the rIC50 and KD values for compound 2 and 3 were 
found only minimally affected compared to the wild type (Figure 2B & Table 1). Particularly, the 
result for compound 3 was not expected, given the generally accepted importance of the Y48 side 
chain towards alkyl- and aryl mannoside binding. Further inquiries into the thermodynamic 
fingerprints of these systems (obtained with ITC) showed reduced binding enthalpies compensated by 
enhanced entropy contributions (Table 1, Figure 3). Subsequent binding free energy calculations 
(Figure S3) revealed (as initially expected) that the loss of enthalpy originated from suppressed 
interactions with residue 48. The beneficial entropy changes were found (by means of molecular 
dynamics simulations) related to a lesser restriction of the binding interface unique to the non-natural 
mutation. Changes in the enthalpy can be interpreted in terms of differences in protein solvation and 
direct interactions between the ligand and protein. These interactions consist of hydrogen bonding-, 
electrostatic-, and van der Waals interactions, which can be identified based on computational 
methods and the structure of ligand-protein complex (58). The source of the entropy contribution, 
however, remains difficult to identify. 
Based on available crystallographic data, the biphenyl aglycone of mannoside derivative 3 was 
predicted to interact primarily with the Y48 side chain. Consequently, the mutation Y137A was not 
foreseen to affect its affinity towards the FimH-CRD. Surprisingly, the competitive binding assay and 
thermodynamic data demonstrated that the Y137A substitution significantly diminished the affinity of 
compound 3. The modeling studies showed significant deformation of the binding site of Y137A 
mutant as demonstrated by the distortion of Y48, Q133, and D135 side chains (Figure 5). However, 
this side chain re-orientation does not lead to a conformational change of the protein backbone. Upon 
ligand binding, the binding site conformation needs to be reassumed which incurs additional enthalpy 
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cost. Furthermore, certain residues (e.g. D135) appear unable to fully reorient, resulting in weaker 
interaction with the mannose moiety in the Y137A mutant. A comparable enthalpic loss was also 
observed in the case of n-heptyl α-D-mannopyranoside (2) and could be attributed to a similar 
induced fit penalty and/or to the loss of some direct interactions between the ligand and Y137 (data 
not shown).  
Based on the presented data we conclude that both tyrosine gate residues are of crucial importance to 
the binding of alkyl and aryl mannosides to FimH, though their respective roles may vary between 
strongly interacting (Y48) and interacting/stabilizing the binding site conformation (Y137). In light of 
this, it would seem appropriate to treat FimH ligands on individual basis (and allowing the thought 
that they might maintain multiple conformations in the bound state) rather than classifying them 
between distinct, rigid binding modes. We believe that it is unlikely (given the corresponding entropic 
and desolvation penalties) that the flexible mannoside aglycones would favor rigid, directional 
interactions with more distant residues to those with the tyrosine gate. Contacts like this may 
nethertheless be observed under non-physiological, crystallographic conditions. 
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Supplementary Material 
 
Figure S1. To differentiate between Y48A and Y137A mutants the proteins were subjected to trypsin digestion 
followed by MS analysis. The arrows indicate the 31 amino acid peptide with the same molecular weight in the 
wild type and Y48A mutants, and with a molecular weight 92 Da smaller in the Y137A mutant. 
MM-GBSA post-processing–To gain insight into binding thermodynamics of respective 
protein-ligand systems, ensembles of equally spaced (120 ps) snapshots were subjected to the 
MM-GBSA free energy calculation (Prime, version 3.0, Schrödinger, LLC, New York, NY, 
2011.). The energies were computed as mean values using equation S1. 
∆Gbind = Gcomplex – (Greceptor + Gligand) (Eq. S1) 
Structures of each molecular species were obtained by decomposing corresponding 
snapshots. All calculations were performed using a continuum solvent model. Because the 
method does not account for large, unfavorable changes in solute conformational entropies, 
the obtained results do not scale with the experimental data and reflect mostly the enthalpic 
changes for each system.  
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Table S1: ΔG values [kcal/mol] calculated over ensembles of 250 MD snapshots along with corresponding 
standard errors of the means (SEM). 
  WT Y48A Y137A 
ΔG SEM ΔG SEM ΔG SEM 
1,5 Anhydro D-mannitol (1) –48.2 0.3 –48.4 0.2 –50.0 0.3 
n-Heptyl α-D-mannopyranoside (2) –65.9 0.4 –60.7 0.4 –60.8 0.4 
4-Biphenyl α-D-mannopyranoside (3) –65.6 0.4 –61.1 0.4 –58.0 0.3 
Analysis of FimH MD simulations–We developed an in-house script to post-process MD 
simulations of FimH (free and in complex with different ligands) and highlight statistically 
significant differences between them. The python script computes various geometrical and 
energetic parameters for snapshots along the MD simulation using Schrödinger Suite API 
(Schrödinger, LLC, New York, NY, 2011). Afterwards, statistical analysis was performed on 
the collected time series data and a difference map was generated for every studied pair of 
simulations. Table S1 lists studied parameters and explains their calculation methodologies 
and intended purposes. 
Difference map for free FimH wild type vs. Y137A mutant–Table S2 lists parameters that 
showed statistically significant variation upon the Y137A mutation in FimH binding-site. In 
our study, binding-site residues were defined as residues with at least one atom within 8 Å 
distance from any ligand atom. For the ligand free simulations binding-site residues were 
defined based on the position of 4-biphenyl α-D-mannopyranoside (3) (out mode). Our 
assessment of the effects of Y137A mutation indicated an important role for the Y137 residue 
in stabilizing binding-site conformation. When Y137 was mutated into alanine, the FimH 
binding-site suffered from obvious distortion reflected by noticeable changes in protein–2d 
intramolecular binding-site interaction energies as well as several binding-site COM 
distances. Additionally, several dihedral angles (backbone and side chain) demonstrated 
statistically significant alteration between the wild type and the Y137A mutant. Results 
indicate that Y48 is one of the most affected residues by the studied mutation. The observed 
distortion also involves other binding-site residues such as Phe1, Ile52, Ile13, and Asn138. 
However, it is difficult to link the observed binding-site distortion to specific backbone 
and/or side chain dihedral angle(s). 
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Table S2. Geometrical and energetic parameters used for assessment of differences between MD simulations. 
Parameter name Computation methodology Purpose 
phi angle Geometrical Assessment of backbone rearrangement 
psi angle Geometrical Assessment of backbone rearrangement 
chi angle Geometrical Assessment of side chain conformational 
distribution 
COM distance Geometrical, distance (in Å) between 
centers-of-mass of pairs of binding-site 
residues 
Assessment of overall conservation of binding-
site conformation 
ligand–protein Sum of non-bonded forcefield terms 
(OPLS_2005) between ligand and 
individual binding-site residues 
(MacroModel, version 9.9, 
Schrödinger, LLC, New York, NY, 
2011) 
Assessment of loss or gain of interaction(s) 
between the ligand and binding-site residue(s) 
protein–2d Intramolecular interaction energies 
between pairs of binding-site residues 
calculated using the same approach 
used for ligand–protein parameter 
Assessment of conservation of proper binding-
site conformation. A collective parameter for 
phi/psi/chi angles and COM distance 
parameters, since any changes in binding-site 
geometry, on the level of one or more residues, 
would be reflected in a change in its interaction 
energy with neighboring residue(s). 
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Table S3. Difference map for ligand free FimH wild type vs. Y137A mutant highlighting statistically significant 
changes in binding-site residues. 
Parameter Average 
(wild type) 
Average 
(Y137A 
mutant) 
Difference 
(S.D.) 
phi angles (degrees) 
Gly15 205.8 113.9 –92.0 (1.4) 
Ala10 275.1 243.8 –31.3 (0.7) 
Gly16 158.9 134.1 –24.7 (1.3) 
Asp47 242.6 261.6 19.0 (0.5) 
Asn136 269.4 287.1 17.7 (0.5) 
Gly73 219.6 195.5 –24.0 (1.4) 
Val75 257.2 234.6 –22.7 (0.5) 
Ala18 233.3 215.0 –18.3 (0.7) 
Asn138 221.7 239.0 17.3 (0.7) 
Ile13 284.6 300.3 15.7 (0.6) 
Lys101 245.3 259.9 14.6 (0.6) 
Ile52 231.8 243.9 12.2 (0.6) 
psi angles (degrees) 
Gly16 251.7 202.7 –48.9 (1.5) 
Val30 116.3 90.1 –26.1 (1.2) 
Asp47 9.2 346.4 –22.9 (0.5) 
Gly15 172.5 193.3 20.8 (1.4) 
Pro12 150.3 170.4 20.1 (0.8) 
Ile52 136.2 117.4 –18.8 (0.5) 
Ile42 103.5 121.6 18.0 (0.7) 
Ser72 140.4 158.0 17.6 (0.9) 
Asn70 326.4 342.3 15.9 (0.6) 
Phe144 127.3 111.5 –15.7 (0.5) 
chi angles (degrees) 
Tyr55-2 292.3 115.5 –176.8 (2.1) 
Asp54-2 301.2 114.8 173.5 (1.5) 
Asn138-1 58.7 248.9 –169.7 (1.0) 
Thr99-1 189.7 55.6 –134.1 (0.5) 
Asp141-2 272.8 167.9 –104.9 (2.4) 
Tyr48-1 46.3 302.4 –103.9 (0.8) 
Asp140-1 36.6 294.0 –102.6 (1.3) 
Phe142-1 205.9 303.5 97.6 (1.5) 
Thr53-1 298.7 34.6 95.9 (1.0) 
Ile11-2 250.1 176.6 –73.5 (0.5) 
Ile52-2 167.7 231.2 63.5 (1.4) 
Tyr48-2 41.9 97.9 56.0 (1.5) 
Thr51-1 103.8 56.4 –47.4 (0.5) 
protein-2d energies (kJ/mol) 
His45-Asp47 –15.7 –24.2 –8.4 (0.5) 
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Phe1-Tyr48 –10.5 –2.8 7.7 (0.2) 
Thr53-Asn136 –19.1 –11.3 7.8 (0.4) 
Asn46-Tyr48 –23.9 –18.9 5.1 (0.2) 
Phe1-Gln133 –12.4 –17.3 –4.9 (0.2) 
Tyr48-Ile52 –21.9 –17.1 4.7 (0.2) 
Asn138-Phe142 -0.7 –4.8 –4.1 (0.1) 
Phe1- Phe144 –4.0 –8.0 –4.0 (0.1) 
Ile13-Phe144 –7.2 –3.2 3.9 (0.2) 
Thr53-Tyr55 –15.2 –11.7 3.6 (0.2) 
Leu131-Phe144 –27.2 –30.6 –3.4 (0.2) 
Ile13-Phe142 –5.1 –1.7 3.4 (0.2) 
Asn46-Thr53 –1.3 –4.1 –2.8 (0.1) 
Tyr48-Asn135 –3.3 -0.5 2.8 (0.1) 
Asn46-Ile52 –9.2 –11.9 –2.7 (0.2) 
Thr53-Asn135 –11.4 –9.2 2.3 (0.1) 
COM distances (Å) 
Asn138-Phe142 10.1 7.8 –2.3 (0.04) 
Tyr48-Arg132 16.4 18.5 2.2 (0.04) 
Tyr48-Tyr55 11.2 13.4 2.2 (0.04) 
Tyr48-Thr134 11.6 13.7 2.1 (0.04) 
Tyr48-Val56 13.5 15.7 2.2 (0.03) 
Ile13-Asn138 14.7 12.7 –2.0 (0.06) 
Tyr48-Leu131 16.5 18.3 1.7 (0.03) 
Tyr48-Tyr95 10.8 12.5 1.7 (0.03) 
Tyr48-Thr53 7.3 9.1 1.7 (0.04) 
Tyr48-Asn135 8.6 10.3 1.7 (0.04) 
Tyr48-Asn136 9.5 11.1 1.6 (0.03) 
Tyr48-Gln133 10.9 12.5 1.6 (0.04) 
Asn136-Phe142 14.2 12.6 –1.6 (0.03) 
Asn138-Phe144 16.1 14.5 –1.6 (0.03) 
Asn135-Phe142 9.7 8.1 –1.6 (0.03) 
Ile13-Thr51 17.9 16.5 –1.4 (0.06) 
Ile13-Ile52 15.1 13.7 –1.4 (0.06) 
Phe1-Tyr48 8.2 9.5 1.4 (0.02) 
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Difference map for 4-biphenyl α-D-mannopyranoside (3) in complex with FimH-CRD wild 
type vs. Y137A mutant–For the purpose of this study, MD simulations were carried out for the 
wild type FimH in complex with 4-biphenyl α-D-mannopyranoside (3) adopting the out 
binding mode observed in crystal structure of an analogous derivative (PDB: 3MCY). The 
Y137A mutant was created starting from the same pose and relaxed using the default 
relaxation protocol in Desmond MD package. Table S3 lists parameters that showed 
statistically significant variation upon the Y137A mutation in FimH complex with antagonist 
3. The resulting difference map shows a relatively smaller number of differences compared to 
the ligand free simulations. 
The comparatively limited differences associated with Y137A mutation when antagonist 3 is 
bound indicate that in presence of the ligand the binding-site maintains its conformation 
relative to the wild type. For instance, a significant distortion of Y48 at the tyrosine gate was 
observed upon mutating Y137 to alanine in the ligand free simulations. Notably, no sign of 
this distortion was observed in antagonist 3-bound simulations. This led us to the conclusion 
that the bioactive binding-site conformation is more or less maintained when a ligand is 
bound and that the distortion observed in the apo simulations needs to be first rectified to 
accommodate the ligand, which would incur an extra induced fit penalty as discussed in text. 
Difference map for ligand–protein interactions also revealed drop in interaction energies with 
Asn135, Asp47, and Gln133. The proposed readjustment of the Y137A mutant binding-site 
upon ligand binding, thus, seems to be incomplete.  
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Table S4. Difference map for the 4-biphenyl α-D-mannopyranoside bound to FimH-CRD wild type vs. Y137A 
mutant highlighting statistically significant changes in binding-site residues. 
Parameter Average 
(wild type) 
Average 
(Y137A 
mutant) 
Difference 
(S.D.) 
phi angles (degrees) 
Asn138 273.4 216.4 –57.0 (0.6) 
Asp140 227.4 275.5 48.1 (0.8) 
Ser139 238.6 269.5 31.0 (0.6) 
Asp141 270.6 241.9 –28.7 (0.7) 
Asn136 295.4 270.3 –25.1 (0.5) 
psi angles (degrees) 
Asp140 125.8 151.4 25.6 (0.6) 
Gly61 100.2 118.3 18.2 (0.6) 
Phe144 104.9 120.1 15.2 (0.4) 
chi angles (degrees) 
Asn138-1 185.2 58.0 –127.2 (0.6) 
Asp141-2 47.3 323.0 –84.3 (2.4) 
Phe142-1 302.7 222.2 –80.5 (1.0) 
Glu50-2 77.5 43.8 –33.7 (1.4) 
Asp140-1 88.5 35.3 –53.2 (1.9) 
protein-2d energies (kJ/mol) 
Phe1-Asp47 –120.9 –112.2 8.8 (0.4) 
His45-Asp47 –25.7 –18.8 6.9 (0.5) 
Asp141-Phe142 –142.4 –136.4 6.1 (0.2) 
Gln133-Phe142 –32.5 –27.6 4.8 (0.2) 
Asn135-Asn136 –128.3 –123.5 4.8 (0.3) 
Asn138-Phe142 –4.3 -0.5 3.8 (0.1) 
Phe1-Phe144 –10.0 –6.4 3.6 (0.1) 
Asp54-Asn135 –17.8 –14.7 3.0 (0.1) 
Asp54-Gln133 –32.8 –38.7 –5.8 (0.4) 
ligand–protein energies (kJ/mol) 
lig-Phe1 –121.5 –108.8 12.7 (0.5) 
lig-Ile13 –10.0 –1.3 8.7 (0.1) 
lig-Asn135 –19.0 –12.0 6.9 (0.3) 
lig-Gln133 –15.2 –10.6 4.6 (0.2) 
lig-Asp47 –14.7 –18.0 –3.3 (0.2) 
lig-Phe142 –4.1 –1.4 2.6 (0.1) 
COM distances (Å) 
Asn138-Phe142 7.7 10.3 2.5 (0.03) 
Asn136-Phe142 12.6 14.4 1.8 (0.03) 
Ser139-Phe142 9.3 11.1 1.8 (0.03) 
Asn135-Asp140 8.8 7.1 –1.7 (0.03) 
Asn135-Phe142 8.2 10.0 1.7 (0.03) 
Thr134-Phe142 6.7 8.3 1.6 (0.02) 
Thr51-Phe142 16.8 18.3 1.5 (0.03) 
Asp47-Asn138 15.0 13.5 –1.5 (0.02) 
 
Chapter 3.4. – Manuscript 6 
 
 280 
Table S5. Data collection and refinement statistics 
 
 
  
FimH wild type 
with 
n-Heptyl α-D-
mannopyranoside 
FimH Y48A with 
n-Heptyl α-D-
mannopyranoside 
FimH Y137A with 
n-Heptyl α-d-
mannopyranoside 
Crystallization 
conditions 
  
  
  
  
Ligand 
 !
5% PGA-LM!
0.1M Tris-HCl pH 
7.8!
30% v/v PEG 550 
MME!
10 mM n-Heptyl α-
D-mannopyranoside!
  
 !
5% w/v PGA-LM 
100 mM Na 
cacodylate pH 6.5!
200 mM MgCl2!
 !
10 mM n-Heptyl α-
D-mannopyranoside !
5% PGA-LM!
100 mM Na 
cacodylate pH 6.5!
12 % w/v PEG 8K !
 !
10 mM n-Heptyl α-
D-mannopyranoside!
Data collection       
X-ray wavelength (Å) 0.918410 0.96 0.918410 
Beamline/Synchrotron PX14.2, BESSY II Proxima 1, SOLEIL PX14.2, BESSY II 
Resolution range (Ǻ) 45 – 2.20 Å 41 - 3.01 Å 15 - 1.40 Å 
Number of reflections 
(of which unique) 
146524 
(20238) 
65358 
(9163) 
170620 
(25691) 
<I/sigI>  12.33 (3.77) 8.58 (3.02) 17.03 (4.15) 
Completeness (%)  98.0 (90.8) 97.7 (99.1) 98.4 (91.8) 
Crystal mosaicity (°) 0.448 0.111 0.445 
Rmeas b (%)  13.3 (57.1) 22.0 (81.1) 9.1 (47.4) 
Wilson B-factor 35.92 (sfcheck) 43.085 (correct) 9.50 (scala) 
Space group P 21 21 21 P 43 21 2 P 2 21 21 
# molecules / a.u. 2 2 1 
Unit cell dimensions 
a (Å) 
b (Å) 
c (Å) 
α, β,γ  (°) 
 
60.305 
68.070 
95.607 
 
 
89.850 
89.850 
91.870 
 
 
45.974 
59.552 
96.885 
Refinement   - 1.70 
Rwork 0.2042 0.1787 0.1493 
Rfree (test set = 5%) 0.2501 0.2346 0.1829 
R.m.s.d. 
stereochemistry 
   
Bonds (Å) 0.013 0.015 0.006 
Angles (°) 1.474 1.712 1.232 
Residues in favored 
and allowed regions 
(%) of Ramachandran  
96.83 
3.17 
 
96.90 
6.18 
96.20 
3.80 
 
PDB entry 4BUQ 4CA4 Unpublished 
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Capsule 
Background: Effect of FimH variants as found in clinical isolates of uropathogenic E. coli 
on α-D-mannopyranoside based antagonist binding. 
Results: All investigated antagonist classes were efficacious in preventing E. coli binding, 
however, with distinct behavior of a squaric acid substituted α-D-mannopyranoside. 
Conclusion: FimH antagonists might be successful therapeutics for uropathogenic E. coli 
with different naturally occurring mutations in FimH. 
Significance: This is the first study to date that demonstrates efficacy of different FimH 
antagonist classes to various types of FimH. 
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Summary 
FimH is a bacterial lectin located on type 1 pili of uropathogenic E. coli (UPEC) that 
mediates shear-enhanced adhesion to mannoyslated surfaces. Binding of UPEC to 
uroepithelial cells initiates urinary tract infections (UTI), one of the most prevalent infections 
worldwide. Anti-adhesive glycomimetics based on α-D-mannopyranosides present an 
effective alternative to antibiotics for UTI treatment. However, genetic variation of fimH 
found in clinical isolated UPECs leads to distinct binding modes. FimH antagonists have not 
been systematically evaluated with these naturally occurring FimH variants to date. 
In this study we investigated the genetic variation of fimH in 57 clinical UPEC isolates and 
demonstrated the distinct binding characteristics of four FimH variants to mannose-based 
ligands under static and hydrodynamic conditions. Furthermore, we evaluated binding 
potencies of four FimH antagonist representing four different classes.  
We showed that the FimH variants exhibited individual binding behavior, thus covering a 
range of FimH binding phenotypes (low to strong binding) found in patients with cystitis. 
Inhibition assays showed that the FimH variants were sensitive to all antagonist classes. The 
alkyl-, indolinylphenyl-, and biphenyl derivatives showed a phenotype-dependent binding 
affinity, while the squaric acid derivative inhibited the different FimH variants independent 
of their binding phenotype. Our results demonstrate the efficacy of FimH antagonists towards 
the clinically relevant FimH variants. 
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Introduction  
Urinary tract infections are one of the most prevalent bacterial infections with millions of 
people affected each year causing high costs in health care. In 70–95 % of all cases, UTIs are 
caused by uropathogenic Escherichia coli (UPEC) (1). The infection is initiated by the 
adhesion of UPECs through type 1 pili that are presented on the bacterial surface (2). These 
filamentous organelles consist of a rigid helical rod with up to 5000 of FimA subunits and a 
short tip with the subunits FimF, FimG, and FimH. It is the bacterial lectin FimH that confers 
the adhesion to bladder epithelial cells by allowing the interaction to mannosylated surface 
glycoproteins, mainly uroplakin Ia (UPIa) (3,4). FimH is composed of two domains, the pilin 
domain (FimHPD) and lectin domain (FimHLD) (5). The mannose binding pocket is located in 
the FimHLD, while being anchored to the pili via the FimHPD. Both domains have a beta-
barrel fold. FimH has been shown to adopt two conformational states with distinct binding 
characteristics (5,6). In the unstrained low binding affinity conformation, interdomain bonds 
between the FimHPD and FimHLD compress the latter. The FimHLD consequently displays a 
shallow binding groove that allows only for weak mannose binding. In the strained high 
binding affinity conformation, the loss of interdomain bonds induces a finger-trap like 
constriction of beta-sheets and an overall elongation of the FimHLD. In this state, a deep 
mannose binding pocket is formed with a high affinity towards mannose. The switching 
between the two conformational states allows FimH to exhibit catch-bond behavior, i.e. the 
lifetime of a FimH-mannose bond is increased upon tensile force (7,8), an uncommon feature 
among protein-ligand bonds. Both the complexation of the chaperone FimC to FimH, as 
observed in FimC-FimH crystal structures (5), as well as the absence of the PD (9) allow the 
FimHLD to adopt the high-affinity state due to the absence of the interdomain bonds. Using an 
antibody specific for the high-affinity state, Tchesnokova et al. demonstrated the allosteric 
connection between the high-affinity state and the open conformation of the interdomain 
region (10). Genetic variation in the fimH gene among UPEC strains was shown to alter 
mannose-binding affinities, despite the fact that the majority of all naturally occurring 
variations are not located in or in close proximity to the highly conserved mannose-binding 
site, but in the PD-LD interdomain region and (7,8,11,12). UPEC bearing the high-affinity 
form of FimH evolved under positive selection due to their enhanced virulence (11). At the 
same time, however, these UPEC strains are more sensitive to soluble inhibitors, e.g. the 
Tamm-Horsfall glycoprotein, and have a diminished ability to spread (13-15). Therefore, the 
catch bond behavior of FimH is believed to present a mechanism for UPEC to withstand 
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clearance from the bladder under tensile forces as they arise during micturition, while being 
insensitive towards soluble inhibitors (16). 
Since the FimH-mediated adhesion of UPECs to the urothelium is the initial step of an 
infection, this bacterial lectin has drawn a lot of attention as drugable target for the treatment 
of UTIs. FimH antagonists provide a novel therapeutic opportunity for the treatment and 
prevention of UTIs, as opposed to traditional treatment with antibiotics which trigger 
bacterial resistance (17-19). Efforts in identifying potent FimH antagonists has lead to the 
identification of several classes of substituted α-D-mannopyranoside based compounds, e.g. 
alkyl- (9,20,21), biphenyl- (22,23), indolylphenyl- and indolinylphenyl- (24), and squaric 
acid (23) substituted α-D-mannopyranosides. The in vitro potency of FimH antagonists is 
usually determined in target-based assays using recombinantly expressed protein, either the 
FimHLD alone (25) or full FimH in presence of FimC (26). In in vitro cell-based 
hemagglutination assays, a single clinical isolate (UTI89) with preferably high mannose 
affinity is commonly employed (27,28). Since UPEC strains cover a wide range of binding 
affinities towards mannose based upon their genetic variation, FimH antagonists are required 
to be efficacious to all binding states, a feature uninvestigated to date. We therefore identified 
commonly found mutations in UPECs isolated from patients with acute cystitis and generated 
corresponding isogenic E. coli strains expressing the FimH variants found therein. We further 
evaluated four classes of FimH antagonists for their binding affinity. 
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Experimental Procedures 
Sequencing of clinical isolates–Clinical isolates were collected at the University Hospital 
Basel, Switzerland during 2009 and were selectively cultivated. Age and sex of the patient 
and the antibiotic resistances are known." The fimH gene was amplified by standard colony 
PCR using the two sequencing primers shown in Tab. 1. DNA samples were submitted for 
sequencing (Microsynth, Balgach, Switzerland). A list of all sequenced isolates and their 
antibiotic resistances are listed in Tab. S1. 
TABLE 1. 
Primers used in this study (5’ to 3’). Mutations are underlined. 
Sequencing Primers 
FimH seq forward 
FimH seq reverse 
 
ACCGCGCAAAACATCCAGTT 
CCGGTGGCGCTTTATTTG 
Flanking Primers 
FimH forward 
FimH reverse 
 
GCGTGCACTCAGGGGAACCAT 
GCGCATGCTTATTGATAAACAAAAGT 
V27A mutation 
V27A forward 
V27A reverse 
 
CCCGCCGTGAATGTGGGGC 
CACGGCGGGCGCAAGGTTTAC 
S62A mutation 
S62A forward 
S62A reverse 
 
CAACGAGGCGCCGCTTATGGC 
GCCATAAGCGGCGCCTCGTTG 
N70S_S78N mutation 
N70S_S78N forward 
N70S_S78N reverse 
 
TTATCTAGTTTTTCCGGGACCGTAAAATATAATGGCAGTAGC 
GCTACTGCCATTATATTTTACGGTCCCGGAAAAACTAGATAA 
V128M mutation 
V128M forward 
V128M reverse 
 
TTAATTGCCATGCTTATTTTGCGA"
TCGCAAAATAAGCATGGCAATTAA"
A188D mutation 
A188D forward 
A188D reverse 
 
ACCGTTTATTGTGATAAAAGCCAAAAC 
GTTTTGGCTTTTATCACAATAAACGGT 
Generation of isogenic strains–The strains used herein are summarized in Tab. 2. The KB18 
strain containing the pPKL114 plasmid and the ELT115 strain were kindly provided by Prof. 
Evgeni Sokurenko, University of Washington, Seattle, WA (29). The pPKL114 plasmid 
encodes the whole fim operon with a stop linker upstream of the fimH gene. The plasmid 
pGB2-24 containing fimHJ96 was isolated from the ELT115 strain and served as template. 
Single nucleotide point mutations in FimH were introduced with the primers shown in Tab. 1 
using overlap PCR following standard molecular techniques. The mutated fimH gene was 
inserted into ApaLI and SphI (New England BioLabs, Allschwil, Switzerland) treated pGB2-
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24 plasmid. The plasmid was amplified in the DH5α E.coli strain (Novagen, Lucerne, 
Switzerland). The presence of mutations was confirmed by standard DNA sequencing 
(Microsynth, Balgach, Switzerland). The plasmids were transformed into the KB18 strain by 
electroporation. Successful transformation was verified by ampicillin (pPKL114) and/or 
chloramphenicol (pGB2-24) resistance. 
TABLE 2 
List of E. coli strains employed in this study.  
FimH Variant Background Plasmids Mutations Original Name 
Original 
Reference 
ΔFimH AAEC191A pPKL114 -  KB18 (14) 
FimHJ96 KB18  
pPKL114 
pGB2-24 
Wild Type ELT115 (14) 
FimHF18 KB18  
pPKL114 
pGB2-24 
V27A, N70S, 
S78N KB18 (14) 
FimHUTI89 KB18 
pPKL114 
pGB2-24 
V27A, S62A, 
N70S, S78N - (30) 
FimHB126 KB18  
pPKL114 
pGB2-24 
V27A, 
V128M - (10) 
FimHhigh KB18  
pPKL114 
pGB2-24 
A188D - (15) 
Preparation of bacterial suspensions–The bacteria were grown overnight under shaking 
conditions in LB medium at 37 °C with appropriate antibiotics. Bacteria were washed three 
times with phosphate-buffered saline (PBS, pH 7.4) and diluted to final concentrations of 
1·109 CFU/ml for static assays, 5·108 CFU/ml for competitive assays, and 1.5·108 CFU/ml for 
flow chamber assays with PBS containing 0.2 % bovine serum albumin (BSA). 
Type 1 pili immunostaining–Immunostaining was performed to verify equal expression of 
type 1 pili among the recombinant strains. Bacteria were incubated for 30 min at 25 °C with 
rabbit serum raised against type 1 pili (1:300 in PBS, 2 % BSA, kind gift from Prof. Dr. 
Krogfelt, Statens Serum Institut, Copenhagen, Denmark). After a washing step, the bacteria 
were treated with the secondary anti-rabbit Alexa647 conjugated antibody (10 µg/ml, 
Invitrogen, Lucerne, Switzerland) for 30 min at 25 °C. The bacteria were washed and 
resuspended in 300 µl PBS. Samples were measured with a CyAn ADP flow cytometer 
(BeckmanCoulter, Brea, CA). A total of 5·104 bacteria were measured per sample. Data were 
acquired in a linear mode for the side scatter (SSC), a logarithmic mode for forward scatter 
(FSC) and the red fluorescent channel FL8-H (Alexa647). Quantification of fluorescent 
labeling was evaluated with FlowJo 7.6.3 software (Tree Star, Inc., Ashland, USA). The 
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KB18 strain was used as negative control, since it expresses only a few non-adhesive pili 
(31). 
Bacterial binding under flow–Parallel plate flow chamber assays were performed similar as 
described previously (32). Cell culture dishes (35 mm, Corning, Inc., Corning, NY) were 
coated overnight at 4 °C with 50 µl of 50 µg/ml mono-mannosylated bovine serum albumin 
(1M-BSA, Dextra Ltd., Reading, UK) in 20 mM sodium bicarbonate buffer (pH 8.5). All 
subsequent steps were carried out at 25 °C. The 1M-BSA coated culture dishes were blocked 
and washed with 2 % PBS-BSA. The parallel plate flow chamber apparatus (GlycoTech, 
Gaithersburg, MD) with gasket size of 2.5 cm x 0.25 cm x 250 µm was fixed on the culture 
dish and vacuum sealed, followed by equilibration of the system with 0.2 % PBS-BSA with a 
Harvard Apparatus PHD2000 syringe pump (Instech Laboratories, Inc., Plymouth, PA) and 
mounted on a Nikon Eclipse Ti phase-contrast microscope (Nikon AG, Zurich, CH). was 
applied. Bacteria were perfused at wall shear stress between 0.01 pN/µm2 and 1.0 pN/µm2 
and counted after 10 min at 20x magnification (460 µm x 343 µm field of view) at three 
different points along the centre of the flow path. Exposure time was set according to the 
shear stress to allow distinction of flowing and bound bacteria. Bacteria were counted 
automatically with NIS-Elements Advanced Research 3.2 imaging software.  
Static bacterial binding and inhibition assay–Nunc MaxiSorpTM 96-well plates (Nunc GmbH, 
Langenselbold, Germany) were coated with 50 µl of 1M-BSA (50 µg/ml) or ribonuclease B 
(RNase B, 2 µg/ml, Sigma-Aldrich Co. LLC., Buchs, Switzerland) diluted in 20 mM sodium 
bicarbonate buffer while shaking overnight at 4 °C. The wells were blocked with 2 % PBS-
BSA for 2 h under the same conditions. After washing the blocked wells, the bacterial 
suspension was added to the plate (50 µl/well). For competitive binding assays, 25 µl/well 
bacterial suspension was pretreated with a serial dilution of soluble antagonist (25 µl/well) 
for 15 min before adding it to the plate. The plate was centrifuged for 3 min at 25 °C and 600 
x g before incubation for 1 h at 37 °C and 300 rpm. Unbound bacteria were subsequently 
removed by washing with 0.2 % PBS-BSA and bound bacteria were fixed with 100 µl/well 
Roti®-Histofix 1 % (Carl Roth GmbH, Karlsruhe, Germany). Bacteria were then labeled for 
30 min with the cell-permeable fluorescent dye Syto®16 (Life Technologies Corp., Zug, 
Switzerland), diluted to 2 µM in 10 mM HEPES. Fluorescence was measured at 485 nm 
excitation and 528 nm emission with a BioTek Synergy™ HT fluorometer (BioTek 
Instruments Inc., Winooski, VT). Static binding assays were performed in duplicate and 
repeated at least twice. IC50 values from competitive assays were calculated using the Prism 
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software (GraphPad Software, Inc., La Jolla, CA) by non-linear, four-parameter curve fitting 
for minimum, maximum, logIC50, and slope. 
Transmission electron microscopy–The bacteria from overnight culture were applied on 200-
400 mesh per inch copper grids coated with a Formvar® support film. The grids were glow 
discharged shortly before they were treated with the bacterial suspension for 10 minutes. 
Afterwards, the grids were washed with distilled water and negatively stained with a 0.5 % 
aqueous uranyl acetate solution for 30 seconds. Following air drying, the samples were 
examined in a Philips CM 100 transmission electron microscope at an 100 kV acceleration 
voltage. 
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Results 
Clinical isolates display high variability in the fimH gene–Analysis of the variability in the 
fimH gene from 57 isolates from patients with acute cystitis revealed numerous mutations 
(Tab. 3), none of which concern the residues in the binding site (Fig. 1). FimH as found in the 
pathogenic strain J96 (considered as wild type herein) represented the largest population with 
14 % of all isolates. The most frequently found mutations are V27A, N70S, S78N. These 
three mutations together correspond to the FimH of the fecal F18 isolate and were found in 7 
% of the isolates. In combination with additional mutations, the V27A, N70S, and S78N were 
found in 21 % of all tested isolates. The V128M/G (9 %), G66S (9 %), and R166H (10 %) 
mutations were also found frequently, almost exclusively in combination with the V27A 
mutation and further, non-consistent mutations. The S62A mutation as found in the highly 
pathogenic UTI89 clinical isolate was not found in any of the 57 clinical isolates. 
TABLE 3 
Sequence analysis of 57 UPEC strains isolated from patients with acute cystitis. The residue 
number, as well as the most frequent mutation are given. FimHJ96 was considered as wild type. 
Residue # 
Mutation  
7 
N→K 
27 
V→A 
41 
Q→R 
66 
G→S 
68 
L→V 
70 
N→S 
74 
T→I 
78 
S→N 
101 
K→N 
Frequency  1 46 1 5 1 16 3 19 1 
Residue # 
Mutation 
106 
A→V 
117 
G→R 
118 
A→V 
119 
A→V 
122 
A→V 
128 
V→M 
130 
T→A 
147 
N→S 
163 
V→I 
Frequency  2 1 1 3 1 5 1 1 3 
Residue # 
Mutation 
166 
R→H 
192 
N→Δ 
202 
A→V 
238 
V→E 
242 
A→V 
273 
G→A 
279 
Q→K 
  
Frequency 6 1 1 1 2 2 1   
Although mutations of the fimH gene known for altering the binding phenotype were found 
in this set of clinical isolates, their binding affinity towards mannose did not correlate with 
mutations (data not shown). This was a consequence of phase variation and the distinct 
expression of type I pili. 
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FIGURE 1. Mutations of the fimH gene identified in 57 clinical isolates. The mutations are 
mapped as red spheres of the Cα atom on the high-affinity conformation (left, PDB code 1QUN) and 
low-affinity conformation (right, PDB code 3JWN) structures. Sphere size correlates with the 
frequency of the mutation. The orange sphere corresponds to the S62A mutation found in the clinical 
isolate UTI89 which is frequently used in in vitro and in vivo studies. Green spheres represent 
residues involved in ligand binding (33). 
FimH variants found in clinical isolates show differential binding profiles–To overcome the 
problem of phase-variation, bacteria constitutively expressing type I pili were generated (Fig. 
2A). A set of four naturally occurring mutations that cover a wide range from low to strong 
affinity binding were chosen (Tab. 2). Furthermore, an artificial mutant (A188D, FimHhigh) 
that exclusively adopts the high affinity state, was generated as positive control (7,15). To 
verify the equal expression profile among the isogenic strains, quantitative staining with an 
anti-type 1 pili antibody was performed, which confirmed the similar expression level of type 
I pili (Fig. 2B). The mannose binding profile was evaluated in a static assay using 1M-BSA 
and RNase B, a glycoprotein expressing oligomannose-type structures (Man5GlcNAc2 to 
Man9GlcNAc2 N-linked glycans) (Fig. 2C) (34). Bacteria were allowed to bind to 
glycoprotein coated surfaces and were quantified using a nucleic acid stain and subsequent 
fluorescence readout. The natural FimH variants exhibited diverse binding to the 
glycoproteins, while the ΔFimH strain showed no binding towards the mannosylated surface. 
Binding to RNase B was higher when compared to 1M-BSA due to the presence of α1-3 and 
α1-6 linked oligosaccharides that confer strong binding. While RNase B binding was more 
uniform, the effect of the mutations was more distinctive for 1M-BSA binding. The artificial 
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FimHhigh variant showed the highest binding affinity, followed by the FimHUTI89 and FimHJ96 
variants. The FimHF18 and FimHB126 variants exhibited only weak binding to 1M-BSA. 
 
FIGURE 2. Isogenic bacteria expressing naturally occurring FimH variants show distinct 
binding under static and flow conditions. Electron micrographs (A) show type 1 pili expression of 
the isogenic strain expressing FimHUTI89 (bottom) in comparison to the negative control ΔFimH (top, 
KB18). Homologous type 1 pili expression was verified by FACS analysis after labeling with 
antibodies raised against type-1 fimbriae and detection with fluorescently labeled secondary antibody. 
(B). Static binding (C) was measured on 1M-BSA (50 µg/ml) and RNase B (2 µg/ml) coated surfaces. 
Bound bacteria were fluorescently labeled with of Syto®16 (2 µM). The error bars represent the 
standard error of the mean of two experiments, each performed in duplicate. Binding to 1M-BSA 
(50 µg/ml) under flow conditions (D) was performed at wall shear stress from 0.01–1.0 pN/µm2. Bound 
bacteria were counted after 10 minutes of perfusion at three points along the center of the flow path. 
We further assessed the binding behavior to 1M-BSA of the FimH variants under 
physiological flow conditions at wall shear stress of 0.01–1.0 pN/µm2 (Fig. 2D). The 
FimHhigh variant showed strongest binding that was constant up to a wall shear stress of 0.1 
pN/µm2. The FimHUTI89 variant exhibited generally decreased attachment and was capable of 
binding at a wide range of shear force, showing a slight decrease at low shear. The FimHJ96, 
FimHF18, and FimHB126 variants displayed catch-bond behavior within the applied range of 
wall shear force. Consistent with the static assay, FimHJ96 showed highest attachment 
followed by FimHF18 and FimHB126, the latter only with limited binding. Furthermore, the 
maximal attachment was shifted towards higher force, with FimHJ96 peaking at 0.05 pN/µm2, 
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FimHF18 at 0.1 pN/µm2, and FimHB126 at 0.15 pN/µm2. In conclusion, the selection of FimH 
variants covers a wide range of binding and is representative for the clinical isolate strains.  
Mannoside-based FimH antagonists show differential binding to FimH variants–The potency 
of FimH antagonists to the clinically relevant FimH variants were evaluated. A set of FimH 
antagonists representing four different classes of potent α-D-mannopyranosides substituted 
with various aglycons were chosen (Fig. 3): an alkyl- (n-heptyl, 1) (33), an indolinylphenyl- 
(2), a biphenyl- (3) (22,24), and a squaric acid derivative (4) substituted mannoside. The 
analysis was performed with a static cell-based inhibition assay, in which the antagonists 
compete with a mannosylated surface (Fig. 4A). Since binding to 1M-BSA was too weak for 
the low affinity FimH variants and therefore unsuitable for proper detection, RNase B coated 
surfaces were used. 
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FIGURE 3. FimH antagonists tested with the FimH variants in the static cell-based competition 
assay. α-D-mannopyranoside substituted either with n-heptyl (1), an indolinylphenyl derivative (2), a 
biphenyl derivative (3), and a squaric acid derivative (4). 
The FimH antagonists 1–4 showed IC50 values in the micromolar range for all of the tested 
FimH variants (Tab. 4). Antagonist 1 was the weakest compound for all types of FimH. 
Compared to antagonist 1, antagonists 2 and 3 showed an increase in relative potency (rIP) 
between ten- to twenty-fold. This increase in affinity was similar for all FimH variants. The 
squaric acid derivative 4 was the most potent antagonist with an affinity in the low 
micromolar range. For antagonists 1, 2, and 3 we observed a FimH variant-dependent 
affinity. They exhibited best inhibition towards the locked high affinity FimHhigh variant, 
followed by the FimHUTI89 and FimHJ96 variants. The binding affinities towards the low-
affinity variants FimHF18 and FimHB126 were similarly low. The largest difference in IC50 
value between the FimH variants was observed for antagonist 1, with a five-fold lower 
affinity towards FimHB126 (97.4 µM) compared to FimHhigh (21.8 µM). Taking only the 
affinity of antagonist 1 to naturally occurring FimH variants into account, the greatest 
difference was a two-fold decrease between FimHUTI89 (48.7 µM) and FimHB126 (97.4 µM). 
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TABLE 4 
Inhibition potencies of antagonists to the FimH variants determined with the cell-based 
inhibition assay. The bacteria (5·108 CFU/mL) were incubated with serial dilutions of the 
soluble antagonist (1–4) for 15 minutes and allowed to bind to RNase B (2 µg/ml) coated 
surfaces under static conditions. All inhibition assays were performed in duplicates and at 
least twice. The corresponding relative inhibitory potencies (rIP) were calculated for each 
FimH variant with antagonist 1 as reference compound. 
Compound 
 
1 2 3 4 
IC50 [µM] rΙP IC50 [µM] rΙP IC50 [µM] rΙP IC50 [µM] rΙP 
FimHhigh 21.8 ± 12.9 1 1.5 ± 0.5 15 1.5 ± 0.1 15 1.6 ± 0.1 14 
FimHUTI89 48.7 ± 4.9 1 3.0 ± 0.5 16 3.5 ± 0.7 14 2.3 ± 0.2 21 
FimHJ96 66.2 ± 16.2 1 4.4 ± 0.8 15 3.6 ± 0.7 18 1.2 ± 0.1 55 
FimHF18 83.0 ± 20.0 1 8.4 ± 0.7 10 4.5 ± 1.5 18 1.3 ± 0.1 64 
FimHB126 97.4 ± 26.2 1 9.9 ± 1.8 10 5.4 ± 0.5 18 1.3 ± 0.6 75 
Unlike antagonists 1–3, antagonist 4 exhibited almost uniform binding affinity to all FimH 
variants, leading to considerably differing rIP values. While antagonist 4 bound with 75-fold 
higher affinity to FimHB126, only a 21-fold increase was observed for the natural FimHUTI89. 
Moreover, compound 4 was not more efficacious for the FimHhigh variant (rIP = 14) than 
compounds 2 (rIP = 15) and 3 (rIP = 15). The squaric acid derivative 4 was therefore the only 
FimH antagonist of the herein tested compounds that showed a FimH variant-independent 
affinity. 
  
FIGURE 4. FimH antagonists prevent binding of FimH bearing bacteria to a mannosylated 
surface. Typical IC50 curves as observed in the cell-based inhibition assay on the example of the 
FimHJ96 variant (A). Correlation of binding affinity of the FimH variants towards 1M-BSA with the IC50 
values obtained for the four compound classes (B). Higher 1M-BSA binding correlated with increase 
affinity towards antagonists 1–3. This correlation was not observed for antagonist 4, for which similar 
IC50 values were observed for all FimH variants. 
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Discussion 
The colonization of the urinary tract by UPECs that ultimately leads to acute cystitis is a 
serious health risk. Since bacterial resistance due to overuse of antibiotics is increasingly 
problematic (35), drug discovery is focused on alternative treatment possibilities for UTIs. 
The mannose-specific bacterial adhesin FimH, being essential for UPEC pathogenicity (36-
38), is a suitable therapeutic target. Recent efforts have led to α-D-mannopyranosides 
substituted with various aglycons that show micromolar to nanomolar affinity, depending on 
the employed assay format (22,24,33,39-41). Such anti-adhesive therapy is believed not to 
trigger bacterial resistances, since they act neither bacteriostatic, nor bacteriolytic. Numerous 
assay formats exist with which FimH antagonists are evaluated. For cell-free assays (target-
based competitive binding assays (25), isothermal titration calorimetry (24,42), and surface 
plasmon resonance (33), recombinantly expressed and purified FimHLD is employed. 
However, due to the missing of the FimHPD, antagonists only encounter the high-affinity state 
of FimH, which does not correctly reflect the situation in vivo. Unfortunately, expression of 
full length FimH, i.e. LD and PD, is not possible due to the missing donor strand rendering 
FimH alone unstable. Constructs bearing FimHLD+PD in conjunction with FimC are stable, 
however, in such dimers the high-affinity state of FimH is adopted (37). FimH antagonists 
have also extensively been evaluated using cell-based in vitro assays, e.g. hemagglutinin 
assays (27,39,43,44) and a flow cytometry based assay (45). In these assays, the highly 
pathogenic clinical isolate UTI89 is employed due to its high degree of binding and ease of 
handling. A comparison of target- and cell-based assays used for testing antagonists 1–4 is 
shown in Tab. 5. Not only do the absolute numbers (nM vs µM) differ significantly between 
the target- and cell-based assays, also the relative potencies differ considerably. With the 
exception of compound 2 in the aggregometry assay, the three cell-based assays correlate 
well. For example, compound 4 shows merely a three-fold improvement over compound 1 in 
the target-based assay, while it is 14 to 35-fold more potent in cell-based assays. This might 
be a consequence of the proper display of full length FimH with its ability of adopting the 
high- and the low-affinity conformation.  
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TABLE 5 
Comparison of relative inhibitory potencies (rIP) for compounds 2–4 in relation to compound 1 
determined in a target-based competitive binding assay, a flow cytometry assay, an 
erythrocyte aggregometry assay, and the cell-based inhibition assays presented herein. The 
range of rIP values for the various FimH variants are given in the cell-based inhibition assay. 
The affinity for compound 1 is given for each assay. 
 Target Competitor 
1 2 3 4 
rΙP rΙP rΙP rΙP 
Target-based assay 
(22,24,25,40) 
FimHLD 
Recomb. 
Trimannose-
polymer 
1 
(55 nM) 
3.7 11.1 3.1 
Flow cytometry assay 
(22,24,40,45) 
UTI89 
Clin. Isol. 
Bladder epithelial 
cells (5637) 
1 
(4 µM) 
27.8 11.8 35.7 
Aggregometry assay 
(22,27,40) 
UTI89 
Clin. Isol. 
Guinea Pig 
Erythrocytes 
1 
(77 µM) 
2.9 14.6 15.4 
Cell-based inhibition 
assay (This study) 
Isogenic 
FimH var. 
RNase B 
(Man5-Man9) 
1 
(22–78 µM) 
10–16 14–18 14–75 
The UTI89 clinical isolate is not only used in cell-based in vitro assays, it is also the strain of 
choice for in vivo efficacy studies (9,22,40). The S62A mutation in the fimH gene of UTI89 is 
crucial for its high binding affinity (30), while otherwise being identical to the low-affinity 
FimHF18 variant. Indeed, FimHUTI89 displayed flow adhesion properties distinct from FimHJ96, 
FimHF18, and FimHB126, i.e. no catch-bond behavior within the applied range (Fig. 2D). The 
sequence analysis of 57 clinical UPEC strains revealed that not a single strain possessed the 
S62A mutation. This is also the case in previously published studies (11,46). While most 
isolates possess the FimHJ96 variant, many have the V27A mutation, which is known to 
stabilize the low affinity conformation and weaken mannose binding (47). Other mutations, 
e.g. the M128V mutation, even further weaken mannose binding. Nonetheless, strains 
bearing low-affinity FimH appear to be able of causing UTIs since they benefit from reduced 
affinity to the Tamm-Horsfall protein. It was therefore of great importance to evaluate the 
efficacy of FimH antagonists towards a set of naturally occurring FimH variants. The FimH 
antagonists belonging to four separate classes were all capable of binding to all of the FimH 
variants with distinct mannose-binding phenotypes and are able of inhibiting their adhesion 
to a mannosylated surface. The affinity of compounds 1–3 thereby correlated with the 
binding phenotype of the FimH variants. These antagonists showed highest affinity towards 
the high 1M-BSA binding FimH variant (FimHhigh) and a gradually decreased binding to the 
low 1M-BSA binding variants (Fig. 4B). This was however not true for the squaric acid 
derivative 4, which showed similar affinity towards all FimH variants resulting in great 
differences in rIP values compared to compound 1. Since the possibility of covalent binding 
for squaric acid derivatives to FimH has been excluded (48), perhaps an alternative 
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mechanism of action of 4, e.g. an alternative binding mode that does not discriminate 
between the two affinity states of FimH might explain this behavior.  
In summary, this study systematically demonstrates the efficacy of FimH antagonists towards 
several naturally occurring FimH variants for the first time. While there is a correlation 
between the affinity of antagonists and the binding phenotype of the various FimH types, 
these differences are small. We therefore postulate that potent FimH antagonists are suitable 
for treatment and prevention of UTI in which a wide spectrum of FimH variants are involved. 
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Supplementary Material 
SUPPLEMENTAL TABLE S1. List of clinical UPEC isolates with fimH gene sequence and 
antibiotic resistance analysis. FimHJ96 was considered as wild type. Amx: Amoxicillin, Clv: 
Clavulanic acid, Ctr: Cotrimoxazole, Cip: Ciprofloxacin. N.d. = not determined. 
Name Mutations Resistances 
B1 1 N7K / V27A / V128M n.d. 
B1 2 V27A None 
B1 3 V27A None 
B1 4 V27A n.d. 
B1 5 V27A / S78N / A242V Amx/Clv 
B1 7 G117R n.d. 
B1 10 No mutations n.d. 
B1 11 V27A None 
B1 12 No mutations Ctr 
B1 14 No mutations Amx/Clv 
B1 15 V27A / N70S None 
B1 16 V27A / R166H Amx/Clv, Ctr, Cip 
B1 17 V27A / N70S / S78N None 
B1 18 No mutations None 
B1 19 V27A / G66S / A202V None 
B1 20 No mutations None 
B1 23 V27A / V128G / R166H None 
B1 24 V27A / Q41R / V128M None 
B1 26 V27A / V128M None 
B1 27 N70S None 
B1 29 V27A / V163I / T130A None 
B1 31 G66S / S78N /A242V Ctr 
B1 32 V27A / S78N None 
B1 33 V27A / G66S / N70S / S78N Cip 
B1 34 V27A / N70S / S78N None 
B1 35 No mutations None 
B1 37 V27A / S78N None 
B1 38 V27A / A118V Cip 
B1 39 V27A / R166H Cip 
B1 40 V27A / V128M None 
B1 45 V27A / L68V / N70S / S78N None 
B1 46 V27A / N70S / S78N / V163A Ctr 
B1 47 V27A / N70S / T74I / S78N / V238E Amx/Clv 
B1 49 V27A / A119V / G273A Amx/Clv, Ctr, Cip 
Chapter 3.5. – Manuscript 7 
 304 
B1 51 V27A Amx/Clv, Cip 
B1 53 V27A / N70S / S78N Amx/Clv  
B1 55 V27A / N70S / S78N / N147S None  
B1 56 V27A / N70S / T74I / S78N / V163A Ctr  
B1 57 V27A None 
B1 58 V27A / N192∆ Ctr 
B1 59 No mutations None 
B1 60 V27A / N70S / S78N / A106V / A122V None 
B1 61 V27A / S78N None 
B3 1 V27A / R166H n.d. 
B3 2 V27A / Q279K None 
B3 3 V27A / N70S / S78N / K101N None 
B3 4 V27A / T74I None 
B3 5 V27A / N70S / S78N / A106V None 
B3 6 V27A / N70S / S78N None 
B3 7 V27A / A119V None 
B3 8 V27A / G66S / N70S / S78N Ctr 
B3 13 V27A / R166H None 
B3 14 V27A / G66S / N70S / S78N None 
B3 15 V27A / A119V / G273A None 
B3 16 V27A Cip 
B3 17 No mutations None 
B3 18 V27A / R166H None 
 
